

JlA ubqšY Kiguli 16 Amó 2017 Zwi tL AbjZ 248 Zg mfvi KihēeiYx

“” I cwi eri KJ “Y gšYj tqi “” tmev wefvM mipe Rbve tgvT imivRj nK Lvb Gu mfvcwZtZ; JlA ubqšY Kiguli 248Zg mfvi weMZ 16 Amó 2017 ZwiL mKij 11:00 NuUKiq gšYj tqi mfvi Kt¶ AbjZ nq|

সভায় কমিটির নিম্নবর্ণিত সদস্যগণ উপস্থিত ছিলেন (জ্যেষ্ঠতার ক্রমানুসারে নয়) :

- 1| Rbve mKigvi iÄb tNvl , cÄZubwa, evsj vt`k dvgfmDiuK`ij m&Bt`uivUvm`Gtmvmtqkb, XvKv|
- 2| Aa`vcK Wrt tgvT BmgvBj Lvb, dvgfKvj wR wefvM I DcivPvh, PÆMög tgvWtKj wekpe`ij q, PÆMög|
- 3| tgrI tRbtij tgvT Ave`j Avj x wgv, Kbmij tUu wclwRukqvb tRbtij , evsj vt`k Avgw tclvmtm tgvWtKj mwfmm|
- 4| Rbve mfvl P`amiKvi, AwZwi 3 mipe (JlA cÄkvb I AvBb), “” tmev wefvM, “” I cwi eri KJ “Y gšYj q, evsj vt`k mipej q, XvKv|
- 5| cvifxb AvKZvi, hMmipe, Rb“”, “” tmev wefvM, “” I cwi eri KJ “Y gšYj q, evsj vt`k mipej q, XvKv|
- 6| Wrt`mq` Gbvgj tnvmb, Dc mipe, gv`K`è` ubqšY Awa`Bi, tZRMvU, XvKv|
- 7| Wrt tgvT Avāj nvi g, wPd tftUwibwi Awdmvi, tK`xq tftUwibwi nvmcvZij XvKv, c¶ gnvcwi Pij K, cÄY m`u` Awa`Bi, XvKv|
- 8| Aa`vcK W. Gm Gg Avāj ingvb, Wxb, dvtgfm Aby`, XvKv wekpe`ij q|
- 9| Aa`vcK Wrt tgvT wUtUv wgvTv, tgvWmb wefvM, XvKv tgvWtKj Ktj R I nvmcvZij , XvKv|
- 10| Aa`vcK Wrt RwkI tnmvBb Mvi e, Pg¶ thSb tivM wekIA, m`vi mvi gjwntgvWtKj Ktj R, XvKv|
- 11| Wrt G, tK, Gg, Avt ie, mnKvix cwi Pij K (nvmcvZij -3), “” Awa`Bi, gnvlvj x, XvKv|
- 12| Wrt tgvTgbj nK, mvtEK wmbqi mn mfvcwZ, evsj vt`k JlA wkI mvgwZ Ges e`e`vcbv cwi Pij K, tRbtij dvgfmDiuK`ij m&ij t|
- 13| Rbve Gg tgvQtI K tnvmb, cÄZubwa, evsj vt`k dvtgfm KivwYj , XvKv|
- 14| Rbve tgvT Ave`j iv34vK, tgvWtKj wfvBm wekIA Ges e`e`vcbv cwi Pij K, tRGgAvB wmw tÄm GÜ tgvWtKj wfvBtmm ij t, Kvgj |
- 15| KweivR kÄKö.Kvšivq, m`m`, evsj vt`k BDbvix I Avqte¶ K tevW, XvKv|
- 16| tgrI tRbtij tgvT tgv`wvRij ingvb, gnvcwi Pij K, JlA cÄkvb Awa`Bi, XvKv|

mfvi Avtj vP` wLq mgn ubgēc t

- 1| JlA ubqšY Kiguli 247 Zg mfvi KihēeiYx wbuÖZKiY|
- 2| JlA ubqšY Kiguli tUKubK`ij mve Kiguli MZ 31-07-2017 Zwi tL AbjZ mfvi mzwikmgn t
 - 2.1 `vbxqfite Drcv`tbi Rb` Avtew`Z 190wU wDg`vb JItai tiwRt`÷k`tbi Abtgv`tbi mzwikmgn wLq Avtj vPbv I wvšI MhY cñt½|
 - 2.2 Avg`vbx Rb` Avtew`Z 30 wU wDg`vb JlA I 2wU fvkumtbi tiwRt`÷k`tbi Abtgv`tbi mzwikmgn wLq Avtj vPbv I wvšI MhY cñt½|
 - 2.3 `vbxqfite Drcv`tbi Rb` Avtew`Z 30wU wDg`vb JItai tiwRt`÷k`tbi Abtgv`tbi mzwikmgn wLq Avtj vPbv I wvšI MhY cñt½|
 - 2.4 Avg`vbx Rb` Avtew`Z 34wU tftUwibvix JItai tiwRt`÷k`tbi Abtgv`tbi mzwikmgn wLq Avtj vPbv I wvšI MhY cñt½|
 - 2.5 NASVAC [HBsAg 100µg + HBcAg 100µg/ml Subcutaneous Injection I HBsAg 100µg + HBcAg 100µg/ml Solution for Nasal spray] JItai tiwRt`÷k`tbi Abtgv`tbi mzwikmgn wLq Avtj vPbv I wvšI MhY cñt½|

2.1 "ibxqfite Drcv`tbi Rb" Avew`Z 190 uJ mDg`vb JI`tai tirRt÷k`tbi Abjgv`tbi mgywikmg`tni vel`tq Avtj`Pbv I m×vš`MÄY cõt½|

"ibxq Drcv`tbi Rb" tirRt÷k`tbi ibig`E`vLj KZ.190 uJ bZb JIa mfvq Dc`vcb Kiv ntj m`m`MY KZ` JIa, wj i Safety, Efficacy and Usefulness wetePbv Kti বিস্তারিত আলোচনাক্রমে ibxq uLZ m×vš`MpxZ nq t

K| Abjgv`Z = 81uJ;

L| bvg`ÄjKZ.= 109 uJ ; (Annex-A)|

JIa ibqšy` Kigui`i tUKubK`vj mve-Kigui`i 31 RjvB 2017 Zwi`L Abjv`Z mfvq Moxifloxacin 0.50gm + Dexamethasone Phosphate 0.10gm/100ml Sterile Ophthalmic Solution bvg`xq c`uLi Abjgv`tbi vel`tq Ac_vj tgv`tj vRó Gi gZvg`Z tbi qvi mgywik Kiv nq| AZtci Aa`vck Wrt `xb tgv`t b`y`aj nK, tPqvi g`vb, `xb tgv`t AvB nmucUvj GÜ mi mvP`tmUvi, tmvenvbevM, XivKv I Aa`vck Wrt tgv`t kvi d`z`xb Avntg`, tcl`w`f`im (cl`vmb) I tPqvi g`vb, KigDibui`U Ad_vj tgv`t wR wefvM, e`zeÜztkL gyRe tgv`tKj nekje`vj q, kvnevM, XivKv-Gi ubKU D³ JIa uLi Safety, Efficacy and Usefulness Gi vel`tq gZvg`Z c`v`tbi Rb` tcl`Y Kiv nq| Zuiv Df`tqB JIa uLi Safety, Efficacy and Usefulness gj`vqbc`e` t`tk cl`qvRbxqZv itq`tQ weavq tirRt÷k`b c`v`b Kivi mgywik Ktib| Zv`i mgywik`i wfi`E`Z JIa ibqšy` Kigui`i mfvq Moxifloxacin 0.50gm + Dexamethasone Phosphate 0.10gm/100ml Sterile Ophthalmic Solution bvg`xq JIa uLi Abjgv`b Kiv nq|

2.2 Avg`vbx`i Rb" Avew`Z 30 uJ mDg`vb JIa I 2uJ f`vKimb`tbi tirRt÷k`tbi Abjgv`tbi mgywikmg`tni vel`tq Avtj`Pbv I m×vš`MÄY cõt½|

Avg`vbx`i Rb" tirRt÷k`tbi ibig`E` Avew`Z 30 uJ mDg`vb JIa I 2uJ f`vKimb`tbi vel`tq mfvq Dciv`Z m`m`MY KZ` বিস্তারিত আলোচনাক্রমে ibxq uLZ m×vš`MpxZ nq t

K| Abjgv`Z = 22uJ JIa I 2uJ f`vKimb

L| bvg`ÄjKZ.= 08 uJ JIa ; (Annex-B)|

2.3 "ibxqfite Drcv`tbi Rb" Avew`Z 30 uJ tft`Umbvix JI`tai tirRt÷k`tbi Abjgv`tbi mgywikmg`tni vel`tq Avtj`Pbv I m×vš`MÄY cõt½|

"ibxq Drcv`tbi Rb" tirRt÷k`tbi ibig`E` Avew`Z 30uJ bZb tft`Umbvix JI`tai vel`tq mfvq Dciv`Z m`m`MY KZ` বিস্তারিত আলোচনাক্রমে ibxq uLZ m×vš`MpxZ nq t

K| Abjgv`Z = 25uJ I

L| bvg`ÄjKZ.= 05 uJ ; (Annex-C)|

2.4 Avg`vbx`i Rb" Avew`Z 34 uJ tft`Umbvix JI`tai tirRt÷k`tbi Abjgv`tbi mgywikmg`tni vel`tq Avtj`Pbv I m×vš`MÄY cõt½|

Avg`vbx`i ibig`E` tft`Umbvix JI`tai tirRt÷k`tbi Rb" Avew`Z 34uJ bZb JI`tai vel`tq mfvq m`m`MY JIa, wj i JIa ibqšy` Kigui`i tUKubK`vj mve-Kigui`i mgywik`i Avtj`tK we`hwi`Z আলোচনাক্রমে ibxq uLZ m×vš`MpxZ nq t

K| Abjgv`Z = 16 uJ I

L| bvg`ÄjKZ.= 18 uJ ; (Annex-D)|

tgWtKj WfVbM MbWj vBtbi mt_ GKU Zvij Kv mshy AvtQ| GB Zvij Kv Ašf Gy tgWtKj WfVbMmgn xNp b hver Dbz wekfn cxi wefba t k e'euZ nt"Q|

Riax cqvRtb tKvb tgWtKj WfVbM thgb: nftUP ÷ vU I Gi Gt. mmiR, BvU tKvj vi tj Y ev At_ cWk Bgc tUi tiRt ÷ kb cVb Kivi cqvRb ntj, j vBtmYs A_wiU Ae Wm-Gi ctY Zv t`qv m e bq| tKbbv The Drugs Control Ordinance 1982-Gi 5 aviv tgvZteK th tKvb bZb tgWtKj WfVbMti tiRt ÷ kb cVtbi Rb" Jla mbqšy KguU Z_v Gi tUKvbK'ij mve-KguUi সুপারিশ প্রয়োজন হয়; যা একটি সময় সাপেক্ষ প্রক্রিয়া।

Rb`i Rb` cqvRbxq Gme tgWtKj WfVbMmgn Wm KtUj KguU KZR tiRt ÷ k tbi Rb` Abtgw` Z ntj, cieZ j vBtmYs A_wiU Wm KZR c'ij Z AvBb I wea Abtyq Avte`Z cZv tbi WkzUmgn gj`iqbceR tgWtKj WfVbMmgn tKvqjU I tmdU wvDZceR tiRt ÷ kb cVb Kitz cvi te|

mfiq সদস্যগণ বিস্তারিত আলোচনাক্রমে মেডিকেল ডিভাইস রেজিস্ট্রেশন গাইডলাইন B, C, D Kmfx tgWtKj WfVbMmgn Abtgw` tbi mgnik Ktib|

mxst tgWtKj WfVbM tiRt ÷ kb MbWj vBtbi Ašf Gy B, C, D Kmfx tgWtKj WfVbMmgn Zvij Kv Abtgw` b Kiv nj; (Annex-G)|

5) tiRt ÷ kb mguqK emZj KZ.02()U JI tai tiRt ÷ kb emZj ch t

gibemfZ nI qvi Kvi tY j vBtmYs A_wiU (Wm) KZR mguqK emZj KZ.02U cZv tbi Cipro S Tablet I DEXAMET Tablet bvgvq e tUi JI tai tiRt ÷ kb emZj i Rb` mfiq Dc`vcb Kiv nq| GZ` el tQ JIa ckimb Ana` Bti i gnrcui Pij K tgRi tRbtij tgv tgv`ndRy ingvb etj b AvBbx eva` evaKZvi Kvi tY c`_ij i tiRt ÷ kb emZj i Rb` KguUi Abtgw` b cqvRb|

mxst সভায় বিস্তারিত আলোচনাক্রমে mguqK emZj KZ.02U JI tai tiRt ÷ kb emZj Kivi mxst MpxZ nq|

6) RbKj`Ygj-K Askx`vivenb DevBueU vjt0 bvgvq tKvubxi gva`tg t`kvq ch tZ Drcw`Z tgWtKj WfVbMti Drcv` b Kvi Lubvi j vBtmY nd Ges tgWtKj WfVbMti tiRt ÷ kb nd gl K tdi el q ch t

mfi vi Avtj vPbv t

mfi vi m`m` mipe tgRi tRbtij tgv tgv`ndRy ingvb mfiq Dc`vcb Ktib th, XvKv wekbe` vj tqi etqt tgWtKi vclwR. GU tUKt vj wR wefv tMi Abvix Aa`vcK c'dmi tL`v`Kvi iveYvbx Avte` tbi gva`tg Rivvb th, 1994 tbi ersj vt`k tKvubx AvBb -18 Gi tmKkb 29Gi AvI Zvq tKvubx-ij vgtUW evB M`vi vU tntmte DevBueU vjt0 bvtg GKU GKU tKvubx vbeUb Kti tQb| tmKkb 29 Gi AvI Zvq vbeUJ tKvubx RbKj`Ygj-K Ges Gi tKvb Askx`vi ev gvij K`v`K bv Ges tKvb e`v` ev tMv`x Gi gvvdv v tZ cvi bv | G ai tbi tKvubxi tCBW Avc K`vclUj v`v`v` gj-ab kY|

Abÿtbi gra'tg G aitbi tKv'úvbxí 'iæntZ nq| Zt' i wR'^mvgvb' A_©l mgq Abÿvb wntmte
 w'tq Gi cY' t'v cixÿvgj-Kfvte evRviRvZ Kivi tP÷v Ki'tQb| DtjL', wWfvBm, t'v %Zix Kivi I
 mvariY cixÿvi Rb' Zt' i GKwU tQvU KviLvbr AvtQ, Zte nek` , br, b cixÿvi Rb' Zivv GLbl
 XvKv nekæ`vj tqi evtqvtgWtKj wdlwR' GÜ tUKt'bvj wR wfvvMi mnvqZv wbtq_vtKb Kvi Y Gi Rb'
 cÖqvRbxq `vgx hšcwZ tKbvi Aw_R mvg_© Zv't i t'bb| Zivv BtZvgta' 09wU tgvWtKi wWfvBm
 `Zvi Kt'itQb| wKŠ'tgvWtKj wWfvBtmi KviLvbrí jvBtmÝ MhY I wWfvBmmgñi tiwRt÷k'tbi Rb'
 miKvi wbañiZ cÖqvRbxq wdl w'tq tgvWtKj wWfvBm Drcv`tbi Rb' Drcv`b jvBtmÝ MhY I
 tgvWtKi wWfvBmmgñi tiwRt÷k'tbi Kivi mvg_©t'bb| Gme wdl gl Kzd Kt' i t'kxq cÖv'p'tZ `Zvi
 Gme tgvWtKj wWfvBm evRviRvZ Kivi Avte`b Kt'itQb|

mfvq ðevBweU wj tÓ bvgxq tKv'úvbxí Avte`tbi wltq we`ñiZ AvtjvPbr tk'tl meñi'wZক্রমে মত
 cÖvk Kt'ib th, t'kxq wki weKv'tki Rb' tKv'úvbxíwU'tK mñhM t'qv cÖqvRb Ges ðevBweU wj tÓ
 bvgxq tKv'úvbxí Drcv`b KviLvbrí jvBtmÝ wdl I tgvWtKj wWfvBtmi tiwRt÷k'b wdl gl Kzdi wltq
 GKgz cÖvk Kt'ib |

wm×vš' t ðevBweU wj tÓ bvgxq tKv'úvbxí tgvWtKj wWfvBtmi Drcv`b KviLvbrí jvBtmÝ wdl I
 tgvWtKj wWfvBtmi tiwRt÷k'b wdl gl Kzdi Rb' mšwmi k Kiv nj |

Ab' tKvb AvtjvP' wltq br_vKvq mfvvZ gñv`q Dcw`Z mKj'tK ab'ev` Ávcb Kt' mfvv mgwB
 tNvl Yv Kt'ib|

tgRi tRbt'ij tgv'tgv`lndRj'ingub
 gñvwi Pvj K
 JIa cÖvmb Aw`Bi
 I
 m`m'-mPe
 JIa wqšY KvgwU|

tgv'tmivRj'nK Lub
 mPe
 t'v' tmev wfvM
 t'v' I cwi evi Kj vY gšYvj q
 I
 mfvvZ
 JIa wqšY KvgwU|

Annex-A: Proposed Product for locally manufacture (Human)

bs	cŪZKviŕK big	Jlŕai big	ŕRŕbii K big	ŕ_i wC DiŪK Km	ibŕ` kbv	Contra-indication & Side-effect	Status (New Molecule/ Existing)	Avŕe` bKvix KZŕ USFDA/BNF /MHRA Ref.	ŕUKŕbK`yj me Kugŕli mfvi mŕvŕŕ	mfvi mŕvŕŕ
1.	Aristopharma Ltd.	Mesalazine 1.0 gm Suppository	Mesalazine (Micronized) 1.0gm BP	Aminosalicylates	Mesalazine is indicated for the remission in patients with active mild to moderate ulcerative colitis and for the maintenance of remission of ulcerative colitis. The suppositories release the active ingredient slowly which then acts locally to reduce the inflammation and help relieve or stop the pain.	<p>Contra-indication: Mesalazine is contraindicated in patients with known or suspected hypersensitivity to salicylates or aminosalicylates or to any excipients of Mesalazine suppository.</p> <p>Side-effect: Following rectal administration local reactions such as itching, rectal discomfort and urge may occur. The commonly reported adverse effect are headache, Abdominal pain, Eructation, pain, Nausea, Pharyngitis, Dizziness, Asthenia, Diarrhea, Back pain, Fever, Rash, Dyspepsia, Rhinitis, Arthralgia, Hypertonia, Vomiting, Constipation, Flatulence, Chest pain, Flu syndrome, Sweating, Pruritus, Acne, Increased cough, Arthritis.</p>	Mesalazine (Mesalamine) 1200 mg DR Tablet 400mg Tablet 800mg Tab	USFDA	Abŕgr` b Kiv thŕZ cŕti	Abŕgr` b Kiv nj
2.	Eskayef Pharmaceuticals Limited	Phenazopyridine Hydrochloride 100mg FC Tablet	Phenazopyridine Hydrochloride 100mg USP	Analgesic	It is indicated for the symptomatic relief of pain, burning, urgency, frequency, and other discomforts resulting from irritation of the mucosa of the lower urinary tract caused by infection, trauma, surgery, endoscopic procedures, or the passage of sounds or catheters. It is compatible with antimicrobial therapy and can help relieve pain and discomfort during the interval before an antimicrobial therapy controls the infection.	<p>Contraindications: Patients who are hypersensitive to the drug or its ingredients, Patients with renal insufficiency or any liver disease.</p> <p>Side effects: Gastrointestinal: nausea, vomiting and diarrhea, Nervous System: headache, aseptic meningitis, Integumentary: rash, pruritus, discoloration, jaundice, Renal: renal toxicity usually associated with overdose, renal calculi.</p>	New		cŕŕqŕRb ŕbB weavŕ Avŕe` b bigÄy Kiv thŕZ cŕti	cŕŕqŕRb ŕbB weavŕ Avŕe` b bigÄy Kiv nj

bs	cŃZKviŃK big	JlŃai big	ŃRŃbniŃK big	Ń_ iwcDitŃK Km	ibŃ Rbv	Contra-indication & Side-effect	Status (New Molecule/ Existing)	AŃe`bKvix KZŃ USFDA/BNF / MHRA Ref.	ŃUKibK`ij mve KugŃli mfvi mŃvŃŃ	mfvi mŃvŃŃ
3.	Eskayef Pharmaceuticals Limited	Phenazopyridine Hydrochloride 200mg FC Tablet	Phenazopyridine Hydrochloride USP 200mg	Analgesic	It is indicated for the symptomatic relief of pain, burning, urgency, frequency, and other discomforts resulting from irritation of the mucosa of the lower urinary tract caused by infection, trauma, surgery, endoscopic procedures, or the passage of sounds or catheters. It is compatible with antimicrobial therapy and can help relieve pain and discomfort during the interval before an antimicrobial therapy controls the infection.	Contraindications: Patients who are hypersensitive to the drug or its ingredients, Patients with renal insufficiency or any liver disease. Side effects: Gastrointestinal: nausea, vomiting and diarrhea, Nervous System: headache, aseptic meningitis, Integumentary: rash, pruritus, discoloration, jaundice, Renal: renal toxicity usually associated with overdose, renal calculi.	New		cŃqŃRb ŃbB ŃeaiŃ cŃiŃ AŃe`b bigÄy Kiv thŃZ	cŃqŃRb ŃbB ŃeaiŃ AŃe`b bigÄy Kiv nj
4.	Unimed & Unihealth Mfg. Ltd.	Paracetamol 1000mg Tablet	Paracetamol BP 1000mg	Analgesic & Pyretic	Mild to moderate pain(osteoarthritis pain), Pyrexia	Contra-indication: Hypersensitivity to paracetamol or any of the other constituents. Side effect: Rare Acute generalised exanthematous pustulosis . malaise . skin reactions Stevens-Johnson syndrome. toxic epidermal necrolysis. Frequency not known Blood disorders . leucopenia. neutropenia thrombocytopenia	500mg Tablet 665mg Tablet	BNF-73 Page-414	i`ayŃŃ cŃB eq`Ń`i Rb` c`ŃK DŃj Ń KŃi eŃRvi RŃZ KiŃZ nŃe GB kŃZ® AbŃŃv`b Kiv thŃZ cŃiŃ	i`ayŃŃ cŃB eq`Ń`i Rb` c`ŃK DŃj Ń KŃi eŃRvi RŃZ KiŃZ nŃe GB kŃZ® AbŃŃv`b Kiv nj
5.	Incepta Pharmaceuticals Ltd.; Zirabo, Savar, Dhaka	Pramoxine HCl 1.0gm + Calamine 3.0gm/100gm Cream	Pramoxine HCl USP 1.0gm + Calamine BP 3.0gm/100gm	Analgesic + Antipruritic	Topical Pain. For the relief of itching, pain, and discomfort of ivy, oak, sumac poisoning >2 years: Apply to affected area q6-8hr PRN <2 years: Safety and efficacy not established	Contra-indication: Hypersensitivity to any product component. Side effect: Irritation and Pruritus	New		AbŃŃv`b Kiv thŃZ cŃiŃ	AbŃŃv`b Kiv nj
6.	Eskayef Pharmaceuticals Limited	Paracetamol 650mg Tablet	Paracetamol BP 650mg	Analgesic + Antipyretic	Analgesic and Antipyretic	Contraindications: Hypersensitivity to paracetamol or to any of the excipients. Side effects: Allergic reactions such as skin rash or itching •Breathing problems or swelling of the lips, tongue, throat or face.	Paracetamol BP 665mg Tablet		cŃqŃRb ŃbB ŃeaiŃ AŃe`b bigÄy Kiv thŃZ cŃiŃ	cŃqŃRb ŃbB ŃeaiŃ AŃe`b bigÄy Kiv nj

bs	c0ZKvi#K big	Jl#ai big	#R#buiK big	#_i wC D#UK Km	ib#`Rbv	Contra-indication & Side-effect	Status (New Molecule/ Existing)	A#e`bKvix KZ# USFDA/BNF /MHRA Ref.	#UK#K`vj me Kug#i mfvi m#v#S#	mfvi m#v#S#
7.	Eskayef Pharmaceuticals Limited	Lidocaine Hydrochloride 4% (w/w) Lotion	Lidocaine Hydrochloride USP 40mg/ml	Anesthetics	It is indicated for pruritus, pruritic eczemas, abrasions, minor burns, insect bites, pain, soreness and discomfort due to pruritus ani, pruritus vulvae, hemorrhoids, anal fissures and similar conditions of the skin and mucous membranes.	Contraindications: Traumatized mucosa, Secondary bacterial infection, known hypersensitivity. Side effects: Erythema or edema, Abnormal sensation.	2% Gel 1% Solution 4% Injection		c#q#Rb #bB weavq Av#e`b bv g#y Kiv th#Z c#ti	c#q#Rb #bB weavq Av#e`b bv g#y Kiv nj
8.	Incepta Pharmaceuticals Ltd (Dhamrai Unit).	Dronabinol 5mg Capsule	Dronabinol INN 5mg	Anorexia	DRONABINOL Capsules is indicated for the treatment of: <ul style="list-style-type: none"> • anorexia associated with weight loss in patients with AIDS; and • nausea and vomiting associated with cancer chemotherapy in patients who have failed to respond adequately to conventional antiemetic treatments. 	Contraindications: DRONABINOL Capsules is contraindicated in any patient who has a known sensitivity to DRONABINOL Capsules or any of its ingredients. It contains cannabinoil and sesame oil and should never be used by patients allergic to these substances. Side effect: Body as a whole: Asthenia. Cardiovascular: Palpitations, tachycardia, vasodilation/ facial flush. Digestive: Abdominal pain, nausea, vomiting. Nervous system: (Amnesia), anxiety/nervousness, (ataxia), confusion, depersonalization, dizziness, euphoria, (hallucination), paranoid reaction, somnolence, thinking abnormal.	New	USFDA	c#q#Rb #bB weavq Av#e`b bv g#y Kiv th#Z c#ti	c#q#Rb #bB weavq Av#e`b bv g#y Kiv nj
9.	Eskayef Pharmaceuticals Limited	Sodium Bicarbonate 1.76gm + Sodium Citrate 0.63gm + Anhydrous Citric Acid 0.72gm + Tartaric Acid 0.89gm Effervescent Powder in Sachet	Sodium Bicarbonate BP 1.76gm + Sodium Citrate (Anhydrous) USP 0.63gm + Anhydrous Citric Acid BP 0.72gm + Tartaric Acid BP 0.89gm	Antacid	Urinary alkalization where indicated as an adjunct therapy for urinary tract infection to relieve dysuria and enhance the action of certain antibiotics, anti-urolithic that reduces and prevents the crystallization of uric acid, cysteine and calcium oxalate stones, also for symptomatic treatment of gastric hyperacidity.	Contraindications: Renal failure or hypernatraemia, overt and occult cardiac failure. Side effects: Laxative effect, systemic alkalosis or hypernatraemia.			c#q#Rb #bB weavq Av#e`b bv g#y Kiv th#Z c#ti	c#q#Rb #bB weavq Av#e`b bv g#y Kiv nj

bs	cŃZKviŃK big	JlŃai big	ŃRŃbniŃK big	Ń_ iwcDitŃK Km	ibŃ Rbv	Contra-indication & Side-effect	Status (New Molecule/ Existing)	AŃte` bKvix KZŃ USFDA/BNF / MHRA Ref.	ŃUKibK`ij me KugŃli mfvi imxvŃŃ	mfvi imxvŃŃ
10.	GlaxoSmithKline Bangladesh Ltd Fouzderhat industrial Area PO:North Kattali Chittagong	Sodium Bicarbonate 2.32gm + Citric Acid 2.18 gm + Sodium Carbonate Anhydrous 0.50gm/5gm Powder in Sachet	Sodium Bi Carbonate USP 2.32gm + Citric Acid USP 2.18 gm + Sodium Carbonate Anhydrous USP 0.50gm/5gm Sachet	Antacid	-HEART BURN -ACID INDIGESTION -SOUR Stomach ---upset stomach due to these symptoms	Contraindication: Patients with impaired hepatic and renal fuction. Persons on a sodium restricted diet e.g those suffering from hypertension or congestive heart failure should not use this product unless directed by a doctor. Side effects: Minor gastrointestinal irritations, including bleacheing flautulence and abdominal distention.	New	MHRA	cŃŃqŃRb ŃbB wearq AŃte` b bigÄy Kiv thiZ citi	cŃŃqŃRb ŃbB wearq AŃte` b bigÄy Kiv nj
11.	Globe Pharmaceutic als ltd.	Hydrotalcite 500mg Chewable Tablet	Hydrotalcite BP 500 mg	Antacid	It is indicated for the symptomatic relief of the following conditions like peptic ulceration, dyspepsia, hyperacidity, gastritis, especially when associated with reflux Oesophagitis or hiatus hernia, and heartburn in pregnancy.	Contraindications: Hydrotalcite is contraindicated who are allergic to Hydrotalcite, mint oil or any of the other ingredients of this medicine in conditions like Neonates. Side Effects: Common side effects are diarrhea, soft stools etc. Patients with poor function of the kidneys (renal insufficiency) taking high doses for a long time may experience aluminium deposits, in particular in nerve and bone tissue and low phosphate levels.	New		cŃŃqŃRb ŃbB wearq AŃte` b bigÄy Kiv thiZ citi	cŃŃqŃRb ŃbB wearq AŃte` b bigÄy Kiv nj
12.	Globe Pharmaceutic als ltd.	Hydrotalcite 500mg/ 5 ml Oral Suspension	Hydrotalcite BP 500mg/5ml	Antacid	Hydrotalcite is indicated for the symptomatic relief of the following conditions like peptic ulceration, dyspepsia, hyperacidity, gastritis, especially when associated with reflux Oesophagitis or hiatus hernia, and heartburn in pregnancy.	Contraindications: Unknown. Side Effects: Side effects are uncommon. Diarrhea and vomiting have been reported.	New		cŃŃqŃRb ŃbB wearq AŃte` b bigÄy Kiv thiZ citi	cŃŃqŃRb ŃbB wearq AŃte` b bigÄy Kiv nj

<i>bs</i>	<i>cŃZKviŃK big</i>	<i>JlŃai big</i>	<i>ŃRŃbniŃK big</i>	<i>Ń_ iwcDitŃK Km</i>	<i>ibŃ Rbv</i>	Contra-indication & Side-effect	Status (New Molecule/ Existing)	<i>AŃe` bKvir KZŃ</i> USFDA/BNF / MHRA Ref.	<i>ŃUKibK`ij me KugŃli mŃvi imxvŃŃ</i>	<i>mŃvi imxvŃŃ</i>
13.	ACI Ltd.	Defibrotide Sodium 200mg/2.50 ml Injection (Intravenous Infusion)	Defibrotide Sodium Sterile ready to fill solution Ph. Grade 2.50 ml per vial eqv. to 200 mg/2.50 ml Defibrotide Sodium INN	Anti Coagulant	It is indicated for the treatment of adult and pediatric patients with hepatic veno-occlusive disease (VOD), also known as sinusoidal obstruction syndrome (SOS), with renal or pulmonary dysfunction following hematopoietic stem-cell transplantation (HSCT).	Contraindications: Concomitant administration with systemic anticoagulant or fibrinolytic therapy and it is also contraindicated in Known hypersensitivity to Defibrotide Sodium or to any of its excipients. Side Effects: The most common adverse reactions (incidence =10% and independent ofcausality) with Defibrotide Sodium treatment were hypotension, diarrhea, vomiting, nausea and epistaxis.	New	USFDA	<i>AbŃgv` b Kiv thŃZ cŃi </i>	<i>AbŃgv` b Kiv nj </i>
14.	Unimed & Unihealth Mfg. Ltd.	Glucosamine Sulfate 500mg + Chondroitin Sulfate 400mg Tablet	Glucosamine Sulfate Potassium Chloride USP 663.36mg eqv. to 500mg Glucosamine Sulfate + Chondroitin Sulfate Sodium USP 440mg eqv. to 400mg Chondroitin Sulfate	Anti- arthritis supplement	Arthritic condition of the joint and acts as a cartilage matrix enhancer.	Contra-indication: There are no known contraindications for Glucosamine and Chondroitin. But proven hypersensitivity (e. g. allergic to shellfish or sulfur) to Glucosamine and Chondroitin is a contraindication. Side effect: Both Glucosamine and Chondroitin Sulfates are virtually nontoxic. Side effects are rare and are limited to stomach upset, nausea or diarrhea. These usually disappear when the tablet is taken with meals	Glucosamine 250mg + Chondroitin 200mg Tablet		<i>cŃqŃRb ŃbB wearŃ AŃe` b bigÄy Kiv thŃZ cŃi </i>	<i>cŃqŃRb ŃbB wearŃ AŃe` b bigÄy Kiv nj </i>
15.	Unimed & Unihealth Mfg. Ltd.	Glucosamine Sulfate 750mg + Chondroitin Sulfate 600mg Tablet	Glucosamine Sulfate Potassium Chloride USP 995.04mg eq. to 750mg Glucosamine Sulfate + Chondroitin Sulfate Sodium USP 660 mg eq. to 600mg Chondroitin Sulfate	Anti- arthritis supplement	Arthritic condition of the joint and acts as a cartilage matrix enhancer.	Contra-indication: There are no known contraindications for Glucosamine and Chondroitin. But proven hypersensitivity (e. g. allergic to shellfish or sulfur) to Glucosamine and Chondroitin is a contraindication. Side effect: Both Glucosamine and Chondroitin Sulfates are virtually nontoxic. Side effects are rare and are limited to stomach upset, nausea or diarrhea. These usually disappear when the tablet is taken with meals	Glucosamine 250mg + Chondroitin 200mg Tablet		<i>AbŃgv` b Kiv thŃZ cŃi </i>	<i>AbŃgv` b Kiv nj </i>

<i>bs</i>	<i>c0ZKvi#K big</i>	<i>Jl#ai big</i>	<i>#R#biiK big</i>	<i>#_i wicDi#K Kim</i>	<i>ib#`Rbv</i>	Contra-indication & Side-effect	Status (New Molecule/ Existing)	<i>A#e`bKvix KZ# USFDA/BNF /MHRA Ref.</i>	<i>#UK#bK`vj me Kug#i mfvi m#v#S#</i>	<i>mfvi m#v#S#</i>
16.	Beximco Pharmaceuticals Ltd.	Formoterol Fumarate dehydrate BP 6.0mcg + Anhydrous Beclometasone Dipropionate BP 100mcg/Actuation on HFA Inhaler	Formoterol Fumarate dehydrate BP 6.0mcg + Anhydrous Beclometasone Dipropionate BP 100mcg/Actuation	Antiasthmatic	<p>A. Maintenance therapy: Beclomethasone dipropionate/ Formoterol fumarate is taken as regular maintenance treatment with a separate as needed rapid-acting bronchodilator.</p> <p>B. Maintenance and reliever therapy: The inhaler is taken as regular maintenance treatment and as needed in response to asthma symptoms.</p>	<p>Contraindications: Hypersensitivity to active substances or to any of the excipients</p> <p>Side effects: As with other inhalation therapy, paradoxical bronchospasm may occur Among the observed adverse reactions those typically associated with formoterol are: hypokalaemia, headache, tremor, palpitations, cough, muscle spasms and prolongation of QTc interval. Adverse reactions typically associated with the administration of beclometasone dipropionate are: oral fungal infections, oral candidiasis, dysphonia, throat irritation. Dysphonia and candidiasis may be relieved by gargling or rinsing the mouth with water or brushing the teeth after using the product. Symptomatic candidiasis can be treated with topical anti-fungal therapy whilst continuing the treatment with the fixed dose combined inhaler.</p>		MHRA	<i>Ab#gv`b Kiv th#Z c#i </i>	<i>Ab#gv`b Kiv nj </i>
17.	Beximco Pharmaceuticals Ltd.	Formoterol Fumarate dehydrate BP 6.0mcg + Anhydrous Beclometasone Dipropionate BP 200mcg/Actuation on HFA Inhaler	Formoterol Fumarate dehydrate BP 6.0mcg + Anhydrous Beclometasone Dipropionate BP 200mcg/Actuation	Antiasthmatic	<p>The fixed dose combination inhaler is indicated in the regular treatment of asthma where use of a combination product (inhaled corticosteroid and long-acting beta2-agonist) is appropriate: - patients not adequately controlled with inhaled corticosteroids and 'as needed' inhaled short-acting beta2-agonist or - patients already adequately controlled on both inhaled corticosteroids and long-acting beta2-agonists</p>	<p>Contraindications: • Hypersensitivity to active substances or to any of the excipients</p> <p>Side effects: As with other inhalation therapy, paradoxical bronchospasm may occur . Among the observed adverse reactions those typically associated with formoterol are: hypokalaemia, headache, tremor, palpitations, cough, muscle spasms and prolongation of QTc interval. Adverse reactions typically associated with the administration of beclometasone</p>	New	MHRA	<i>Ab#gv`b Kiv th#Z c#i </i>	<i>Ab#gv`b Kiv nj </i>

						dipropionate are: oral fungal infections, oral candidiasis, dysphonia, throat irritation. Dysphonia and candidiasis may be relieved by gargling or rinsing the mouth with water or brushing the teeth after using the product. Symptomatic candidiasis can be treated with topical anti-fungal therapy whilst continuing the treatment with the fixed dose combined inhaler.				
18.	Concord Pharmaceuticals Ltd.	Zileuton 600mg Extended Release Tablet	Zileuton USP 600mg	Antiasthmatic	Zileuton is indicated for the prophylaxis and chronic treatment of asthma in adults and children 12 years of age and older. Zileuton is not indicated for use in the reversal of bronchospasm in acute asthma attacks. Therapy with zileuton can be continued during acute exacerbations of asthma.	Contraindication: Zileuton is contraindicated in patients with active liver disease or persistent hepatic function enzymes elevations greater than three times the upper limit of normal. Hepatic function should be assessed prior to initiating this tablet, monthly for the first 3 months, every 2–3 months for the remainder of the first year, and periodically thereafter. Neuropsychiatric events, including sleep disorders and behavioral changes, may occur. Patients should be instructed to notify their healthcare provider if neuropsychiatric events occur. Adverse Reactions: The most common adverse reactions reported by patients treated with this tablet were sinusitis (6.5%), nausea (5%), and pharyngolaryngeal pain (5%) vs. placebo, 4%, 1.5%, and 4% respectively.	New	USFDA	চল্লিকিRb ত্বB ঞাঐq Aঐte`b bigĂy Kiv thtZ cঐti	চল্লিকিRb ত্বB ঞাঐq Aঐte`b bigĂy Kiv nj
19.	Incepta Pharmaceuticals Ltd., Zirabo, Savar, Dhaka	Doxofylline 650mg Controlled Release Tablet	Doxofylline INN 650mg	Antiasthmatic	Doxofylline is mostly administered for maintenance treatment in subjects experiencing COPD (Chronic Obstructive Pulmonary Disease) and bronchial asthma. Doxofylline is not designed for use as an emergency treatment during an asthma attack.	Contraindications: This is contraindicated for individuals who have shown hypersensitivity to doxofylline and its components. It is also contraindicated in patients with acute myocardial infarction, hypotension, and in lactating women. Side-effects: After xanthine administration, nausea, vomiting, epigastric pain, cephalalgia, irritability, insomnia,	400mg CR Tablet		চল্লিকিRb ত্বB ঞাঐq Aঐte`b bigĂy Kiv thtZ cঐti	চল্লিকিRb ত্বB ঞাঐq Aঐte`b bigĂy Kiv nj

						tachycardia, extrasystole, tachypnea and occasionally, hyperglycemia and albuminuria, may occur. If a potential oral overdose is established, the patient may present with severe arrhythmias and seizure; these symptoms could be the first sign of intoxication. Adverse reactions may cause the withdrawal from treatment; a lower dose rechallenge may start only after the advice of a physician				
20.	Incepta Pharmaceuticals Ltd.; Zirabo, Savar, Dhaka	Acebrophylline 100mg Capsule	Acebrophylline INN 100mg	Antiasthmatic	Acebrophylline is indicated for asthma, bronchitis and other respiratory conditions.	Contra-indication: Hypersensitivity to ambroxol, acebrophylline, theophylline or any other xanthine derivative, Patient suffering from acute myocardial infarction, hypotension, hemodynamic instability and arrhythmias, renal disease or liver disorder. Side effect: Patients administering Acebrophylline might be affected by some adverse events. A list consisting of some examples is given here: Sickness, Diarrhea, Flatulence, Constipation Abdominal discomfort. It is worth noting that other side effects which are not referenced here are also possible.	New		চিকিৎসা ঐচ্ছিক আবেদন বর্গায় কীব থিত্ৰ চিত্ৰ	চিকিৎসা ঐচ্ছিক আবেদন বর্গায় কীব নজ
21.	Incepta Pharmaceuticals Ltd.; Zirabo, Savar, Dhaka	Acebrophylline 200mg SR Tablet	Acebrophylline INN 200mg	Antiasthmatic	Acebrophylline is indicated for asthma, bronchitis and other respiratory conditions.	Contra-indication: Hypersensitivity to ambroxol, acebrophylline, theophylline or any other xanthine derivative, Patient suffering from acute myocardial infarction, hypotension, hemodynamic instability and arrhythmias, renal disease or liver disorder. Side effect: Patients administering Acebrophylline might be affected by some adverse events. A list consisting of some examples is given here: Sickness, Diarrhea, Flatulence, Constipation Abdominal discomfort. It is worth noting that other side effects which are not referenced here are also possible.	New		চিকিৎসা ঐচ্ছিক আবেদন বর্গায় কীব থিত্ৰ চিত্ৰ	চিকিৎসা ঐচ্ছিক আবেদন বর্গায় কীব নজ

bs	cŃZKviŃK big	JlŃai big	ŃRŃbniŃK big	Ń_ iwcDitŃK Km	ibŃ Rbv	Contra-indication & Side-effect	Status (New Molecule/ Existing)	AŃe`bKvir KZŃ USFDA/BNF / MHRA Ref.	ŃUKibK`ij me KugŃli mfvi imxvŃŃ	mfvi imxvŃŃ
22.	Incepta Pharmaceuticals Ltd.; Zirabo, Savar, Dhaka	Acebrophylline 50mg/5ml Syrup	Acebrophylline INN 50mg/5ml	Antiasthmatic	Acebrophylline is indicated for asthma, bronchitis and other respiratory conditions.	Contra-indication: Hypersensitivity to ambroxol, acebrophylline, theophylline or any other xanthine derivative, Patient suffering from acute myocardial infarction, hypotension, hemodynamic instability and arrhythmias, renal disease or liver disorder. Side effect: Patients administering Acebrophylline might be affected by some adverse events. A list consisting of some examples is given here: Sickness, Diarrhea, Flatulence, Constipation Abdominal discomfort. It is worth noting that other side effects which are not referenced here are also possible.	New		cŃqŃRb ŃbB wearq AŃe`b bigÄy Kiv thŃZ cŃti	cŃqŃRb ŃbB wearq AŃe`b bigÄy Kiv nj
23.	Eskayef Pharmaceuticals Limited	Montelukast 10mg + Fexofenadine 120mg FC Tablet	Montelukast USP 10mg + Fexofenadine USP 120mg	Antiasthmatic + Antihistamine	It is indicated for Asthma, Allergic rhinitis	Contraindications: Hypersensitivity Side effects: Headache, dizziness, cough and fever.	Montelukast 10mg Tablet Fexofenadine 120mg Tablet		cŃqŃRb ŃbB wearq AŃe`b bigÄy Kiv thŃZ cŃti	cŃqŃRb ŃbB wearq AŃe`b bigÄy Kiv nj
24.	Eskayef Pharmaceuticals Limited	Montelukast 4mg + Levocetirizine 2.5mg Tablet	Montelukast USP 4mg + Levocetirizine USP 2.5mg	Antiasthmatic + Antihistamine	It is indicated for Asthma, Exercise induced bronchospasm, Allergic Rhinitis, Urticaria, Seasonal and perennial allergic rhinitis, Uncomplicated skin manifestations of chronic idiopathic urticaria.	Contraindications: Hypersensitivity Side effects: Calcium Orotate is generally well tolerated.	Montelukast 4mg Tablet Levocetirizine 5mg Tablet		cŃqŃRb ŃbB wearq AŃe`b bigÄy Kiv thŃZ cŃti	cŃqŃRb ŃbB wearq AŃe`b bigÄy Kiv nj

bs	cŃZKviŃK big	JlŃai big	ŃRŃbniŃK big	Ń_ iwcDŃUK KŃm	ŃbŃ Rbv	Contra-indication & Side-effect	Status (New Molecule/ Existing)	AŃŃe bKvix KZŃ USFDA/BNF / MHRA Ref.	ŃUKŃbK'ij me KŃgŃli mfvi ŃmŃvŃŃ	mfvi ŃmŃvŃŃ
25.	Acme Laboratories Ltd., Dhamrai, Dhaka	Doxycycline 100 mg Dispersible Tablet	Doxycycline Monohydrate BP 104.05 mg eqv. to Doxycycline 100 mg	Antibiotic	Doxycycline 100mg dispersible tablet is used to treat many different types of infections including: • Chest, lung or nasal infections e.g. bronchitis, pneumonia, sinusitis. • Urinary tract infections (the passage through which urine passes) e.g. cystitis, urethritis. • Acne (a skin condition). • Eye infections. • Sexually transmitted diseases e.g. gonorrhoea, syphilis, chlamydia. • Fevers associated with louse or tick bites. • Malaria, when chloroquine is not effective. It is also used to prevent certain infections developing, these are scrub typhus (a disease carried by small insects) travellers' diarrhoea, malaria and leptospirosis (a bacterial infection).	Contraindication: It is contraindicated to patients with known hypersensitivity to any of the tetracyclines. It is also contraindicated in severe hepatic disorder and patients with systemic lupus erythematosus. Concomitant intake of alkalis, antacids and iron may interfere with the absorption of Doxycycline. It is advisable to avoid giving doxycycline in conjunction with penicillin. Doxycycline should not be used in pregnant women unless, in the judgment of the physician, it is essential for the welfare of the patient. The use of drugs of tetracycline group during tooth development (last half of pregnancy, infancy and childhood to the age of 12 years) may cause permanent discoloration of the teeth. Tetracyclines, therefore, should not be used in this age group unless other drugs are not likely to be effective or are contraindicated. Side effects: POSSIBLE SIDE EFFECTS Doxycycline may produce gastrointestinal irritation to a varying degree in some individuals. Epigastric distress, abdominal discomfort, nausea, and vomiting may occur. Long term therapy with Doxycycline may produce changes in the peripheral blood. Various skin reactions including rashes, urticaria, exfoliative dermatitis may follow the use of Doxycycline but they are rare.	Doxycycline 50&100mg Capsule, Doxycycline 100 mg/gm Powder	BNF-73 Page:522	cŃŃqŃRb ŃbB ŃearŃ AŃŃe b bigŃŃy KŃiv ŃhŃZ cŃŃŃ	cŃŃqŃRb ŃbB ŃearŃ AŃŃe b bigŃŃy KŃiv Ńj

<i>bs</i>	<i>c0ZKvi#K big</i>	<i>Jl#ai big</i>	<i>#R#biiK big</i>	<i>#_i wC DiiUK Kim</i>	<i>ib#`Rbv</i>	Contra-indication & Side-effect	Status (New Molecule/ Existing)	<i>Av#`bKvix KZ# USFDA/BNF /MHRA Ref.</i>	<i>#UKibK`vj me Kigi#i mfvi m#v#S#</i>	<i>mfvi m#v#S#</i>
26.	Biopharma Limited	Minocycline 105.00mg Extended Release Tablet	Minocycline HCl USP 113.400 mg eq.to Minocycline 105.00 mg	Antibiotic	Treat the inflammatory lesions of non-nodular moderate to severe acne vulgaris in patients 12 years of age and older.	<p>Contraindication: Patients who have shown hypersensitivity to any of the tetracyclines</p> <p>Side Effects: <u>Clinical Trials Experience:</u> Headache, Fatigue, Dizziness, Pruritus, Malaise, Mood alteration, Somnolence, Urticaria, Tinnitus, Arthralgia, Vertigo, Dry mouth, Myalgia</p> <p><u>Postmarketing Experience:</u> Skin and hypersensitivity reactions: fixed drug eruptions, balanitis, erythema multiforme, Stevens-Johnson syndrome, anaphylactoid purpura, photosensitivity, pigmentation of skin and mucous membranes, hypersensitivity reactions, angioneurotic edema, anaphylaxis, DRESS syndrome. Autoimmune conditions: polyarthralgia, pericarditis, exacerbation of systemic lupus, pulmonary infiltrates with eosinophilia, transient lupus-like syndrome. Central nervous system: pseudotumor cerebri, bulging fontanels in infants, decreased hearing. Endocrine: brown-black microscopic thyroid discoloration, abnormal thyroid function. Oncology: thyroid cancer. Oral: glossitis, dysphagia, tooth discoloration. Gastrointestinal: enterocolitis, pancreatitis, hepatitis, liver failure.</p>	100mg Tablet	USFDA	<i>c#q#Rb #b# weavq Av#`b big#y Kiv thiZ citi </i>	<i>c#q#Rb #b# weavq Av#`b big#y Kiv nj </i>

bs	c0ZKvi#K big	Jl#ai big	#R#biiK big	#_i wC DiiUK Kim	ib#`Rbv	Contra-indication & Side-effect	Status (New Molecule/ Existing)	A#e`bKvix KZ# USFDA/BNF /MHRA Ref.	#UKibK`vj me Kigidi mfvi m#v#S#	mfvi m#v#S#
27.	Biopharma Limited	Minocycline 135.00mg Extended Release Tablet	Minocycline Hydrochloride USP 145.800mg eqv. to Minocycline 135.00 mg Extended Release Tablet	Antibiotic	Treat the inflammatory lesions of non- nodular moderate to severe acne vulgaris in patients 12 years of age and older.	Contraindication: Patients who have shown hypersensitivity to any of the tetracyclines Side Effects: Clinical Trials Experience: Headache, Fatigue, Dizziness, Pruritus, Malaise, Mood alteration, Somnolence , Urticaria, Tinnitus, Arthralgia , Vertigo , Dry mouth , Myalgia Postmarketing Experience: Skin and hypersensitivity reactions: fixed drug eruptions, balanitis, erythema multiforme, Stevens-Johnson syndrome, anaphylactoid purpura, photosensitivity, pigmentation of skin and mucous membranes, hypersensitivity reactions, angioneurotic edema, anaphylaxis, DRESS syndrome. Autoimmune conditions: polyarthralgia, pericarditis, exacerbation of systemic lupus, pulmonary infiltrates with eosinophilia, transient lupus-like syndrome. Central nervous system: pseudotumor cerebri, bulging fontanels in infants, decreased hearing. Endocrine: brown-black microscopic thyroid discoloration, abnormal thyroid function. Oncology: thyroid cancer. Oral: glossitis, dysphagia, tooth discoloration. Gastrointestinal: enterocolitis, pancreatitis, hepatitis, liver failure.	100mg Tablet	USFDA	c#qirb #b weavq A#e`b bigAy Kiv thiZ citi	c#qirb #bB weavq A#e`b bigAy Kiv nj

bs	cŃZKviŃK big	JlŃai big	ŃRŃbniK big	Ń_ iwcDitUK Km	ibŃ Rbv	Contra-indication & Side-effect	Status (New Molecule/ Existing)	AŃe`bKvix KZŃ USFDA/BNF / MHRA Ref.	ŃUKibK`ij me Kugili mfvi imxvŃŃ	mfvi imxvŃŃ
28.	Eskayef Pharmaceuticals Limited	Cefexime 100mg + Clavulanic Acid 62.5mg FC Tablet	Cefexime Trihydrate USP 100mg + Clavulanic Acid BP 62.5mg	Antibiotic	It is indicated in uncomplicated urinary tract infections caused by <u>Escherichia coli</u> and <u>Proteus mirabilis</u> , Otitis media caused by <u>Haemophilus influenzae</u> (beta-lactamase positive and negative strains), <u>Moraxella</u> (Branhamella) <u>catarrhalis</u> , (most of which are beta-lactase positive) and <u>S. pyogenes</u> . Pharyngitis and Tonsillitis, caused by <u>S. pyogenes</u> . Acute bronchitis and acute exacerbations of chronic bronchitis, caused by <u>Streptococcus pneumoniae</u> and <u>Haemophilus influenza</u> (beta-lactamase positive and negative strains), uncomplicated gonorrhoea (cervical/urethral), caused by <u>Neisseria gonorrhoeae</u> (penicillinase and non-penicillinase-producing strains).	Contraindications: It is contraindicated in patients with a known hypersensitivity to any of the ingredients. Side effects: Diarrhoea and stool changes, nausea, vomiting, transient elevation in liver transaminases, alkaline phosphatase and jaundice, thrombocytosis, thrombocytopenia, leucopenia, hypereosinophilia, neutropenia and agranulocytosis.			cŃqirB ŃbB weariq AŃe`b bigÄy Kiv thŃZ cŃti	cŃqirB ŃbB weariq AŃe`b bigÄy Kiv nj
29.	Eskayef Pharmaceuticals Limited	Cefexime 200mg + Clavulanic Acid 125mg FC Tablet	Cefexime Trihydrate USP 200mg + Clavulanic Acid BP 125mg	Antibiotic	It is indicated in uncomplicated urinary tract infections caused by <u>Escherichia coli</u> and <u>Proteus mirabilis</u> , Otitis media caused by <u>Haemophilus influenzae</u> (beta-lactamase positive and negative strains), <u>Moraxella</u> (Branhamella) <u>catarrhalis</u> , (most of which are beta-lactase positive) and <u>S. pyogenes</u> . Pharyngitis and Tonsillitis, caused by <u>S. pyogenes</u> . Acute bronchitis and acute exacerbations of chronic bronchitis, caused by <u>Streptococcus pneumoniae</u> and <u>Haemophilus influenza</u> (beta-lactamase positive and negative strains), uncomplicated gonorrhoea (cervical/urethral), caused by <u>Neisseria gonorrhoeae</u> (penicillinase and non-penicillinase-producing strains).	Contraindications: It is contraindicated in patients with a known hypersensitivity to any of the ingredients. Side effects: Diarrhoea and stool changes, nausea, vomiting, transient elevation in liver transaminases, alkaline phosphatase and jaundice, thrombocytosis, thrombocytopenia, leucopenia, hypereosinophilia, neutropenia and agranulocytosis.			cŃqirB ŃbB weariq AŃe`b bigÄy Kiv thŃZ cŃti	cŃqirB ŃbB weariq AŃe`b bigÄy Kiv nj

bs	cŃZKviŃK big	JlŃai big	ŃRŃbniŃK big	Ń_ iwcDitŃK Kvm	ibŃ Rbv	Contra-indication & Side-effect	Status (New Molecule/ Existing)	AŃe`bKvir KZŃ USFDA/BNF /MHRA Ref.	ŃUKibK`ij me KugŃli mfvi mŃvŃŃŃ	mfvi mŃvŃŃ
30.	Eskayef Pharmaceuticals Limited	Ceftriaxone 1.0 gm + Tazobactam 125mg Powder For Injection	Ceftriaxone Sodium BP 1.0gm + Tazobactam Sodium INN 125mg	Antibiotic	It is indicated to reduce the development of drug-resistance bacteria and maintain the effectiveness of this injection, it should be used only to treat or prevent infections that are proven or strongly suspected to be caused by susceptible bacteria.	Contraindications: Hypersensitivity Side effects: Rash, pruritus, fever or chills.			cŃqirb ŃbB weariq AŃe`b bigÄy Kiv thŃZ cŃti	cŃqirb ŃbB weariq AŃe`b bigÄy Kiv nj
31.	Incepta Pharmaceuticals Ltd.; Zirabo, Savar, Dhaka	Cefazolin 1.0 gm/Vial Injection	Cefazolin Sodium USP 1.050gm eq. to Cefazolin 1 gm/Vial	Antibiotic	To reduce the development of drug-resistant bacteria and maintain the effectiveness of Cefazolin for Injection, USP and other antibacterial drugs, Cefazolin for Injection, USP should be used only to treat or prevent infections that are proven or strongly suspected to be caused by susceptible bacteria. When culture and susceptibility information are available, they should be considered in selecting or modifying antibacterial therapy. In the absence of such data, local epidemiology and susceptibility patterns may contribute to the empiric selection of therapy	Contra-indication: Hypersensitivity To Cefazolin Or The Cephalosporin Class Of Antibacterial Drugs, Penicillins, Or Other Beta-lactams. Cefazolin for injection is contraindicated in patients who have a history of immediate hypersensitivity reactions (e.g., anaphylaxis, serious skin reactions) to cefazolin or the cephalosporin class of antibacterial drugs, penicillins, or other beta-lactams. Side effect: The following serious adverse reactions to cefazolin are described below and elsewhere in the labeling: Hypersensitivity reactions. Clostridium difficile-associated diarrhea Clinical Trials Experience The following adverse reactions were reported from clinical trials: Gastrointestinal Diarrhea, oral candidiasis (oral thrush), mouth ulcers, vomiting, nausea, stomach cramps, epigastric pain, heartburn, flatus, anorexia and pseudomembranous colitis. Onset of pseudomembranous colitis symptoms may occur during or after antibacterial treatment Allergic Anaphylaxis, eosinophilia, urticaria,	New	USFDA	AbŃgr`b Kiv thŃZ cŃti	AbŃgr`b Kiv nj

						<p>itching, drug fever, skin rash, Stevens-Johnson syndrome.</p> <p>Hematologic Neutropenia, leukopenia, thrombocytopenia, thrombocythemia.</p> <p>Hepatic Transient rise in SGOT, SGPT, and alkaline phosphatase levels has been observed. As with other cephalosporins, reports of hepatitis have been received.</p> <p>Renal As with other cephalosporins, reports of increased BUN and creatinine levels, as well as renal failure, have been received.</p> <p>Local Reactions Instances of phlebitis have been reported at site of injection. Some induration has occurred.</p> <p>Other Reactions Pruritus (including genital, vulvar and anal pruritus, genital moniliasis, and vaginitis). Dizziness, fainting, lightheadedness, confusion, weakness, tiredness, hypotension, somnolence and headache.</p> <p><u>Cephalosporin-class Adverse Reactions</u> In addition to the adverse reactions listed above that have been observed in patients treated with cefazolin, the following adverse reactions and altered laboratory tests have been reported for cephalosporin-class antibacterials: Stevens-Johnson syndrome, erythema multiforme.</p>				
--	--	--	--	--	--	--	--	--	--	--

<i>bs</i>	<i>cŃZKviŃK big</i>	<i>JlŃai big</i>	<i>ŃRŃbniŃK big</i>	<i>Ń_ iwcDitŃK Km</i>	<i>ibŃ Rbv</i>	Contra-indication & Side-effect	Status (New Molecule/ Existing)	<i>AŃe`bKvir KZŃ USFDA/BNF /MHRA Ref.</i>	<i>ŃUKibK`ij me KigiŃi mfvi imxvŃŃ</i>	<i>mfvi imxvŃŃ</i>
32.	Incepta Pharmaceuticals Ltd.; Zirabo, Savar, Dhaka	Cefazolin Sodium 500mg/Vial injection	Cefazolin Sodium USP 525.00mg eq. to Cefazolin 500mg /Vial	Antibiotic	To reduce the development of drug-resistant bacteria and maintain the effectiveness of Cefazolin for Injection, USP and other antibacterial drugs, Cefazolin for Injection, USP should be used only to treat or prevent infections that are proven or strongly suspected to be caused by susceptible bacteria. When culture and susceptibility information are available, they should be considered in selecting or modifying antibacterial therapy. In the absence of such data, local epidemiology and susceptibility patterns may contribute to the empiric selection of therapy	Contra-indication: Hypersensitivity To Cefazolin Or The Cephalosporin Class Of Antibacterial Drugs, Penicillins, Or Other Beta-lactams. Cefazolin for injection is contraindicated in patients who have a history of immediate hypersensitivity reactions (e.g., anaphylaxis, serious skin reactions) to cefazolin or the cephalosporin class of antibacterial drugs, penicillins, or other beta-lactams. Side effect: The following serious adverse reactions to cefazolin are described below and elsewhere in the labeling: Hypersensitivity reactions. Clostridium difficile-associated diarrhea Clinical Trials Experience The following adverse reactions were reported from clinical trials: Gastrointestinal Diarrhea, oral candidiasis (oral thrush), mouth ulcers, vomiting, nausea, stomach cramps, epigastric pain, heartburn, flatus, anorexia and pseudomembranous colitis. Onset of pseudomembranous colitis symptoms may occur during or after antibacterial treatment Allergic Anaphylaxis, eosinophilia, urticaria, itching, drug fever, skin rash, Stevens-Johnson syndrome. Hematologic Neutropenia, leukopenia, thrombocytopenia, thrombocytopenia, thrombocytopenia, thrombocytopenia. Hepatic Transient rise in SGOT, SGPT, and	New	USFDA	<i>AbŃgr`b Kiv thŃZ cŃi </i>	<i>AbŃgr`b Kiv nj </i>

						<p>alkaline phosphatase levels has been observed. As with other cephalosporins, reports of hepatitis have been received.</p> <p>Renal As with other cephalosporins, reports of increased BUN and creatinine levels, as well as renal failure, have been received.</p> <p>Local Reactions Instances of phlebitis have been reported at site of injection. Some induration has occurred.</p> <p>Other Reactions Pruritus (including genital, vulvar and anal pruritus, genital moniliasis, and vaginitis). Dizziness, fainting, lightheadedness, confusion, weakness, tiredness, hypotension, somnolence and headache.</p> <p><u>Cephalosporin-class Adverse Reactions</u> In addition to the adverse reactions listed above that have been observed in patients treated with cefazolin, the following adverse reactions and altered laboratory tests have been reported for cephalosporin-class antibacterials: Stevens-Johnson syndrome, erythema multiforme.</p>				
--	--	--	--	--	--	--	--	--	--	--

<i>bs</i>	<i>cŃZKviŃK big</i>	<i>JlŃai big</i>	<i>ŃRŃbniŃK big</i>	<i>Ń_ iwcDitŃK Km</i>	<i>ibŃ Rbv</i>	Contra-indication & Side-effect	Status (New Molecule/ Existing)	<i>AvŃe bKvix KZŃ USFDA/BNF / MHRA Ref.</i>	<i>ŃUKibK'ij me KugŃli mfvi imxvŃŃ</i>	<i>mfvi imxvŃŃ</i>
33.	Popular Pharmaceuticals Limited	Cefixime 100mg + Clavulanic Acid 62.5mg Tablet	Cefixime BP 100mg + Diluted Clavulanate Potassium BP 148.920mg eq. to Clavulanic Acid 62.5mg	Antibiotic	It is used only to treat or prevent infections that are proven or strongly suspected to be caused by susceptible bacteria. Cefixime-Clavulanic Acid is indicated for the treatment of – 1) Uncomplicated Urinary Tract Infections. 2) Otitis Media. 3) Pharyngitis and Tonsillitis. 4) Acute Bronchitis and Acute Exacerbations of Chronic Bronchitis. 5) Uncomplicated gonorrhea etc.	Contraindications: Cefixime is contraindicated in patients with known allergy to the Cephalosporin class of antibiotics. Clavulanic Acid does not inactivate all β -Lactamases. Most chromosomally mediated β -Lactamases, the enzyme produced by pseudomonas aeruginosa, are resistant to its action. Other organism have different mechanisms of acquired resistance to β -Lactam antibiotics, against which clavulanic acid is ineffective. Side effects: Cefixime-Clavulanic Acid are diarrhea and stool changes. Events like nausea/vomiting, transient elevation in liver transaminases, alkaline phosphatase and jaundice can also occur. Thrombocytosis, thrombocytopenia, leucopenis, hypereosinophilia, neutropenia and agranulocytosis may also occur. Other adverse events that may occur are abdominal pain, abdominal cramps, flatulence, indigestion, headache, vaginitis, vulvar itch, rash, hives, itch, dysuria, chills, chest pain, shortness of breath, mouth ulcers, swollen tongue, sleepiness, thirst, anorexia.			<i>cŃqivRb ŃbB weariq AvŃe b bigÄy Kiv thŃZ citi </i>	<i>cŃqivRb ŃbB weariq AvŃe b bigÄy Kiv nj </i>

bs	cŃZKviŃK big	JlŃai big	ŃRŃbniK big	Ń_ iwcDitUK Kvm	ibŃ Rbv	Contra-indication & Side-effect	Status (New Molecule/ Existing)	AŃe`bKvir KZŃ USFDA/BNF / MHRA Ref.	ŃUKibK`ij me KugŃli mfvi m×vŃŃ	mfvi m×vŃŃ
34.	Popular Pharmaceutic als Limited	Cefixime 200mg + Clavulanic Acid 125mg Tablet	Cefixime BP 200mg + Diluted Clavulanate Potassium BP 297.840mg eq. to Clavulanic Acid 125mg	Antibiotic	It is used only to treat or prevent infections that are proven or strongly suspected to be caused by susceptible bacteria. Cefixime-Clavulanic Acid is indicated for the treatment of – 1) Uncomplicated Urinary Tract Infections. 2) Otitis Media. 3) Pharyngitis and Tonsillitis. 4) Acute Bronchitis and Acute Exacerbations of Chronic Bronchitis. 5) Uncomplicated gonorrhoea etc.	Contraindications: Cefixime is contraindicated in patients with known allergy to the Cephalosporin class of antibiotics. Clavulanic Acid does not inactivate all β -Lactamases. Most chromosomally mediated β -Lactamases, the enzyme produced by pseudomonas aeruginosa, are resistant to its action. Other organism have different mechanisms of acquired resistance to β - Lactam antibiotics, against which clavulanic acid is ineffective. Side effects: Cefixime-Clavulanic Acid are diarrhea and stool changes. Events like nausea/vomiting, transient elevation in liver transaminases, alkaline phosphatase and jaundice can also occur. Thrombocytosis, thrombocytopenia, leucopenis, hypereosinophilia, neutropenia and agranulocytosis may also occur. Other adverse events that may occur are abdominal pain, abdominal cramps, flatulence, indigestion, headache, vaginitis, vulvar itch, rash, hives, itch, dysuria, chills, chest pain, shortness of breath, mouth ulcers, swollen tongue, sleepiness, thirst, anorexia.			cŃqirB ŃbB wearq AŃe`b bigÄy Kiv ŃŃZ cŃti	cŃqirB ŃbB wearq AŃe`b bigÄy Kiv nj
35.	Popular Pharmaceutic als Limited	Cefixime 50mg + Clavulanic Acid 31.25mg Tablet	Cefixime BP 50mg + Diluted Clavulanate Potassium BP 74.460mg eq. to Clavulanic Acid 62.5mg	Antibiotic	It is used only to treat or prevent infections that are proven or strongly suspected to be caused by susceptible bacteria. Cefixime-Clavulanic Acid is indicated for the treatment of – 1) Uncomplicated Urinary Tract Infections. 2) Otitis Media. 3) Pharyngitis and Tonsillitis. 4) Acute Bronchitis and Acute Exacerbations of	Contraindications: Cefixime is contraindicated in patients with known allergy to the Cephalosporin class of antibiotics. Clavulanic Acid does not inactivate all β -Lactamases. Most chromosomally mediated β -Lactamases, the enzyme produced by pseudomonas aeruginosa, are resistant to its action. Other organism have different			cŃqirB ŃbB wearq AŃe`b bigÄy Kiv ŃŃZ cŃti	cŃqirB ŃbB wearq AŃe`b bigÄy Kiv nj

					Chronic Bronchitis. 5) Uncomplicated gonorrhoea etc.	mechanisms of acquired resistance to β -Lactam antibiotics, against which clavulanic acid is ineffective. Side effects: Cefixime-Clavulanic Acid are diarrhea and stool changes. Events like nausea/vomiting, transient elevation in liver transaminases, alkaline phosphatase and jaundice can also occur. Thrombocytosis, thrombocytopenia, leucopenis, hypereosinophilia, neutropenia and agranulocytosis may also occur. Other adverse events that may occur are abdominal pain, abdominal cramps, flatulence, indigestion, headache, vaginitis, vulvar itch, rash, hives, itch, dysuria, chills, chest pain, shortness of breath, mouth ulcers, swollen tongue, sleepiness, thirst, anorexia.				
36.	Sanofi Bangladesh Limited	Cefixime 100mg Chewable Tablet	Cefixime Trihydrate BP 100mg	Antibiotic	Cefixime is a cephalosporin antibacterial drug indicated in the treatment of adults and pediatric patients six months of age or older with the following infections when caused by susceptible isolates of the designated bacteria: <ul style="list-style-type: none"> • Uncomplicated Urinary Tract Infection. • Otitis Media • Pharyngitis & tonsillitis. • Acute exacerbations of Chronic Bronchitis. • Uncomplicated Gonorrhoea (Cervical/urethral) 	Contraindications: Cefixime is contraindicated in patients with known allergy to cefixime or other cephalosporins. Side-effects: Diarrhoea, Fever, sore throat, joint pain, numbness, warmth, redness, swelling, pounding heartbeat, chest pain, increased night time urination, runny nose, headache, anxiety.	New	USFDA	চল্লিৱব ত্বব ঱েৱৱ ঐৱে`ব ব্রিঐৱ কিৱ থিZ সিৱি	চল্লিৱব ত্বব ঐৱৱ ঐৱে`ব ব্রিঐৱ কিৱ নজ

bs	cŃZKviŃK big	JlŃai big	ŃRŃbniK big	Ń_ iwcDitUK Kvm	ibŃ Rbv	Contra-indication & Side-effect	Status (New Molecule/ Existing)	AŃe`bKvir KZŃ USFDA/BNF /MHRA Ref.	ŃUKibK`ij me KigŃli mfvi imxvŃŃ	mfvi imxvŃŃ
37.	Square Pharmaceutic als Ltd., Dhaka Unit, Kaliakoir, Gazipur	Cefoperazone 1000mg/Vial Injection	Cefoperazone Sodium Sterile USP 1034.08mg eq. to 1000mg Cefoperazone	Antibiotic	Cefoperazone is indicated for the treatment of the following infections when caused by susceptible organisms: Respiratory Tract Infections caused by S. pneumoniae, H. influenzae, S. aureus (penicillinase and non-penicillinase producing strains), S. pyogenes* (Group A beta-hemolytic streptococci), P. aeruginosa, Klebsiella pneumoniae, E. coli, Proteus mirabilis, and Enterobacter species. Peritonitis and Other Intra-abdominal Infections caused by E. coli, P. aeruginosa,* and anaerobic gram-negative bacilli (including Bacteroides fragilis). Bacterial Septicemia caused by S. pneumoniae, S. agalactiae,* S. aureus, Pseudomonas aeruginosa,* E. coli, Klebsiella spp.,* Klebsiella pneumoniae,* Proteus species* (indole-positive and indole-negative), Clostridium spp.* and anaerobic gram-positive cocci.* Infections of the Skin and Skin Structures caused by S. aureus (penicillinase and non-penicillinase producing strains), S. pyogenes,* and P. aeruginosa. Pelvic Inflammatory Disease, Endometritis, and Other Infections of the Female Genital Tract caused by N. gonorrhoeae, S. epidermidis,* S. agalactiae, E. coli, Clostridium spp.,* Bacteroides species (including Bacteroides fragilis), and anaerobic gram-positive cocci. it has no activity	Contraindications: Cefoperazone is contraindicated in patients with known allergy to the cephalosporin-class of antibacterial drugs. Side effects: hypersensitivity reactions serious and occasionally fatal hypersensitivity (anaphylactic) reactions have been reported in patients receiving beta-lactam antibacterials, including cefoperazone. These reactions are more apt to occur in individuals with a history of hypersensitivity reactions to multiple allergens. Before therapy with cefobid is instituted, careful inquiry should be made to determine whether the patient has had previous hypersensitivity reactions to cephalosporins, penicillins, carbapenems or other drugs. This product should be given cautiously to beta-lactam allergic patients. If an allergic reaction occurs, cefoperazone should be discontinued and appropriate therapy instituted.	New	USFDA	AbŃgr`b Kiv thŃZ cŃi	AbŃgr`b Kiv nj

					<p>against Chlamydia trachomatis. Therefore, when Cefoperazone is used in the treatment of patients with pelvic inflammatory disease and C. trachomatis is one of the suspected pathogens, appropriate anti-chlamydial coverage should be added.</p> <p>Urinary Tract Infections caused by Escherichia coli and Pseudomonas aeruginosa.</p> <p>Enterococcal Infections: Although cefoperazone has been shown to be clinically effective in the treatment of infections caused by enterococci in cases of peritonitis and other intra-abdominal infections, infections of the skin and skin structures, pelvic inflammatory disease, endometritis and other infections of the female genital tract, and urinary tract infections,* the majority of clinical isolates of enterococci tested are not susceptible to cefoperazone but fall just at or in the intermediate zone of susceptibility, and are moderately resistant to cefoperazone. However, in vitro susceptibility testing may not correlate directly with in vivo results. Despite this, cefoperazone therapy has resulted in clinical cures of enterococcal infections, chiefly in polymicrobial infections. Cefoperazone should be used in enterococcal infections with care and at doses that achieve satisfactory serum levels of cefoperazone.</p>					
38.	Square Pharmaceutical Ltd., Dhaka Unit, Kaliakoir, Gazipur	Cefoperazone 500mg/Vial Injection	Cefoperazone Sodium Sterile USP 517.04mg eqv. to 500mg Cefoperazone/Vial Injection	Antibiotic	-Do-	-Do-	-Do-		Abşgr`b Kiv thZ cıti	Abşgr`b Kiv nj

bs	c0ZKviTK big	Jl tai big	tRtbiK big	t_i wC DiUK Km	ibf` Rbv	Contra-indication & Side-effect	Status (New Molecule/ Existing)	Ate` bKviX KZP USFDA/BNF /MHRA Ref.	tUKibK`vj me Kugidi mfvi mxiSf	mfvi mxiS
39.	a) Aristopharma Ltd. b) Navana Healthcare Ltd.	Moxifloxacin 0.50g + Dexamethasone Phosphate 0.10gm/100ml Sterile Ophthalmic Solution	Moxifloxacin Hydrochloride BP 0.5454gm eq. Moxifloxacin 0.50gm + Dexamethasone Sodium Phosphate USP 0.1093gm eq. Dexamethasone Phosphate 0.10gm/100ml	Antibiotic + Steroid	It is indicated for steroid-responsive inflammatory ocular conditions for which a corticosteroid is indicated and where bacterial infection or a risk of bacterial ocular infection exists. The combination can also be used for post-operative inflammation and any other ocular inflammation associated with infection.	Contra-indication: It is contraindicated in epithelial herpes simplex keratitis (Dendritic Keratitis), Vaccinia, Varicella, and in many other viral diseases of the conjunctiva and cornea, Mycobacterial infection of the eye and fungal diseases of ocular structures and in individuals hypersensitive to any of the components of the medication. Side-effect: The most frequently reported drug-related undesirable effects seen with moxifloxacin are conjunctival irritation, increased lacrimation, Keratitis and papillary conjunctivitis.	Moxifloxacin 0.5% Eye Drops & Ointment, Dexamethasone 0.1% Eye Drops & Ear Drops,		Ac_vj tgrtj mRo Gi gZigZ tbi qv thtZ cti	Aa'vcK Wrt`xb igrt byj nk, I Aa'vcK Wrt igrt krid'xb Avntg` JIa'ul gf`iqbceK i`tk c'q'RbiqZv itq'Q weavq ti'Rt`-kb c'lvb Kivi mzwik Ktib/ D ³ mzwiki m'fE'tZ c`u' Abtgv`b Kiv nj
40.	Beacon Pharmaceutical Ltd.	Bortezomib 2.00mg lyophilized powder for injection	Bortezomib INN 2.00mg/Vial	Anticancer	It is a proteasome inhibitor indicated for: Treatment of patients with multiple myeloma Treatment of patients with mantle cell lymphoma	Contra-indication: Patients with hypersensitivity (not including local reactions) to bortezomib, boron, or mannitol, including anaphylactic reactions. Contraindicated for intrathecal administration Side effect: Most commonly reported adverse reactions (incidence = 20%) in clinical studies include nausea, diarrhea, thrombocytopenia, neutropenia, peripheral neuropathy, fatigue, neuralgia, anemia, leukopenia, constipation, vomiting, lymphopenia, rash, pyrexia, and anorexia.	3.5 mg/Vial Injection		Abtgv`b Kiv thtZ cti	Abtgv`b Kiv nj
41.	Beacon Pharmaceutical Ltd.	Mitotane 500mg Tablet	Mitotane USP 500mg	Anticancer	It is an adrenal cytotoxic agent indicated for the treatment of inoperable, functional or nonfunctional, adrenal cortical carcinoma.	Contraindication: None Side effect: 15% include: anorexia, nausea, vomiting and ≥ Common adverse reactions (diarrhea; depression, dizziness or vertigo; and rash	New	USFDA	Abtgv`b Kiv thtZ cti	Abtgv`b Kiv nj

<i>bs</i>	<i>cŃZKviŃK big</i>	<i>JlŃai big</i>	<i>ŃRŃbniŃK big</i>	<i>Ń_ iwcDitŃK Km</i>	<i>ibŃ Rbv</i>	Contra-indication & Side-effect	Status (New Molecule/ Existing)	<i>AŃe bKvir KZŃ USFDA/BNF /MHRA Ref.</i>	<i>ŃUKibK'ij me KugŃli mfvi imxvŃŃ</i>	<i>mfvi imxvŃŃ</i>
42.	Beacon Pharmaceutical Ltd.	Oxaliplatin 200mg/40ml vial injection (Lyophilized)	Oxaliplatin 200mg/40ml BP	Anticancer	Oxaliplatin injection is a platinum-based drug used in combination with infusional 5-fluorouracil/leucovorin, which is indicated for: <input type="checkbox"/> adjuvant treatment of Stage III colon cancer in patients who have undergone complete resection of the primary tumor. <input type="checkbox"/> treatment of advanced colorectal cancer	Contraindication: Known allergy to oxaliplatin or other platinum compounds Side effect: Most common adverse reactions (incidence = 40%) were peripheral sensory neuropathy, neutropenia, thrombocytopenia, anemia, nausea, increase in transaminases and alkaline phosphatase, diarrhea, emesis, fatigue and stomatitis. Other adverse reactions, including serious adverse reactions, have been reported	50mg/10ml & 100mg/20ml	USFDA	<i>AbŃgr b Kiv thŃZ cŃi </i>	<i>AbŃgr b Kiv nj </i>
43.	Beacon Pharmaceutical Ltd.	Temozolomide 25mg Capsule	Temozolomide 25mg USP	Anticancer	It is an alkylating drug indicated for the treatment of adult patients with: <ul style="list-style-type: none"> Newly diagnosed glioblastoma multiforme (GBM) concomitantly with radiotherapy and then as maintenance treatment. Refractory anaplastic astrocytoma patients who have experienced disease progression on a drug regimen containing nitrosourea and procarbazine. 	Contraindication: Known hypersensitivity to any temozolomide component or to dacarbazine (DTIC) Side effect: The most common adverse reactions ($\geq 10\%$ incidence) are: alopecia, fatigue, nausea, vomiting, headache, constipation, anorexia, convulsions, rash, hemiparesis, diarrhea, asthenia, fever, dizziness, coordination abnormal, viral infection, amnesia, and insomnia. <ul style="list-style-type: none"> The most common Grade 3 to 4 hematologic laboratory abnormalities ($\geq 10\%$ incidence) that have developed during treatment with temozolomide are: lymphopenia, thrombocytopenia, neutropenia, and leukopenia. Allergic reactions have also been reported. 	5mg, 100mg, 250mg Capsule		<i>AbŃgr b Kiv thŃZ cŃi </i>	<i>AbŃgr b Kiv nj </i>

bs	cŃZKviŃK bug	JlŃai bug	ŃRŃbniŃK bug	Ń_ iwcDitŃK Kym	ibŃ Rbv	Contra-indication & Side-effect	Status (New Molecule/ Existing)	AŃe`bKvir KZŃ USFDA/BNF /MHRA Ref.	ŃUKibK`ij me KugŃli mfvi m×vŃŃ	mfvi m×vŃŃ
44.	Drug International Ltd. (UNIT- 2) Plot#13A & 14A, Tongi Industrial Area, Tongi, Gazipur	Brigatinib 90mg Tablet	Brigatinib INN 90mg	Anticancer	It is indicated for the treatment of patients with anaplastic lymphoma kinase (ALK)-positive metastatic non-small cell lung cancer (NSCLC) who has progressed on or are intolerant to crizotinib.	Contra-indication: It is contraindicated in patients with known hypersensitivity to Brigatinib or any other components of this product. Side-effect: The most common serious adverse reactions were <u>pneumonia</u> (5.5% overall, 3.7% in the 90 mg group, and 7.3% in the 90→180 mg group) and ILD/pneumonitis (4.6% overall, 1.8% in the 90 mg group and 7.3% in the 90→180 mg group). Fatal adverse reactions occurred in 3.7% of patients and consisted of pneumonia (2 patients), sudden death, dyspnea, respiratory failure, pulmonary embolism, bacterial meningitis and urosepsis (1 patient each).	New	USFDA	AbŃgr`b Kiv thŃZ ciŃi	AbŃgr`b Kiv nj
45.	Incepta Pharmaceutic als Ltd.; Zirabo, Savar, Dhaka	Evolocumab 140mg/ml Pre- filled syringe Injection	Evolocumab INN 140mg/ml	Anticancer	<u>Primary Hyperlipidemia</u> Evolocumab is indicated as an adjunct to diet and maximally tolerated statin therapy for the treatment of adults with heterozygous familial hypercholesterolemia (HeFH) or clinical atherosclerotic cardiovascular disease (CVD), who require additional lowering of low density lipoprotein cholesterol (LDLC). Homozygous Familial Hypercholesterolemia Evolocumab is indicated as an adjunct to diet and other LDL-lowering therapies (e.g., statins, ezetimibe, LDL apheresis) for the treatment of patients with homozygous familial hypercholesterolemia (HoFH) who	Contraindications: Evolocumab is contraindicated in patients with a history of a serious hypersensitivity reaction to Evolocumab. Side Effects: Evolocumab can cause side effects including: □ allergic reactions. Evolocumab may cause allergic reactions. Call your healthcare provider or go to the nearest hospital emergency room right away if you have any symptoms of an allergic reaction including a severe rash, redness, severe itching, a swollen face, or trouble breathing. The most common side effects of Evolocumab include: runny nose, sore throat, symptoms of the common cold, flu or flu-like symptoms, back pain, and	New	USFDA	AbŃgr`b Kiv thŃZ ciŃi	AbŃgr`b Kiv nj

					require additional lowering of LDL-C.	redness, pain, or bruising at the injection site. Tell your healthcare provider if you have any side effect that bothers you or that does not go away. These are not all the possible side effects of Evolocumab. Ask your healthcare provider or pharmacist for more information. Call your healthcare provider for medical advice about side effects.				
46.	Incepta Pharmaceuticals Ltd.; Zirabo, Savar, Dhaka	Rucaparib 300mg Tablet	Rucaparib Camsylate INN 516 mg eq. to 300 mg Rucaparib	Anticancer	Rucaparib is a poly (ADP-ribose) polymerase (PARP) inhibitor indicated as monotherapy for the treatment of patients with deleterious BRCA mutation (germline and/or <u>somatic</u>) associated advanced <u>ovarian cancer</u> who have been treated with two or more chemotherapies.	Contraindications: None. Side Effects: The most common side effects include: <ul style="list-style-type: none"> • Nausea • Fatigue • Vomiting • stomach-area pain • changes in how food tastes • constipation • decreased appetite • diarrhea • shortness of breath • decrease in hemoglobin (anemia) • low blood cell counts • changes in liver or kidney function blood tests • increased cholesterol levels 	New	USFDA	Abjgr` b Kiv thZ citi	Abjgr` b Kiv nj

bs	c0ZKvi#K big	Jl#ai big	#R#biiK big	#_i wicDi#K Km	ib#`Rbv	Contra-indication & Side-effect	Status (New Molecule/ Existing)	A#e`bKvix KZ# USFDA/BNF /MHRA Ref.	#UK#bK`vj me Kug#Di mfvi w#v#S#	mfvi w#v#S#
47.	Incepta Pharmaceuticals Ltd.; Zirabo, Savar, Dhaka	Sunitinib Malate 37.5mg Capsule	Sunitinib Malate INN 50.10mg eq. to Sunitinib 37.5 mg	Anticancer	<p>Sunitinib is indicated for:</p> <ul style="list-style-type: none"> The treatment of gastrointestinal stromal tumour (GIST) after failure of imatinib mesylate treatment due to resistance or intolerance. Approval of Sunitinib malate is based on Time to Tumour Progression (TTP). Overall survival advantage could not be confirmed. The treatment of metastatic renal cell carcinoma (MRCC) of clear cell histology. Approval for MRCC is based on statistically significant progression free survival in patients with good performance status. There was a trend for overall survival advantage. The treatment of patients with unresectable locally advanced or metastatic, well-differentiated pancreatic neuroendocrine tumours (pancreatic NET), whose disease is progressive. Approval for pancreatic NET is based on progression free survival in patients with good performance status. 	<p>Contraindications:</p> <ul style="list-style-type: none"> Sunitinib is contraindicated in patients with hypersensitivity to sunitinib maleate or to any other component of sunitinib. Sunitinib is contraindicated in pregnant women. <p>Side Effects: Common sunitinib side effects:</p> <ul style="list-style-type: none"> Skin or hair changes Tiredness or weakness Fever Diarrhea Nausea/vomiting Mouth pain Upset stomach Body pain Constipation Altered taste Loss of appetite Pain/swelling in the arms/legs Cough Shortness of breath Bleeding <p>Serious sunitinib side effects:</p> <ul style="list-style-type: none"> Liver problems that can lead to death Heart problems that can lead to death Increased blood pressure Bleeding that can lead to death Jaw-bone problems (osteonecrosis) Tumor lysis syndrome (TLS) Damage to the smallest blood vessels Protein in urine Serious skin and mouth reactions Hormone problems, including thyroid and adrenal gland problems Low blood sugar (hypoglycemia) 	12.50mg, 25mg & 50mg Capsule	USFDA	Ab#gv`b Kiv th#Z c#i	Ab#gv`b Kiv nj

bs	cŃZKviŃK big	JlŃai big	ŃRŃbniŃK big	Ń_ iwcDŃUK Km	ibŃ Rbv	Contra-indication & Side-effect	Status (New Molecule/ Existing)	AŃe bKvix KZŃ USFDA/BNF / MHRA Ref.	ŃUKŃbK'ij me KŃgŃli mfvi ŃmŃvŃŃ	mfvi ŃmŃvŃŃ
48.	Incepta Pharmaceuticals Ltd.; Zirabo, Savar, Dhaka	Ramucirumab 500mg/50 ml Injection	Ramucirumab INN 500mg/50ml	Anti-cancer	<p><u>Gastric Cancer</u> Ramucirumab ® as a single agent, or in combination with paclitaxel, is indicated for the treatment of patients with advanced or metastatic, gastric or gastro-esophageal junction adenocarcinoma with disease progression on or after prior fluoropyrimidine- or platinum-containing chemotherapy.</p> <p><u>Non-Small Cell Lung Cancer</u> Ramucirumab, in combination with docetaxel, is indicated for the treatment of patients with metastatic non-small cell lung cancer (NSCLC) with disease progression on or after platinum-based chemotherapy. Patients with EGFR or ALK genomic tumor aberrations should have disease progression on FDA-approved therapy for these aberrations prior to receiving Ramucirumab.</p> <p><u>Colorectal Cancer</u> Ramucirumab, in combination with FOLFIRI (irinotecan, folinic acid, and 5-fluorouracil), is indicated for the treatment of patients with metastatic colorectal cancer (mCRC) with disease progression on or after prior therapy with bevacizumab, oxaliplatin, and a fluoropyrimidine.</p>	<p>Contraindications:</p> <ul style="list-style-type: none"> Sunitinib is contraindicated in patients with hypersensitivity to sunitinib maleate or to any other component of sunitinib. Sunitinib is contraindicated in pregnant women. <p>Side-effects: Common sunitinib side effects:</p> <ul style="list-style-type: none"> <u>Skin or hair changes</u> <u>Tiredness or weakness</u> <u>Fever</u> <u>Diarrhea</u> <u>Nausea/vomiting</u> <u>Mouth pain</u> <u>Upset stomach</u> <u>Body pain</u> <u>Constipation</u> <u>Altered taste</u> <u>Loss of appetite</u> <u>Pain/swelling in the arms/legs</u> <u>Cough</u> <u>Shortness of breath</u> <u>Bleeding</u> <p>Serious sunitinib side effects:</p> <ul style="list-style-type: none"> <u>Liver problems that can lead to death</u> <u>Heart problems that can lead to death</u> <u>Increased blood pressure</u> <u>Bleeding that can lead to death</u> <u>Jaw-bone problems (osteonecrosis)</u> <u>Tumor lysis syndrome (TLS)</u> <u>Damage to the smallest blood vessels</u> Protein in urine <u>Serious skin and mouth reactions</u> <u>Hormone problems, including thyroid and adrenal gland problems</u> <u>Low blood sugar (hypoglycemia)</u> 	100mg/10ml	USFDA	AbŃgr b Kiv thŃZ cŃi	AbŃgr b Kiv nj

bs	c0ZKvi#K big	Jl#ai big	#R#biiK big	#_i wC D#UK Km	ib#`Rbv	Contra-indication & Side-effect	Status (New Molecule/ Existing)	A#e`bKvix KZ# USFDA/BNF /MHRA Ref.	#UK#bK`vj me Kug#Di mfvi m#v#S#	mfvi m#v#S#
49.	Healthcare Pharmaceutical Ltd., Rajendrapur, Gazipur	Ursodeoxycholic acid 500mg Film-coated Tablets	Ursodeoxycholic acid BP 500mg	Anticholelit hic	It is indicated for the treatment of patients with primary biliary cirrhosis.	Contra-Indication: Hypersensitivity or intolerance to ursodiol or any of the components of the formulation. Side effects: In clinical trials, reports of pasty stools or diarrhoea during ursodeoxycholic acid therapy were common.	150mg & 300mg Capsule 250mg Tablet 250 mg/5 ml Suspension	USFDA	c#q#Rb #bB weavq Av#e`b bigAy Kiv th#Z c#ti	c#q#Rb #bB weavq Av#e`b bigAy Kiv nj
50.	Beacon Pharmaceutical Ltd.	Betrixaban 80mg Capsule	Betrixaban Maleate INN 100.544mg eqv. to Betrixaban 80mg	Anticlotting	It is a factor Xa (FXa) inhibitor indicated for the prophylaxis of venous thromboembolism (VTE) in adult patients hospitalized for an acute medical illness who are at risk for thromboembolic complications due to moderate or severe restricted mobility and other risk factors for VTE.	Contraindication: Active pathological bleeding. Severe hypersensitivity reaction to betrixaban Side effect: Most common adverse reaction (incidence >5%) is bleeding	New	USFDA	Ab#gr`b Kiv th#Z c#ti	Ab#gr`b Kiv nj
51.	Beacon Pharmaceutical Ltd.	Betrixaban 40mg Capsule	Betrixaban Maleate INN 50.272mg eq. to Betrixaban 40mg	Anticlotting	It is a factor Xa (FXa) inhibitor indicated for the prophylaxis of venous thromboembolism (VTE) in adult patients hospitalized for an acute medical illness who are at risk for thromboembolic complications due to moderate or severe restricted mobility and other risk factors for VTE.	Contraindication: Active pathological bleeding. Severe hypersensitivity reaction to betrixaban Side effect: Most common adverse reaction (incidence >5%) is bleeding	New	USFDA	Ab#gr`b Kiv th#Z c#ti	Ab#gr`b Kiv nj
52.	ACI Ltd.	Escitalopram 20.00 mg Film Coated Tablet	Escitalopram Oxalate USP 25.552 mg eq. 20.0mg Escitalopram	Antidepress ant	It is a selective serotonin reuptake inhibitor (SSRI) indicated for: Acute and Maintenance Treatment of Major Depressive Disorder (MDD) in adults and adolescents aged 12-17 years Acute Treatment of Generalized Anxiety Disorder (GAD) in adults.	Contraindications: Serotonin Syndrome and MAOIs: Do not use MAOIs intended to treat psychiatric disv effc v orders with this or within 14 days of stopping treatment with this drug. Do not use within 14 days of stopping an MAOI intended to treat psychiatric disorders. In addition, do not start in a patient who is being treated with linezolid or intravenous methylene blue Pimozide, Do not use concomitantly. Known hypersensitivity to escitalopram or citalopram or any of the	5mg & 10mg	USFDA	Ab#gr`b Kiv th#Z c#ti	Ab#gr`b Kiv nj

						inactive ingredients. Side effects: Most commonly observed adverse reactions (incidence = 5% and at least twice the incidence of placebo patients) are: insomnia, ejaculation disorder (primarily ejaculatory delay), nausea, sweating increased, fatigue and somnolence, decreased libido, and anorgasmia.				
53.	a) Concord Pharmaceuticals Ltd. b) Drug International Ltd. C) M/s. Julphar Bangladesh Ltd.	Dapagliflozin 10mg + Saxagliptin 5 mg Tablet	Dapagliflozin INN 10 mg + Saxagliptin INN 5 mg	Antidiabetic	Dapagliflozin & Saxagliptin is a sodium-glucose co-transporter 2 (SGLT-2) inhibitor and a dipeptidyl peptidase-4 (DPP-4) inhibitor combination product indicated as an adjunct to diet and exercise to improve glycemic control	Contraindication: History of a serious hypersensitivity reaction to dapagliflozin or to saxagliptin, including anaphylaxis, angioedema or exfoliative skin conditions. *Moderate to severe renal impairment (eGFR less than 45 mL/min/1.73 m ²), end-stage renal disease (ESRD), or patients on dialysis. Adverse Reactions: Adverse reactions reported in ≥5% of subjects treated with 10 mg Dapagliflozin and 5 mg Saxagliptin were: upper respiratory tract infection, urinary tract infection, and dyslipidemia.	Dapagliflozin 10mg Tablet	USFDA	চীকিRb ঠbB ঞearq Avte`b bigÁy Kiv thtZ cıti	চীকিRb ঠbB ঞearq Avte`b bigÁy Kiv nj
54.	a) Eskayef Pharmaceuticals Limited b) NIPRO JMI Pharma Ltd. C) Unimed & Unihealth Mfg. Ltd.	Empagliflozin 10mg Tablet	Empagliflozin INN 10 mg	Antidiabetic	It is a sodium-glucose co-transporter 2 (SGLT2) inhibitor indicated as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus	Contraindications: <ul style="list-style-type: none"> History of serious hypersensitivity reaction to Empagliflozin Severe renal impairment, end-stage renal disease, or dialysis Side effects: <ul style="list-style-type: none"> Urinary tract infections Female genital mycotic infections 	New	USFDA	Abşgr`b Kiv thtZ cıti	Abşgr`b Kiv nj

<i>bs</i>	<i>cŃZKviŃK big</i>	<i>JlŃai big</i>	<i>ŃRŃbniŃK big</i>	<i>Ń_ iwcDitŃK Km</i>	<i>ibŃ Rbv</i>	Contra-indication & Side-effect	Status (New Molecule/ Existing)	<i>AvŃe`bKvir KZŃ USFDA/BNF /MHRA Ref.</i>	<i>ŃUKibK`ij me KugŃli mŃvi imxvŃŃ</i>	<i>mŃvi imxvŃŃ</i>
55.	a) Eskayef Pharmaceuticals Limited b) NIPRO JMI Pharma Ltd. c) Unimed & Unihealth Mfg. Ltd.	Empagliflozin 25mg Tablet	Empagliflozin INN 25 mg	Antidiabetic	It is a sodium-glucose co-transporter 2 (SGLT2) inhibitor indicated as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus	Contraindications: <ul style="list-style-type: none"> History of serious hypersensitivity reaction to Empagliflozin Severe renal impairment, end-stage renal disease, or dialysis Side effects: <ul style="list-style-type: none"> Urinary tract infections Female genital mycotic infections 	New	USFDA	<i>AbŃgr`b Kiv thŃZ cŃti </i>	<i>AbŃgr`b Kiv nj </i>
56.	a) Eskayef Pharmaceuticals Limited b) NIPRO JMI Pharma Ltd.	Empagliflozin 10mg + Linagliptin 5mg Film Coated Tablet	Empagliflozin INN 10mg + Linagliptin INN 5mg	Antidiabetic	It is a combination of empagliflozin and Linagliptin indicated as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus when treatment with both empagliflozin and linagliptin is appropriate, Limitation of use: It is not recommended for patients with type 1 diabetes or for the treatment of diabetic ketoacidosis.	Contraindications: <ul style="list-style-type: none"> Renal Impairment, ESRD, or on dialysis. History of hypersensitivity reaction to Linagliptin such as anaphylaxis, angioedema, exfoliative skin conditions, urticaria or bronchial hyperreactivity. History of serious hypersensitivity reaction to Empagliflozin. Side effects: <ul style="list-style-type: none"> Most common adverse reactions associated with this combination (5% or greater incidence) were urinary tract infections, nasopharyngitis and upper respiratory tract infections. 	Linagliptin 5 mg Tablet	USFDA	<i>ŃŃqŃRb ŃbB wearq AvŃe`b bigÄy Kiv thŃZ cŃti </i>	<i>ŃŃqŃRb ŃbB wearq AvŃe`b bigÄy Kiv nj </i>
57.	a) Eskayef Pharmaceuticals Limited b) NIPRO JMI Pharma Ltd.	Empagliflozin 25mg + Linagliptin 5mg Film Coated Tablet	Empagliflozin INN 25mg + Linagliptin INN 5mg	Antidiabetic	Do	Do	Linagliptin 5 mg Tablet	USFDA	<i>ŃŃqŃRb ŃbB wearq AvŃe`b bigÄy Kiv thŃZ cŃti </i>	<i>ŃŃqŃRb ŃbB wearq AvŃe`b bigÄy Kiv nj </i>

bs	cŃZKviŃK big	JlŃai big	ŃRŃbniŃK big	Ń_ iwcDitŃK Kvm	ibŃ Rbv	Contra-indication & Side-effect	Status (New Molecule/ Existing)	AŃe`bKvir KZŃ USFDA/BNF /MHRA Ref.	ŃUKibK`ij me KugŃli mfvi mmxvŃŃ	mfvi mmxvŃŃ
58.	ACI Ltd.	Gliclazide 60 mg + Metformin HCl 500 mg Extended Release Tablet	Gliclazide BP 60 mg + Metformin HCl BP 500 mg	Antidiabetic	It is indicated for the non-insulin dependent diabetes mellitus; diabetes with or without obesity in adults	Contraindications: Gliclazide plus Metformin is contraindicated in patients with hypersensitivity to any ingredients of this product. It is also contraindicated in Insulin-dependent diabetes mellitus, renal or hepatic failure, alcoholism, NIDDM complicated by severe ketosis and acidosis, diabetic precoma and coma, patients undergoing surgery, after severe trauma or during infections, chronic obstructive pulmonary disease, coronary heart disease, cardiac failure, peripheral vascular disease, pregnancy, known hypersensitivity to any of the ingredients. Side Effects: The most common side effects are Nausea, diarrhoea, gastric pain, constipation, vomiting, metallic taste in mouth, rash, pruritus, urticaria, erythema, flushing, headache and dizziness.	Gliclazide 60mg Tablet Metformin HCl BP 500 mg Tablet		cŃqirb ŃbB weariq AŃe`b bigÄy Kiv thŃZ citi	cŃqirb ŃbB weariq AŃe`b bigÄy Kiv nj
59.	Eskayef Pharmaceuticals Limited	Empagliflozin 12.5mg + Metformin 500 mg Film Coated Tablet	Empagliflozin INN 12.5mg + Metformin BP 500 mg	Antidiabetic	It is a combination of empagliflozin and metformin HCl indicated as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus who are not adequately controlled on a regimen containing empagliflozin or metformin, or in patients already being treated with both empagliflozin and metformin. Limitation of use: It is not recommended for patients with type 1 diabetes or for the treatment of diabetic ketoacidosis.	Contraindications: • Renal Impairment, ESRD, or on dialysis • Metabolic acidosis, including diabetic ketoacidosis • History of serious hypersensitivity reaction to empagliflozin or metformin Side effects: • Most common adverse reactions associated with empagliflozin (5% or greater incidence) were urinary tract infection and female genital mycotic infections. • Most common adverse reactions associated with metformin (>5%) are diarrhea, nausea/vomiting, flatulence, abdominal discomfort, indigestion, asthenia, and headache.	Metformin 500mg Tablet	USFDA	cŃqirb ŃbB weariq AŃe`b bigÄy Kiv thŃZ citi	cŃqirb ŃbB weariq AŃe`b bigÄy Kiv nj

60.	Eskayef Pharmaceuticals Limited	Empagliflozin 5mg + Metformin 500mg Film Coated Tablet	Empagliflozin INN 5mg + Metformin BP 500 mg	Antidiabetic	It is a combination of empagliflozin and metformin HCl indicated as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus who are not adequately controlled on a regimen containing empagliflozin or metformin, or in patients already being treated with both empagliflozin and metformin. Limitation of use: It is not recommended for patients with type 1 diabetes or for the treatment of diabetic ketoacidosis.	Contraindications: • Renal Impairment, ESRD, or on dialysis • Metabolic acidosis, including diabetic ketoacidosis • History of serious hypersensitivity reaction to empagliflozin or metformin Side effects: • Most common adverse reactions associated with empagliflozin (5% or greater incidence) were urinary tract infection and female genital mycotic infections. • Most common adverse reactions associated with metformin (>5%) are diarrhea, nausea/vomiting, flatulence, abdominal discomfort, indigestion, asthenia, and headache.	Metformin 500mg Tablet	USFDA	ሪቫሪብ ትቤ ወላግ ላቲፕ ትቤ ካብ ትኒረ ርቲ	ሪቫሪብ ትቤ ወላግ ላቲፕ ትቤ ካብ ትኒረ ርቲ
61.	Unimed & Unihealth Mfg. Ltd.	Desmopressin 360mcg/1ml oral solution	Desmopressin Acetate USP 38.016mg eq. to 36mg Desmopressin/100ml	Antidiuretic Hormone	Diabetes insipidus, treatment Primary nocturnal enuresis	Contra-indication: Cardiac insufficiency . conditions treated with diuretics . history of hyponatraemia . polydipsia in alcohol dependence . psychogenic polydipsia . syndrome of inappropriate ADH secretion (in adults) Side effect : Common or very common Hyponatraemia (in more serious cases with convulsions) on administration without restricting fluid intake . nausea ► Frequency not known Allergic reactions . emotional disturbance in children . epistaxis . fluid retention . headache . nasal congestion . stomach pain . vomiting		BNF-73 Page-611, 612	ላቲፕ ትቤ ካብ ትኒረ ርቲ	ላቲፕ ትቤ ካብ ትኒረ ርቲ

<i>bs</i>	<i>c0ZKvi#K big</i>	<i>Jl#ai big</i>	<i>#R#biiK big</i>	<i>#_i wicDi#K Kim</i>	<i>ib#`Rbv</i>	Contra-indication & Side-effect	Status (New Molecule/ Existing)	<i>A#e`bKvix KZ# USFDA/BNF /MHRA Ref.</i>	<i>#UK#bK`vj me Kigi#i mfvi #m#v#S#</i>	<i>mfvi #m#v#S#</i>
62.	Navana Healthcare Ltd.	Hyoscine Hydrobromide 300mcg ChewableTablet	Hyoscine Hydrobromide BP 300 mcg	Antiemetic	For the prevention of motion sickness	Contraindicated in Glaucoma. Some patients may experience cholinergic signs and symptoms such as dry mouth, dizziness, blurred vision, dilatation of the pupils with loss of accommodation, photophobia, closed angle glaucoma (very rare), urinary disturbances (urinary emergency and retention), reduced bronchial secretions, transient bradycardia (followed by tachycardia, palpitation and arrhythmias), flushing and dryness of the skin, constipation, nausea and vomiting. Other signs and symptoms may include hallucination, high temperature (due to decreased sweating) and confusion. These may occur in all patient groups although certain populations (children and the elderly) are more susceptible to anticholinergic toxicity.	150 mcg Tablet	BNF-73 Page-410	<i>c#q#Rb #bB weavq A#e`b big#y Kiv th#Z c#i </i>	<i>c#q#Rb #bB weavq A#e`b big#y Kiv nj </i>
63.	Radiant Pharmaceuticals limited	Netupitant 300mg + Palonosetron 0.5mg Capsule	Netupitant INN 300mg + Palonosetron USP 0.5mg	Antiemetic	It is a fixed combination of netupitant, a substance P/neurokinin 1 (NK 1) receptor antagonist, and palonosetron, a serotonin -3 (5-HT3) receptor antagonist indicated for the prevention of acute and delayed nausea and vomiting associated with initial and repeat courses of cancer chemotherapy, including, but not limited to, highly emetogenic chemotherapy. Oral palonosetron prevents nausea and vomiting during the acute phase and netupitant prevents nausea and vomiting during both the acute and delayed phase after cancer chemotherapy.	Contraindications: None Side effects: Most common adverse reactions (incidence \geq 3% and greater than palonosetron) are headache, asthenia, dyspepsia, fatigue, Constipation and erythema.	Palonosetron USP 0.5mg Tablet	USFDA	<i>Ab#gr`b Kiv th#Z c#i </i>	<i>Ab#gr`b Kiv nj </i>

64.	General Pharmaceuticals Ltd., Mouchak, Kaliakair, Gazipur	Clobetasol Propionate 0.05gm + Ofloxacin 0.75gm + Ornidazole 2.0gm + Terbinafine 1.0gm/100gm Cream	Clobetasol Propionate USP 0.05gm + Ofloxacin USP 0.75gm + Ornidazole INN 2.0gm +Terbinafine BP 1.0gm/100gm	Antifungal	<p>Ofloxacin, Ornidazole, Terbinafine& Clobetasol) Cream is highly effective against:</p> <ul style="list-style-type: none"> Mixed and complicated Fungal, Protozoal & Bacterial infections Mild to Moderate Vaginitis Candidiasis and Trichomonas Infection Pruritis Vulvae Inflammatory Dermatoses Genito-urinary infections 	<p>Contraindications: Hypersensitivity to Terbinafine Clobetasol Ofloxacin Ornidazole Cream is a contraindication. In addition, Terbinafine Clobetasol Ofloxacin Ornidazole Cream should not be used if you have the following conditions:</p> <ul style="list-style-type: none"> Alcohol Blood Pressure Breastfeeding Decreased function of the adrenal gland Depression Diabetes <p>Side-effects: The following is a list of possible <u>side-effects</u> that may occur from all constituting ingredients of <u>Terbinafine Clobetasol Ofloxacin Ornidazole Cream</u>. This is not a comprehensive list. These side-effects are possible, but do not always occur. Some of the side-effects may be rare but serious. Consult your doctor if you observe any of the following side-effects, especially if they do not go away.</p> <ul style="list-style-type: none"> Red Skin Indigestion Rash Itchy Skin Loss of appetite Feeling of fullness 			Abjgr`b Kiv thtZ cti	Abjgr`b Kiv nj
-----	---	--	--	------------	--	---	--	--	----------------------	----------------

bs	cŃZKviŃK big	JlŃai big	ŃRŃbniŃK big	Ń_ iwcDitŃK Km	ibŃ Rbv	Contra-indication & Side-effect	Status (New Molecule/ Existing)	AŃe` bKvir KZŃ USFDA/BNF /MHRA Ref.	ŃKŃbK`ij me KŃŃli mŃvi imxvŃŃ	mŃvi imxvŃŃ
65.	Incepta Pharmaceuticals Ltd.; Zirabo, Savar, Dhaka	Micafungin Sodium 100mg/Vial Infusion	Micafungin sodium INN 101.73mg eq. to Micafungin 100mg	Antifungal	Treatment of Candidemia, Acute Disseminated Candidiasis, Candida Peritonitis and Abscesses* Treatment of Esophageal Candidiasis Prophylaxis of Candida Infections in HSCT Recipients	Contra-indication: Micafungin Sodium is contraindicated in persons with known hypersensitivity to micafungin sodium, any component of Micafungin Sodium, or other echinocandins Side effect: Most common adverse reactions include diarrhea, nausea, vomiting, pyrexia, thrombocytopenia, and headache, Histamine-mediated symptoms including rash, pruritus, facial swelling, and vasodilatation	New	USFDA	AbŃŃv` b Kiv thŃZ cŃti	AbŃŃv` b Kiv nj
66.	Incepta Pharmaceuticals Ltd.; Zirabo, Savar, Dhaka	Micafungin Sodium 50mg/Vial Infusion	Micafungin Sodium INN 50.86mg eq. to Micafungin 50mg/Vial	Antifungal	Treatment of Candidemia, Acute Disseminated Candidiasis, Candida Peritonitis and Abscesses* Treatment of Esophageal Candidiasis Prophylaxis of Candida Infections in HSCT Recipients	Contra-indication: Micafungin Sodium is contraindicated in persons with known hypersensitivity to micafungin sodium, any component of Micafungin Sodium, or other echinocandins Side effect: Most common adverse reactions include diarrhea, nausea, vomiting, pyrexia, thrombocytopenia, and headache, Histamine-mediated symptoms including rash, pruritus, facial swelling, and vasodilatation	New	USFDA	AbŃŃv` b Kiv thŃZ cŃti	AbŃŃv` b Kiv nj
67.	Incepta Pharmaceuticals Ltd.; Zirabo, Savar, Dhaka	Oxymetazoline Hydrochloride 1.0gm/100gm cream	oxymetazoline Hydrochloride BP 1gm/100gm Cream	Anti-histamine	Oxymetazoline hydrochloride is an alpha 1A adrenoceptor agonist indicated for the topical treatment of persistent facial erythema associated with rosacea in adults	Contra-indication: None. Side effect: Most common adverse reactions (incidence > 1%) are application site dermatitis, worsening inflammatory lesions of rosacea, application site pruritus, application site erythema, and application site pain.	0.025% & 0.5% Nasal Drops	USFDA	AbŃŃv` b Kiv thŃZ cŃti	AbŃŃv` b Kiv nj
68.	Popular Pharmaceuticals Limited	Ebastine 10mg + Montelukast 10mg Tablet	Ebastine BP 10mg + Montelukast Sodium BP 10.40mg eq. to Montelukast 10mg	Antihistamine+ Antiasthmatic	It is indicated for the prophylaxis and chronic treatment of Asthma, Exercise-Induced Bronchoconstriction & Allergic Rhinitis	Contraindications: Hypersensitivity to any component of this product Side effects: The most frequently occurring adverse effects of Ebastine are: headache, dry mouth, drowsiness, nausea, and insomnia. The most frequently occurring adverse effects of Montelukast are: headache; stomach pain, heartburn, upset stomach, nausea, diarrhea; tooth pain; tired feeling; fever, stuffy nose, sore throat, cough, hoarseness; or mild rash.			cŃŃŃv`Rb ŃbB ŃeaiŃ AŃte` b bigÄy Kiv thŃZ cŃti	cŃŃŃv`Rb ŃbB ŃeaiŃ AŃte` b bigÄy Kiv nj

bs	cŃZKviŃK big	JlŃai big	ŃRŃbniK big	Ń_ iwcDitUK Km	ibŃ Rbv	Contra-indication & Side-effect	Status (New Molecule/ Existing)	AŃe` bKvir KZŃ USFDA/BNF / MHRA Ref.	ŃUKibK`ij me KigiŃi mfv i mŃvŃŃ	mfv i mŃvŃŃ
69.	ACI Ltd.	Indapamide 1.5mg + Amlodipine 5mg Bi-layer Extended Release F/C Tablet	Indapamide BP 1.5 mg + Amlodipine Besilate BP 6.935mg eq. Amlodipine 5 mg	Antihypertensive	It is indicated as substitution therapy for treatment of essential hypertension in patients already controlled with indapamide and amlodipine given concurrently at the same dose level.	Contraindications: Hypersensitivity to the active substances to other sulphonamides to dihydropyridine derivatives or to any of the excipients, severe renal failure (creatinine clearance below 30 ml/min), hepatic encephalopathy or severe impairment of liver function, hypokalaemia, lactation, severe hypotension, shock (including cardiogenic shock), obstruction of the outflow tract of the left ventricle (e.g., high grade aortic stenosis), haemodynamically unstable heart failure after acute myocardial infarction. Side Effects: The most commonly reported adverse reactions with indapamide and amlodipine given separately are somnolence, dizziness, headache, palpitations, flushing, abdominal pain, nausea, ankle swelling, oedema and fatigue.			AbŃgr` b Kiv thŃZ cŃi	AbŃgr` b Kiv nj
70.	ACI Ltd.	Perindopril arginine 10 mg + Indapamide 2.5 mg + Amlodipine 10 mg Film coated Tablet	Perindopril arginine INN 10 mg eq. 6.790mg Perindopril + Indapamide BP 2.5mg + Amlodipine Besilate BP 13.870mg eq. Amlodipine 10 mg	Antihypertensive	It is indicated as substitution therapy for treatment of essential hypertension, in patients already controlled with perindopril/indapamide fixed dose combination and amlodipine, taken at the same dose level.	Contraindications: Dialysis patients, Patients with untreated decompensated heart failure, Severe renal impairment (creatinine clearance below 30 mL/min), Moderate renal impairment (creatinine clearance below 60 mL/min) for doses containing 10mg/2.5mg of perindopril/indapamide combination (i.e., Triplixam 10mg/2.5mg/5mg and 10mg/2.5mg/10mg), Hypersensitivity to the active substances, to other sulphonamides, to dihydropyridine derivatives, any other ACE-inhibitor or to			cŃŃqirB ŃbB wearq AŃe` b bigÄy Kiv thŃZ cŃi	cŃŃqirB ŃbB wearq AŃe` b bigÄy Kiv nj

					<p>any of the excipients, History of angioedema (Quincke's oedema) associated with previous ACE inhibitor therapy, Hereditary/idiopathic angioedema, Second and third trimesters of pregnancy ,Lactation), Hepatic encephalopathy, Severe hepatic impairment , Hypokalaemia , Severe hypotension , Shock including cardiogenic shock , Obstruction of the outflow, tract of the left ventricle (e.g. high grade aortic stenosis) , Haemodynamically unstable heart failure after acute myocardial infarction , Concomitant use with aliskiren in patients with diabetes mellitus or renal impairment (GFR < 60mL/min/1.73m2).</p> <p>Side Effects : The most commonly reported adverse reactions with perindopril, indapamide and amlodipine given separately are: dizziness, headache, paresthesia, vertigo, somnolence, visual disturbances, tinnitus, palpitations, flushing, hypotension (and effects related to hypotension), cough, dyspnea, gastrointestinal disorders (abdominal pain, constipation, diarrhea, dysgeusia, nausea, dyspepsia, vomiting), pruritus, rash, maculopapular rashes, muscle cramps, ankle swelling, asthenia, oedema and fatigue.</p>				
--	--	--	--	--	--	--	--	--	--

bs	cŃZKviŃK bug	JlŃai bug	ŃRŃbniK bug	Ń_ iwcDitUK Kvm	ibŃ Rbv	Contra-indication & Side-effect	Status (New Molecule/ Existing)	AŃe` bKvix KZŃ USFDA/BNF / MHRA Ref.	ŃUKibK`ij me Kugli mfvi m×vŃŃ	mfvi m×vŃŃ
71.	ACI Ltd.	Perindopril arginine 10 mg + Indapamide 2.5 mg + Amlodipine 5 mg Film coated Tablet	Perindopril arginine INN 10 mg eq. 6.790 mg Perindopril + Indapamide BP 2.5mg + Amlodipine Besilate BP 6.935mg eq. Amlodipine 5 mg	Antihyperte nsive	It is indicated as substitution therapy for treatment of essential hypertension, in patients already controlled with perindopril/indapamide fixed dose combination and amlodipine, taken at the same dose level.	Contraindications: Dialysis patients, Patients with untreated decompensated heart failure , Severe renal impairment (creatinine clearance below 30 mL/min), Moderate renal impairment (creatinine clearance below 60 mL/min) for doses containing 10mg/2.5mg of perindopril/indapamide combination (i.e., Triplixam 10mg/2.5mg/5mg and 10mg/2.5mg/10mg), Hypersensitivity to the active substances, to other sulphonamides, to dihydropyridine derivatives, any other ACE-inhibitor or to any of the excipients, History of angioedema (Quincke's oedema) associated with previous ACE inhibitor therapy, Hereditary/idiopathic angioedema, Second and third trimesters of pregnancy ,Lactation), Hepatic encephalopathy, Severe hepatic impairment , Hypokalaemia , Severe hypotension , Shock including cardiogenic shock , Obstruction of the outflow, tract of the left ventricle (e.g. high grade aortic stenosis) , Haemodynamically unstable heart failure after acute myocardial infarction , Concomitant use with aliskiren in patients with diabetes mellitus or renal impairment (GFR < 60mL/min/1.73m2). Side Effects : The most commonly reported adverse reactions with perindopril, indapamide and amlodipine given separately are: dizziness, headache, paresthesia, vertigo, somnolence, visual disturbances, tinnitus, palpitations, flushing, hypotension (and effects related to hypotension), cough, dyspnea, gastro-intestinal disorders (abdominal pain, constipation, diarrhea, dysgeusia, nausea, dyspepsia, vomiting), pruritus, rash, maculopapular rashes, muscle cramps, ankle swelling, asthenia, oedema and fatigue.			cŃqirb ŃbB weariq AŃe` b bŃ gÄy Kiv thŃZ cŃti	cŃqirb ŃbB weariq AŃe` b bŃgÄy Kiv nj

<i>bs</i>	<i>c0ZKvi#K big</i>	<i>Jl#ai big</i>	<i>#R#biiK big</i>	<i>#_i wC Di#K Km</i>	<i>ib#`Rbv</i>	Contra-indication & Side-effect	Status (New Molecule/ Existing)	<i>Av#`bKvix KZ# USFDA/BNF /MHRA Ref.</i>	<i>#UK#bK`vj me Kig#Di mfvi m#v#S#</i>	<i>mfvi m#v#S#</i>
72.	ACI Ltd.	Perindopril Arginine 2.5 mg + Indapamide 0.625 mg + Amlodipine 5 mg Film coated Tablet	Perindopril arginine INN 2.5 mg eqv. 1.6975 mg Perindopril + Indapamide BP 0.625mg + Amlodipine Besilate BP 6.935 mg eq. Amlodipine 5 mg	Antihypertensive	It is indicated as substitution therapy for treatment of essential hypertension, in patients already controlled with perindopril/indapamide fixed dose combination and amlodipine, taken at the same dose level.	<p>Contraindications: Dialysis patients, Patients with untreated decompensated heart failure, Severe renal impairment (creatinine clearance below 30 mL/min), Moderate renal impairment (creatinine clearance below 60 mL/min) for doses containing 10mg/2.5mg of perindopril/indapamide combination (i.e., Triplixam 10mg/2.5mg/5mg and 10mg/2.5mg/10mg), Hypersensitivity to the active substances, to other sulphonamides, to dihydropyridine derivatives, any other ACE-inhibitor or to any of the excipients, History of angioedema (Quincke's oedema) associated with previous ACE inhibitor therapy, Hereditary/idiopathic angioedema, Second and third trimesters of pregnancy, Lactation), Hepatic encephalopathy, Severe hepatic impairment, Hypokalaemia, Severe hypotension, Shock including cardiogenic shock, Obstruction of the outflow tract of the left ventricle (e.g. high grade aortic stenosis), Haemodynamically unstable heart failure after acute myocardial infarction, Concomitant use with aliskiren in patients with diabetes mellitus or renal impairment (GFR < 60mL/min/1.73m²).</p> <p>Side Effects : The most commonly reported adverse reactions with perindopril, indapamide and amlodipine</p>			<i>c#q#Rb #bB weavq Av#`b big#y Kiv thiZ citi </i>	<i>c#q#Rb #bB weavq Av#`b big#y Kiv nj </i>

						given separately are: dizziness, headache, paresthesia, vertigo, somnolence, visual disturbances, tinnitus, palpitations, flushing, hypotension (and effects related to hypotension), cough, dyspnea, gastrointestinal disorders (abdominal pain, constipation, diarrhea, dysgeusia, nausea, dyspepsia, vomiting), pruritus, rash, maculopapular rashes, muscle cramps, ankle swelling, asthenia, oedema and fatigue.				
73.	ACI Ltd.	Perindopril arginine 5 mg + Indapamide 1.250 mg + Amlodipine 10 mg Film coated Tablet	Perindopril arginine INN 5 mg eq. 3.395mg Perindopril + Indapamide BP 1.250 mg + Amlodipine Besilate BP 13.870 mg ev. Amlodipine 10 mg	Antihypertensive	It is indicated as substitution therapy for treatment of essential hypertension, in patients already controlled with perindopril/indapamide fixed dose combination and amlodipine, taken at the same dose level.	Contraindications: Dialysis patients, Patients with untreated decompensated heart failure, Severe renal impairment (creatinine clearance below 30 mL/min), Moderate renal impairment (creatinine clearance below 60 mL/min) for doses containing 10mg/2.5mg of perindopril/indapamide combination (i.e., Triplixam 10mg/2.5mg/5mg and 10mg/2.5mg/10mg), Hypersensitivity to the active substances, to other sulphonamides, to dihydropyridine derivatives, any other ACE-inhibitor or to any of the excipients, History of angioedema (Quincke's oedema) associated with previous ACE inhibitor therapy, Hereditary/idiopathic angioedema, Second and third trimesters of pregnancy, Lactation), Hepatic encephalopathy, Severe hepatic impairment, Hypokalaemia, Severe hypotension, Shock including cardiogenic shock, Obstruction of the outflow tract of the left ventricle (e.g. high grade aortic stenosis), Haemodynamically unstable heart failure after acute myocardial infarction, Concomitant use with aliskiren in patients with diabetes mellitus or renal			<p> <i>cllqirB tbB wearq</i> <i>Avte`b brgAy Kiv</i> <i>thtZ cirt </i> </p>	<p> <i>cllqirB tbB</i> <i>wearq Avte`b</i> <i>brgAy Kiv</i> <i>nj </i> </p>

						impairment (GFR < 60mL/min/1.73m2). Side Effects : The most commonly reported adverse reactions with perindopril, indapamide and amlodipine given separately are: dizziness, headache, paresthesia, vertigo, somnolence, visual disturbances, tinnitus, palpitations, flushing, hypotension (and effects related to hypotension), cough, dyspnea, gastrointestinal disorders (abdominal pain, constipation, diarrhea, dysgeusia, nausea, dyspepsia, vomiting), pruritus, rash, maculopapular rashes, muscle cramps, ankle swelling, asthenia, oedema and fatigue.				
74.	ACI Ltd.	Perindopril arginine 5 mg + Indapamide 1.250 mg + Amlodipine 5 mg Film coated Tablet	Perindopril arginine INN 5 mg eqv. 3.395mg Perindopril + Indapamide BP 1.250 mg + Amlodipine Besilate BP 6.935 mg eq. Amlodipine 5 mg	Antihypertensive	It is indicated as substitution therapy for treatment of essential hypertension, in patients already controlled with perindopril/indapamide fixed dose combination and amlodipine, taken at the same dose level.	Contraindications: Dialysis patients, Patients with untreated decompensated heart failure, Severe renal impairment (creatinine clearance below 30 mL/min), Moderate renal impairment (creatinine clearance below 60 mL/min) for doses containing 10mg/2.5mg of perindopril/indapamide combination (i.e., Triplixam 10mg/2.5mg/5mg and 10mg/2.5mg/10mg), Hypersensitivity to the active substances, to other sulphonamides, to dihydropyridine derivatives, any other ACE-inhibitor or to any of the excipients, History of angioedema (Quincke's oedema) associated with previous ACE inhibitor therapy, Hereditary/idiopathic angioedema, Second and third trimesters of pregnancy, Lactation), Hepatic encephalopathy, Severe hepatic impairment, Hypokalaemia, Severe hypotension, Shock including cardiogenic shock, Obstruction of the outflow tract of the left ventricle (e.g.			<i>c00q1Rb tbB weavq Arte`b bi gAjy Kiv thtZ cirt </i>	<i>c00q1Rb tbB weavq Arte`b bigAjy Kiv nj </i>

						<p>high grade aortic stenosis) , Haemodynamically unstable heart failure after acute myocardial infarction , Concomitant use with aliskiren in patients with diabetes mellitus or renal impairment (GFR < 60mL/min/1.73m2).</p> <p>Side Effects : The most commonly reported adverse reactions with perindopril, indapamide and amlodipine given separately are: dizziness, headache, paresthesia, vertigo, somnolence, visual disturbances, tinnitus, palpitations, flushing, hypotension (and effects related to hypotension), cough, dyspnea, gastrointestinal disorders (abdominal pain, constipation, diarrhea, dysgeusia, nausea, dyspepsia, vomiting), pruritus, rash, maculopapular rashes, muscle cramps, ankle swelling, asthenia, oedema and fatigue.</p>				
75.	Acme Laboratories Ltd., Dhamrai, Dhaka	Azilsartan Medoxomil 40mg + Chlorthalidone 12.50 mg Tablet	Azilsartan Kamedoxomil INN 42.68 mg eq. to Azilsartan Medoxomil 40 mg + Chlorthalidone INN 12.50 mg	Antihypertensive	Azilsartan/chlorthalidone a thiazide like diuretic combination product indicated for the treatment of hypertension, to lower blood pressure: <input type="checkbox"/> In patients not adequately controlled with monotherapy <input type="checkbox"/> As initial therapy in patients likely to need multiple drugs to help achieve blood pressure goals	<p>Contraindication: -Contraindicated in patients with anuria - Not to coadminister with aliskiren in patients with diabetes Side effects: • Low blood pressure (hypotension) and dizziness • Kidney problems • Increased uric acid levels in the blood (e.g.: dry mouth, weakness, drowsiness)</p>	Chlorthalidone 25 & 50 mg Tablet, Azilsartan Medoxomil 40mg & 80mg Tablet	USFDA	Abtgr`b Kiv thZ cti	Abtgr`b Kiv nj
76.	Acme Laboratories Ltd., Dhamrai,	Azilsartan Medoxomil 40mg + Chlorthalidone 25mg Tablet	Azilsartan Kamedoxomil INN 42.68 mg eq. to Azilsartan Medoxomil 40mg + Chlorthalidone INN 25 mg	Antihypertensive	Azilsartan/chlorthalidone a thiazide like diuretic combination product indicated for the treatment of hypertension, to lower blood pressure: <input type="checkbox"/> In patients not adequately controlled with monotherapy <input type="checkbox"/> As initial therapy in patients likely to need multiple drugs to help achieve blood pressure	<p>Contraindication: -Contraindicated in patients with anuria - Not to coadminister with aliskiren in patients with diabetes Side effects: • Low blood pressure (hypotension) and dizziness • Kidney problems • Increased uric acid levels in the blood (e.g.: dry</p>	Chlorthalidone 25 & 50 mg Tablet, Azilsartan Medoxomil 40 & 80 mg Tablet	USFDA	Abtgr`b Kiv thZ cti	Abtgr`b Kiv nj

	Dhaka				goals	mouth, weakness, drowsiness)				
--	--------------	--	--	--	-------	------------------------------	--	--	--	--

bs	cŃZKviŃK big	JlŃai big	ŃRŃbniK big	Ń_ iwcDitUK Kym	ibŃ Rbv	Contra-indication & Side-effect	Status (New Molecule/ Existing)	AvŃe`bKvir KZŃ USFDA/BNF /MHRA Ref.	ŃUKibK`ij me KugŃli mfvi imxvŃŃ	mfvi imxvŃŃ
77.	Aristopharma Ltd. Plot No.21, Road No.11, Shampur- Kadamtali I/A Dhaka- 1204	Felodipine 5 mg Extended Release Tablet	Felodipine USP 5 mg	Antihyperte nsive	Felodipine extended release tablet is indicated for the treatment of hypertension. It may be used alone or concomitantly with other antihypertensive.	Contra-indication: Felodipine extended release tablets are contraindicated in patients who are hypersensitive to this product. Side-effect: The most common side effects are dizziness, fatigue, flushing, headache, hypotension and peripheral oedema may occur.	New	US FDA BNF-73 Page: 150	AbŃgv`b Kiv thŃZ cŃti	AbŃgv`b Kiv nj
78.	Eskayef Pharmaceuticals Limited	Spirolactone 25mg + Hydrochlorothiazide 25mg FC Tablet	Spirolactone USP 25mg + Hydrochlorothiazide USP 25mg	Antihyperte nsive	It is indicated in Congestive heart failure, Cirrhosis of the liver accompanied by edema and/or ascites, Essential hypertensoin	Contraindications: Hypersensitivity, Anuria, Acute renal insufficiency, Significant impairment of renal excretory function, Hypercalcemia Side effects: Weakness, Hypotension, Jaundice, Diarrhea, Vomiting	New	USFDA	cŃqŃRb ŃbB weavq AvŃe`b bv gŃj Kiv thŃZ cŃti	cŃqŃRb ŃbB weavq AvŃe`b bigŃj Kiv nj
79.	Eskayef Pharmaceuticals Limited	Spirolactone 50mg + Hydrochlorothiazide 50mg FC Tablet	Spirolactone USP 50mg + Hydrochlorothiazide USP 50mg	Antihyperte nsive	It is indicated in Congestive heart failure, Cirrhosis of the liver accompanied by edema and/or ascites, Essential hypertensoin	Contraindications: Hypersensitivity, Anuria, Acute renal insufficiency, Significant impairment of renal excretory function, Hypercalcemia Side effects: Weakness, Hypotension, Jaundice, Diarrhea, Vomiting	New	USFDA	cŃqŃRb ŃbB weavq AvŃe`b bv gŃj Kiv thŃZ cŃti	cŃqŃRb ŃbB weavq AvŃe`b bigŃj Kiv nj
80.	Julphar Bangladesh Ltd. Sreepur, Gazipur, Dhaka	Selexipag 0.2 mg Film Coated Tablet	Selexipag INN 0.2 mg	Antihyperte nsive	Selexipag is indicated for the treatment of pulmonary arterial hypertension (PAH, WHO Group I) to delay disease progression and reduce the risk of hospitalization for PAH	Contra-indication: None Adverse Effect: Headache, diarrhea, jaw pain, nausea, myalgia, vomiting, pain in extremity, and flushing.	New	USFDA	AbŃgv`b Kiv thŃZ cŃti	AbŃgv`b Kiv nj
81.	Julphar Bangladesh Ltd. Sreepur, Gazipur, Dhaka	Selexipag 0.4 mg Film Coated Tablet	Selexipag INN 0.4 mg	Antihyperte nsive	Selexipag is indicated for the treatment of pulmonary arterial hypertension (PAH, WHO Group I) to delay disease progression and reduce the risk of hospitalization for PAH	Contra-indication: None Adverse Effect: Headache, diarrhea, jaw pain, nausea, myalgia, vomiting, pain in extremity, and flushing.	New	USFDA	AbŃgv`b Kiv thŃZ cŃti	AbŃgv`b Kiv nj

bs	cŃZKviŃK big	JlŃai big	ŃRŃbniŃK big	Ń_ iwcDitŃK Km	ibŃ Rbv	Contra-indication & Side-effect	Status (New Molecule/ Existing)	AŃe`bKvir KZŃ USFDA/BNF / MHRA Ref.	ŃUKibK`ij me KugŃli mŃvi imxvŃŃ	mŃvi imxvŃŃ
82.	Popular Pharmaceuticals Limited	Bisoprolol Fumarate 2.50mg + Amlodipine 5mg Film Coated Tablet	Bisoprolol Fumarate USP 2.50mg + Amlodipine Besilate BP 6.93mg eq. to Amlodipine 5mg	Antihypertensive	it is indicated for the treatment of hypertension, alone or with other antihypertensive agents. (Amlodipine+Bisoprolol) may also be used as initial therapy in patients who are likely to need multiple antihypertensive agents to achieve their blood pressure goals. It is also used to treat angina pectoris, stable chronic heart failure.	Contraindications: Combination of Amlodipine and Bisoprolol is contraindicated in patients who are hypersensitive to any component of this product or to any of its ingredients. Side effects: The common side effects include edema, upper respiratory tract infection, hypotension, dizziness, headache, nausea, vomiting, diarrhoea, constipation, hypersensitivity reactions (itching, flush, rash) etc.			AbŃgv`b Kiv thŃZ cŃti	AbŃgv`b Kiv nj
83.	Popular Pharmaceuticals Limited	Bisoprolol Fumarate 5.00mg + Amlodipine 5mg Film Coated Tablet	Bisoprolol Fumarate USP 5.00mg + Amlodipine Besilate BP 6.93mg eq. to Amlodipine 5mg	Antihypertensive	it is indicated for the treatment of hypertension, alone or with other antihypertensive agents. (Amlodipine+Bisoprolol) may also be used as initial therapy in patients who are likely to need multiple antihypertensive agents to achieve their blood pressure goals. It is also used to treat angina pectoris, stable chronic heart failure.	Contraindications: Combination of Amlodipine and Bisoprolol is contraindicated in patients who are hypersensitive to any component of this product or to any of its ingredients. Side effects: The common side effects include edema, upper respiratory tract infection, hypotension, dizziness, headache, nausea, vomiting, diarrhoea, constipation, hypersensitivity reactions (itching, flush, rash) etc.			cŃqŃRb tbB weariq AŃe`b bigAŃy Kiv thŃZ cŃti	cŃqŃRb tbB weariq AŃe`b bigAŃy Kiv nj
84.	Ziska Pharmaceuticals Ltd.	Eprosartan Mesylate 400 mg Tablet	Eprosartan Mesylate USP 400 mg	Antihypertensive	It is indicated for the treatment of hypertension. It may be used alone or in combination with other antihypertensives such as diuretics and calcium channel blockers. Warning: fetal toxicity When pregnancy is detected, discontinue it as soon as possible. Drugs that act directly on the renin-angiotensin system can cause injury and death to the developing fetus.	Contraindications: It is contraindicated in patients who are hypersensitive to this product or any of its components. Do not co-administer aliskiren with it in patients with diabetes. Side-effects: Infection viral, Injury, Fatigue, Abdominal pain, Hypertriglyceridemia, Arthralgia, Depression, Upper respiratory tract infection, Rhinitis, Pharyngitis, Coughing, Urinary tract infection.	New	USFDA	AbŃgv`b Kiv thŃZ cŃti	AbŃgv`b Kiv nj

<i>bs</i>	<i>cŃZKviŃK big</i>	<i>JlŃai big</i>	<i>ŃRŃbniŃK big</i>	<i>Ń_ iwcDitŃK Km</i>	<i>ibŃ Rbv</i>	Contra-indication & Side-effect	Status (New Molecule/ Existing)	<i>AvŃe` bKvir KZŃ USFDA/BNF / MHRA Ref.</i>	<i>ŃUKibK`ij me KugŃli mŃvi imxvŃŃ</i>	<i>mŃvi imxvŃŃ</i>
85.	Ziska Pharmaceuticals Ltd.	Eprosartan Mesylate 600 mg Tablet	Eprosartan Mesylate USP 600 mg	Antihypertensive	It is indicated for the treatment of hypertension. It may be used alone or in combination with other antihypertensives such as diuretics and calcium channel blockers. Warning: fetal toxicity When pregnancy is detected, discontinue it as soon as possible. Drugs that act directly on the renin-angiotensin system can cause injury and death to the developing fetus.	Contraindications: It is contraindicated in patients who are hypersensitive to this product or any of its components. Do not co-administer aliskiren with it in patients with diabetes. Side-effects: Infection viral, Injury, Fatigue, Abdominal pain, Hypertriglyceridemia, Arthralgia, Depression, Upper respiratory tract infection, Rhinitis, Pharyngitis, Coughing, Urinary tract infection.	New	USFDA	<i>AbŃgv` b Kiv thŃZ cŃti </i>	<i>AbŃgv` b Kiv nj </i>
86.	Ziska Pharmaceuticals Ltd.	Nisoldipine 17 mg Extended Release Tablet	Nisoldipine INN 17 mg	Antihypertensive	It is indicated for the treatment of hypertension. It may be used alone or in combination with other antihypertensive agents	Contraindications: It is contraindicated in patients with known hypersensitivity to dihydropyridine calcium channel blockers. Side effects: Peripheral Edema, Headache, Dizziness, Pharyngitis, Vasodilation, Sinusitis, Palpitation, Chest Pain, Nausea, Rash	Nisoldipine 10 mg & 20 mg Extended Release Tablet	USFDA	<i>AbŃgv` b Kiv thŃZ cŃti </i>	<i>AbŃgv` b Kiv nj </i>
87.	Ziska Pharmaceuticals Ltd.	Nisoldipine 34 mg Extended Release Tablet	Nisoldipine INN 34 mg	Antihypertensive	It is indicated for the treatment of hypertension. It may be used alone or in combination with other antihypertensive agents	Contraindications: It is contraindicated in patients with known hypersensitivity to dihydropyridine calcium channel blockers. Side effects: Peripheral Edema, Headache, Dizziness, Pharyngitis, Vasodilation, Sinusitis, Palpitation, Chest Pain, Nausea, Rash	Nisoldipine 10 mg & 20 mg Extended Release Tablet	USFDA	<i>cŃŃqŃRb ŃbB weavq AvŃe` b bv gŃjy Kiv thŃZ cŃti </i>	<i>cŃŃqŃRb ŃbB weavq AvŃe` b bigŃjy Kiv nj </i>
88.	Ziska Pharmaceuticals Ltd.	Nisoldipine 8.5 mg Extended Release Tablet	Nisoldipine INN 8.5 mg	Antihypertensive	It is indicated for the treatment of hypertension. It may be used alone or in combination with other antihypertensive agents	Contraindications: It is contraindicated in patients with known hypersensitivity to dihydropyridine calcium channel blockers. Side effects: Peripheral Edema, Headache, Dizziness, Pharyngitis, Vasodilation, Sinusitis, Palpitation, Chest Pain, Nausea, Rash	Nisoldipine 10 mg & 20 mg Extended Release Tablet	USFDA	<i>cŃŃqŃRb ŃbB weavq AvŃe` b bv gŃjy Kiv thŃZ cŃti </i>	<i>cŃŃqŃRb ŃbB weavq AvŃe` b bigŃjy Kiv nj </i>

bs	cŃZKviŃK big	JlŃai big	ŃRŃbniK big	Ń_ iwcDitŃK Kvm	ibŃ Rbv	Contra-indication & Side-effect	Status (New Molecule/ Existing)	AvŃe`bKvir KZŃ USFDA/BNF / MHRA Ref.	ŃUKibK`ij me KugŃli mfvi mmxvŃŃ	mfvi mmxvŃŃ
89.	a) ACI Ltd. b) Navana Healthcare Ltd. C) NIPRO JMI Pharma Ltd.	Lorcaserin HCl 10mg Film Coated Tablet	Lorcaserin HCl Hemihydrate INN 10.40 mg eq. 10 mg Lorcaserin HCl	Anti- Obesity	Lorcaserin hydrochloride is indicated as an adjunct to a reduced-calorie diet and increased physical activity for chronic weight management in adult patients with an initial body mass index (BMI) of: 30 kg/m ² or greater (obese), or 27 kg/m ² or greater (overweight) in the presence of at least one weight related comorbid condition (e.g., hypertension, dyslipidemia, type 2 diabetes) Limitations of use: The safety and efficacy of coadministration of Lorcaserin hydrochloride with other products intended for weight loss including prescription drugs (e.g., phentermine), over-the-counter drugs, and herbal preparations have not been established The effect of Lorcaserin hydrochloride on cardiovascular morbidity and mortality has not been established	Contraindications: It is contraindicated in Pregnancy. Side Effects: Most common adverse reactions (greater than 5%) in non-diabetic patients are headache, dizziness, fatigue, nausea, dry mouth, and constipation, and in diabetic patients are hypoglycemia, headache, back pain, cough, and fatigue.	New	USFDA	cŃqŃRb ŃbB wearq AvŃe`b bigÄy Kiv ŃhŃZ cŃti	cŃqŃRb ŃbB wearq AvŃe`b bigÄy Kiv nj
90.	Incepta Pharmaceutic als Ltd.; Zirabo, Savar, Dhaka	Phenetermine HCl 11.25 mg + Topiramate 69 mg Extended Release Capsule	Phenetermine HCl USP 11.25 mg + Topiramate USP 69 mg	Anti-obesity	Phentermine +Topiramateis indicated as an adjunct to a reduced-calorie diet and increased physical activity for chronic weight management in adult patients with an initial body mass index (BMI) of 30 kg/m ² or greater (obese), or 27 kg/m ² or greater (overweight) in the presence of at least one weight related comorbidity such as hypertension, type 2 diabetes mellitus, or dyslipidemia.	Contra-indication: Pregnancy , Glaucoma, Hyperthyroidism, During or within 14 days of taking monoamine oxidase inhibitor. Side effect: Most common adverse reactions (incidence greater than or equal to 5% and at a rate at least 1.5 times placebo) are: paraesthesia, dizziness, dysgeusia, insomnia, constipation, and dry mouth	New	USFDA	cŃqŃRb ŃbB wearq AvŃe`b bigÄy Kiv ŃhŃZ cŃti	cŃqŃRb ŃbB wearq AvŃe`b bigÄy Kiv nj

bs	cŃZKviŃK big	JlŃai big	ŃRŃbniK big	Ń_ iwcDitUK Km	ibŃ Rbv	Contra-indication & Side-effect	Status (New Molecule/ Existing)	AŃe`bKvir KZŃ USFDA/BNF /MHRA Ref.	ŃUKibK`ij me Kugli mŃvi imxvŃŃ	mŃvi imxvŃŃ
91.	Incepta Pharmaceuticals Ltd.; Zirabo, Savar, Dhaka	Phentermine HCl 15mg +Topiramate 92mg Extended Release Capsule	Phentermine HCl USP 15 mg +Topiramate USP 92 mg	Anti-obesity	Phentermine +Topiramate is indicated as an adjunct to a reduced-calorie diet and increased physical activity for chronic weight management in adult patients with an initial body mass index (BMI) of 30 kg/m ² or greater (obese), or 27 kg/m ² or greater (overweight) in the presence of at least one weight related comorbidity such as hypertension, type 2 diabetes mellitus, or dyslipidemia.	Contra-indication: Pregnancy, Glaucoma, Hyperthyroidism, During or within 14 days of taking monoamine oxidase inhibitor. Side effect: Most common adverse reactions (incidence greater than or equal to 5% and at a rate at least 1.5 times placebo) are: paraesthesia, dizziness, dysgeusia, insomnia, constipation, and dry mouth	New	USFDA	cŃqirb ŃbB weariq AŃe`b bŃ gÄy Kiv thŃZ citi	cŃqirb ŃbB weariq AŃe`b bŃ gÄy Kiv nj
92.	Incepta Pharmaceuticals Ltd.; Zirabo, Savar, Dhaka	Phentermine HCl 3.75mg + Topiramate USP 23 mg Extended Release Capsule	Phentermine HCl USP 3.75mg + Topiramate USP 23 mg	Anti-obesity	Phentermine +Topiramate is indicated as an adjunct to a reduced-calorie diet and increased physical activity for chronic weight management in adult patients with an initial body mass index (BMI) of 30 kg/m ² or greater (obese), or 27 kg/m ² or greater (overweight) in the presence of at least one weight related comorbidity such as hypertension, type 2 diabetes mellitus, or dyslipidemia.	Contra-indication: Pregnancy, Glaucoma, Hyperthyroidism, During or within 14 days of taking monoamine oxidase inhibitor. Side effect: Most common adverse reactions (incidence greater than or equal to 5% and at a rate at least 1.5 times placebo) are: paraesthesia, dizziness, dysgeusia, insomnia, constipation, and dry mouth	New	USFDA	cŃqirb ŃbB weariq AŃe`b bŃ gÄy Kiv thŃZ citi	cŃqirb ŃbB weariq AŃe`b bŃ gÄy Kiv nj
93.	Incepta Pharmaceuticals Ltd.; Zirabo, Savar, Dhaka	Phentermine HCl 7.50mg + Topiramate 46 mg Extended Release Capsule	Phentermine HCl USP 7.50mg + Topiramate USP 46 mg	Anti-obesity	Phentermine +Topiramate is indicated as an adjunct to a reduced-calorie diet and increased physical activity for chronic weight management in adult patients with an initial body mass index (BMI) of 30 kg/m ² or greater (obese), or 27 kg/m ² or greater (overweight) in the presence of at least one weight related comorbidity such as hypertension, type 2 diabetes mellitus, or dyslipidemia.	Contra-indication: Pregnancy, Glaucoma, Hyperthyroidism, During or within 14 days of taking monoamine oxidase inhibitor. Side effect: Most common adverse reactions (incidence greater than or equal to 5% and at a rate at least 1.5 times placebo) are: paraesthesia, dizziness, dysgeusia, insomnia, constipation, and dry mouth	New	USFDA	cŃqirb ŃbB weariq AŃe`b bŃ gÄy Kiv thŃZ citi	cŃqirb ŃbB weariq AŃe`b bŃ gÄy Kiv nj

bs	cŃZKviŃK big	JlŃai big	ŃRŃbniK big	Ń_ iwcDŃUK KŃm	ibŃ Rbv	Contra-indication & Side-effect	Status (New Molecule/ Existing)	AŃe`bKvir KZŃ USFDA/BNF /MHRA Ref.	ŃUKŃbK`ij me KŃgŃli mŃvi Ńm`vŃŃ	mŃvi Ńm`vŃŃ
94.	Square Pharmaceutic als Ltd., Pabna Unit, Salgaria, Pabna	Rasagiline 0.5mg Tablet	Rasagiline Mesylate INN 0.780mg eqv. to 0.5mg Rasagiline	Antiparkins on`s	It is a monoamine oxidase (MAO)-B Inhibitor (MAOI) and is indicated for the treatment of Parkinson`s diseases.	Contraindications: Concomitant use of meperidine, tramadol, methadone, propoxyphene dextromethorphan, St. John`s wort, cyclobenzaprine, or another (selective or non-selective) MAO inhibitor. Adverse effect: Most common adverse reactions (incidence 3% or greater than placebo): • Rasagiline monotherapy: flu syndrome, arthralgia, depression, dyspepsia • Rasagiline used as adjunct without levodopa: peripheral edema, fall, arthralgia, cough, and insomnia • Rasagiline used as adjunct to levodopa: dyskinesia, accidental injury, weight loss, postural hypotension, vomiting, anorexia, arthralgia, abdominal pain, nausea, constipation, dry mouth, rash, abnormal dreams, fall, and tenosynovitis	New	USFDA	AbŃgv`b Kiv thŃZ cŃi	AbŃgv`b Kiv nj
95.	Healthcare Pharmaceutic al ltd., Rajendrapur, Gazipur	Safinamide 100 mg tablet	Safinamide INN 100mg	Antiparkins onian	Safinamide is indicated as adjunctive treatment to levodopa/carbidopa in patients with Parkinson`s disease (PD) experiencing “off” episodes.	Contra-Indication: Concomitant use of other drugs in the monoamine oxidase inhibitor (MAOI) class other drugs that are potent inhibitors of monoamine oxidase, including linezolid. The combination may result in increased blood pressure, including hypertensive crisis Side effects: Hypertension ✓ Serotonin Syndrome ✓ Dyskinesia ✓ Hallucinations / Psychotic Behavior	New	USFDA	AbŃgv`b Kiv thŃZ cŃi	AbŃgv`b Kiv nj

bs	cŃZKviŃK big	JlŃai big	ŃRŃbniK big	Ń_ iwcDitŃK Km	ibŃ Rbv	Contra-indication & Side-effect	Status (New Molecule/ Existing)	AvŃe`bKvir KZŃ USFDA/BNF / MHRA Ref.	ŃUKibK`ij me KugŃli mfvi imxvŃŃ	mfvi imxvŃŃ
96.	Healthcare Pharmaceutical Ltd., Rajendrapur, Gazipur	Safinamide 50 mg Tablet	Safinamide INN 50mg	Antiparkinsonian	Safinamide is indicated as adjunctive treatment to levodopa/carbidopa in patients with Parkinson's disease (PD) experiencing "off" episodes.	<p>Contra-Indication Concomitant use of other drugs in the monoamine oxidase inhibitor (MAOI) class other drugs that are potent inhibitors of monoamine oxidase, including linezolid. The combination may result in increased blood pressure, including hypertensive crisis</p> <p>Side effects: <ul style="list-style-type: none"> ✓ Hypertension ✓ Serotonin Syndrome ✓ Dyskinesia ✓ Hallucinations / Psychotic Behavior </p>	New	USFDA	AbŃgr`b Kiv thŃZ cŃti	AbŃgr`b Kiv nj
97.	Ziska Pharmaceuticals Ltd.	Levodopa 100 mg + Benserazide 25 mg capsule	Levodopa BP 100 mg + Benserazide INN 25 mg	Antiparkinsonian	It is indicated for the treatment of all forms of Parkinson's syndrome with the exception of medicine-induced parkinsonism. Limitations of Use: Use only if a clear diagnosis of migraine headache has been established. Not indicated for the prophylactic therapy of migraine attacks. Not indicated for the treatment of cluster headache.	<p>Contraindications: History of coronary artery disease or coronary vasospasm. History of coronary artery bypass graft surgery. (Wolff-Parkinson-White syndrome or other cardiac accessory conduction, pathway disorders. History of stroke, transient ischemic attack, or hemiplegic or basilar migraine. Peripheral vascular disease. Ischemic bowel disease. Uncontrolled hypertension.</p> <p>Side effects: Haemolytic anaemia, transient leucopenia and thrombocytopenia have been reported in rare cases. Anorexia, Agitation, anxiety, insomnia, hallucinations, delusions and temporal disorientation may occur particularly in elderly patients. Ageusia, Cardiac arrhythmia, muscle cramps, hypotonia may occur.</p>	New		cŃqŃRb ŃbB wearq AvŃe`b bigÄy Kiv thŃZ cŃti	cŃqŃRb ŃbB wearq AvŃe`b bigÄy Kiv nj

bs	cŃZKviŃK big	JlŃai big	ŃRŃbniŃK big	Ń_ iwcDitŃK Km	ibŃ Rbv	Contra-indication & Side-effect	Status (New Molecule/ Existing)	AŃe` bKvir KZŃ USFDA/BNF / MHRA Ref.	ŃUKibK`ij me KugŃli mfvi imxvŃŃ	mfvi imxvŃŃ
98.	Ziska Pharmaceuticals Ltd.	Levodopa 200 mg + Benserazide 50mg capsule	Levodopa BP 200 mg + Benserazide INN 50 mg	Antiparkinsonian	It is indicated for the treatment of all forms of Parkinson's syndrome with the exception of medicine-induced parkinsonism. Limitations of Use: Use only if a clear diagnosis of migraine headache has been established. Not indicated for the prophylactic therapy of migraine attacks. Not indicated for the treatment of cluster headache.	Contraindications: History of coronary artery disease or coronary vasospasm. History of coronary artery bypass graft surgery. (Wolff-Parkinson-White syndrome or other cardiac accessory conduction, pathway disorders. History of stroke, transient ischemic attack, or hemiplegic or basilar migraine. Peripheral vascular disease. Ischemic bowel disease. Uncontrolled hypertension. Side effects: Haemolytic anaemia, transient leucopenia and thrombocytopenia have been reported in rare cases. Anorexia, Agitation, anxiety, insomnia, hallucinations, delusions and temporal disorientation may occur particularly in elderly patients. Ageusia, Cardiac arrhythmia, muscle cramps, hypotonia may occur.	New		cŃqirB ŃbB weariq AŃe` b bi gÄy Kiv thŃZ citi cŃqirB ŃbB weariq AŃe` b bi gÄy Kiv nj	
99.	Ziska Pharmaceuticals Ltd.	Levodopa 50 mg + Benserazide 12 .5 mg capsule	Levodopa BP 50 mg + Benserazide INN 12 .5 mg	Antiparkinsonian	It is indicated for the treatment of all forms of Parkinson's syndrome with the exception of medicine-induced parkinsonism. Limitations of Use: Use only if a clear diagnosis of migraine headache has been established. Not indicated for the prophylactic therapy of migraine attacks. Not indicated for the treatment of cluster headache.	Contraindications: History of coronary artery disease or coronary vasospasm. History of coronary artery bypass graft surgery. (Wolff-Parkinson-White syndrome or other cardiac accessory conduction, pathway disorders. History of stroke, transient ischemic attack, or hemiplegic or basilar migraine. Peripheral vascular disease. Ischemic bowel disease. Uncontrolled hypertension. Side effects: Haemolytic anaemia, transient leucopenia and thrombocytopenia have been reported in rare cases. Anorexia, Agitation, anxiety, insomnia, hallucinations, delusions and temporal disorientation may occur particularly in elderly patients. Ageusia, Cardiac arrhythmia, muscle cramps, hypotonia may occur.	New		cŃqirB ŃbB weariq AŃe` b bi gÄy Kiv thŃZ citi cŃqirB ŃbB weariq AŃe` b bi gÄy Kiv nj	

<i>bs</i>	<i>c0ZKvi#K big</i>	<i>Jl#ai big</i>	<i>#R#biiK big</i>	<i>#_i wC DiiUK Km</i>	<i>ib#`Rbv</i>	Contra-indication & Side-effect	Status (New Molecule/ Existing)	<i>A#e`bKvix KZ# USFDA/BNF /MHRA Ref.</i>	<i>#UKibK`vj me Kigi#i mfvi m#v#S#</i>	<i>mfvi m#v#S#</i>
100.	Beacon Pharmaceutical Ltd.	Paliperidone 75mg/0.75ml pre-filled syringe	Paliperidone Palmitate INN 117.00mg eq. to Paliperidone 75mg/0.75ml	Antipsychotic	It is an atypical antipsychotic indicated for <ul style="list-style-type: none"> • Treatment of schizophrenia. • Treatment of schizoaffective disorder as monotherapy and as an adjunct to mood stabilizers or antidepressants. 	Contraindication: Known hypersensitivity to paliperidone, risperidone, or to any excipients in Paliperidone Side effect: The most common adverse reactions (incidence \geq 5% and occurring at least twice as often as placebo) were injection site reactions, somnolence/sedation, dizziness, akathisia, and extrapyramidal disorder	New	USFDA	<i>Ab#gr`b Kiv th#Z c#i </i>	<i>Ab#gr`b Kiv nj </i>
101.	Beacon Pharmaceutical Ltd.	Paliperidone 100mg/1.0ml pre-filled syringe	Paliperidone Palmitate INN 156.00mg eq. to Paliperidone 100mg/1.0ml	Antipsychotic	It is an atypical antipsychotic indicated for <ul style="list-style-type: none"> • Treatment of schizophrenia. • Treatment of schizoaffective disorder as monotherapy and as an adjunct to mood stabilizers or antidepressants. 	Contraindication: Known hypersensitivity to paliperidone, risperidone, or to any excipients in Paliperidone Side effect: The most common adverse reactions (incidence \geq 5% and occurring at least twice as often as placebo) were injection site reactions, somnolence/sedation, dizziness, akathisia, and extrapyramidal disorder	New	USFDA	<i>Ab#gr`b Kiv th#Z c#i </i>	<i>Ab#gr`b Kiv nj </i>
102.	Beacon Pharmaceutical Ltd.	Paliperidone 150mg/1.5ml pre-filled Syringe	Paliperidone Palmitate INN 234.00mg eq. to Paliperidone 150mg/1.5ml	Antipsychotic	It is an atypical antipsychotic indicated for <ul style="list-style-type: none"> • Treatment of schizophrenia. • Treatment of schizoaffective disorder as monotherapy and as an adjunct to mood stabilizers or antidepressants. 	Contraindication: Known hypersensitivity to paliperidone, risperidone, or to any excipients in Paliperidone Side effect: The most common adverse reactions (incidence \geq 5% and occurring at least twice as often as placebo) were injection site reactions, somnolence/sedation, dizziness, akathisia, and extrapyramidal disorder	New	USFDA	<i>Ab#gr`b Kiv th#Z c#i </i>	<i>Ab#gr`b Kiv nj </i>
103.	Beacon Pharmaceutical Ltd.	Paliperidone 25mg/0.25ml pre-filled syringe	Paliperidone Palmitate INN 39.00mg eq. to Paliperidone 25mg/0.25ml	Antipsychotic	It is an atypical antipsychotic indicated for <ul style="list-style-type: none"> • Treatment of schizophrenia. • Treatment of schizoaffective disorder as monotherapy and as an adjunct to mood stabilizers or antidepressants. 	Contraindication: Known hypersensitivity to paliperidone, risperidone, or to any excipients in Paliperidone Side effect: The most common adverse reactions (incidence \geq 5% and occurring at least twice as often as placebo) were injection site reactions, somnolence/sedation, dizziness, akathisia, and extrapyramidal disorder	New	USFDA	<i>Ab#gr`b Kiv th#Z c#i </i>	<i>Ab#gr`b Kiv nj </i>

bs	cŃZKviŃK big	JlŃai big	ŃRŃbniK big	Ń_ iwcDitUK Kvm	ibŃ Rbv	Contra-indication & Side-effect	Status (New Molecule/ Existing)	AvŃe`bKvir KZŃ USFDA/BNF /MHRA Ref.	ŃUKibK`ij me KugŃli mfvi m×vŃŃ	mfvi m×vŃŃ
104.	Beacon Pharmaceutic al Ltd.	Paliperidone 50mg/0.5ml pre- filled syringe	Paliperidone Palmitate INN 78.00mg eq. to Paliperidone 50mg/0.5ml	Antipsychotic	It is an atypical antipsychotic indicated for • Treatment of schizophrenia. • Treatment of schizoaffective disorder as monotherapy and as an adjunct to mood stabilizers or antidepressants.	Contraindication: Known hypersensitivity to paliperidone, risperidone, or to any excipients in Paliperidone Side effect: The most common adverse reactions (incidence ≥ 5% and occurring at least twice as often as placebo) were injection site reactions, somnia/sedation, dizziness, akathisia, and extrapyramidal disorder	New	USFDA	AbŃgr`b Kiv thŃZ cŃi	AbŃgr`b Kiv nj
105.	M/s. Julphar Bangladesh Ltd. Sreepur, Gazipur, Dhaka	Brexipiprazole 0.5 Tablet	Brexipiprazole INN 0.50mg	Antipsychot ic	Use as an adjunctive therapy to antidepressants for the treatment of major depressive disorder, Treatment of schizophrenia	Contra-indication: Reactions have included rash, facial swelling, urticaria, and anaphylaxis. Elderly patients with dementia-related psychosis treated with antipsychotic drugs are at an increased risk of death. Side-effect: Most common adverse reactions Weight increased and Akathisia	New	USFDA	AbŃgr`b Kiv thŃZ cŃi	AbŃgr`b Kiv nj
106.	M/s. Julphar Bangladesh Ltd. Sreepur, Gazipur, Dhaka	Brexipiprazole 1.0mg Tablet	Brexipiprazole INN 1.0mg	Antipsychot ic	Use as an adjunctive therapy to antidepressants for the treatment of major depressive disorder, Treatment of schizophrenia	Contra-indication: Reactions have included rash, facial swelling, urticaria, and anaphylaxis. Elderly patients with dementia-related psychosis treated with antipsychotic drugs are at an increased risk of death. Side-effect: Most common adverse reactions Weight increased and Akathisia	New	USFDA	AbŃgr`b Kiv thŃZ cŃi	AbŃgr`b Kiv nj
107.	Eskayef Pharmaceutic als Limited	Levodropropizin e 30mg/5ml Syrup	Levodropropizine BP 0.6gm /100ml	Antitussives	It is indicated for the symptomatic therapy of cough.	Contraindications: Hypersensitivity Side effects: Urticaria, erythema, exanthema, itching.			cŃqŃRb ŃbB weavq AvŃe`b bŃ gŃj Kiv thŃZ cŃi	cŃqŃRb ŃbB weavq AvŃe`b bŃgŃj Kiv nj

<i>bs</i>	<i>cŃZKviŃK big</i>	<i>JlŃai big</i>	<i>ŃRŃbniŃK big</i>	<i>Ń_ iwcDitŃK Km</i>	<i>ibŃ Rbv</i>	Contra-indication & Side-effect	Status (New Molecule/ Existing)	<i>AŃe` bKvix KZŃ USFDA/BNF / MHRA Ref.</i>	<i>ŃUKibK`ij me KugŃli mfvi imxvŃŃ</i>	<i>mfvi imxvŃŃ</i>
108.	Popular Pharmaceuticals Limited	Esomeprazole 20mg + Domperidone 30mg Capsule	Esomeprazole Magnesium Trihydrate USP 22.300 mg eq. to 20mg Esomeprazole + Domperidone BP 30 mg	Antiulcerant + Antiemetic	It is indicated for the management of: Functional Dyspepsia (Non-ulcer Dyspepsia) symptom complex associated with gastroesophageal reflux disease (GERD): epigastric sense of fullness, feeling of abdominal distension, upper abdominal pain, nausea, vomiting, belching, flatulence, and early satiety,	Contraindications: It is contraindicated in patients with known hypersensitivity to Esomeprazole or other substituted benzimidazoles or to Domperidone or other dopamine antagonists. ESOMEPRAZOLE + DOMPERIDONE should not be used whenever stimulation of gastrointestinal motility might be dangerous such as in the presence of gastrointestinal haemorrhage, mechanical obstruction, or perforation. ESOMEPRAZOLE + DOMPERIDONE is contraindicated in patients with prolactinoma (a prolactin releasing pituitarytumour). Side Effects: Esomeprazole Common adverse events reported with Esomeprazole in clinical trials include headache, nausea, vomiting, diarrhoea, abdominal pain, flatulence, constipation and dry mouth. Other less commonly reported adverse effects include dizziness, insomnia, allergic reactions, asthenia, bowel irregularity, urticaria, etc. The incidence of treatment-related adverse events during 6-month maintenance treatment with Esomeprazole was similar to placebo. There were no differences in types of related adverse events seen during maintenance treatment up to 12 months compared to short-term treatment. Domperidone The most frequent reactions to Domperidone are those related to elevated			<i>cŃqirb ŃbB weariq AŃe` b bigÄy Kiv thŃZ cŃti </i> <i>cŃqirb ŃbB weariq AŃe` b bigÄy Kiv nj </i>	

						<p>prolactin levels including breast tenderness, galactorrhoea, gynaecomastia and amenorrhoea. These effects are dose-related and gradually resolve after lowering the dose or discontinuing treatment.</p> <p>Other rarely reported adverse reactions include headache, diarrhoea, dizziness, mild and transient abdominal cramps, dry mouth and drowsiness. Rare allergic reactions, such as rash and urticaria, have also been reported. Extrapyrimal reactions occur very rarely in adults and usually resolve completely and spontaneously after cessation of treatment.</p>				
109.	Popular Pharmaceuticals Limited	Esomeprazole 40 mg + Domperidone 30mg Capsule	Esomeprazole Magnesium Trihydrate USP 44.600 mg eq. to 40mg Esomeprazole + Domperidone BP 30 mg	Antiulcerant + Antiemetic	<p>It is indicated for the management of: Functional Dyspepsia (Non-ulcer Dyspepsia) Dyspeptic symptom complex associated with gastroesophageal reflux disease (GERD): epigastric sense of fullness, feeling of abdominal distension, upper abdominal pain, nausea, vomiting, belching, flatulence, and early satiety,</p>	<p>Contraindications: It is contraindicated in patients with known hypersensitivity to Esomeprazole or other substituted benzimidazoles or to Domperidone or other dopamine antagonists.</p> <p>ESOMEPRAZOLE + DOMPERIDONE should not be used whenever stimulation of gastrointestinal motility might be dangerous such as in the presence of gastrointestinal haemorrhage, mechanical obstruction, or perforation.</p> <p>ESOMEPRAZOLE + DOMPERIDONE is contraindicated in patients with prolactinoma (a prolactin releasing pituitarytumour).</p> <p>Side Effects: Esomeprazole Common adverse events reported with Esomeprazole in clinical trials include headache, nausea, vomiting, diarrhoea, abdominal pain, flatulence, constipation and dry mouth.</p> <p>Other less commonly reported adverse effects include dizziness, insomnia, allergic reactions, asthenia, bowel irregularity, urticaria, etc.</p> <p>The incidence of treatment-related adverse</p>			<p>ሪባራብ ትቤ ወላግ ላገጥጥ ብሮ ገላጅ ክብ ስከረ ርከብ </p>	<p>ሪባራብ ትቤ ወላግ ላገጥጥ ብሮ ገላጅ ክብ ስከረ ርከብ </p>

						<p>events during 6-month maintenance treatment with Esomeprazole was similar to placebo. There were no differences in types of related adverse events seen during maintenance treatment up to 12 months compared to short-term treatment.</p> <p>Domperidone</p> <p>The most frequent reactions to Domperidone are those related to elevated prolactin levels including breast tenderness, galactorrhoea, gynaecomastia and amenorrhoea. These effects are dose-related and gradually resolve after lowering the dose or discontinuing treatment.</p> <p>Other rarely reported adverse reactions include headache, diarrhoea, dizziness, mild and transient abdominal cramps, dry mouth and drowsiness. Rare allergic reactions, such as rash and urticaria, have also been reported. Extrapyrarnidal reactions occur very rarely in adults and usually resolve completely and spontaneously after cessation of treatment.</p>				
110.	<p>a) Incepta Pharmaceuticals Ltd.; Zirabo, Savar, Dhaka</p> <p>b) Julphar Bangladesh Ltd. Sreepur, Gazipur, Dhaka</p> <p>c) Beacon Pharmaceutical Ltd.</p>	Tenofovir Alafenamide 25 mg Tablet	Tenofovir Alafenamide Fumarate INN 28.0mg eq. to Tenofovir Alafenamide 25 mg	Antiviral	It is a hepatitis B virus (HBV) nucleoside analog reverse transcriptase inhibitor and is indicated for the treatment of chronic hepatitis B virus infection in adults with compensated liver disease	<p>Contraindication: None</p> <p>Side effect: Most common adverse reactions (incidence greater than or equal to 5%, all grades) are headache, abdominal pain, fatigue, cough, nausea, and back pain</p>	Tenofovir Disoproxil Fumarate 300mg Tablet	USFDA	Abşgr b Kiv thZ cıı /	Abşgr b Kiv nj /

						serious adverse events. In other hepatitis B vaccines, anaphylaxis and other types of immediate hypersensitivity reactions in very low proportion, which have Place in the first hours after the administration of the vaccine. To date there is no confirmed scientific evidence that Hepatitis B causes diseases of the central or peripheral nervous system such as Guillain Barré, optic neuritis, multiple sclerosis or other demyelinating diseases, Chronic fatigue syndrome, rheumatoid arthritis or autoimmune diseases. It is recommended to evaluate the suitability of using an effective treatment for chronic hepatitis B and its Sequelae through therapeutic vaccination against risk, not scientifically confirmed, To induce any of these diseases				
112.	Beacon Pharmaceutical Ltd.	HBV Surface Antigen (HBsAg) 0.10mg + HBV Nucleocapsid Antigen (AgnHB) 0.10mg/ml Solution for Intranasal spray	HBV Surface Antigen (HBsAg)INN 0.10mg + HBV Nucleocapsid Antigen (AgnHB) INN 0.10mg/ml	Antiviral	HBV surface antigen (HBsAg) & HBV nucleocapsid antigen (AgnHB) is indicated for active immunotherapy against chronic infection by the virus of hepatitis B, once established, and for the prevention of its potential consequences such as cirrhosis of the liver, chronic liver failure, and primary hepatocellular carcinoma. HBV surface antigen (HBsAg) & HBV nucleocapsid antigen (AgnHB) is not recommended for use in children under 18 years of age, as clinical experience with this product	Contra-indication: It should not be given to individuals with febrile conditions due to severe infections, or Persons allergic to any component of the vaccine, or who have undergone a reaction Severe adverse events at a previous dose. HBV surface antigen (HBsAg) & HBV nucleocapsid antigen (AgnHB) should not be administered to patients with ALAT or ASAT enzyme levels Above 500 IU / L, respectively. Nor should it be given to patients with Hepatocellular carcinoma, cirrhosis of the liver, or history of liver transplantation Side effect: Clinical studies show that the HBV surface antigen (HBsAg) & HBV nucleocapsid antigen (AgnHB) therapeutic vaccine is highly safe. Adverse events occur only in a small number of people and are mild and of short duration. The most frequent events, according to the total doses administered, were: pain at the site of Injection (27.8%), sneezing	New	किडवा	Abtgv`b Kiv thtZ cti	Abtgv`b Kiv nj

						(20.5%), nasal secretion (6.8%), mild local burning at the site of Inoculation (6.8%), nasal pruritus (5.1%), mild fever below 38°C (4.4%), and malaise (4.4%). All these symptoms disappear spontaneously in the first few hours without Need for treatment. In any case, it is recommended to consult the doctor before Occurrence of any undesirable manifestation. So far, in the studies conducted there have been no reports of major Intensity or events ad So far, in the studies conducted there have been no reports of major Intensity or serious adverse events. In other hepatitis B vaccines, anaphylaxis and other types of immediate hypersensitivity reactions in very low proportion, which have Place in the first hours after the administration of the vaccine. To date there is no confirmed scientific evidence that Hepatitis B causes diseases of the central or peripheral nervous system such as Guillain Barré, optic neuritis, multiple sclerosis or other demyelinating diseases, Chronic fatigue syndrome, rheumatoid arthritis or autoimmune diseases. It is recommended to evaluate the suitability of using an effective treatment for chronic hepatitis B and its Sequelae through therapeutic vaccination against risk, not scientifically confirmed, To induce any of these diseases				
113.	Eskayef Pharmaceuticals Limited	Tamsulosin Hydrochloride 0.4mg + Solifenacin Succinate 6mg Modified Release FC Tablet	Tamsulosin Hydrochloride BP 0.4mg + Solifenacin Succinate INN 6mg	Benign Prostatic Hypertrophy Agent + Urinary Antispasmodic	It is used for the treatment of moderate to severe storage symptoms (urgency, increased micturition frequency) and voiding symptoms associates with benign prostatic hyperplasia in men.	Contraindications: Hypersensitivity, patients undergoing hemodialysis, hepatic impairment, renal impairment. Side effects: Constipation, dyspepsia, dizziness, vision blurred fatigue.	Dutasteride 500 mcg + Tamsulosin Hydrochloride 400 mcg Capsule		<i>cłqıRb tbB wearıq Arıte`b bıgÄy Kıv thıZ cıti </i>	<i>cłqıRb tbB wearıq Arıte`b bıgÄy Kıv nj </i>

<i>bs</i>	<i>c0ZKvi#K big</i>	<i>Jl#ai big</i>	<i>#R#biiK big</i>	<i>#_i wicDi#K Kim</i>	<i>ib#`Rbv</i>	Contra-indication & Side-effect	Status (New Molecule/ Existing)	<i>Av#`bKvix KZ# USFDA/BNF /MHRA Ref.</i>	<i>#UK#bK`vj me Kigi#i mfvi m#x#S#</i>	<i>mfvi m#x#S#</i>
114.	Incepta Pharmaceuticals Ltd.; Zirabo, Savar, Dhaka	Labetalol Hydrochloride 300mg Tablet	Labetalol Hydrochloride BP 300mg	Antihypertensive	It is indicated in the management of hypertension. Labetalol tablets may be used alone or in combination with other antihypertensive agents, especially thiazide and loop diuretics.	<p>Contra-indication: Labetalol Tablets are contraindicated in bronchial asthma, overt cardiac failure, greater-than-first-degree heart block, cardiogenic shock, severe bradycardia, other conditions associated with severe and prolonged hypotension, and in patients with a history of hypersensitivity to any component of the product. Beta-blockers, even those with apparent cardioselectivity, should not be used in patients with a history of obstructive airway disease, including asthma</p> <p>Side effect: Body as a Whole: Fever. Cardiovascular: Hypotension, and rarely, syncope, bradycardia, heart block. Central and Peripheral Nervous Systems: Paresthesia, most frequently described as scalp tingling. In most cases, it was mild and transient and usually occurred at the beginning of treatment. Collagen Disorders: Systemic lupus erythematosus, positive antinuclear factor. Eyes: Dry eyes. Immunological System: Antimitochondrial antibodies. Liver and Biliary System: Hepatic necrosis, hepatitis, cholestatic jaundice, elevated liver function tests. Musculoskeletal System: Muscle cramps, toxic myopathy. Respiratory System: Bronchospasm. Skin and Appendages: Rashes of various types, such as generalized maculopapular, lichenoid, urticarial, bullous lichen planus,</p>	100mg & 200mg Tablet 5.0 mg/ml IV injection	USFDA	<i>c#q#Rb #bB weavq Av#`b big#y Kiv thiZ citi </i>	<i>c#q#Rb #bB weavq Av#`b big#y Kiv nj </i>

						psoriaform, and facial erythema; Peyronie's disease; reversible alopecia. Urinary System: Difficulty in micturition, including acute urinary bladder retention. Hypersensitivity: Rare reports of hypersensitivity (e.g., rash, urticaria, pruritus, angioedema, dyspnea) and anaphylactoid reactions.				
115.	Eskayef Pharmaceuticals Limited	Dexpanthenol 5% Ointment	Dexpanthenol BP 5gm/100gm	Cicatrizant	It is used for the prevention and treatment of chafed, cracked or split skin, dry skin, regular breast care, for the treatment of sore nipples, protective barrier against nappy (diaper) wetness and for the prevention and treatment of chafing, redness and diaper rash.	Contraindications: Hypersensitivity. Side effects: Allergic reaction	New		Abjgr`b Kiv thZ cwi	Abjgr`b Kiv nj
116.	Beacon Pharmaceutical Ltd.	Deutetrabenazine 12mg Tablet	Deutetrabenazine INN 12mg	CNS Agent	It is a vesicular monoamine transporter 2 (VMAT2) inhibitor indicated for the treatment of chorea associated with Huntington's disease	Contra-indication: Suicidal, or untreated/inadequately treated depression, Hepatic impairment; Taking MAOIs, reserpine, or tetrabenazine Side effect: Most common adverse reactions (>8% of AUSTEDO-treated patients and greater than placebo) were: somnolence, diarrhea, dry mouth, and fatigue	New	USFDA	Abjgr`b Kiv thZ cwi	Abjgr`b Kiv nj
117.	Beacon Pharmaceutical Ltd.	Deutetrabenazine 6mg Tablet	Deutetrabenazine INN 6mg	CNS Agent	It is a vesicular monoamine transporter 2 (VMAT2) inhibitor indicated for the treatment of chorea associated with Huntington's disease	Contra-indication: Suicidal, or untreated/inadequately treated depression, Hepatic impairment; Taking MAOIs, reserpine, or tetrabenazine Side effect: Most common adverse reactions (>8% of AUSTEDO-treated patients and greater than placebo) were: somnolence, diarrhea, dry mouth, and fatigue	New	USFDA	Abjgr`b Kiv thZ cwi	Abjgr`b Kiv nj
118.	Beacon Pharmaceutical Ltd.	Deutetrabenazine 9mg Tablet	Deutetrabenazine INN 9mg	CNS Agent	It is a vesicular monoamine transporter 2 (VMAT2) inhibitor indicated for the treatment of chorea associated with Huntington's disease	Contra-indication: Suicidal, or untreated/inadequately treated depression, Hepatic impairment; Taking MAOIs, reserpine, or tetrabenazine Side effect: Most common adverse reactions (>8% of AUSTEDO-treated patients and greater than placebo) were: somnolence, diarrhea, dry mouth, and fatigue	New	USFDA	Abjgr`b Kiv thZ cwi	Abjgr`b Kiv nj

bs	cŃZKviŃK big	JlŃai big	ŃRŃbniŃK big	Ń_ iwcDŃUK Km	ŃbŃ Rbv	Contra-indication & Side-effect	Status (New Molecule/ Existing)	AŃe`bKvix KZŃ USFDA/BNF /MHRA Ref.	ŃUKŃbK`ij me KŃgŃli mfvi ŃmŃvŃŃ	mfvi ŃmŃvŃŃ
119.	UniMed & UniHealth Mfg. Ltd.	Riluzole 50mg Tablet	Riluzole USP 50mg	CNS Agent	To extend life in patients with amyotrophic lateral sclerosis, initiated by specialist experienced in the management of motor neurone disease	<p><u>Contra-indication:</u> Acute porphyria</p> <p><u>Side effect:</u></p> <ul style="list-style-type: none"> ➤ Common or very common: Abdominal pain, asthenia, diarrhea, dizziness, drowsiness headache, nausea, oral, par aesthesia , tachycardia, vomiting ➤ Uncommon: Anaemia, angioedema, interstitial lung, disease, pancreatitis ➤ Rare Neutropenia ➤ Very rare Hepatitis 		BNF-73 Page-983	AbŃgv`b Kiv thŃZ cŃi	AbŃgv`b Kiv nj
120.	GLOBE Pharmaceutic als ltd.	Sargramostim 250 mcg/Vial Lyophilized Powder for Injection	Sargramostim INN 250 mcg/ml (1.4 x 10 ⁶ IU) in a Vial	Colony Stimulating Factor	<p>In Acute Myelogenous Leukemia Sargramostim is indicated for use following induction chemotherapy in older adult patients with acute myelogenous leukemia (AML) to shorten time to neutrophil recovery and to reduce the incidence of severe and life-threatening infections and infections resulting in death.</p> <p>In Mobilization of Autologous Peripheral Blood Progenitor Cells (PBPC) Sargramostim is indicated for the mobilization of hematopoietic progenitor cells into peripheral blood for collection by leukapheresis.</p> <p>In Autologous Bone Marrow Transplantation Sargramostim is indicated for acceleration of myeloid recovery in patients with non-Hodgkin's lymphoma (NHL), acute lymphoblastic leukemia (ALL) and Hodgkin's disease undergoing autologous bone marrow</p>	<p>Contraindications: Sargramostim is contraindicated-</p> <ul style="list-style-type: none"> ◆ In patients with excessive leukemic myeloid blasts in the bone marrow or peripheral blood (≥ 10%). ◆ In patients with known hypersensitivity to GM-CSF, yeast derived products or any component of the product. ◆ For concomitant use with chemotherapy and radiotherapy. <p>Due to the potential sensitivity of rapidly dividing hematopoietic progenitor cells, Sargramostim should not be administered simultaneously with cytotoxic chemotherapy or radiotherapy or within 24 hours preceding or following chemotherapy or radiotherapy. In one controlled study, patients with small cell lung cancer received Sargramostim and concurrent thoracic radiotherapy and chemotherapy or the identical radiotherapy</p>	New	USFDA	AbŃgv`b Kiv thŃZ cŃi	AbŃgv`b Kiv nj

				<p>transplantation (BMT).</p> <p>In Allogeneic Bone Marrow Transplantation Sargramostim is indicated for acceleration of myeloid recovery in patients undergoing allogeneic BMT from HLA matched related donors.</p> <p>In Bone Marrow Transplantation Failure or Engraftment Delay Sargramostim is indicated in patients who have undergone allogeneic or autologous bone marrow transplantation (BMT) in whom engraftment is delayed or has failed.</p>	<p>and chemotherapy without Sargramostim. The patients randomized to Sargramostim had significantly higher incidence of adverse events, including higher mortality and a higher incidence of grade 3 and 4 infections and grade 3 and 4 thrombocytopenia.</p> <p>Side effects: Adverse events observed for the patients treated with Sargramostim in the historically-controlled BMT failure study were similar to those reported in the placebo-controlled studies. In addition, headache (26%), pericardial effusion (25%), arthralgia (21%) and myalgia (18%) were also reported in patients treated with Sargramostim in the graft failure study.</p> <p>The most frequent adverse events were fever, asthenia, headache, bone pain, chills and myalgia. These systemic events were generally mild or moderate and were usually prevented or reversed by the administration of analgesics and antipyretics such as acetaminophen. Reports of events occurring with Sargramostim include arrhythmia, fainting, eosinophilia, dizziness, hypotension, injection site reactions, pain (including abdominal, back, chest, and joint pain), tachycardia, thrombosis, and transient liver function abnormalities. In patients with preexisting edema, capillary leak syndrome, pleural and/or pericardial effusion, administration of Sargramostim may aggravate fluid retention.</p>				
--	--	--	--	---	--	--	--	--	--

bs	cŃZKviŃK bug	JlŃai bug	ŃRŃbniŃK bug	Ń_ iwcDitŃK Kvm	ibŃ Rbv	Contra-indication & Side-effect	Status (New Molecule/ Existing)	AŃe`bKvir KZŃ USFDA/BNF /MHRA Ref.	ŃUKibK`ij me KugŃi mfvi m×vŃŃ	mfvi m×vŃŃ
121.	Globe Pharmaceutic als ltd.	Sargramostim 500 mcg Solution for Injection	Sargramostim INN 500 mcg/ ml (2.8 x 10 ⁶ IU/ ml) in a vial	Colony Stimulating Factor	<p>In Acute Myelogenous Leukemia Sargramostim is indicated for use following induction chemotherapy in older adult patients with acute myelogenous leukemia (AML) to shorten time to neutrophil recovery and to reduce the incidence of severe and life-threatening infections and infections resulting in death.</p> <p>In Mobilization of Autologous Peripheral Blood Progenitor Cells (PBPC) Sargramostim is indicated for the mobilization of hematopoietic progenitor cells into peripheral blood for collection by leukapheresis.</p> <p>In Autologous Bone Marrow Transplantation Sargramostim is indicated for acceleration of myeloid recovery in patients with non-Hodgkin's lymphoma (NHL), acute lymphoblastic leukemia (ALL) and Hodgkin's disease undergoing autologous bone marrow transplantation (BMT).</p> <p>In Allogeneic Bone Marrow Transplantation Sargramostim is indicated for acceleration of myeloid recovery in patients undergoing allogeneic BMT from HLA matched related donors.</p> <p>In Bone Marrow Transplantation</p>	<p>Contraindications: Sargramostim is contraindicated-</p> <ul style="list-style-type: none"> ◆ In patients with excessive leukemic myeloid blasts in the bone marrow or peripheral blood (≥ 10%). ◆ In patients with known hypersensitivity to GM-CSF, yeast derived products or any component of the product. ◆ For concomitant use with chemotherapy and radiotherapy. <p>Due to the potential sensitivity of rapidly dividing hematopoietic progenitor cells, Sargramostim should not be administered simultaneously with cytotoxic chemotherapy or radiotherapy or within 24 hours preceding or following chemotherapy or radiotherapy. In one controlled study, patients with small cell lung cancer received Sargramostim and concurrent thoracic radiotherapy and chemotherapy or the identical radiotherapy and chemotherapy without Sargramostim. The patients randomized to Sargramostim had significantly higher incidence of adverse events, including higher mortality and a higher incidence of grade 3 and 4 infections and grade 3 and 4 thrombocytopenia.</p> <p>Side effects: Adverse events observed for the patients treated with Sargramostim in the historically-controlled BMT failure</p>	New	USFDA	AbŃgr`b Kiv thŃZ cŃi	AbŃgr`b Kiv nj

					<p>Failure or Engraftment Delay Sargramostim is indicated in patients who have undergone allogeneic or autologous bone marrow transplantation (BMT) in whom engraftment is delayed or has failed.</p>	<p>study were similar to those reported in the placebo-controlled studies. In addition, headache (26%), pericardial effusion (25%), arthralgia (21%) and myalgia (18%) were also reported in patients treated with Sargramostim in the graft failure study.</p> <p>The most frequent adverse events were fever, asthenia, headache, bone pain, chills and myalgia. These systemic events were generally mild or moderate and were usually prevented or reversed by the administration of analgesics and antipyretics such as acetaminophen. Reports of events occurring with Sargramostim include arrhythmia, fainting, eosinophilia, dizziness, hypotension, injection site reactions, pain (including abdominal, back, chest, and joint pain), tachycardia, thrombosis, and transient liver function abnormalities. In patients with preexisting edema, capillary leak syndrome, pleural and/or pericardial effusion, administration of Sargramostim may aggravate fluid retention.</p>				
122.	GLOBE Pharmaceutic als Ltd.	Baricitinib 2 mg Tablet	Baricitinib INN 2 mg	Antiheumatic Drugs	<p>Baricitinib is indicated for the treatment of moderate to severe active rheumatoid arthritis in adult patients who have responded inadequately to, or who are intolerant to one or more disease-modifying anti-rheumatic drugs (DMARDs).</p>	<p>Contraindications: Hypersensitivity to the active substance or to any of the excipients of the formulation and in pregnancy.</p> <p>Side Effects: Common side effects are Upper respiratory tract infections, Hypercholesterolemia, Herpes zoster, Herpes simplex, Gastroenteritis, Urinary tract infections, Nausea etc.</p>	New		<p><i>c#q1Rb #bB wearq Aite`b bigÄy Kiv thtZ citi </i></p>	<p><i>c#q1Rb #bB wearq Aite`b bigÄy Kiv nj </i></p>

bs	cŃZKviŃK big	JlŃai big	ŃRŃbniK big	Ń_ iwcDitŃK Km	ibŃ Rbv	Contra-indication & Side-effect	Status (New Molecule/ Existing)	AŃe` bKvix KZŃ USFDA/BNF / MHRA Ref.	ŃUKibK`ij me KugŃli mfvi imxvŃŃ	mfvi imxvŃŃ
123.	GLOBE Pharmaceuticals Ltd.	Baricitinib 4 mg Tablet	Baricitinib INN 4 mg	Antiheumatic Drugs	Baricitinib is indicated for the treatment of moderate to severe active rheumatoid arthritis in adult patients who have responded inadequately to, or who are intolerant to one or more disease-modifying anti-rheumatic drugs (DMARDs).	Contraindications: Hypersensitivity to the active substance or to any of the excipients of the formulation and in pregnancy. Side Effects: Common side effects are Upper respiratory tract infections, Hypercholesterolemia, Herpes zoster, Herpes simplex, Gastroenteritis, Urinary tract infections, Nausea etc.	New		cŃqivRb ŃbB weariq AŃe` b bŃ gÄy Kiv thŃZ cŃti	cŃqivRb ŃbB weariq AŃe` b bigÄy Kiv nj
124.	UniMed & UniHealth Mfg. Ltd.	Liquid Paraffin 50% + White Soft Paraffin 50% Ointment	Liquid Paraffin BP 50gm + White Soft Paraffin 50gm/100gm	Emollient	For general use as an emollient in the symptomatic relief of dry skin conditions.	Contra-indication: Hypersensitivity to either White Soft paraffin or Liquid Paraffin. Side effect: Rarely hypersensitivity reactions. Prolonged use of large quantities may cause folliculitis, should this occur, use of the product should be discontinued.	Light Liquid Paraffin 6% + White Soft Paraffin 15% Cream	BNF-73 Page-1081	AbŃgv` b Kiv thŃZ cŃti	AbŃgv` b Kiv nj
125.	1) Beximco Pharma Ltd. 2) Eskayef Pharmaceuticals Limited. Gazipur.	Dextromethorphan Hydrobromide 0.40gm + Phenylephrine HCl 0.20gm + Triprolidine HCl 0.05gm/100ml Syrup	Dextromethorphan Hydrobromide BP 0.40gm + Phenylephrine HCl BP 0.20gm + Triprolidine HCl BP 0.05gm/100ml	Antitussive + Decongestant + Antihistamines	temporarily relieves these symptoms due to common cold, hay fever (allergic rhinitis) or other upper respiratory allergies: • cough due to minor throat or bronchial irritation • runny nose • sneezing • itching of the nose or throat • itchy, watery eyes • nasal congestion • reduces swelling of nasal passages	Contraindications: The product should be avoided in patients with liver disease or asthmatic patients and is contraindicated in patients taking monoamine oxidase inhibitors or within 2 weeks from stopping such treatment, known hypersensitivity to phenylephrine and during acute attacks of asthma. It is contra-indicated in patients with severe hypertension or severe coronary artery disease. Side effects: The combination may cause drowsiness, dizziness and constipation. Other side effects that may occur include GIT discomfort. No apparent evidence of physical dependence of the morphine type. Other less common side-effects may include transient hypertension, dry mouth, insomnia, restlessness.	Dextromethorphan Hydrobromide 10mg/5 ml Syrup		AbŃgv` b Kiv thŃZ cŃti	AbŃgv` b Kiv nj

bs	c0ZKvi#K big	Jl#ai big	#R#biiK big	#_i wicDi#K Kim	ib#`Rbv	Contra-indication & Side-effect	Status (New Molecule/ Existing)	A#e`bKvix KZ# USFDA/BNF /MHRA Ref.	#UK#bK`vj me Kug#i mfvi m#v#S#	mfvi m#v#S#
126.	Beximco Pharma Ltd.	Guaifenesin 4.00gm + Dextromethorphan hydrobromide 0.30gm + Menthol 0.30gm/100ml syrup.	Guaifenesin BP 4.0gm + Dextromethorphan Hydrobromide BP 0.30gm + Menthol USP 0.30gm/100ml	Expectorant + Antitussive + Analgesic	The combination is indicated for the effective relief of : • Cough with Phlegm • Chest Congestion • Sore Throat Pain	Contraindications: If one taking monoamine oxidase inhibitor (MAOI) (certain drugs for depression, psychiatric or emotional conditions, or Parkinson's disease), or for two weeks after stopping the MAOI drug. Do not use for children less than 12 years of age. Side effects: Common side effects may include: • dizziness, drowsiness; • sleep problems (insomnia); • diarrhea; or • feeling nervous, restless, anxious, or irritable.	Dextromethorphan Hydrobromide 10mg/5 ml Syrup		Ab#gv`b Kiv th#Z c#i	Ab#gv`b Kiv nj
127.	Eskayef Pharmaceuticals Limited	Ambroxol HCl 0.6gm/100ml Syrup	Ambroxol HCl BP 0.6gm/100ml	Expectorant	It is indicated as an auxiliary for the liquefaction of the mucus secretions of the respiratory tracts, in case of acute and chronic bronchoalveolar disorders (bronchitis, emphysema, tracheobronchitis, and chronic asthmatic bronchitis).	Contraindications: Hypersensitivity Side effects: Nausea, vomiting, diarrhoea, dyspepsia, abdominal pain, oral and pharyngeal numbness, dry mouth, dry throat.	15 mg/5 ml Syrup		c#q#Rb #bB #earq A#e`b big#y Kiv th#Z c#i	c#q#Rb #bB #earq A#e`b big#y Kiv nj
128.	Eskayef Pharmaceuticals Limited	Diphenhydramine Hydrochloride 14mg + Ammonium Chloride 135mg + levomenthol 1.1mg/5ml Syrup	Diphenhydramine Hydrochloride BP 0.28gm + Ammonium Chloride BP 2.7gm + levomenthol BP 0.022gm/100ml	Expectorant	For the oral symptomatic relief of common coughs (such as dry or tickly, or troublesome cough) associated with upper respiratory tract congestion and aids restful sleep.	Contraindications: Hypersensitivity to any of the ingredients. Side effects: CNS effects such as nervous drowsiness, paradoxical stimulation, Antimuscarinic effects such as urinary retention, dry mouth, blurred vision, hypotension, tremor, palpitation.			c#q#Rb #bB #earq A#e`b big#y Kiv th#Z c#i	c#q#Rb #bB #earq A#e`b big#y Kiv nj

bs	c0ZKvi#K big	Jl#ai big	#R#buiK big	#_i wicDi#K Km	ib#`Rbv	Contra-indication & Side-effect	Status (New Molecule/ Existing)	Av#`bKvix KZ# USFDA/BNF /MHRA Ref.	#UK#K`vj me Kug#i mfvi m#v#S#	mfvi m#v#S#
129.	Globe Pharmaceuticals Ltd.	Dextromethorphan Hydrobromide 5mg + Doxylamine Succinate 2 mg + Acetaminophen 108mg/5ml Syrup	Dextromethorphan Hydrobromide USP 5 mg + Doxylamine succinate USP 2 mg + Acetaminophen BP 108mg/5 ml	Expectorant	Indicated for the treatment of cough, sore throat, cold flu (fever, headache), sinus congestion, nasal congestion, runny nose, sneezing and rhinitis.	Contraindications: It is contraindicated if anyone has any allergy to one or any ingredients from this formulation or anyone have high blood pressure, severe heart blood vessel disease, rapid heartbeat, or severe heart problems. It's also contraindicated for asthmatic patients or those who are unable to urinate. Side effects: The common side effects are weakness, constipation, diarrhea, dizziness, drowsiness, excitability, headache, nausea, nervousness or anxiety.	New		c#q#Rb #bB weavq Av#`b bv g#y Kiv th#Z c#i	c#q#Rb #bB weavq Av#`b big#y Kiv nj
130.	Incepta Pharmaceuticals Ltd., Zirabo, Savar, Dhaka	Dextromethorphan HBr 60mg + Guaifenesin 1200mg Extended Release Bi-Layer Tablet	Dextromethorphan HBr BP 60mg + Guaifenesin BP 1200mg	Expectorant	Helps loosen phlegm (mucus) and thin bronchial secretions to rid the bronchial passageways of bothersome mucus and make coughs more productive temporarily relieve cough due to minor throat and bronchial Irritation as may occur with the common cold or inhaled irritants, the intensity of coughing.	Contraindications: None Side-effects: Not found	New	USFDA	Ab#gr`b Kiv th#Z c#i	Ab#gr`b Kiv nj
131.	Incepta Pharmaceuticals Ltd.; Zirabo, Savar, Dhaka	Betamethasone sodium phosphate BP 3.9750mg eq. to Betamethasone 3mg + Betamethasone Acetate BP 3mg/ml Injection 5ml Vial for Injection	Betamethasone sodium phosphate BP 3.9750mg eq. to Betamethasone 3mg + Betamethasone Acetate BP 3mg/ml	Glucocorticoids	When oral therapy is not feasible, the intramuscular use of Betamethasone sodium phosphate and betamethasone acetate Injectable Suspension is indicated as follows: Allergic States Control of severe or incapacitating allergic conditions intractable to adequate trials of conventional treatment in asthma, atopic dermatitis, contact dermatitis, drug hypersensitivity reactions, perennial or seasonal allergic rhinitis, serum sickness, transfusion reactions.	Contra-indication Betamethasone sodium phosphate and betamethasone acetate Injectable Suspension is contraindicated in patients who are hypersensitive to any components of this product. Intramuscular corticosteroid preparations are contraindicated for idiopathic thrombocytopenic purpura. Side effect Allergic Reactions Anaphylactoid reaction, anaphylaxis, angioedema.	New	USFDA	c#q#Rb #bB weavq Av#`b bv g#y Kiv th#Z c#i	c#q#Rb #bB weavq Av#`b big#y Kiv nj

				<p><u>Dermatologic Diseases</u> Bullous dermatitis herpetiformis, exfoliative erythroderma, mycosis fungoides, pemphigus, severe erythema multiforme (Stevens-Johnson syndrome).</p> <p><u>Endocrine Disorders</u> Congenital adrenal hyperplasia, hypercalcemia associated with cancer, nonsuppurative thyroiditis. Hydrocortisone or cortisone is the drug of choice in primary or secondary adrenocortical insufficiency. Synthetic analogs may be used in conjunction with mineralocorticoids where applicable; in infancy mineralocorticoid supplementation is of particular importance.</p> <p><u>Gastrointestinal Diseases</u> To tide the patient over a critical period of the disease in regional enteritis and ulcerative colitis.</p> <p><u>Hematologic Disorders</u> Acquired (autoimmune) hemolytic anemia, Diamond-Blackfan anemia, pure red cell aplasia, selected cases of secondary thrombocytopenia.</p> <p><u>Miscellaneous</u> Trichinosis with neurologic or myocardial involvement, tuberculous meningitis with subarachnoid block or impending block when used with appropriate antituberculous chemotherapy.</p> <p><u>Neoplastic Diseases</u> For palliative management of leukemias and lymphomas.</p> <p>Nervous System Acute exacerbations of multiple sclerosis; cerebral edema associated with primary or metastatic brain tumor</p>	<p><u>Cardiovascular</u> Bradycardia, cardiac arrest, cardiac arrhythmias, cardiac enlargement, circulatory collapse, congestive heart failure, fat embolism, hypertension, hypertrophic cardiomyopathy in premature infants, myocardial rupture following recent myocardial infarction, pulmonary edema, syncope, tachycardia, thromboembolism, thrombophlebitis, vasculitis.</p> <p><u>Dermatologic</u> Acne, allergic dermatitis, cutaneous and subcutaneous atrophy, dry scaly skin, ecchymoses and petechiae, edema, erythema, hyperpigmentation, hypopigmentation, impaired wound healing, increased sweating, rash, sterile abscess, striae, suppressed reactions to skin tests, thin fragile skin, thinning scalp hair, urticaria.</p> <p><u>Endocrine</u> Decreased carbohydrate and glucose tolerance, development of cushingoid state, glucosuria, hirsutism, hypertrichosis, increased requirements for insulin or oral hypoglycemic adrenocortical and pituitary unresponsiveness (particularly in times of stress, as in trauma, surgery, or illness), suppression of growth in pediatric patients.</p> <p><u>Fluid And Electrolyte Disturbances</u> Congestive heart failure in susceptible patients, fluid retention, hypokalemic alkalosis, potassium loss, sodium retention.</p> <p><u>Gastrointestinal</u> Abdominal distention, bowel/bladder dysfunction (after intrathecal administration), elevation in serum liver enzyme levels (usually reversible upon discontinuation), hepatomegaly, increased</p>				
--	--	--	--	---	--	--	--	--	--

				<p>or craniotomy.</p> <p><u>Ophthalmic Diseases</u> Sympathetic ophthalmia, temporal arteritis, uveitis and ocular inflammatory conditions unresponsive to topical corticosteroids.</p> <p><u>Renal Diseases</u> To induce diuresis or remission of proteinuria in idiopathic nephritic syndrome or that due to lupus erythematosus.</p> <p><u>Respiratory Diseases</u> Berylliosis, fulminating or disseminated pulmonary tuberculosis when used concurrently with appropriate antituberculous chemotherapy, idiopathic eosinophilic pneumonias, symptomatic sarcoidosis.</p> <p><u>Rheumatic Disorders</u> As adjunctive therapy for short-term administration (to tide the patient over an acute episode or exacerbation) in acute gouty arthritis; acute rheumatic carditis; ankylosing spondylitis; psoriatic arthritis; rheumatoid arthritis, including juvenile rheumatoid arthritis (selected cases may require low-dose maintenance therapy). For the treatment of dermatomyositis, polymyositis, and systemic lupus erythematosus.</p> <p>The intra-articular or soft tissue administration of celestone soluspan Injectable Suspension is indicated as adjunctive therapy for short-term administration (to tide the patient over an acute episode or exacerbation) in acute gouty arthritis, acute and subacute bursitis, acute nonspecific tenosynovitis, epicondylitis, rheumatoid arthritis, synovitis of osteoarthritis.</p>	<p>appetite, nausea, pancreatitis, peptic ulcer with possible perforation and hemorrhage, perforation of the small and large intestine (particularly in patients with inflammatory bowel disease), ulcerative esophagitis.</p> <p><u>Metabolic</u> Negative nitrogen balance due to protein catabolism.</p> <p><u>Musculoskeletal</u> Aseptic necrosis of femoral and humeral heads, calcinosis (following intra-articular or intralesional use), Charcot-like arthropathy, loss of muscle mass, muscle weakness, osteoporosis, pathologic fracture of long bones, postinjection flare (following intra-articular use), steroidmyopathy, tendon rupture, vertebral compression fractures.</p> <p><u>Neurologic/Psychiatric</u> Convulsions, depression, emotional instability, euphoria, headache, increased intracranial pressure with papilledema (pseudotumor cerebri) usually following discontinuation of treatment, insomnia, mood swings, neuritis, neuropathy, paresthesia, personality changes, psychic disorders, vertigo. Arachnoiditis, meningitis, paraparesis/paraplegia, and sensory disturbances have occurred after intrathecal administration.</p> <p><u>Ophthalmic</u> Exophthalmos, glaucoma, increased intraocular pressure, posterior subcapsular cataracts, rare instances of blindness associated with periocular injections. Other abnormal fat deposits, decreased resistance to infection, hiccups, increased or decreased motility and number of spermatozoa, malaise, moon face, weight gain.</p>				
--	--	--	--	--	--	--	--	--	--

					<p>The intralesional administration of celestone soluspan Injectable Suspension is indicated for alopecia areata; discoid lupus erythematosus; keloids; localized hypertrophic, infiltrated, inflammatory lesions of granuloma annulare, lichen planus, lichen simplex chronicus (neurodermatitis), and psoriatic plaques; necrobiosis lipoidica diabetorum.</p> <p>celestone soluspan Injectable Suspension may also be useful in cystic tumors of an aponeurosis or tendon (ganglia).</p>					
132.	Incepta Pharmaceuticals Ltd (Dhamrai Unit).	Drospirenone 3mg, Ethinylestradiol 0.03mg and L-methylfolate calcium 0.451mg Tablet	<p>Each blister pack (28 film-coated tablets) contains in the following order:</p> <ul style="list-style-type: none"> • 21 orange tablets each containing Drospirenone BP (DRSP) 3mg + Ethinylestradiol BP 0.03 mg + Levomefolate Calcium INN 0.451mg • 7 light orange tablets each containing L-methylfolate Calcium INN 0.451 mg 	Hormone (Oral Contraceptive)	<p>Oral Contraceptive This combination tablet is indicated for use by women to prevent pregnancy.</p> <p>Folate Supplementation This combination tablet is indicated in women who choose to use an oral contraceptive as their method of contraception, to raise folate levels for the purpose of reducing the risk of a neural tube defect in a pregnancy conceived while taking the product or shortly after discontinuing the product.</p>	<p>Contraindications: Do not prescribe this medication to women who are known to have the following:</p> <ul style="list-style-type: none"> • Renal impairment • Adrenal insufficiency • A high risk of arterial or venous thrombotic diseases. Examples include women who are known to: <ul style="list-style-type: none"> ○ Smoke, if over age 35 ○ Have deep vein thrombosis or pulmonary embolism, now or in the past ○ Have cerebrovascular disease ○ Have coronary artery disease ○ Have thrombogenic valvular or thrombogenic rhythm diseases of the heart (for example, subacute bacterial endocarditis with valvular disease, or atrial fibrillation). ○ Have inherited or acquired hypercoagulopathies [see Warnings and Precautions ○ Have uncontrolled hypertension ○ Have diabetes mellitus with vascular disease 	New	USFDA	Abjgr`b Kiv thZ cvti	Abjgr`b Kiv nj

						<ul style="list-style-type: none"> ○ Have headaches with focal neurological symptoms or have migraine headaches with or without aura if over age 35 • Undiagnosed abnormal uterine bleeding • Breast cancer or other estrogen- or progestin-sensitive cancer, now or in the past • Liver tumors, benign or malignant, or liver disease <p>Pregnancy, because there is no reason to use COCs during pregnancy</p> <p>Side effect: The most frequent adverse reactions ($\geq 2\%$) in contraception, acne and folate clinical trials are headache/migraine (5.9%), menstrual irregularities (4.1%), nausea/vomiting (3.5%) and breast pain/tenderness (3.2%).</p> <p>The most frequent adverse reactions ($\geq 2\%$) in PMDD clinical trials are menstrual irregularities (24.9%), nausea (15.8%), headache (13.0%), breast tenderness (10.5%), fatigue (4.2%), irritability (2.8%), decreased libido (2.8%), increased weight (2.5%), and affect lability.</p>				
--	--	--	--	--	--	---	--	--	--	--

bs	c0ZKvi#K big	Jl#ai big	#R#biiK big	#_iwcDiUK Kim	ib#`Rbv	Contra-indication & Side-effect	Status (New Molecule/ Existing)	A#e`bKvix KZ# USFDA/BNF /MHRA Ref.	#UKibK`vj me Kugidi mfvi m#v#S#	mfvi m#v#S#
133.	Beacon Pharmaceutical Ltd.	Human Immune Globulin 1.00gm/5ml (20%)Subcutaneous injection	Human Immune Globulin INN 1.00gm/5ml	Immune globulin	It is an Immune Globulin Subcutaneous (Human) (IGSC), 20% Liquid indicated for the treatment of primary immunodeficiency (PI) in adults and pediatric patients 2 years of age and older	Contraindication: • Anaphylactic or severe systemic reaction to human immune globulin or components of Hizentra, such as polysorbate 80 • Hyperprolinemia (type I or II) (Hizentra contains the stabilizer L-proline) • IgA-deficient patients with antibodies against IgA and a history of hypersensitivity Side effect: The most common adverse reactions observed in =5% of study subjects were local reactions (i.e., swelling, redness, heat, pain, and itching at the injection site), headache, diarrhea, fatigue, back pain, nausea, pain in extremity, cough, rash, pruritus, vomiting, abdominal pain (upper), migraine, and pain	New	USFDA	Ab#gr`b Kiv th#Z c#i	Ab#gr`b Kiv nj
134.	GLOBE Pharmaceuticals Ltd.	Dimethyl Fumarate 120 mg Delayed Release Capsule	Dimethyl Fumarate INN 120 mg	Immunomodulators	It is indicated for the treatment of patients with relapsing forms of multiple sclerosis.	Contraindications: None. Side effects: Most common adverse reactions were flushing, abdominal pain, diarrhea, and nausea.	New	USFDA	Ab#gr`b Kiv th#Z c#i	Ab#gr`b Kiv nj
135.	GLOBE Pharmaceuticals Ltd.	Dimethyl Fumarate 240 mg Delayed Release Capsule	Dimethyl Fumarate INN 240 mg	Immunomodulators	Do	Do	New	USFDA	Ab#gr`b Kiv th#Z c#i	Ab#gr`b Kiv nj
136.	Gonoshasthaya Pharmaceuticals Ltd.	G-Haemodialysis	POWDERED ACID CONCENTRATE (For Solution - A) Each litre of reconstituted solution contains: Sodium Chloride BP 172.19 gm + Potassium Chloride	Kidney Dialysis Fluid	Concentrated Haemodialysis Solutions are solutions of electrolytes formulated in concentrations similar to those of extracellular fluid. G- Haemodialysis solutions are used in the management of renal failure and poisoning; they allow the selective renal of toxic substances, electrolytes and excessive body fluid from the blood.	Contraindications: No such contraindications are remarked. Side effects: High concentrations can lead to protein loss, hyperlipidaemia and excessive dehydration.	Calcium Chloride .257 % + Dextrose Anhydrous 7 % + Magnesium Chloride .0152 % + Sodium	Ab#gr`b Kiv th#Z c#i	Ab#gr`b Kiv nj	

		<p>BP 5.49 gm + Calcium Chloride BP 8.12 gm + Magnesium Chloride BP 3.74 gm \Sodium Acetate BP 1.50 gm + Citric Acid BP 5.66 gm + * Dextrose BP 36.83 gm * Dextrose packed separately, use as required</p> <p>DRY BICARBONATE CONCENTRATE: (For Solution -B) Each litre of reconstituted solution contains: Sodium Chloride BP 27.00 gm + Sodium Bicarbonate BP 57.00 gm</p> <p>Solution-A and Solution-B to be used in the dilution ratio of; Solution-A (Acidic) - 1.00 Vol. Solution-B (Bicarbonate) - 1.83 Vol. Purified Water BP - 34.00 Vol.</p>	<p>Haemodialysis solution, the changes of ions between the solution & the patients blood is made across a synthetic semipermeable membrane.</p>		<p>Acetate 3.69 % + Sodium Chloride .561 % Dialysis Solution</p>			
--	--	--	---	--	--	--	--	--

bs	cŪZKviİK big	Jlİtai big	İRİbii K big	İ_ i wıDıİJK Kım	ıbt` Rbv	Contra-indication & Side-effect	Status (New Molecule/ Existing)	Aıte` bKvix KZİ USFDA/BNF / MHRA Ref.	İUKıBK`vj me Kugıİi mfvi mııİİ	mfvi mıııİİ
137.	Concord Pharmaceuticals Ltd.	Plecanatide 3 mg Tablet	Plecanatide INN 3 mg	Laxative Drugs	Plecanatide is a guanylate cyclase-C agonist indicated in adults for treatment of chronic idiopathic constipation (CIC).	Contraindication: • Patients less than 6 years of age due to the risk of serious dehydration. • Patients with known or suspected mechanical gastrointestinal obstruction. Adverse Reactions: Most common adverse reaction (≥2%) is diarrhea.	New	USFDA	cİİqıRb İbB İearq Aıte` b bı gÄy Kiv İtıZ cıti	cİİqıRb İbB İearq Aıte` b bı gÄy Kiv İnj
138.	Healthcare Pharmaceutical Ltd. ajendrapur, Gazipur	Plecanatide 3 mg Oral Tablet	Plecanatide INN 3mg	Laxative Drugs	Plecanatide is indicated in adults for the treatment of chronic idiopathic constipation (CIC).	Contraindication: Patients less than 6 years of age due to the risk of serious dehydration. Side effects: Diarrhea was the most common adverse reaction in the two placebo-controlled clinical trials. Severe diarrhea was reported in 0.6% of patients.	New	USFDA	cİİqıRb İbB İearq Aıte` b bı gÄy Kiv İtıZ cıti	cİİqıRb İbB İearq Aıte` b bı gÄy Kiv İnj
139.	Incepta Pharmaceuticals Ltd.; Zirabo, Savar, Dhaka	Plecanatide tablet	Plecanatide INN 3mg	Laxative Drugs	Plecanatide is a guanylate cyclase-C agonist indicated in adults for treatment of chronic idiopathic constipation (CIC).	Contra-indication: Patients less than 6 years of age due to the risk of serious dehydration. Patients with known or suspected mechanical gastrointestinal obstruction. Side effect: Most common adverse reaction (≥2%) is diarrhea.	New	USFDA	cİİqıRb İbB İearq Aıte` b bı gÄy Kiv İtıZ cıti	cİİqıRb İbB İearq Aıte` b bı gÄy Kiv İnj
140.	Navana Healthcare Ltd.	Plecanatide 3 mg tablet.	Plecanatide INN 3mg tablet	Laxative Drugs	It is indicated in adults for treatment of chronic idiopathic constipation	Contraindications: 1. Patients less than 6 years of age due to the risk of serious dehydration. 2. Patients with known or suspected mechanical gastrointestinal obstruction. Side effects: Diarrhea	NEW	USFDA	cİİqıRb İbB İearq Aıte` b bı gÄy Kiv İtıZ cıti	cİİqıRb İbB İearq Aıte` b bı gÄy Kiv İnj

bs	c0ZKvi#K big	Jl#ai big	#R#biiK big	#_i wicDi#K Km	ib#`Rbv	Contra-indication & Side-effect	Status (New Molecule/ Existing)	A#e`bKvix KZ# USFDA/BNF /MHRA Ref.	#UK#bK`vj me Kig#i mfvi m#v#S#	mfvi m#v#S#
141.	General Pharmaceuticals Ltd., Mouchak, Kaliakair, Gazipur	Zinc Carnosine 75 mg Capsule	Zinc Carnosine INN 75 mg	Mineral	H.Pylori infection Zinc also has direct anti-inflammatory effects, helping to stabilize the membranes of mast cells. Mast cells release bursts of inflammatory cytokines when stimulated by injury or allergy. Further, zinc in an immune modulator that can reduce the recurrence rate of certain inflammation-sensitive cancers. Another essential nutrient called carnosine can boost those effects further.	Contraindication: Zinc-Carnosine has not been evaluated for long-term use. Because zinc inhibits copper absorption, copper intake should be increased if zinc supplementation continuous long-term. Side-effects: The most common adverse reactions in patients treated with Zinc-Carnosine is indigestion with heartburn, upset stomach, nausea and bloating			c#q#Rb #bB weavq A#e`b bv g#y Kiv th#Z c#i	c#q#Rb #bB weavq A#e`b big#y Kiv nj
142.	Incepta Pharmaceuticals Ltd.; Zirabo, Savar, Dhaka	Iron 1000mg/20ml Injection	Ferric Carboxymaltose INN 2680mg eq. to elemental Iron 1000mg	Mineral	It is indicated for treatment of iron deficiency when oral iron preparations are ineffective or cannot be used. The diagnosis of iron deficiency must be based on laboratory tests	Contra-indication: The use of Ferric carboxymaltose is contraindicated in cases of: -hypersensitivity to the active substance, to Ferric carboxymaltose or any of its excipients. -known serious hypersensitivity to other parenteral iron products. -anaemia not attributed to iron deficiency, e.g. other microcytic anaemia -evidence of iron overload or disturbances in the utilisation of iron Side effect: The most commonly reported ADR is nausea (occurring in 3.1% of the patients), followed by headache, dizziness, and hypertension. Injection site reaction.	Ferric Carboxymaltose 750mg/15ml vial Injection	MHRA	Ab#gv`b Kiv th#Z c#i	Ab#gv`b Kiv nj

bs	c0ZKvi#K big	Jl#ai big	#R#biiK big	#_i wicDi#K Km	ib#`Rbv	Contra-indication & Side-effect	Status (New Molecule/ Existing)	Av#`bKvix KZ# USFDA/BNF /MHRA Ref.	#UK#K`vj me Kig#i mfvi m#v#S#	mfvi m#v#S#
143.	Incepta Pharmaceuticals Ltd.; Zirabo, Savar, Dhaka	Zinc Orotate 50mg Tablet	Zinc Orotate INN 50mg	Mineral	Zinc deficiency, Diarrhea, An inherited disorder called Wilson's disease	Contra-indication: Large doses of zinc can lower blood sugar in people with diabetes. High doses above the recommended amounts might cause fever, coughing, stomach pain, fatigue. Side effect: Side-effects include constipation, dry mouth, nausea, vomiting, tachycardia, dizziness, confusion, euphoria, hallucinations, impaired memory, anxiety, restlessness, urinary retention, blurred vision, and rash. Angle-closure glaucoma may occur very rarely.	Zinc Orotate 60mg Tablet		c#q#Rb #bB weavq Av#`b bv g#y Kiv th#Z c#i	c#q#Rb #bB weavq Av#`b bv g#y Kiv th#Z c#i
144.	UniMed & UniHealth Mfg. Ltd.	Urea 25% Cream	Urea BP 25gm/100gm	Moisturizing Agent	For the treatment of dry, cracked skin and hyperkeratosis on the soles of the feet including the heels. Suitable for general and diabetic foot care.	Contra-indication: For use only on the soles of the feet and the heels unless otherwise directed by the prescriber. Pregnant women should consult their healthcare professional before use. For External Use only. Avoid contact with eyes. Keep out of reach of children. Always replace cap after use. Do not use if tube seal is broken or appears tampered with. Side effect: May irritate inflamed skin or exudative lesions. Transient stinging may occur in deep cracks'. Discontinue use if local irritation or rash occurs during use.	10% Cream	BNF-73 Page-1081	Ab#gv`b Kiv th#Z c#i	Ab#gv`b Kiv nj
145.	Navana Healthcare Ltd.	Erdosteine 175mg/5ml Powder for Suspension	Erdosteine INN 175mg/5ml Powder for Suspension	Mucolytic	It is indicated for the treatment of patients with acute and chronic bronchopulmonary disease, rhinosinusitis, laryngo pharyngitis or exacerbations of these chronic disease in association with mucus production and mucus transport.	Hypersensitivity to the active substance or to any of the excipients or to free SH – group containing products. Hepatic disorders and abnormalities (e.g. increase of serum alkaline phosphatase, transaminases, etc.). Renal insufficiency (creatinine clearance <25mL/min). Homocystinuria (the active substance is	300mg Capsule		c#q#Rb #bB weavq Av#`b bv g#y Kiv th#Z c#i	c#q#Rb #bB weavq Av#`b bv g#y Kiv th#Z c#i

						partially metabolised to homocysteine and there are no data concerning administration of erdosteine in case of congenital errors of the Metabolism of aminoacids, especially in those patients obliged to follow a methionine-free dietary regimen). Phenylketonuria (only for powder for suspension due to the presence of aspartame in this presentation). Side effects: Gastric burning, nausea and rarely diarrhea.				
146.	Eskayef Pharmaceuticals Limited	Flibanserin 100mg FC Tablet	Flibanserin INN 100mg	Multifunctional serotonin agonist antagonist (MSAA)	It is indicated for the treatment of premenopausal women with acquired, generalized hypoactive sexual desire disorder (HSDD) as characterized by low sexual desire that causes marked distress or interpersonal difficulty and is NOT due to: <ul style="list-style-type: none"> • A co-existing medical or psychiatric condition, • Problems within the relationship • The effects of a medication or other drug substance. Limitation of use: Flibanserin is not indicated for the treatment of HSDD in postmenopausal women or in men. Flibanserin is not indicated to enhance sexual performance.	Contraindications: Alcohol, Moderate or strong cytochrome P450 3A4 (CYP3A4) inhibitors, Hepatic impairment. Side effects: Most common adverse reactions (incidence $\geq 2\%$) are dizziness, somnolence, nausea, fatigue, insomnia, and dry mouth.	New	USFDA	<i>cllqirB tbb wearq Arte`b br gÄy Kiv thtZ cirt </i>	<i>cllqirB tbb wearq Arte`b br gÄy Kiv nj </i>
147.	Popular Pharmaceuticals Limited	Pregabalin 50mg + Mecobalamin 0.50mg Capsule	Pregabalin INN 50mg + Mecobalamin INN 0.50mg	Neuropathic Pain Agent	prescribed for the treatment of spinal cord injury-related neuropathic pain, fibromyalgia, perioperative pain, migraine, chronic pain, peripheral neuropathy, Sciatica and other conditions. Pregabalin+Mecobalamin can improve energy, memory and learning, supports nervous and immune systems, promotes cardiovascular health, control plasma levels of homocysteine.	Contraindications It is contraindicated in patients who have demonstrated hypersensitivity to Pregabalin & Mecobalamin or to any of the excipients. Side effects: Generally well tolerated. Most common side effects are somnolence, dizziness, dry mouth and blurring of vision.			<i>cllqirB tbb wearq Arte`b br gÄy Kiv thtZ cirt </i>	<i>cllqirB tbb wearq Arte`b br gÄy Kiv nj </i>

bs	cŃZKviŃK big	JlŃai big	ŃRŃbniŃK big	Ń_ iwcDitŃK Km	ibŃ Rbv	Contra-indication & Side-effect	Status (New Molecule/ Existing)	AvŃe` bKvix KZŃ USFDA/BNF / MHRA Ref.	ŃUKibK`ij me KugŃli mfvi imxvŃŃ	mfvi imxvŃŃ
148.	Popular Pharmaceuticals Limited	Pregabalin 75mg + Mecobalamin 0.50mg Capsule	Pregabalin INN 75mg + Mecobalamin INN 0.50mg	Neuropathic Pain Agent	prescribed for the treatment of spinal cord injury-related neuropathic pain, fibromyalgia, perioperative pain, migraine, chronic pain, peripheral neuropathy, Sciatica and other conditions. Pregabalin+Mecobalamin can improve energy, memory and learning, supports nervous and immune systems, promotes cardiovascular health, control plasma levels of homocysteine.	Contraindications: It is contraindicated in patients who have demonstrated hypersensitivity to Pregabalin & Mecobalamin or to any of the excipients. Side effects: Generally well tolerated. Most common side effects are somnolence, dizziness, dry mouth and blurring of vision.			cŃqivRb ŃbB weariq AvŃe` b bŃ gÄy Kiv thŃZ cŃti	cŃqivRb ŃbB weariq AvŃe` b bigÄy Kiv nj
149.	Navana Healthcare Ltd.	Glycerin 200mg + Hypromellose 360mg + Polyethylene glycol 1.0gm + Tetrahydrozoline HCl 50.0mg + Zinc Sulfate 250.0mg/100ml Eye Drop	Glycerin USP 200mg + Hypromellose BP 360mg + Polyethylene glycol USP 1.0gm + Tetrahydrozoline HCl USP 50.0mg + Zinc Sulfate USP 250.0mg/100ml	Ocular Lubricant	for temporary relief of discomfort and redness of the eye due to minor eye irritations relieves dryness of the eye for the temporary relief of burning and irritation due to exposure to wind or sun for protection against further irritation	Contraindication: allergic to any ingredient in this eye drop. If taking furazolidone or have taken a monoamine oxidase (MAO) inhibitor (eg, phenelzine) within the last 14 days. Possible Side Effects: Blurring, tearing, or stinging of the eye; dilation of pupils. rash; hives; difficulty breathing; tightness in the chest; swelling of the mouth, face, lips, or tongue); change in vision; continued redness or irritation of the eye; eye pain; headache.	Glycerol 0.2% + Hypromellose 0.36% + Polyethylene Glycol 400 1% Eye Drops		AbŃgv` b Kiv thŃZ cŃti	AbŃgv` b Kiv nj
150.	Incepta Pharmaceuticals Ltd.; Zirabo, Savar, Dhaka	Chloramphenicol 5.0gm + Beclomethasone Dipropionate 0.025gm + Clotrimazole 1.0 gm + Lignocaine 2.0gm/100ml Solution (Eye Drop)	Chloramphenicol BP/Ph. Eur 5.0gm + Beclomethasone Dipropionate USP 0.025gm + Clotrimazole BP/Ph. Eur 1.0 gm + Lignocaine BP/Ph. Eur 2gm/100ml	Ophthalmic Anti-bacterial Products	Otitis externa, acute otitis media, suppuration of middle ear, infections of middle ear, hot weather ear, swimming pool ear, mastoid surgery, fulminating bacterial infections	Contra-indication: Contraindicated in patients who are hypersensitive to any components of this product. Caution in patients with liver disease. Side effect: Itching, redness, a bad taste in your mouth may occur. Systemic exposure to excessive quantities of lignocaine mainly results in central nervous system (CNS) and cardiovascular effects.	Chloramphenicol 5.0mg + Dexamethasone 1.0mg/100ml		AbŃgv` b Kiv thŃZ cŃti	AbŃgv` b Kiv nj

bs	c0ZKvi#K big	Jl#ai big	#R#biiK big	#_i wC Di#K Km	ib#`Rbv	Contra-indication & Side-effect	Status (New Molecule/ Existing)	A#e`bKvix KZ# USFDA/BNF /MHRA Ref.	#UKibK`vj me Kug#Di mfvi m#v#S#	mfvi m#v#S#
151.	Incepta Pharmaceuticals Ltd.; Zirabo, Savar, Dhaka	Oxycodone HCl 30mg + Naltrexone HCl 3.6mg ER Capsule	Oxycodone HCl (20% W/W) ER Pellets INN 150mg Eq. to Oxycodone HCl 30mg + Naltrexone HCL (2.4% w/w) ER Pellets INN 150mg Eq. to Naltrexone HCl 3.6mg	Opioid agonist/Opioid antagonist	It is a combination opioid agonist/opioid antagonist product indicated for the management of pain severe enough to require daily, around-the-clock, long-term opioid treatment and for which alternative treatment options are inadequate. Limitations of Use Because of the risks of addiction, abuse, and misuse with opioids, even at recommended doses, and because of the greater risks of overdose and death with extended-release opioid formulations, reserve Oxycodone HCl 10mg + Naltrexone HCl 1.2mg ER Capsule for use in patients for whom alternative treatment options (e.g., non-opioid analgesics or immediate-release opioids) are ineffective, not tolerated, or would be otherwise inadequate to provide sufficient management of pain. It is not indicated as an as-needed (prn) analgesic.	Contra-indication <ul style="list-style-type: none"> Significant respiratory depression Acute or severe bronchial asthma in an unmonitored setting or in the absence of resuscitative equipment Known or suspected gastrointestinal obstruction, including paralytic ileus Hypersensitivity to oxycodone or naltrexone Side effect: Most common adverse reactions: nausea, constipation, vomiting, headache, and somnolence	New	USFDA	c#q#Rb #bB weavq Av#e`b bv g#y Kiv th#Z c#ti	c#q#Rb #bB weavq Av#e`b bv g#y Kiv nj
152.	Incepta Pharmaceuticals Ltd.; Zirabo, Savar, Dhaka	Oxycodone HCl 10mg + Naltrexone HCl 1.2mg ER Capsule	Oxycodone HCl (20% W/W) ER Pellets INN 50mg Eq. to Oxycodone HCl 10mg + Naltrexone HCl (2.4% w/w) ER Pellets INN 50mg eq. to Naltrexone HCl 1.2mg	Opioid agonist/Opioid antagonist	It is a combination opioid agonist/opioid antagonist product indicated for the management of pain severe enough to require daily, around-the-clock, long-term opioid treatment and for which alternative treatment options are inadequate. Limitations of Use Because of the risks of addiction, abuse, and misuse with opioids, even at	Contra-indication: <ul style="list-style-type: none"> Significant respiratory depression Acute or severe bronchial asthma in an unmonitored setting or in the absence of resuscitative equipment Known or suspected gastrointestinal obstruction, including paralytic ileus Hypersensitivity to oxycodone or naltrexone Side effect: Most common adverse reactions: nausea, constipation, vomiting,	New	USFDA	c#q#Rb #bB weavq Av#e`b bv g#y Kiv th#Z c#ti	c#q#Rb #bB weavq Av#e`b bv g#y Kiv nj

					recommended doses, and because of the greater risks of overdose and death with extended-release opioid formulations, reserve Oxycodone HCl 10mg + Naltrexone HCl 1.2mg ER Capsule for use in patients for whom alternative treatment options (e.g., non-opioid analgesics or immediate-release opioids) are ineffective, not tolerated, or would be otherwise inadequate to provide sufficient management of pain. It is not indicated as an as-needed (prn) analgesic.	headache, and somnolence				
153.	Eskayef Pharmaceuticals Limited	Potassium Citrate 2.163 gm + Zinc Gluconate 59.80mg + Sodium Citrate Anhydrous 0.86gm + Sodium Chloride 2.045gm + Anhydrous Glucose 25gm/1000ml	Potassium Citrate USP 2.163 gm + Zinc Gluconate BP 59.80mg + Sodium Citrate Anhydrous USP 0.86gm + Sodium Chloride BP 2.045gm + Anhydrous Glucose BP 25gm/1000ml	ORS	To quickly replace vital minerals and nutrients lost during diarrhea and vomiting to help prevent dehydration in infants and children; for maintenance of water and electrolytes following corrective parenteral therapy for diarrhea.	Contraindications: Not found Side effects: Not found	-	<i>cñqıRb tbB wearq Avte`b br gÄy Kiv thtZ cıti </i>	<i>cñqıRb tbB wearq Avte`b br gÄy Kiv nj </i>	
154.	a) Incepta Pharmaceuticals Ltd.; Zirabo, Savar, Dhaka b) Globe Pharmaceuticals Ltd.	Crisaborole 2gm/100gm Ointment	Crisaborole INN 2.0gm/100gm	Phosphodiesterase-4 Inhibitor	Crisaborole is indicated for topical treatment of mild to moderate atopic dermatitis in patients 2 years of age and older.	Contra-indication: Known hypersensitivity to crisaborole or any component of the formulation. Side effect: The most common adverse reaction occurring in ≥1% in subjects is application site pain	New	USFDA	<i>Abjgr`b Kiv thtZ cıti </i>	<i>Abjgr`b Kiv nj </i>

bs	cŃZKviŃK big	JlŃai big	ŃRŃbniK big	Ń_ iwcDitUK Km	ibŃ Rbv	Contra-indication & Side-effect	Status (New Molecule/ Existing)	AŃe` bKvir KZŃ USFDA/BNF / MHRA Ref.	ŃUKibK`ij me KugŃli mfvi imxvŃŃ	mfvi imxvŃŃ
155.	a) Aristopharma Ltd. b) Ziska Pharmaceuticals Ltd. c) Eskayef Pharmaceuticals Limited	Vonoprazan 10 mg Film Coated Tablet	Vonoprazan Fumarate INN 13.36 mg Eq. to Vonoprazan 10 mg	PPI	Vonoprazan Fumarate is a first-in-class potassium-competitive acid blocker. It inhibits H ⁺ , K ⁺ -ATPase activities in a reversible and potassium-competitive manner with a potency of inhibition approximately 350 times higher than the proton pump inhibitor, Lansoprazole. Vonoprazan Fumarate tablet is indicated in the treatment of Gastroduodenal Ulcer, Secondary prevention of Reflux Esophagitis, Secondary prevention of lowdose aspirin or non-steroidal antiinflammatory drug induced Peptic Ulcer, in combination with Clarithromycin and Amoxicillin for the eradication of Hlicobacter pylori.	Contra-indication:- Caution is necessary when oral vonoprazan Fumarate is used in patients with the following conditions and frequent monitoring is necessary: Liver/ Renal disorders, allergic rections (itch, rash, etc.) or in those who are taking any other medicinal products, over-the-counter medicines & dietary supplements as well as other prescription medicines. Caution is also necessary for women who are pregnant & breastfeeding. Side-effect:- The most commonly reported adverse reactions include constipation, diarrhea, enlarged feeling of bdomen, nausea, rash and edema.	New	Japan	cŃqŃRb ŃbB weariq Arte` b bv gÄy Kiv thŃZ citi	cŃqŃRb ŃbB weariq Arte` b bv gÄy Kiv nj
156.	a) Aristopharma Ltd. b) Ziska Pharmaceuticals Ltd. c) Eskayef Pharmaceuticals Limited	Vonoprazan 20 mg Film Coated Tablet	Vonoprazan Fumarate INN 26.72 mg Eqv. to Vonoprazan 20 mg	PPI	Vonoprazan Fumarate is a first-in-class potassium-competitive acid blocker. It inhibits H ⁺ , K ⁺ -ATPase activities in a reversible and potassium-competitive manner with a potency of inhibition approximately 350 times higher than the proton pump inhibitor, Lansoprazole. Vonoprazan Fumarate tablet is indicated in the treatment of Gastroduodenal Ulcer, Secondary prevention of Reflux Esophagitis, Secondary prevention of low dose aspirin or non-steroidal antiinflammatory drug induced Peptic Ulcer, in combination with Clarithromycin and Amoxicillin for the eradication of Hlicobacter pylori.	Contra-indication:- Caution is necessary when oral vonoprazan Fumarate is used in patients with the following conditions and frequent monitoring is necessary: Liver/ Renal disorders, allergic rections (itch, rash, etc.) or in those who are taking any other medicinal products, over-the-counter medicines & dietary supplements as well as other prescription medicines. Caution is also necessary for women who are pregnant & breastfeeding. Side-effect:- The most commonly reported adverse reactions include constipation, diarrhea, enlarged feeling of bdomen, nausea, rash and edema.	New	Japan	cŃqŃRb ŃbB weariq Arte` b bv gÄy Kiv thŃZ citi	cŃqŃRb ŃbB weariq Arte` b bv gÄy Kiv nj

bs	cŌZKvi#K big	Jl#ai big	#R#bniK big	#_iwcDitUK Km	ibt`Rbv	Contra-indication & Side-effect	Status (New Molecule/ Existing)	A#e`bKvix KZ# USFDA/BNF / MHRA Ref.	#UKibK`ij me Kigidi mfvi imxvš	mfvi imxvš
157.	Healthcare Pharmaceutical Ltd., Rajendrapur , Gazipur	Dexrabeprazole 10mg Tablet	Dexrabeprazole 10mg	PPI	Gastro-esophageal Reflux Disease (GERD), erosive esophagitis, gastric and duodenal ulcers. It is more effective and tolerable than rabeprazole.	Contraindications: It is contraindicated in patients with known hypersensitivity to dexrabeprazole, or to any excipients used in formulation. Side effects: Dexrabeprazole can cause side effects such as nausea, vomiting, diarrhoea, stomach pain and flatulence.	New		cŌqirB #bB wearq Avte`b bvi gÄy Kiv thtZ c#ti	cŌqirB #bB wearq Avte`b bvi gÄy Kiv nj
158.	Healthcare Pharmaceutical Ltd., Rajendrapur , Gazipur	Dexrabeprazole 10mg/Vial IV Injection	Dexrabeprazole INN 10mg/Vial	PPI	Gastro-esophageal Reflux Disease (GERD), erosive esophagitis, gastric and duodenal ulcers. It is more effective and tolerable than rabeprazole.	Contraindications: It is contraindicated in patients with known hypersensitivity to dexrabeprazole, or to any excipients used in formulation. Side effects: Dexrabeprazole can cause side effects such as nausea, vomiting, diarrhoea, stomach pain and flatulence.	New		cŌqirB #bB wearq Avte`b bvi gÄy Kiv thtZ c#ti	cŌqirB #bB wearq Avte`b bvi gÄy Kiv nj
159.	Healthcare Pharmaceutical Ltd., Rajendrapur , Gazipur	Dexrabeprazole 5 mg Tablet	Dexrabeprazole INN 5mg	PPI	Gastro-esophageal Reflux Disease(GERD),erosive esophagitis,gastric and duodenal ulcers.It is more effective and tolerable than rabeprazole.	Contraindications: It is contraindicated in patients with known hypersensitivity to dexrabeprazole,or to any excipients used in formulation. Side effects: Dexrabeprazole can cause side effects such as nausea,vomiting, diarrhoea, stomach pain and flatulence.	New		cŌqirB #bB wearq Avte`b bvi gÄy Kiv thtZ c#ti	cŌqirB #bB wearq Avte`b bvi gÄy Kiv nj
160.	Healthcare Pharmaceutical Ltd., Rajendrapur , Gazipur	Esomeprazole Granules 40mg/Sachet Enteric coated Microgranules	Esomeprazole Enteric Coated Microgranules Ph. Grade 22.50% 177.78mg eq. to Magnesium (Trihydrate) USP 40mg/Sachet	PPI	1. Treatment of gastroesophageal reflux disease (GERD) 2. Risk reduction of NSAID associated gastric ulcer 3. H. pylori eradication to reduce the risk of duodenal ulcer recurrence. 4. Pathological hypersecretory conditions, including Zollinger-Elison syndrome.	Contraindications: Patients with known hypersensitivity to proton pump inhibitors (PPIs) Angioedema and anaphylaxis have occurred. side-effects: Nausea, flatulence, constipation, dry mouth	20mg, 40mg capsule 20mg/Sachet	USFDA	cŌqirB #bB wearq Avte`b bvi gÄy Kiv thtZ c#ti	cŌqirB #bB wearq Avte`b bvi gÄy Kiv nj

bs	c0ZKvi#K big	Jl#ai big	#R#biiK big	#_i wicDi#K Km	ib#`Rbv	Contra-indication & Side-effect	Status (New Molecule/ Existing)	A#e`bKvix KZ# USFDA/BNF /MHRA Ref.	#UK#bK`vj me Kug#i mfvi m#v#S#	mfvi m#v#S#
161.	Healthcare Pharmaceutical Ltd., Rajendrapur , Gazipur	Esomeprazole 10mg/Sachet sachet Enteric coated Micro Granules	Esomeprazole Enteric Coated Microgranules Ph. Grade 22.50% 44.45mg eq. to Magnesium (Trihydrate) USP 10mg/Sachet	PPI	1. Treatment of gastroesophageal reflux disease (GERD) 2. Risk reduction of NSAID associated gastric ulcer 3. H. pylori eradication to reduce the risk of duodenal ulcer recurrence. 4. Pathological hypersecretory conditions, including Zollinger-Elison syndrome.	Contraindications: Patients with known hypersensitivity to proton pump inhibitors (PPIs) Angioedema and anaphylaxis have occurred. side-effects: nausea, flatulence, constipation, dry mouth	20mg, 40mg capsule 20mg/Sachet	USFDA	c#q#Rb #bB #earq A#e`b bv g#y Kiv th#Z c#i	c#q#Rb #bB #earq A#e`b bv g#y Kiv nj
162.	Eskayef Pharmaceuticals Limited	Mometasone Furoate 0.1% + Hydroquinone 4% + Tretinoin 0.05% Cream	Mometasone Furoate USP 0.1gm + Hydroquinone USP 4.0gm + Tretinoin BP 0.05gm/100gm	Steroid	•It is primarily used as a skin bleaching agent •To lighten the appearance of the skin •Patients affected by hyperpigmentation are advised to use this combination •Melasma.	Contraindications: Hypersensitivity reaction. Side effects: •Aching, blisters in hair follicles •Thinning of the skin •Irritation of the skin •Burning or itching of the skin •Increased redness of the skin.	Mometasone Furoate 0.1% Cream	c#q#Rb #bB #earq A#e`b bv g#y Kiv th#Z c#i	c#q#Rb #bB #earq A#e`b bv g#y Kiv nj	
163.	GLOBE Pharmaceuticals Ltd.	Menthol BP 20 gm + Eucalyptus Oil BP 15gm + Methyl Salicylate BP 0.015gm + Camphor BP 0.005 gm/ 100 ml Topical Oil	Menthol BP 20 gm + Eucalyptus Oil BP 15gm + Methyl Salicylate BP 0.015gm + Camphor BP 0.005 gm/ 100 ml	Topical Analgesic	Provides temporary relief of headaches, colds and blocked noses, muscular and joint pains, stomach discomforts and wind, giddiness/travel sickness and soothes itching from insect bites.	Contraindications: Unknown. Side effects: Unknown.	New	c#q#Rb #bB #earq A#e`b bv g#y Kiv th#Z c#i	c#q#Rb #bB #earq A#e`b bv g#y Kiv nj	

<i>bs</i>	<i>cŃZKviŃK big</i>	<i>JlŃai big</i>	<i>ŃRŃbniŃK big</i>	<i>Ń_ iwcDitŃK Km</i>	<i>ibŃ Rbv</i>	Contra-indication & Side-effect	Status (New Molecule/ Existing)	<i>AŃe bKvir KZŃ USFDA/BNF /MHRA Ref.</i>	<i>ŃUKibK'ij me KugŃi mfvi imxvŃŃ</i>	<i>mfvi imxvŃŃ</i>
164.	Incepta Pharmaceuticals Ltd.; Zirabo, Savar, Dhaka	10% Fat Emulsion (Refined Soyabean oil 25gm + Egg Yolk phospholipid 3.0gm + Glycerol 5.625gm/250ml) IV Injection	Refined Soyabean oil BP 25gm + Egg Yolk phospholipid INN 3.0gm + Glycerol BP 5.625gm/250ml	Total parenteral nutrition	10% (10% i.v fat emulsion) is indicated as a source of calories and essential fatty acids for patients requiring parenteral nutrition for extended periods of time (usually for more than 5 days) and as a source of essential fatty acids for prevention of efad..	Contra-indication: The administration of intralipid® 10% (10% i.v fat emulsion) is contraindicated in patients with disturbances of normal fat metabolism such as pathologic hyperlipemia, lipoid nephrosis or acute pancreatitis if accompanied by hyperlipidemia. Side effect: The adverse reactions observed can be separated into two classes: 1.Those more frequently encountered are due: either to contamination of the intravenous catheter and result in sepsis, or to vein irritation by concurrently infused hypertonic solutions and may result in thrombophlebitis. these adverse reactions are inseparable from the hyper-alimentation procedure with or without intralipid® 10% (a 10% i.v. fat emulsion). 2.Less frequent reactions more directly related to intralipid® 10% (10% i.v fat emulsion) are: a) immediate or early adverse reactions, each of which has been reported to occur in clinical trials, in an incidence of less than 1 %; dyspnea, cyanosis, allergic reactions, hyperlipemia, hypercoagulability, nausea, vomiting, headache, flush-ing, increase in temperature, sweating, sleepiness, pain in the chest and back, slight pressure over the eyes, dizziness, and irritation at the site of infusion, and, rarely, thrombocytopenia in neonates; b) delayed adverse reactions such as hepatomegaly, jaundice due to central lobular cholestasis, splenomegaly, thrombocytopenia, leukopenia, transient increases in liver function tests, and overloading syndrome (focal seizures, fever, leukocytosis, hepatomegaly, splenomegaly and shock).	20% Fat Emulsion		<i>AbŃgr b Kiv thŃZ cŃi </i>	<i>AbŃgr b Kiv nj </i>

bs	cŃZKviŃK big	JlŃai big	ŃRŃbniŃK big	Ń_ iwcDŃUK KŃm	ŃbŃ Rbv	Contra-indication & Side-effect	Status (New Molecule/ Existing)	AŃe bKvix KZŃ USFDA/BNF /MHRA Ref.	ŃUKŃbK'ij me KŃgŃli mfvi ŃmŃvŃŃ	mfvi ŃmŃvŃŃ
165.	Incepta Pharmaceutic als Ltd.; Zirabo, Savar, Dhaka	10% Fat Emulsion (Refined Soyabean oil 50.0gm + Egg Yolk phospholipid 6.0gm + Glycerol 11.25gm/500ml) IV Injection	Refined Soyabean oil BP 50.0gm + Egg Yolk phospholipid INN 6.0gm + Glycerol BP 11.25gm/500ml	Total parenteral nutrition	10% (10% i.v fat emulsion) is indicated as a source of calories and essential fatty acids for patients requiring parenteral nutrition for extended periods of time (usually for more than 5 days) and as a source of essential fatty acids for prevention of efad..	Contraindication: The administration of intralipid® 10% (10% i.v fat emulsion) is contraindicated in patients with disturbances of normal fat metabolism such as pathologic hyperlipemia, lipoid nephrosis or acute pancreatitis if accompanied by hyperlipidemia. Side effect: The adverse reactions observed can be separated into two classes: 1.Those more frequently encountered are due: either to contamination of the intravenous catheter and result in sepsis, or to vein irritation by concurrently infused hypertonic solutions and may result in thrombophlebitis. these adverse reactions are inseparable from the hyper-alimentation procedure with or without intralipid® 10% (a 10% i.v. fat emulsion). 2.Less frequent reactions more directly related to intralipid® 10% (10% i.v fat emulsion) are: a) immediate or early adverse reactions, each of which has been reported to occur in clinical trials, in an incidence of less than 1 %; dyspnea, cyanosis, allergic reactions, hyperlipemia, hypercoagulability, nausea, vomiting, headache, flush-ing, increase in temperature, sweating, sleepiness, pain in the chest and back, slight pressure over the eyes, dizziness, and irritation at the site of infusion, and, rarely, thrombocytopenia in neonates; b) delayed adverse reactions such as hepatomegaly, jaundice due to central lobular cholestasis, splenomegaly, thrombocytopenia, leukopenia, transient increases in liver function tests, and overloading syndrome (focal seizures, fever, leukocytosis, hepatomegaly, splenomegaly and shock).	20% Fat Emulsion		AbŃgr b Kiv thŃZ cŃi	AbŃgr b Kiv nj

<i>bs</i>	<i>c0ZKvi#K big</i>	<i>Jl#ai big</i>	<i>#R#biiK big</i>	<i>#_i wicDi#K Km</i>	<i>ib#`Rbv</i>	Contra-indication & Side-effect	Status (New Molecule/ Existing)	<i>A#e`bKvix KZ# USFDA/BNF /MHRA Ref.</i>	<i>#UK#bK`vj me Kigi#i mfvi m#x#S#</i>	<i>mfvi m#x#S#</i>
166.	ACI Ltd.	Diosmin 900 mg + Hesperidine 100 mg Film coated Tablet	Micronized purified flavonoids Ph. Grade 1000 mg containing 4% Overage composed of Diosmin INN 900 mg + Hesperidine Ph. Eur. 100mg	Venotonic & Vascular Protector	It is indicated for the treatment of the manifestations of chronic venous insufficiency, treatment of functional symptoms related to venous insufficiency of the hemorrhoidal plexus, in the pre- and postoperative saphenous vein stripping (surgical removal of the saphenous vein) for relief of the signs and Symptoms resulting from this procedure, relief of chronic pelvic pain associated with pelvic congestion syndrome.	Contraindications: This combination is contraindicated in patient with known hypersensitivity to the active substances or to any of the excipients. Side Effects: The common side effects are diarrhea, dyspepsia (indigestion), nausea, vomiting, colitis, dizziness, headache, malaise, rash, pruritus and urticaria	Diosmin 450 mg + Hesperidin 50mg Tablet		<i>Ab#gv`b Kiv th#Z c#i </i>	<i>Ab#gv`b Kiv nj </i>
167.	Beximco Pharmaceutic als Ltd.	Vitamin D ₃ (Cholecalciferol) 0.040gm/100ml Syrup	Vitamin D ₃ (Cholecalciferol) USP 0.040gm eq. to 40,000IU/100ml	Vitamin	Vitamin D is essential for normal bone growth and development and to maintain bone density. Vitamin D acts as a hormone and increases reabsorption of Calcium and Phosphorus by the kidneys and increased bone turnover. Prevention and Treatment of vitamin D deficiency states.	Contraindications: <ul style="list-style-type: none"> • Hypersensitivity to the active substance (cholecalciferol) or to any of the excipients • Hypercalcaemia and/or hypercalciuria • Nephrolithiasis (Renal calculi) • Hypervitaminosis • Severe renal impairment Side effects: Few side-effects can generally occur including hypercalcaemia syndrome or Calcium intoxication (depending on the severity and duration of hypercalcaemia), occasional acute symptoms include anorexia, headache, nausea, vomiting, abdominal pain or stomach ache and constipation with the administration of Cholecaciferol.	Vit. D3 25mcg/5ml Syrup		<i>c#q#Rb #bB #eavq A#e`b big#y Kiv th#Z c#i </i>	<i>c#q#Rb #bB #eavq A#e`b big#y Kiv nj </i>

bs	cŃZKviŃK big	JlŃai big	ŃRŃbniŃK big	Ń_ iwcDitŃK Km	ibŃ Rbv	Contra-indication & Side-effect	Status (New Molecule/ Existing)	AvŃe`bKvix KZŃ USFDA/BNF /MHRA Ref.	ŃUKŃbK`ij me KugŃli mfvi imxvŃŃ	mfvi imxvŃŃ
168.	Beximco Pharmaceuticals Ltd.	Vitamin D ₃ (Cholecalciferol) 0.200gm/100ml Syrup	Vitamin D ₃ (Cholecalciferol) USP 0.200gm eq. to 200000IU/100ml	Vitamin	Vitamin D is essential for normal bone growth and development and to maintain bone density. Vitamin D acts as a hormone and increases reabsorption of Calcium and Phosphorus by the kidneys and increased bone turnover. Prevention and Treatment of vitamin D deficiency states.	Contraindications: <ul style="list-style-type: none"> • Hypersensitivity to the active substance (cholecalciferol) or to any of the excipients • Hypercalcaemia and/or hypercalciuria • Nephrolithiasis (Renal calculi) • Hypervitaminosis • Severe renal impairment Side effects: Few side-effects can generally occur including hypercalcaemia syndrome or Calcium intoxication (depending on the severity and duration of hypercalcaemia), occasional acute symptoms include anorexia, headache, nausea, vomiting, abdominal pain or stomach ache and constipation with the administration of Cholecalciferol.	Vit. D3 25mcg/5ml Syrup		cŃqŃRb ŃbB wearq AvŃe`b br gÄy Kiv thŃZ cŃti	cŃqŃRb ŃbB wearq AvŃe`b br gÄy Kiv nj
169.	GLOBE Pharmaceuticals Ltd.	Cholecalciferol 2740 IU/ml Oral Solution, Pediatric Drops	Vitamin D ₃ (Cholecalciferol) USP 68.5mg eq. to 2740 IU/ml	Vitamin	Prevention and treatment of vitamin D deficiency.	Contraindications: <ul style="list-style-type: none"> • Hypersensitivity to vitamin D or any of the excipients in the product • Hypervitaminosis D • Nephrolithiasis • Diseases or conditions resulting in hypercalcaemia and/or hypercalciuria • Severe renal impairment Side effects: Metabolism and nutrition disorders, hypercalcaemia and hypercalciuria, skin and subcutaneous disorders, pruritus, rash and urticaria.	Cholecalciferol (Vit. D3) 25mcg/5 ml Syrup 40,000 IU Capsule 20,000IU Capsule	MHRA	cŃqŃRb ŃbB wearq AvŃe`b br gÄy Kiv thŃZ cŃti	cŃqŃRb ŃbB wearq AvŃe`b br gÄy Kiv nj

bs	cŌZKviŧK big	Jlŧai big	ŧRŧbniK big	ŧ_ iwcDitUK Km	ibŧ Rbv	Contra-indication & Side-effect	Status (New Molecule/ Existing)	Aŧe` bKvir KZŧ USFDA/BNF / MHRA Ref.	ŧUKibK`ij me Kugidi mfvi imxvŧŧ	mfvi imxvŧŧ
170.	Incepta Pharmaceuticals Ltd.; Zirabo, Savar, Dhaka	Benfotiamine 300 mg eq. to Thiamin 166mg + Riboflavin (Vitamin B2) 4mg + Vitamin B6 (Pyridoxin HCl) 4mg + Folic acid 200 mcg + Vitamin B12(as methylcobalamin) 2000 mcg + Vitamin D3 500 IU Capsule	Benfotiamine BP 300 mg eq. to Thiamin 166mg + Riboflavin (Vitamin B2) BP 4mg + Vitamin B6 (Pyridoxin HCl) 4mg + Folic acid BP 200 mcg + Vitamin B12(as methylcobalamin) 2000 mcg + Vitamin D3 BP 500 IU	Vitamin	Nutritional support for patients with neuropathy.	Contra-indication: No contraindication has been found. Side effects: Both Benfotiamine and vitamin B12 have been shown to be non-toxic and have no known side effects, even in very high dosages.	New		cŧiqiRb ŧbB weariq Aŧe` b bŧ gÄy Kiv thŧZ citi	cŧiqiRb ŧbB weariq Aŧe` b bŧ gÄy Kiv nj
171.	Incepta Pharmaceuticals Ltd.; Zirabo, Savar, Dhaka	L-methylfolate calcium 15mg Tablet	L-methylfolate calcium INN 15mg	Vitamin	Dietary management of low plasma or low red blood cell folate in certain patients. It may also be used for other conditions as determined by your doctor. L-methylfolate is a medical food. It works by providing the body with folate.	Contra-indication: Allergic to any ingredient in L-methylfolate calcium Side effect: No common side effects have been reported with l-methylfolate. Seek medical attention right away if any of these severe side effects occur: Severe allergic reactions (rash; hives; itching; difficulty breathing; tightness in the chest; swelling of the mouth, face, lips, or tongue).	New		cŧiqiRb ŧbB weariq Aŧe` b bŧ gÄy Kiv thŧZ citi	cŧiqiRb ŧbB weariq Aŧe` b bŧ gÄy Kiv nj
172.	Incepta Pharmaceuticals Ltd.; Zirabo, Savar, Dhaka	L-methylfolate Calcium 1mg Tablet	L-methylfolate calcium INN 1mg	Vitamin	Dietary management of low plasma or low red blood cell folate in certain patients. It may also be used for other conditions as determined by your doctor. L-methylfolate is a medical food. It works by providing the body with folate.	Contra-indication: Allergic to any ingredient in L-methylfolate calcium. Side effect: No common side effects have been reported with l-methylfolate. Seek medical attention right away if any of these severe side effects occur: Severe allergic reactions (rash; hives; itching; difficulty breathing; tightness in the chest; swelling of the mouth, face, lips, or tongue).	New		cŧiqiRb ŧbB weariq Aŧe` b bŧ gÄy Kiv thŧZ citi	cŧiqiRb ŧbB weariq Aŧe` b bŧ gÄy Kiv nj

bs	cŃZKviŃK big	JlŃai big	ŃRŃbniŃK big	Ń_ iwcDitŃK Kvm	ibŃ Rbv	Contra-indication & Side-effect	Status (New Molecule/ Existing)	AvŃe`bKvir KZŃ USFDA/BNF /MHRA Ref.	ŃUKibK`ij me KigŃli mfvi mmxvŃŃ	mfvi mmxvŃŃ
173.	Incepta Pharmaceutic als Ltd.; Zirabo, Savar, Dhaka	L-methylfolate calcium 7.5mg Tablet	L-methylfolate calcium INN 7.5 mg	Vitamin	Dietary management of low plasma or low red blood cell folate in certain patients. It may also be used for other conditions as determined by your doctor. L-methylfolate is a medical food. It works by providing the body with folate.	Contra-indication: Allergic to any ingredient in L-methylfolate calcium. Side effect: No common side effects have been reported with l-methylfolate. Seek medical attention right away if any of these SEVERE side effects occur: Severe allergic reactions (rash; hives; itching; difficulty breathing; tightness in the chest; swelling of the mouth, face, lips, or tongue).	New		cŃŃqirb ŃbB weariq AvŃe`b bvi gÄy Kiv ŃhiZ citi	cŃŃqirb ŃbB weariq AvŃe`b bigÄy Kiv nj
174.	Square Pharmaceutic als Ltd., Pabna Unit, Salgaria, Pabna	Colecalciferol BP 60,000 IU/1.0gm Sachet	Colecalciferol Concentrate (Powder Form) BP 600mg eq. to 60,000 IU/1.0gm Sachet	Vitamin	Vitamin D deficiency states including patients of type 2 diabetes mellitus with Vitamin D deficiency. Vitamin D helps the body to utilize calcium necessary for the normal development of healthy bones and teeth. Patients who are not exposed to sufficient sunlight are unable to absorb Vitamin D require additional Vitamin D supplementation. Vitamin D supplementation is required in persons with rickets, inadequate exposure to sunlight infantile tetany and osteomalacia in adults.	Contraindication: Hypersensitivity to Vitamin D. Vitamin D should not be given to patients with hypercalcemia, renal impairment, calculi or heart disease. Side effects: Vitamin D in excessive amounts may cause hypercalcaemia.	40000 IU Capsule, 20000 IU Capsule, 1000 IU Tablet		cŃŃqirb ŃbB weariq AvŃe`b bvi gÄy Kiv ŃhiZ citi	cŃŃqirb ŃbB weariq AvŃe`b bigÄy Kiv nj
175.	Unimed & Unihealth Mfg. Ltd.	Cholecalciferol 10000IU/1ml Oral Drop	Cholecalciferol (Vitamin D ₃) USP 1gm/100 ml	Vitamin	Prevention and Treatment of vitamin D deficiency in children.	Contraindications: Hypersensitivity to vitamin D or any of the excipients in the product Hypervitaminosis D Nephrolithiasis Diseases or conditions resulting in hypercalcaemia and/or hypercalciuria Severe renal impairment Side effects: Metabolism and nutrition disorders, hypercalcaemia and hypercalciuria, skin and subcutaneous disorders, pruritus, rash and urticaria.	Cholecalciferol (Vit. D3) 25mcg/5 ml Syrup 40,000 IU Capsule 20,000IU Capsule	BNF-73 Page: 953- 954	cŃŃqirb ŃbB weariq AvŃe`b bvi gÄy Kiv ŃhiZ citi	cŃŃqirb ŃbB weariq AvŃe`b bigÄy Kiv nj

bs	cŃZKviŃK big	JlŃai big	ŃRŃbniŃK big	Ń_ iwcDŃUK KŃm	ŃbŃ Rbv	Contra-indication & Side-effect	Status (New Molecule/ Existing)	AŃe`bKviŃ KZŃ USFDA/BNF /MHRA Ref.	ŃUKŃbK`ij me KŃgŃli mfvi ŃmŃvŃŃ	mfvi ŃmŃvŃŃ
176.	Aristopharma Ltd.	Biotin 5 mg + Cupric Oxide 2.505 mg Eqv.to Copper 2 mg + Manganese Sulphate Monohydrate 15.380 mg Eqv.to Manganese 5 mg + Sodium Selenate 96 mg Eqv.to Selenium 40 mcg + Zinc Oxide 31.120 mg Eqv.to Zinc 25 mg Tablet	Biotin BP 5 mg + Cupric Oxide Ph. Gr. 2.505 mg Eq.to Copper 2 mg + Manganese Sulphate Monohydrate BP 15.380 mg Eq.to Manganese 5 mg + Sodium Selenate Ph. Gr. 96.0mg Eq.to Selenium 40 mcg + Zinc Oxide BP 31.12mg Eqv.to Zinc 25 mg	Vitamin & Minerals	It is indicated for the treatment, control, prevention, & improvement of the following diseases, conditions and symptoms: <ul style="list-style-type: none"> • <u>Hair loss</u> • <u>Skin and hair growth</u> • Healthy nervous system and bone marrow maintenance • Biotin deficiency in pregnancy • Long-term tube feeding • Malnutrition • Rapid weight loss • Copper deficiency • Wound healing • Osteoarthritis • Brittle bones • Manganese deficiency • Osteoporosis • Diseases of the heart and blood vessels • Stroke • Hardening of the arteries • Cancer of the prostate • Stomach cancer • Lung cancer • Zinc deficiencies • Diarrhea in malnutrition children • Wilson's disease 	Contra-indication: These tablets are contraindicated in patients with a history of hypersensitive reaction to Biotin, Cupric Oxide, Manganese Sulphate Monohydrate, Sodium Selenate and Zinc Oxide. In addition, the mentioned tablet should not be used in the following conditions: <ul style="list-style-type: none"> • Fertility problems in men • High doses • Higher doses • Hypersensitivity • Inhalation by children • Large amounts Side-effect: The various reported side effects of the drug are <ul style="list-style-type: none"> • Always consult your physician for the change of dose regimen or an alternative drug of choice that may strictly be required • <u>Nausea</u> • <u>Vomiting</u> • <u>Bloody diarrhea</u> • <u>Fever</u> • <u>Stomach pain</u> 	New		cŃqŃRb ŃbB ŃeaiŃ AŃe`b bŃ gŃŃ Kiv ŃŃZ cŃti	cŃqŃRb ŃbB ŃeaiŃ AŃe`b bigŃŃ Kiv nj

bs	cŌZKvi#K big	Jl#ai big	#R#bni K big	#_iwcDitUK Km	ib# Rbv	Contra-indication & Side-effect	Status (New Molecule/ Existing)	A#e`bKvix KZ# USFDA/BNF / MHRA Ref.	#UKibK'ij me KuglDi mfvi imxv#l	mfvi imxv#l
177.	Eskayef Pharmaceuticals Limited	Iron 14mg + Folic Acid 200mcg + Cyanocobalamin 3mcg + Ascorbic Acid 100mg	Dried Ferrous Sulphate USP 43.523mg eq. to elemental Iron 14mg + Folic Acid USP 200mcg + Cyanocobalamin USP 3mcg + Ascorbic Acid USP 100mg	Vitamin +Minerals	It is indicated for anemias.	Contraindications: Hypersensitivity, patients undergoing hemodialysis, hepatic impairment, renal impairment. Side effects: Constipation, dyspepsia, dizziness, vision blurred fatigue.			c#qirb #bB weavq Avte`b bv g#y Kiv thiz citi	c#qirb #bB weavq Avte`b big#y Kiv nj
178.	ACI Ltd.	Vitamin C 250 mg + Elemental Zinc 6.50 mg Chewable Tablet	Vitamin C BP/USP 250 mg (Ascorbic Acid BP 150 mg + Sodium Ascorbate USP 112.50 mg eqv. to 100 mg Ascorbic Acid) + Zinc Gluconate USP 45 mg eqv. to 6.50 mg Elemental Zinc	Vitamins and Combinations	It is indicated for: Relief of the symptoms of allergies, may assist in the management of upper respiratory tract infections, may reduce the severity and duration of colds, prevention and treatment of vitamin C and Zinc deficiencies, helps maintain and support healthy immune function, helps maintain a healthy skin and Helps in minor wound healing.	Contraindications: It is contraindicated in patients with known hypersensitivity to any of the component of this preparation. Side effects: The most common side effects are upset stomach, headache and unusual or unpleasant taste in the mouth.	Vitamin C 250mg Tablet		c#qirb #bB weavq Avte`b bv g#y Kiv thiz citi	c#qirb #bB weavq Avte`b big#y Kiv nj
179.	Ziska Pharmaceuticals Ltd.	Naftopidil 25 mg Tablet	Naftopidil INN 25 mg	α_1 -adrenoceptor antagonist	It is indicated for the treatment of dysuria in men with benign prostatic hypertrophy.	Contraindications: Naftopidil is contraindicated for patients with allergic reactions to any ingredients. Precautions General Antihypertensive agents and diuretics in combination with Naftopidil will have additional effects to cause hypotension. Therefore, prescription of such combination should reduce the dosage of Naftopidil. Side effects: Intraoperative floppy iris syndrome, ejaculatory disorders, buzzing or lightheadedness, hypotension.	New		c#qirb #bB weavq Avte`b bv g#y Kiv thiz citi	c#qirb #bB weavq Avte`b big#y Kiv nj

bs	cŃZKviŃK big	JlŃai big	ŃRŃbniŃK big	Ń_ iwcDitŃK Km	ibŃ Rbv	Contra-indication & Side-effect	Status (New Molecule/ Existing)	AvŃe bKvir KZŃ USFDA/BNF / MHRA Ref.	ŃUKibK'ij me KugŃli mfvi imxvŃŃ	mfvi imxvŃŃ
180.	Ziska Pharmaceuticals Ltd.	Naftopidil 50 mg Tablet	Naftopidil INN 50 mg	α_1 -adrenoceptor antagonist	It is indicated for the treatment of dysuria in men with benign prostatic hypertrophy.	Contraindications:Naftopidil is contraindicated for patients with allergic reactions to any ingredients. Precautions General Antihypertensive agents and diuretics in combination with Naftopidil will have additional effects to cause hypotension. Therefore, prescription of such combination should reduce the dosage of Naftopidil. Side effects: Intraoperative floppy iris syndrome, ejaculatory disorders, buzzing or lightheadedness, hypotension.	New		cŃqirB ŃbB wearq AvŃe b bŃ gÄy Kiv thŃZ cŃti	cŃqirB ŃbB wearq AvŃe b bŃ gÄy Kiv nj
181.	Ziska Pharmaceuticals Ltd.	Naftopidil 75 mg Tablet	Naftopidil INN 75 mg	α_1 -adrenoceptor antagonist	It is indicated for the treatment of dysuria in men with benign prostatic hypertrophy.	Contraindications: Naftopidil is contraindicated for patients with allergic reactions to any ingredients. Precautions General Antihypertensive agents and diuretics in combination with Naftopidil will have additional effects to cause hypotension. Therefore, prescription of such combination should reduce the dosage of Naftopidil. Side effects: Intraoperative floppy iris syndrome, ejaculatory disorders, buzzing or lightheadedness, hypotension.	New		cŃqirB ŃbB wearq AvŃe b bŃ gÄy Kiv thŃZ cŃti	cŃqirB ŃbB wearq AvŃe b bŃ gÄy Kiv nj
182.	Beacon Pharmaceutical Ltd.	Deflazacort 6mg/5ml Oral suspension	Deflazacort INN 6mg/5ml	Glucocorticoid	Allergic and inflammatory disorder, Hepatic impairment: Dose reductions may be needed.	Contraindications: Systemic infection; live virus vaccines in those receiving immunosuppressive doses. Side Effects: GI disturbances, musculoskeletal, endocrine, neuropsychiatric, ophthalmic, fluid and electrolyte disturbances; susceptible to infection, impaired healing, hypersensitivity, skin atrophy, striae, telangiectasia, acne, myocardial rupture following recent MI, thromboembolism.	6mg & 24mg Tablet		AbŃgv b Kiv thŃZ cŃti	AbŃgv b Kiv nj

bs	cŃZKviŃK bug	JlŃai bug	ŃRŃbniK bug	Ń_ iwcDitUK Kvm	ibŃ Rbv	Contra-indication & Side-effect	Status (New Molecule/ Existing)	AvŃe`bKvir KZŃ USFDA/BNF /MHRA Ref.	ŃUKibK`ij me Kugli mfvi m×vŃŃ	mfvi m×vŃŃ
183.	Ziska Pharmaceuti cals Ltd.	Sumatriptan Succinate 85mg+Naprox en Sodium 500 mg Tablet	Sumatriptan Succinate BP 119 mg eq. to 85mg Sumatriptan + Naproxen Sodium BP 500 mg	Antimigrai ne	It is a combination of sumatriptan, a serotonin (5-HT) 1b/1d receptor agonist (triptan), and naproxen sodium, a non-steroidal antiinflammatory drug, indicated for the acute treatment of migraine with or without aura in adults and pediatric patients 12 years of age and older. Limitations of Use: Use only if a clear diagnosis of migraine headache has been established. Not indicated for the prophylactic therapy of migraine attacks. Not indicated for the treatment of cluster headache.	Contraindications: History of coronary artery disease or coronary vasospasm. History of coronary artery bypass graft surgery. (Wolff-Parkinson-White syndrome or other cardiac accessory conduction, pathway disorders. History of stroke, transient ischemic attack, or hemiplegic or basilar migraine. Peripheral vascular disease. Ischemic bowel disease. Uncontrolled hypertension. Side Effects: Dizziness, drowsiness, Somnolence, Paresthesia, Nausea, Dyspepsia, dry mouth, chest pain or pressure, tight feeling in neck or jaw, pain spreading to arm or shoulder, sudden numbness or weakness, confusion, problems with vision, speech, or balance, bloody or tarry stools.	Naproxen 250, 500 mg Tablet & Sumatriptan 50mg Tablet	USFDA	cŃqirb ŃbB wearq AvŃe`b bŃ gÄy Kiv ŃŃZ cŃti	cŃqirb ŃbB wearq AvŃe`b bŃgÄy Kiv nj
184.	Ziska Pharmaceuti cals Ltd.	Opicapone 50mg Hard Gelatin Capsules	Opicapone INN 50 mg	Antiparkin son drugs	It is indicated as adjunctive therapy to preparations of levodopa/ DOPA decarboxylase inhibitors (DDCI) in adult patients with Parkinson's disease and end-of-dose motor fluctuations who cannot be stabilised on those combinations.	Contraindications: -Hypersensitivity to the active substance or to any of the excipients listed in section. -Phaeochromocytoma, paraganglioma, or other catecholamine secreting neoplasms. -History of neuroleptic malignant syndrome and/or non-traumatic rhabdomyolysis. Concomitant use with monoamine oxidase (MAO-A and MAO- B) inhibitors (e.g. phenelzine, tranylcypromine and moclobemide) other than those for the treatment of Parkinson's disease. Side effects: Nervous system disorders. Dyskinesia	New		cŃqirb ŃbB wearq AvŃe`b bŃgÄy Kiv ŃŃZ cŃti	cŃqirb ŃbB wearq AvŃe`b bŃgÄy Kiv nj

bs	cŃZKviŃK big	JlŃai big	ŃRŃbniŃK big	Ń_ iwcDitŃK Km	ibŃ Rbv	Contra-indication & Side-effect	Status (New Molecule/ Existing)	AŃe`bKvir KZŃ USFDA/BNF /MHRA Ref.	ŃUKibK`ij me KigŃli mfvi imxvŃŃ	mfvi imxvŃŃ
185.	Ziska Pharmaceuticals Ltd.	Naftidrofuryl Oxalate 100mg capsule	Naftidrofuryl Oxalate INN 100mg	Peripheral vasodilator	It is indicated for - Peripheral vascular disease. - Cerebral vascular disease	Contraindications: Acute phase of a cerebrovascular -accident.recent myocardial infarction Side effects: Epigastric pain.hepatic failure.hepatitis. nausea.rash	New	BNF-73 Page:222	cŃqirB ŃbB wearq AŃe`b br gÄy Kiv thŃZ cŃti	cŃqirB ŃbB wearq AŃe`b br gÄy Kiv nj
186.	Ziska Pharmaceuticals Ltd.	Somatostatin 250mcg Injection	Somatostatin BP 250 mcg	Growth hormone antagonist	It is indicated Severe acute haemorrhage from oesophageal varices; acute gastric or duodenal ulcers, or accompanying acute erosive or haemorrhagic gastritis. Adjuvant treatment in pancreatic, biliary and intestinal fistulae and diabetic ketoacidosis. Prophylaxis and treatment of postoperative complications following pancreatic surgery.	Contraindications: Hypersensitivity to somatostatin or to any of the excipients of it. Side effects: Nausea, vertigo and flushing have been reported rarely. Nausea and vomiting have been reported when the infusion rate is >50 mcg/min.	New		cŃqirB ŃbB wearq AŃe`b br gÄy Kiv thŃZ cŃti	cŃqirB ŃbB wearq AŃe`b br gÄy Kiv nj
187.	Ziska Pharmaceuticals Ltd.	Somatostatin 3mg/ml Injection	Somatostatin BP 3 mg/ml	Growth hormone antagonist	It is indicated Severe acute haemorrhage from oesophageal varices; acute gastric or duodenal ulcers, or accompanying acute erosive or haemorrhagic gastritis. Adjuvant treatment in pancreatic, biliary and intestinal fistulae and diabetic ketoacidosis. Prophylaxis and treatment of postoperative complications following pancreatic surgery.	Contraindications: Hypersensitivity to somatostatin or to any of the excipients of it. Side effects: Nausea, vertigo and flushing have been reported rarely. Nausea and vomiting have been reported when the infusion rate is >50 mcg/min.	New		cŃqirB ŃbB wearq AŃe`b br gÄy Kiv thŃZ cŃti	cŃqirB ŃbB wearq AŃe`b br gÄy Kiv nj

bs	cŃZKviŃK big	JlŃai big	ŃRŃbniŃK big	Ń_ iwcDitŃK Km	ibŃ Rbv	Contra-indication & Side-effect	Status (New Molecule/ Existing)	AvŃe`bKvir KZŃ USFDA/BNF /MHRA Ref.	ŃUKibK`ij me KugŃli mfvi imxvŃŃ	mfvi imxvŃŃ
188.	Ziska Pharmaceuticals Ltd.	L-Methyfolate 1.0mg Tablet	L-Methyfolate USP 1 mg	Vitamin	It is used to - Polycystic ovary syndrome, -Management of low plasma in certain patients, - Management of low red blood cell folate in certain patients, - Acts as medical food, - Protective against Neural Tube Defects.	Contraindications: known hypersensitivity to any of the components contained in this product is a contraindication to its use for any indication. Side effects: Allergic reactions have been reported following the use of both oral and parenteral folic acid, as well as the use of oral L-methylfolate.	New		cŃqirB ŃbB weariq AvŃe`b bvir gÄy Kiv thŃZ cŃti	cŃqirB ŃbB weariq AvŃe`b bvir gÄy Kiv nj
189.	Ziska Pharmaceuticals Ltd.	Nintedanib Esylate 100mg capsule	Nintedanib Esylate INN 100 mg	Antifibrotic agent	It is a kinase inhibitor indicated for the treatment of idiopathic pulmonary fibrosis (IPF).	Contraindications: None Side effects: Most common adverse reactions ($\geq 5\%$) are: diarrhea, nausea, abdominal pain, vomiting, liver enzyme elevation, decreased appetite, headache, weight decreased, and hypertension.	New	USFDA	AbŃgv`b Kiv thŃZ cŃti	AbŃgv`b Kiv nj
190.	Ziska Pharmaceuticals Ltd.	Nintedanib Esylate 150mg capsule	Nintedanib Esylate INN 150 mg	Antifibrotic agent	It is a kinase inhibitor indicated for the treatment of idiopathic pulmonary fibrosis (IPF).	Contraindications: None Side effects: Most common adverse reactions ($\geq 5\%$) are: diarrhea, nausea, abdominal pain, vomiting, liver enzyme elevation, decreased appetite, headache, weight decreased, and hypertension.	New	USFDA	AbŃgv`b Kiv thŃZ cŃti	AbŃgv`b Kiv nj

Annex-B: Proposed Product for Import (Human)

নং	cŪZKviKi big	Jlŕai big	tRiwi K big	t_ iucDiJK Km	ibŕ Rbv	Contraindication & Side-effect	Status (New Molecule/ Existing)	FSC/CPP	tUKibK'ij me-Kugŭji mFvi m×vŕŕ	mFvi m×vŕŕ
1.	<p>Hameln Pharmaceuticals GmbH, Langes Feld 13 31789 hameln, Germany.</p> <p>Local Agent: Zas Corporation 80/22 Mymensingh Road , Nurjehan Tower (3rd Floor) Dhaka</p>	Sufentanil-hameln 50ug/ml Solution for Injection/Infusion	Sufentanil Citrate 0.075mg eq. to Sufentalin 0.05mg/ml	Analgesic	As an analgesic component during induction and maintenance of balanced anaesthesia, anaesthesia agent for induction and maintenance of anaesthesia using epidural administration sufentanil is indication as a supplementary analgesic agent to epidural bupivacaine. Postoperative treatment of pain following general , thoracic and or-treatment of pain during labour and vaginal delivery.	<p>Contra-indication: Hypersensitivity to sufentanil or other opioids, disorders in depression of the respiratory centre must be avoided. Acute hepatic porphyria, with concomitant treatment mixed morphine agonist-antagonists . breast-feeding subsequent to anaesthesia . patients with concomitant treatment or pathology that may contraindicate epidural administration .</p> <p>Side-Effect: The most important and common adverse reactions are respiratory de pression and skeletal muscle rigidity, hypotension , hypertension ,bradycardia may occur commonly. Other adverse reaction like tachycardia ,arrhythmia, apnoe, postoperative res-piratory depression, bronchospasm,</p>	New	Germany	Abŕgr`b Kiv thŕZ cŕŕi	Abŕgr`b Kiv nj
2.	<p>Hameln Pharmaceuticals GmbH Langes Feld 13, 31789 Hameln, Germany</p> <p>Local Agent: Zas Corporation , 80/22 Mymensingh Road , Nurjehan Tower (3rd Floor) Dhaka</p>	Atracurium-hameln 10mg/ml Solution for Injection or infusion	Atracurium besilate 10mg/ml	Anesthetic	Intravenous use during surgical and other procedures and in ICU. Used as an adjunct to general anesthesia, to facilitate tracheal intubation and controlled ventilation.	<p>Contra-indication: Hypersensitivity to active substance or any other excipients.</p> <p>Side-Effect: Immune system disorders Anaphylactic reaction Hypersensitivity. Hypotension Circulatory collapse and shock.</p>	Atracurium Besylate 25ml/2.5 ml Injection	Germany	Abŕgr`b Kiv thŕZ cŕŕi	Abŕgr`b Kiv nj

নং	cŪZKvīKi big	Jlīai big	tRibvīK big	t_iucDīJK Km	ibī Rbv	Contraindication & Side-effect	Status (New Molecule/ Existing)	FSC/CPP	tUKibK'ij me-KugūJi mfvi imxīSī	mfvi imxīSī
6.	Ever Pharma Jene GmbH Otto-Schott-StraBe 15 D-07745 Jena, Germany. Local Agent: Zas Corporation 80/22 Mymensingh Road , Nurjehan Tower (3 rd Floor) Dhaka	Methotrexate PhaRes 25mg/ml Solution for Injection pre-filled syringe	Methotrexate 25mg/ml	Antiarthritis	It is indicated in polyarthritic forms of severe, active juvenile idiopathic arthritis (JIA) , Severe forms of psoriasis vulgaris particularly of the plaque type, which cannot be sufficiently treated with conventional therapy.	Contra-indication: Hypersensitivity to methotrexate or to any of the excipients listed in , Liver insufficiency, Alcohol abuse, Renal insufficiency , pre-existing blood dyscrasia, such as bone marrow hypoplasia , leucopenia , thrombocytopenia significant anaemia , Immunodeficiency. Side-Effect: Local adverse reactions or damage may occasionally occur at the injection site. Subcutaneous methotrexate application indicates a good local tolerability.	Methotrexate 50 mg/vial Injection	Germany	Abjgr`b Kiv thīZ cūti	Abjgr`b Kiv nj
7.	Ferrer International ,S.A Joan Buscalla ,1-9 08173 Sant Cugat del Valles Barcelona, Spain. Local agent: Zas Corporation 80/22, Mymensingh Road , Banglamotor , Dhaka	NADIXA 1% Cream	Nadifloxacin Ph. Eu. 1%	Antibiotic	It is used for the treatment of Acne Vulgaris, Folliculitis and other Conditions.	Contraindication: Hypersensitivity to Nadixa Cream is a Contraindication. In addition, Nadixa Cream should not be taken. Side Effect: The reactions of photosensitivity that are developed during the systems treatment while setveral studies in animals and humans have show that Nadifloxacin lacks phototoxic and photoallergic potential , the base fo the cream may have an effect enhancer on photosensitivity.	New	Spain, Germany	cŪqirB tbb wearq Arte`b bvgĀj Kiv thīZ cūti	cŪqirB tbb wearq Arte`b bvgĀj Kiv nj

নং	cŪZKvī#Ki big	Jl#ai big	tRibvī K big	t_i ucDīJK Km	ib# Rbv	Contraindication & Side-effect	Status (New Molecule/ Existing)	FSC/ CPP	#UKibK'ij me- KugūJi mfvi m×vīŠ	mfvi m×vīŠ
8.	Made in Switzerland by F. Hoffmann-La Roche Ltd, Basel, manufacturing site Kaiseraugst. Local agent: Roche Bangladesh Limited	Herceptin® 600 mg/5 ml Subcutaneous Solution for Injection	Trastuzumab INN 600mg/Vial	Anticancer	Breast Cancer Metastatic Breast Cancer (MBC) Herceptin is indicated for the treatment of patients with metastatic breast cancer who have tumors that overexpress HER2: a) as monotherapy for the treatment of those patients who have received one or more chemotherapy regimens for their metastatic disease b) in combination with paclitaxel or docetaxel for the treatment of those patients who have not received chemotherapy for their metastatic disease c) in combination with an aromatase inhibitor for the treatment of patients with hormone-receptor-positive metastatic breast cancer Early Breast Cancer (EBC) Herceptin is indicated for the treatment of patients with HER2-positive early breast cancer: following surgery, chemotherapy (neoadjuvant or adjuvant) and radiotherapy (if applicable). 1.following adjuvant chemotherapy with doxorubicin and cyclophosphamide, in combination with paclitaxel or docetaxel. 2.in combination with adjuvant chemotherapy consisting of docetaxel and carboplatin. 3.in combination with neoadjuvant chemotherapy followed by adjuvant Herceptin, for locally advanced (including inflammatory) breast cancer or tumours > 2 cm in diameter.	Contraindication: Herceptin is contraindicated in patients with known hypersensitivity to trastuzumab or to any of its excipients. Severe dyspnoea at rest Side effects: Acne . alopecia . alopecia . anaphylaxis . angioedema . anxiety . arthralgia . arthritis . asthenia . bone pain . bone-marrow suppression . cardiotoxicity . chest pain . chills . depression . dizziness . drowsiness . dry eye . dry skin . ecchymosis . extravasation . fever . gastrointestinal symptoms . headache . hepatitis . hypersensitivity reactions . hypertension . hypertonia . hyperuricaemia . hypotension . increased lacrimation . infection . infusion-related side-effects (possibly delayed onset) . insomnia . leg cramps . malaise . mastitis . myalgia . nail disorders . nausea . oedema . oral mucositis . paraesthesia . paresis . peripheral neuropathy . pruritus . pulmonary events (possibly delayed onset) . rash . sweating . taste disturbance . thromboembolism . tremor . tumour lysis syndrome . urticaria . vomiting . weight loss	150mg/Vial 440mg/Vial	Switzerland	Abjgr' b Kiv th#Z cūti	Abjgr' b Kiv nj

নং	cŹZKiiKi big	JlŹai big	tRibii K big	t_iucDiJK Km	ibŹ Rbv	Contraindication & Side-effect	Status (New Molecule/ Existing)	FSC/ CPP	ŹUKibK'ji me-KugŹi mfvi imxvŹi	mfvi imxvŹi
9.	<p>Manufacturer: F. Hoffmann-La Roche Ltd, Wurmisweg CH-4603 kaiseraugst, Switzerland</p> <p>License Holder: Roche Pharma (Schweiz) Ag, Switzerland</p> <p>Local agent: Roche Bangladesh Limited</p>	MabThera® 1400 mg/11.7 ml Subcutaneous Injection	Rituximab INN 1400mg/11.7 ml	Anticancer	<p>It is indicated for the treatment of:</p> <ul style="list-style-type: none"> – Patients with relapsed or chemoresistant low-grade or follicular, CD20- positive, B-cell non-Hodgkin's lymphoma; – Previously untreated patients with stage III-IV follicular lymphoma in combination with chemotherapy; – Patients with follicular lymphoma as maintenance treatment, after response to induction therapy; – Patients with CD20-positive diffuse large B-cell non-Hodgkin's lymphoma in combination with CHOP (cyclophosphamide, doxorubicin, vincristine and prednisone) chemotherapy. 	<p>Contraindication: MabThera SC is contraindicated in patients with known hypersensitivity to Rituximab, to any of its excipients or to murine proteins. Severe heart failure (when used to treat granulomatosis with polyangiitis or microscopic polyangiitis). severe infection . severe, uncontrolled heart disease (when used to treat granulomatosis with polyangiitis or microscopic polyangiitis)</p> <p>Side effects: Abdominal pain, anaemia . antibody formation . aplastic anaemia . arthralgia . asthenia . blood disorders . depression . dyspepsia . headache . hypertension . hypotension . injection-site reactions . leucopenia . lupus erythematosus-like syndrome . migraine . muscle spasm . pancytopenia . paraesthesia . progressive multifocal leucoencephalopathy . pruritus . rhinitis . severe fatal skin reactions . severe skin reactions (permanently discontinue treatment if occurs) . sore throat . Stevens-Johnson syndrome (permanently discontinue treatment if occurs) . thrombocytopenia toxic epidermal necrolysis (permanently discontinue treatment if occurs) . urticaria . worsening heart failure</p>	100mg/10ml 500mg/50ml	Switzerland	AbŹgr' b Kiv thŹZ cŹi	AbŹgr' b Kiv nj

নং	চিকিৎসা বিধি	জিআই বিধি	রিবিক বিধি	ইউসিডিআই কন	ইউআই	Contraindication & Side-effect	Status (New Molecule/ Existing)	FSC/ CPP	ইউআই বিধি	ইউআই বিধি
10.	<p>Manufacturer: Novartis Singapore Pharmaceutical Manufacturing Pte. Ltd</p> <p>Local Agent: Novartis Bangladesh Ltd.</p>	Kisqali 200 mg Film-coated tablet	Ribociclib INN 200mg	Anticancer	Kisqali is indicated for the treatment of postmenopausal women with hormone receptor (HR)-positive, human epidermal growth factor receptor 2 (HER2)-negative advanced or metastatic breast cancer.	<p>Contraindication</p> <ul style="list-style-type: none"> Known hypersensitivity to Ribociclib or to any of the excipients <p>Side Effects:</p> <p>Urinary tract infection, neutropenia, leukopenia, anaemia, lymphopenia, thrombocytopenia, decreased appetite, headache, insomnia, dyspnoea, back pain, nausea, diarrhoea, vomiting, constipation, stomatitis, abdominal pain, alopecia, rash, pruritus, fatigue, peripheral oedema, asthenia, pyrexia, abnormal liver function, leukocyte count decreased, neutrophil count decreased, haemoglobin decreased, lymphocyte count decreased, platelet count decreased, alanine aminotransferase increased, aspartate aminotransferase increased, creatinine increased, phosphorous decreased, potassium decreased</p>	New	USA	Abjgr' b Kiv thZ cti	Abjgr' b Kiv nj
11.	<p>Novo Nordisk A/S Novo Allé DK-2880 Bagsværd Denmark</p> <p>Local agent: Novo Nordisk Pharma (Private) Limited Nina Kabbo, Level-9, 227/A, GulshanTejgaon Link Road, Tejgaon, Dhaka</p>	Fiasp® Penfill® 300 units/3ml, Solution for injection in cartridge, 5×3ml	Insulin aspart 300Units/3ml	Antidiabetic	Treatment of diabetes mellitus in adults.	<p>Contra-indication: Hypersensitivity to the active substance or to any of the excipients.</p> <p>Undesirable effects <u>Summary of the safety profile</u> The most frequently reported adverse reaction during treatment is hypoglycaemia <u>Adverse reactions</u> Adverse reactions listed below</p>	300 Units/3ml	EMA CPP- Denmark	Abjgr' b Kiv thZ cti	Abjgr' b Kiv nj

						are based on clinical trial data from phase 3 trials consisting of 4 completed therapeutic confirmatory trials. Frequency categories are defined according to the following convention: Very common ($\geq 1/10$); common ($\geq 1/100$ to $< 1/10$); uncommon ($\geq 1/1,000$ to $< 1/100$); rare ($\geq 1/10,000$ to $< 1/1,000$); very rare ($< 1/10,000$) and not known Very common: Hypoglycaemia. Common: Allergic skin manifestations and injection/infusion site reactions. Uncommon: Hypersensitivity and lipodystrophy.				
12.	Novo Nordisk A/S Novo Allé DK-2880 Bagsværd Denmark Local agent: Novo Nordisk Pharma (Private) Limited Nina Kabbo, Level-9, 227/A, GulshanTejgaon Link Road, Tejgaon, Dhaka	Fiasp® FlexTouch® 300 units/3ml, Solution for injection in pre- filled pen, 5×3ml	Insulin aspart 300 units/3ml	Antidiabetic	Treatment of diabetes mellitus in adults.	Contra-indication: Hypersensitivity to the active substance or to any of the excipients. Undesirable effects <u>Summary of the safety profile</u> The most frequently reported adverse reaction during treatment is hypoglycaemia <u>Adverse reactions</u> Adverse reactions listed below are based on clinical trial data from phase 3 trials consisting of 4 completed therapeutic confirmatory trials. Frequency categories are defined according to the following convention: Very common ($\geq 1/10$); common ($\geq 1/100$ to $< 1/10$); uncommon ($\geq 1/1,000$ to $< 1/100$); rare ($\geq 1/10,000$ to $< 1/1,000$); very rare ($< 1/10,000$) and not known Very common: Hypoglycaemia. Common: Allergic skin manifestations and injection/infusion site reactions. Uncommon: Hypersensitivity and lipodystrophy.	300 Units/3ml	EMA CPP- Denmark	Abjgr`b Kiv thZ crti	Abjgr`b Kiv nj

নং	cŌZKvīKi big	Jlīai big	tRibii K big	t_i ucDiiK Km	ibī Rbv	Contraindication & Side-effect	Status (New Molecule/ Existing)	FSC/ CPP	Abjgr' b Kiv thīZ cūi m×vī	Abjgr' b Kiv nj m×vī
13.	<p>Novo Nordisk A/S Novo Allé DK-2880 Bagsværd Denmark</p> <p>Local agent: Novo Nordisk Pharma (Private) Limited Nina Kabbo, Level-9, 227/A, GulshanTejgaon Link Road, Tejgaon, Dhaka</p>	<p>Fiasp®; 1000 units/10ml, Solution for injection in vial, 1×10ml</p>	<p>Insulin aspart 300 units/3ml</p>	<p>Antidiabetic</p>	<p>Treatment of diabetes mellitus in adults.</p>	<p>Contra-indication: Hypersensitivity to the active substance or to any of the excipients.</p> <p>Undesirable effects <u>Summary of the safety profile</u> The most frequently reported adverse reaction during treatment is hypoglycaemia <u>Adverse reactions</u> Adverse reactions listed below are based on clinical trial data from phase 3 trials consisting of 4 completed therapeutic confirmatory trials. Frequency categories are defined according to the following convention: Very common (≥ 1/10); common (≥ 1/100 to < 1/10); uncommon (≥ 1/1,000 to < 1/100); rare (≥ 1/10,000 to < 1/1,000); very rare (< 1/10,000) and not known Very common: Hypoglycaemia. Common: Allergic skin manifestations and injection/infusion site reactions. Uncommon: Hypersensitivity and lipodystrophy.</p>	<p>300 Units/3ml</p>	<p>EMA CPP- Denmark</p>	<p>Abjgr' b Kiv thīZ cūi m×vī</p>	<p>Abjgr' b Kiv nj m×vī</p>

নং	cŪZKvi#Ki big	Jl#ai big	fRubwiK big	‡_iucDwK Km	ibf`Rbv	Contraindication & Side-effect	Status (New Molecule/ Existing)	FSC/ CPP	‡UKwbK`ij me-Kugidi mfvi m×všl	mfvi m×všl
14.	Boehringer Ingelheim Pharma GmbH & Co. KG, Binger Strasse 173 55216 Ingelheim am Rhein, Germany Local agent: Radiant Export Import Enterprise. Uttara, Dhaka	Jardiance 10 mg Tablet	Empagliflozin INN 10 mg	Antidiabetic	Type II diabetes as monotherapy (if Metformin inappropriate). Type II diabetes in combination with insulin or other antidiabetic drugs (if existing treatment fails to achieve adequate glycaemic control)	Contraindication: Diabetic ketoacidosis Cautions: Cardiovascular disease (increased risk of volume depletion) complicated urinary tract infections consider temporarily interrupting treatment, concomitant antihypertensive therapy (increased risk of volume depletion) , elderly patients aged over 75 years (increased risk of volume depletion), heart failure, history of hypotension (increased risk of volume depletion) patients at increased risk of volume depletion, predisposition to fluid disturbances e.g. gastro intestinal illness, concomitant use of diuretics (increased risk of volume depletion) Volume depletion: Correct hypovolaemia before starting treatment. Consider interrupting treatment if volume depletion occurs. Side-Effects: Common or very common Genital infection hypoglycaemia (in combination with insulin or sulfonylurea) , Polyuria pruritus urinary tract infection. Uncommon : Dysuria volume depletion	New	Germany	ibiqfite Drcv`b Kivi Rb` Abjgv`b Kivq Aig`vbx Abjgv`b cŵvb Kiv thZ crti	Abjgv`b Kiv nj

নং	cŪZKvīKī big	Jlīai big	tRibvīK big	t_iucDīJK Km	ibf`Rbv	Contraindication & Side-effect	Status (New Molecule/ Existing)	FSC/ CPP	īUKībK`ij me-KugūJī mfvi m×vīŚī	mfvi m×vīŚī
15.	Boehringer Ingelheim Pharma GmbH & Co. KG, Binger Strasse 173 55216 Ingelheim am Rhein, Germany Local agent: Radiant Export Import Enterprise. Uttara, Dhaka	Jardiance 25mg Tablet	Empagliflozin INN 25 mg	Antidiabetic	Type II diabetes as monotherapy (if metformin inappropriate). Type II diabetes in combination with insulin or other antidiabetic drugs (if existing treatment fails to achieve adequate glycaemic control)	Contraindication: Diabetic ketoacidosis Cautions: Cardiovascular disease (increased risk of volume depletion) complicated urinary tract infections consider temporarily interrupting treatment, concomitant antihypertensive therapy (increased risk of volume depletion) , elderly patients aged over 75 years (increased risk of volume depletion), heart failure, history of hypotension (increased risk of volume depletion) patients at increased risk of volume depletion, predisposition to fluid disturbances e.g. gastro intestinal illness, concomitant use of diuretics (increased risk of volume depletion) Volume depletion: Correct hypovolaemia before starting treatment. Consider interrupting treatment if volume depletion occurs. Side-Effects: Common or very common Genital infection hypoglycaemia (in combination with insulin or sulfonylurea), Polyuria pruritus urinary tract infection. Uncommon : Dysuria volume depletion	New	Germany	īibxqfīte Drcī`b Kivi Rb` Abjgv`b Kivq Aig`vbxī Abjgv`b cŌvb Kiv thtZ cvti	Abjgv`b Kiv nj

নং	cŪZKvīKi big	Jlīai big	tRibvīK big	t_iucDīJK Km	ibī Rbv	Contraindication & Side-effect	Status (New Molecule/ Existing)	FSC/ CPP	īUKvīK'ij me-KvīDī mfvī m×vīŚī	mfvī m×vīŚī
16.	F. Trenka Chemisch-Pharmzeutische. Fabrik GmbH, Goldeggasse 5 1040 Wien, Austria Local Agent: Zas Corporation, 80/22 Mymensingh Road, Nurjehan Tower (3 rd Floor) Dhaka	Biocarbon 250mg	Activated Charcoal USP 250mg	Antidiarrheal, Antiflatulent	Diarrhoea particularly when travelling in countries with increased Hygiene risks. Development of gases or air in the intestine, flatulence..	Contraindication: Hypersensitivity to one of the ingredients. Side Effect: Higher Dosager or long-term administration may cause nausea and constipation requiring of laxatives gastro-intestinal obstruction and vomiting.	Activated Charcoal 300mg Tablet	Austria, Germany	Abīgv`b Kiv thīZ cvīi	Abīgv`b Kiv nj
17.	Cenexi 52 Rue Marcel-Jacques Gaucher, Fontenay-Sous-Bois, F-94120, France. Local Agent: Zas Corporation 80/22 Mymensingh Road, Nurjehan Tower (3 rd Floor) Dhaka	URAPIDIL Stragen 25mg/5ml Solution for Injection	Urapidil 25mg/5ml	Antihypertensive	Hypertensive emergencies: Hypertension with visceral damages that threatens the vital prognosis at very short term. Anesthesia: Controlled hypotension, hypertension in perioperative period.	Contra-indication: Hypersensitivity (allergy) to the active substance should not be used in cases of aortic isthmus stenosis and arteriovenous shunt. Side-Effect: Nausea, vomiting Very rare Reduction of the number of Platelets, Palpitations, increase or decrease of the cardiac rhythm.	New	France	Abīgv`b Kiv thīZ cvīi	Abīgv`b Kiv nj
18.	Cenexi 52 Rue Marcel-Jacques Gaucher, Fontenay-Sous-Bois, F-94120, France. Local Agent: Zas Corporation 80/22 Mymensingh Road, Nurjehan Tower (3 rd Floor) Dhaka	URAPIDIL Stragen 50mg/10ml Solution for Injection	Urapidil 50mg/10ml	Antihypertensive	Hypertensive emergencies: Hypertension with visceral damages that threatens the vital prognosis at very short term. Anesthesia: Controlled hypotension, hypertension in perioperative period.	Contra-indication: Hypersensitivity (allergy) to the active substance should not be used in cases of aortic isthmus stenosis and arteriovenous shunt. Side-Effect: Nausea, vomiting Very rare Reduction of the number of Platelets, Palpitations, increase or decrease of the cardiac rhythm.	New	France	cīqvīRb ībB veaq Arīe`b bvgĀj Kiv thīZ cvīi	cīqvīRb ībB veaq Arīe`b bvgĀj Kiv nj

নং	cŪZKvi`Ki big	Jl`ai big	tRibi`K big	t_iucDijK Km	ibf`Rbv	Contraindication & Side-effect	Status (New Molecule/ Existing)	FSC/ CPP	tUKibK`y me- Kugij mfi im`vSf	mfi im`vSf
19.	Ferrer International ,S.A Joan Buscalla ,1-9 08173 Sant Cugat del Valles Barcelona, Spain. Local agent: Zas Corporation 80/22, Mymensingh Road , Banglamotor , Dhaka-1000	Eneas 10mg/20mg tablet	Enalapril Maleate 10mg+ Nitrendipine 20mg	Antihypertensive	Eneas is Indicated in the treatment of high blood pressure in patients who cannot be adequately controlled on enalapril or nitrendipine alone.	Contraindication: Allergic to any of its ingredients have suffered allergic reactions to similar medicinal products. Pregnant , suspect that you might be, breastfeeding , cardiovascular shock, cardiac, insufficiency and you have been diagnosed with angina pectoris. Myocardial infarct or cerebral infarct in the previous days. Side Effect: If taken during the second and third trimesters of pregnancy, angiotensin converting enzyme inhibitors. May damage or kill the foetus.	Enalapril Maleate 10 mg Tablet	Spain, Germany	cŪqRb`tbB neavq`Arte`b bigAj`Kiv thtZ`cvti	cŪqRb`tbB neavq`Arte`b bigAj`Kiv nj
20.	Manufacturer: Baxter Healthcare Pty Ltd. 1 Baxter Drive Old Toongabbie NSW 2146, Australia Local agent : National Trading Syndicate Ltd. 41/1, Kazi Nazrul Islam Avenue, Kawran Bazar, Dhaka- 1215	Dianeal Low Calcium with 1.5% w/v Glucose Pertoneal Dialysis Solution.	Glucose-15gm + Sodium, Chloride- 5.38gm + Sodium lactate -4.48 gm + Calcium chloride dehydrate -183mgm + Magnesium chloride hexahydrate- 50.8 mg/Liter excipients: hydrochloric acid Water for injection	Kidney Dialysis Solution	Dianeal PD-2, PD-4 and 1mmol/L Calcium Peritoneal Dialysis Solution is indicated for use in chronic renal failure patients being maintained on Continuous Ambulatory Peritoneal Dialysis (CAPD).	Contra Indication: Do not administer unless the solution is clear and the seal is intact. Dianeal is contraindicated in patients with: Pre-existing severe lactic acidosis, uncorrectable mechanical defects that prevent effective peritoneal dialysis or increase the risk of infection. Documented loss of peritoneal function or extensive adhesions that compromise peritoneal function. Side effect: Adverse reactions to peritoneal dialysis include mechanical and solution related problems as well as the results of contamination of equipment or improper technique in catheter	Calcium Chloride 22 mg + Dextrose Anhydrous 1.5gm + Magnesium Chloride 15 mg + Potassium Chloride 22 mg + Sodium Acetate 476 mg + Sodium Chloride 556 mg/100 ml Dialysis Solution	Australia	Abjgr`b Kiv thtZ`cvti	Abjgr`b Kiv nj

						placement. Abdominal pain, bleeding, peritonitis, subcutaneous infection around the peritoneal catheter, catheter site infection, catheter blockage, difficulty in fluid removal, and ileus are among the complications of the procedure. Solution related adverse reactions may include peritonitis, electrolyte and fluid imbalances, hypovolaemia, hypervolemia, hypotension, hypertension, disequilibrium syndrome, allergic symptoms and muscle cramping.				
21.	<p>Manufacturer: Baxter Healthcare Pty Ltd. 1 Baxter Drive Old Toongabbie NSW 2146, Australia</p> <p>Local agent : National Trading Syndicate Ltd. 41/1, Kazi Nazrul Islam Avenue Kawran Bazar, Dhaka-1215</p>	Dianeal Low Calcium with 4.25% w/v Glucose Pertoneal Dialysis Solution	<p>Ingredient:</p> <p>Active: Glucose-42.5g/L, Sodium, Chloride-5.38 g/L, sodium lactate -4.48 g/L, Calcium chloride dehydrate -183mg/L,</p> <p>Magnesium chloride hexahydrate- 50.8 mg/L)</p> <p>Excipients: hydrochloric acid Water for injection</p>	Kidney Dialysis Solution	Dianeal PD-2, PD-4 and 1mmol/L Calcium Peritoneal Dialysis Solution is indicated for use in chronic renal failure patients being maintained on Continuous Ambulatory Peritoneal Dialysis (CAPD).	<p>Contra Indication: Do not administer unless the solution is clear and the seal is intact. Dianeal is contraindicated in patients with: Pre-existing severe lactic acidosis, uncorrectable mechanical defects that prevent effective peritoneal dialysis or increase the risk of infection. Documented loss of peritoneal function or extensive adhesions that compromise peritoneal function. Side effect: Adverse reactions to peritoneal dialysis include mechanical and solution related problems as well as the results of contamination of equipment or improper technique in catheter placement. Abdominal pain, bleeding, peritonitis, subcutaneous infection around the peritoneal catheter, catheter site infection, catheter blockage, difficulty in fluid removal, and ileus are among the</p>	Australia	Abjgr`b Kiv thz crti	Abjgr`b Kiv nj	

						complications of the procedure. Solution related adverse reactions may include peritonitis, electrolyte and fluid imbalances, hypovolaemia, hypervolemia, hypotension, hypertension, disequilibrium syndrome, allergic symptoms and muscle cramping.				
22.	<p>Manufacturer: Baxter Healthcare Pty Ltd. 1 Baxter Drive Old Toongabbie NSW 2146, Australia</p> <p>Local agent : National Trading Syndicate Ltd. 41/1, Kazi Nazrul Islam Avenue Kawran Bazar, Dhaka- 1215</p>	Extraneal 7.5% w/v icodextrin Dialysis Solution.	Icodextrin -75gm + Sodium Chloride 5.4gm + Sodium lactate 4.5 gm + Calcium chloride dehydrate -257 mg + Magnesium chloride hexahydrate-51 mg/Liter	Kidney Dialysis Solution	EXTRANEAL (7.5% icodextrin) is indicated for use as an alternative osmotic agent in dialysis solutions for the long dwell exchange in patients treated with peritoneal dialysis.	<p>Contra Indication: EXTRANEAL should not be used in patients with a known allergy to starch based polymers (e.g., corn starch) and/or icodextrin, in patients with maltose or isomaltose intolerance or patients with glycogen storage disease.</p> <p>EXTRANEAL is also contraindicated in patients with: a history of abdominal surgery in the month preceding commencement of therapy or in patients with abdominal fistulae, tumours, open wounds, hernias or other conditions which compromise the integrity of the abdominal wall, abdominal surface or intra-abdominal cavity, pre-existing severe lactic acidosis., uncorrectable mechanical defects that prevent effective PD or increase the risk of infection. documented loss of peritoneal function or extensive adhesions that compromise peritoneal function.</p> <p>Side effect: Extraneal associated skin reactions, including rash and pruritus, are generally mild or moderate in severity. Blood glucose management with Extraneal must be done with a glucose-specific method to avoid interference resulting in unrecognised hypoglycaemia.</p>	Calcium Chloride 9 mg + Dextrose Anhydrous 70 mg + Magnesium Chloride 1.189 mg + Potassium Chloride 594.57 mg + Sodium Acetate .03 mg + Sodium Chloride 5.94 mg/100 ml Dialysis Solution	CPP-Australia	Abjgr' b Kiv thZ crti	Abjgr' b Kiv nj

নং	cŪZKvi#Ki big	Jl#ai big	tRibii K big	t_i ucDiJK Km	ib# Rbv	Contraindication & Side-effect	Status (New Molecule/ Existing)	FSC/ CPP	#UKibK'ij me- Kugūji mfvi imxvš	mfvi imxvš
23.	<p>Manufacturer: Baxter Healthcare Pty Ltd. 1 Baxter Drive Old Toongabbie NSW 2146, Australia</p> <p>Local agent : National Trading Syndicate Ltd. 41/1, Kazi Nazrul Islam Avenue Kawran Bazar, Dhaka-1215</p>	Dianeal Low Calcium with 2.5% w/v Glucose Pertoneal Dialysis Solution	<p>Ingredient: Active: Glucose-25g/L, Sodium, Chloride-5.38 g/L, sodium lactate -4.48 g/L, Calcium chloride dehydrate -183mg/L,</p> <p>Magnesium chloride hexahydrate- 50.8 mg/L)</p> <p>excipients: hydrochloric acid Water for injection</p>	Kidney Dialysis Solution.	Dianeal PD-2, PD-4 and 1mmol/L Calcium Peritoneal Dialysis Solution is indicated for use in chronic renal failure patients being maintained on Continuous Ambulatory Peritoneal Dialysis (CAPD).	<p>Contra Indication: Do not administer unless the solution is clear and the seal is intact. Dianeal is contraindicated in patients with: Pre-existing severe lactic acidosis, uncorrectable mechanical defects that prevent effective peritoneal dialysis or increase the risk of infection. Documented loss of peritoneal function or extensive adhesions that compromise peritoneal function. Side effect: Adverse reactions to peritoneal dialysis include mechanical and solution related problems as well as the results of contamination of equipment or improper technique in catheter placement. Abdominal pain, bleeding, peritonitis, subcutaneous infection around the peritoneal catheter, catheter site infection, catheter blockage, difficulty in fluid removal, and ileus are among the complications of the procedure. Solution related adverse reactions may include peritonitis, electrolyte and fluid imbalances, hypovolaemia, hypervolemia, hypotension, hypertension, disequilibrium syndrome, allergic symptoms and muscle cramping.</p>	Calcium Chloride 22 mg + Dextrose Anhydrous 1.5 gm + Magnesium Chloride 15 mg + Potassium Chloride 22 mg + Sodium Acetate 476 mg + Sodium Chloride 556 mg/100 ml Dialysis Solution	Australia	Abjgr' b Kiv th#Z cūi	Abjgr' b Kiv nj

নং	cŪZKvī#Ki big	Jl#ai big	tRibvīK big	t_iucDīJK Km	ib# Rbv	Contraindication & Side-effect	Status (New Molecule/ Existing)	FSC/ CPP	#UKibK'ij me- KugūJi mfvi im×vī#	mfvi im×vī#
24.	<p>Manufacturer: Baxter Healthcare Pty Ltd. 1 Baxter Drive Old Toongabbie NSW 2146, Australia</p> <p>Local agent : National Trading Syndicate Ltd. 41/1, Kazi Nazrul Islam Avenue Kawran Bazar, Dhaka-1215</p>	Dianeal PD4 Peritoneal Dialysis solution with 0.55% w/v Glucose Low Calcium Freeline Solo	Glucose Monohydrate-5.5gm + Sodium, Chloride-5.39 gm + Sodium lactate -4.48 gm + Calcium chloride dehydrate -0.183g + Magnesium chloride Hexahydrate-0.0508g/Liter	Kidney Dialysis Solution.	Dianeal PD-2, PD-4 and 1mmol/L Calcium Peritoneal Dialysis Solution is indicated for use in chronic renal failure patients being maintained on Continuous Ambulatory Peritoneal Dialysis (CAPD).	<p>Contra Indication: Do not administer unless the solution is clear and the seal is intact. Dianeal is contraindicated in patients with: Pre-existing severe lactic acidosis, uncorrectable mechanical defects that prevent effective peritoneal dialysis or increase the risk of infection. Documented loss of peritoneal function or extensive adhesions that compromise peritoneal function.</p> <p>Side effect: Adverse reactions to peritoneal dialysis include mechanical and solution related problems as well as the results of contamination of equipment or improper technique in catheter placement. Abdominal pain, bleeding, peritonitis, subcutaneous infection around the peritoneal catheter, catheter site infection, catheter blockage, difficulty in fluid removal, and ileus are among the complications of the procedure. Solution related adverse reactions may include peritonitis, electrolyte and fluid imbalances, hypovolaemia, hypervolemia, hypotension, hypertension, disequilibrium syndrome, allergic symptoms and muscle cramping.</p>	Calcium Chloride 0.257% + Dextrose Anhydrous 7.0 % + Magnesium Chloride .0152% + Sodium Acetate 3.69 % + Sodium Chloride 0.561 % Dialysis Solution	CPP- Australia	Abjgr' b Kiv th#Z cr#i	Abjgr' b Kiv nj

নং	cŹKviKi big	JlŹai big	tRibiK big	t_iucDiJK Km	ibŹ Rbv	Contraindication & Side-effect	Status (New Molecule/ Existing)	FSC/ CPP	ŹUKibK'ji me-KugŹi mfvi imxŹi	mfvi imxŹi
25.	Pharma Sia 4 Rupnica Street , Olaine Lv-2114 Lettonie, Latvia. Local Agent: Zas Corporation80/22 Mymensingh Road , Nurjehan Tower (3 rd Floor) Dhaka-1000. Bangladesh	Atosiban Stragen 6.75mg/0.9ml Solution for Injection	Atosiban 6.75mg/0.9ml	Oxytocin receptor antagonist	Atosiban is indicated to delay imminent pre-term birth in pregnant adult women.	Contra-indication: Gestational age below 24 or over 33 completed weeks , premature rupture of the membranes , abnormal foetal heart rate. Side-Effect: Respiratory events like dyspnoea and pulmonary oedema , particularly in association with concomitant administration of other medicinal products.	New	CPP-Latvia, Germany.	AbŹgr`b Kiv thŹZ cŹti	AbŹgr`b Kiv nj
26.	Pharma Sia 4 Rupnica Street , Olaine Lv-2114 Lettonie, Latvia. Local Agent: Zas orporation80/22 Mymensingh Road , Nurjehan Tower (3 rd Floor) Dhaka-1000. Bangladesh	Atosiban Stragen 37.5mg/5ml Concentrate for Solution for Infusion	Atosiban 37.5mg/5ml	Oxytocin receptor antagonist	Atosiban is indicated to delay imminent pre-term birth in pregnant adult women.	Contra-indication: Gestational age below 24 or over 33 completed weeks , premature rupture of the membranes , abnormal foetal heart rate. Side-Effect: Respiratory events like dyspnoea and pulmonary oedema , particularly in association with concomitant administration of other medicinal products.	New	CPP-Latvia, Germany	AbŹgr`b Kiv thŹZ cŹti	AbŹgr`b Kiv nj
27.	Manufacturer: Abbott Biologicals B.V., Veerweg 12 , 8121 AA Olst, The Netherlands UniHealth Ltd. House No. 46, Sheikh Kamal Saroni, Road No. 16, RangNasim Square, Dhanmondi	Femoston Conti 1/5mg Film coated Tablet	Estradiol INN 1mg + Dydrogesterone BP 5mg	Steroid	# Menopausal symptoms in women with a uterus whose last menstrual period ocured over 12 months previously. # Osteoporosis prophylaxis in women with a uterus whose last menstrual period ocured over 12 months previously.	Contra-indications: Acute prophyrias p.918. genital or breast cancer, History during pregnancy of idiopathic jaundice, severe pruritus, or pemphigoid gestationis. History of liver tumours, Severe arterial disease, Undiagnosed vaginal bleeding Side-Effects: Acne, alopecia, anaphylatoid, reaction, bloating, breast tenderness, change in libido, depression, dizziness, drowsiness, fluid retention, headache, hirsutism, insomnia, jaundice, menstrual disturbances, nausea, premenstrual-like syndrome, pruritus, rash, skin reaction, urticaria, weight change	Estradiol 2 mg Tablet Dydrogesterone 10 mg Tablet	The Netherlands & UK	cŹqRb ŹbB weavq AŹte`b bvgÄj Kiv thŹZ cŹti	cŹqRb ŹbB weavq AŹte`b bvgÄj Kiv nj

नं	cŪZKvi#Ki big	Jl#ai big	fRubiK big	‡_iucDlJK Km	ibf`Rbv	Contraindication & Side-effect	Status (New Molecule/ Existing)	FSC/CPP	‡UKibK`ij me-Kuglji mfvi imxvšl	mfvi imxvšl
28.	<p>Manufacturer: Abbott Biologicals B.V., Veerweg 12 , 8121 AA Olst, The Netherlands</p> <p>UniHealth Ltd. House No. 46, Sheikh Kamal Saroni, Road No. 16, RangNasim Square, Dhanmondi</p>	Femoston 2/10mg Film coated Tablet	Estradiol INN 2mg + Dydrogesterone BP 10mg	Steroid	<p># Menopausal symptoms in women with a uterus</p> <p># Osteoporosis prophylaxis in women with a uterus</p>	<p>Contraindications: Acute prophyrias p.918. genital or breast cancer, History during pregnancy of idiopathic jaundice, severe pruritus, or pemphigoid gestationis. History of liver tumours, Severe arterial disease, Undiagnosed vaginal bleeding</p> <p>Side-Effects: Acne, alopecia, anaphylatoid, reaction, bloating, breast tenderness, change in libido, depression, dizziness, drowsiness, fluid retention, headache, hirsutism, insomnia, jaundice, menstrual disturbances, nausea, premenstrual-like syndrome, pruritus, rash, skin reaction, urticaria, weight change</p>	<p>Estradiol 2 mg Tablet</p> <p>Dydrogesterone 10 mg Tablet</p>	The Netherlands & UK	<p>cŹqRb #bB #eavq Arte`b bvgAjy Kiv thtZ cŹti </p>	<p>cŹqRb #bB #eavq Arte`b bvgAjy Kiv nj </p>
29.	<p>Manufacturer: Abbott Biologicals B.V., Veerweg 12 , 8121 AA Olst, The Netherlands</p> <p>UniHealth Ltd. House No. 46, Sheikh Kamal Saroni, Road No. 16, RangNasim Square, Dhanmondi</p>	Femoston 1/10mg Film coated Tablet	Estradiol INN 1mg + Dydrogesterone BP 10mg	Steroid	<p># Menopausal symptoms in women with a uterus</p> <p># Osteoporosis prophylaxis in women with a uterus</p>	<p>Contraindications: Acute prophyrias p.918. genital or breast cancer, History during pregnancy of idiopathic jaundice, severe pruritus, or pemphigoid gestationis. History of liver tumours, Severe arterial disease, Undiagnosed vaginal bleeding.</p> <p>Side-Effects: Acne, alopecia, anaphylatoid, reaction, bloating, breast tenderness, change in libido, depression, dizziness, drowsiness, fluid retention, headache, hirsutism, insomnia, jaundice, menstrual disturbances, nausea, premenstrual-like syndrome, pruritus, rash, skin reaction, urticaria, weight change</p>	<p>Estradiol 2 mg Tablet</p> <p>Dydrogesterone 10 mg Tablet</p>	The Netherlands & UK	<p>cŹqRb #bB #eavq Arte`b bvgAjy Kiv thtZ cŹti </p>	<p>cŹqRb #bB #eavq Arte`b bvgAjy Kiv nj </p>

নং	cŪZKvīKi big	Jlīai big	tRibvīK big	t_iucDīJK Km	ibī`Rbv	Contraindication & Side-effect	Status (New Molecule/ Existing)	FSC/ CPP	†UKibK`yj me-KugūJi mfvi um×vīŚ	mfvi um×vīŚ
30.	URSAPHARM Arzneimittel GmbH. Industriestraße 35 66129 Saarbrücken Germany Local agent: Zas Corporation 80/22, Mymensingh Road, Banglamotor, Dhaka-1000	Dexa-Gentamicin (Preservative free Eye Drops 5ml Bottle)	Dexamethasone Sodium Phosphate 1.0 mg + Gentamicin Sulphate 5.0mg/ml	Steroid + Antibiotic	Infections of the anterior eye including conjunctivitis, keratitis, blepharitis, and hordeolum, caused by gentamicin-sensitive Spathogens; allergic inflammation of the anterior eye with bacterial superinfection	Contraindication: Hypersensitivity to one of the ingredients (see composition), herpes cornea superficialis, injuries and ulcerations of the cornea, closed and open angle glaucoma, tuberculosis or fungal infection of the eye. Side Effect: In rare cases the sensation of temporary burning in the eye has been reported. Prolonged use may result in glaucoma and cataract formation.	Gentamicin 0.3% + Hydrocortisone Acetate 1% Eye and Ear Drops	Germany	cŪqīRb `tbB neavq Arte`b bigĀj Kiv thīZ cīti	cŪqīRb `tbB neavq Arte`b bigĀj Kiv nj

Annex-B: Import Products for Human (Vaccine)

SI No.	Name of the manufacturer	Name of the product	Generic Name	Indication	Contraindication & side effect	Status (New Molecule / Existing)	CPP/FSC	তউকবক'জ মে-কুগ'জি মবি উম'সি	মবি উম'সি
1.	Sanofi Pasteur SA, 2 avenue pont Pasteur, 69007 Lyon, France (Sanofi Bangladesh Limited)	VaxigripTetra™ Quadrivalent influenza vaccine (Split virion, inactivated)	Influenza Vaccine	The Quadrivalent Influenza Vaccine is indicated for active immunization of adults and children from 3 years of age and older for the prevention of influenza disease caused by the two influenza A virus subtypes and the two influenza B virus types contained in the vaccine. The use of the Quadrivalent Influenza Vaccine should be based on official recommendations.	Contraindications: Hypersensitivity to the active substances, to any of the excipients listed in section 6.1 or to any component that may be present as traces such as eggs (ovalbumin, chicken proteins), neomycin, formaldehyde and octoxinol-9. Vaccination should be postponed in case of moderate or severe febrile disease or acute disease. Side-effects: Severe allergic reactions: ○ that may lead to medical emergency with low blood pressure, rapid, shallow breathing, rapid heart rate and weak pulse, cold, clammy skin, dizziness, that may lead to collapse (shock). These side effects were not observed with VaxigripTetra but have been rarely reported with other vaccines given to prevent flu (may affect up to 1 in 1,000 people). ○ swelling most apparent in the head and neck, including the face, lips, tongue, throat or any other part of the body and which may cause difficulty in swallowing or breathing (angioedema). ● Allergic reactions such as skin reactions that may spread throughout the body including itching, hives, rash, redness.	New	France	Ab'gr`b Kiv thiZ cti	Ab'gr`b Kiv nj
2.	Sanofi Pasteur ParIndustrield'Incarville, 27100 Val de Reuil, France (Sanofi Bangladesh Limited)	Dengvaxia Dengue tetravalent vaccine (live, attenuated)	Dengue tetravalent Vaccine	CYD dengue vaccine is indicated for the prevention of dengue disease caused by dengue virus serotypes 1, 2, 3 and 4 in individuals from 9 to 45 years of age living in endemic areas.	Contraindications Do not use Dengvaxia if the patient is allergic (hypertensive) to the active substances or any of the other ingredients of Dengvaxia listed in Description (see Description); has developed an allergic reaction after prior administration of Dengvaxia. Signs of an allergic reaction may include an itchy rash, shortness of breath and swelling of the face and tongue; is suffering from a disease with mild to high fever or	New	France, , Australa Mexico, Philippines,	Ab'gr`b Kiv thiZ cti	Ab'gr`b Kiv nj

Annex-C: Proposed Product for Locally Manufacture (Veterinary)

Sl. No	Name of the Manufacturer	Name of the Product	Generic Name	Therapeutic Class	Indication	Contra-indication & Side effect	Status (New Molecule /Existing)	USFDA, BNF or MHRA Reference	তുകিবক'ij me Kug'li mfvi imxvš	mfvi imxvš
1.	Acme Laboratories Ltd., Dhamrai, Dhaka	Meloxicam 100mg + Paracetamol 1500 mg Bolus (For Veterinary Use Only)	Meloxicam BP 100mg + Paracetamol BP 1500 mg	Analgesic + Antipyretic	Treatment of pneumonia, broncho pneumonia, arthritis, otitis, pyrexia of unknown origin, pain and fever associated with inflammation.	Contraindications: Contraindicated in animals with known hypersensitivity to Meloxicam and Paracetamol or any other ingredients of the product. It is also contraindicated in animals less than six weeks old animals with impaired renal, hepatic or cardiac function. Side effects: Usually well tolerated at recommended doses. Prolong use may cause gastrointestinal lesions, inappetance,, vomiting and diarrhea.	Meloxicam 20mg + Paracetamol 150mg/ml Injection Meloxicam 100 mg + Paracetamol 750 mg/5 ml Injection Meloxicam 200 mg + Paracetamol 1.5 gm/10 ml Injection		Abjgr`b Kiv thZ cti	Abjgr`b Kiv nj
2.	Acme Laboratories Ltd., Dhamrai, Dhaka	Paracetamol 50gm/100gm Water Soluble Powder (WSP) (For Veterinary Use Only)	Paracetamol BP 50gm/100 gm	Analgesic, Antipyretic	Fever & pain of poultry & livestock.	Contraindications: The drug is contraindicated where there is possibility of gastro-intestinal ulceration or bleeding and animals hypersensitive to Paracetamol. Side effects: Occasional constipation may occur.	2 g Bolus		Abjgr`b Kiv thZ cti	Abjgr`b Kiv nj
3.	Eskayef Pharmaceuticals Limited	Eprinomectin 0.25gm/Vial SC Injection (Vet)	Eprinomectin USP 0.25gm/Vial	Anthelmintic	It can be used against both internal and external parasites like Bunostomumsp., Cooperia sp., Haemonchus sp., Oesophagostomum sp., Ostertagia sp., Trichostrongylus sp., etc.	Contraindication: Hypersensitivity	New		Abjgr`b Kiv thZ cti	Abjgr`b Kiv nj
4.	Eskayef Pharmaceuticals Limited	Closantel 5.0gm/100ml Injection (Vet)	Closantel Sodium Dihydrate BP 5.43gm eq. to Closantel 5.0gm/100ml	Anthelmintic agent	Treatment and prevention of several infections caused by parasites sensitive for closantel like Fasciola hepatica, Fasciola gigantica, Haemonchus concortus, Bunostomum phlebotomum, Oesophagostomum radiatum and Stronglyoides papillosus in cattle and sheep.	Contraindication: Hypersensitivity Side effects: Hyper acute anaphylactic reactions in cattle, hypersensitivity reactions.	New		Abjgr`b Kiv thZ cti	Abjgr`b Kiv nj

Sl. No	Name of the Manufacturer	Name of the Product	Generic Name	Therapeutic Class	Indication	Contra-indication & Side effect	Status (New Molecule /Existing)	USFDA, BNF or MHRA Reference	তউকিবক'জ মে কুগুডি মফবি মমখিঈ	মফবি মমখিঈ
					Limitation: Do not use for IV or IM.					
5.	Acme Laboratories Ltd., Dhamrai, Dhaka	Fenbendazole 20.0gm/ 100 ml Liquid (For Veterinary Use Only)	Fenbendazole BP 20gm/100 ml	Anthelmintics	Poultry: Fenbendazole (Fenazol Vet) is used for the treatment of round worm such as Ascaridia galli, Heterakis gallinarum, Syngamus trachea, Capillaria sp etc. and tape worm such as Davainea proglottina, Metroliaesthes lucida, Raillietina etc. infestations in poultry. Cattle, Horse, Dogs: Fenbendazole (Fenazol Vet) is used for the treatment of round worm and tape worm infestations.	Contraindications: Do not use in animals with known hypersensitivity to Fenbendazole Side effects: No known side effects have been observed with Fenbendazole.	10gm/100ml Suspension, 250mg Bolus, 22.2gm/100 gm Powder	USFDA	Abjgr` b Kiv thZ cti /	Abjgr` b Kiv nj /
6.	Acme Laboratories Ltd., Dhamrai, Dhaka	Cefquinome 225 mg/ Vial Powder for Injection (PFI) (For Veterinary Use Only)	Cefquinome Sulfate (Sterile) INN 281.25 mg eqv. to 225 mg Cefquinome/Vial	Antibiotic	Cattle: For the treatment of Respiratory tract diseases Mastitis, Foot rot, Septicemia etc. Horse: Respiratory tract diseases, bacterial infections. Pigs: Respiratory tract diseases, Metritis-Mastitis-Agalactia (MMA) syndrome.	Contraindications: Contraindicated for use in animals with known hypersensitivity to Cefquinome or cephalosporin group of antibiotics. Side effects: Localized tissue reaction may occur in some cases, but the tissue lesions will resolve 15 days after last administration.	2.5 gm/100 ml Injection	Veterinary Formulary, 5th Edition, P: 154	Abjgr` b Kiv thZ cti /	Abjgr` b Kiv nj /
7.	Acme Laboratories Ltd., Dhamrai, Dhaka	Cefquinome 450 mg /Vial Powder for Injection (PFI) (For Veterinary Use Only)	Cefquinome Sulfate (Sterile) INN 562.50 mg eqv. to 450 mg Cefquinome/Vial	Antibiotic	Cattle: For the treatment of Respiratory tract diseases Mastitis, Foot rot, Septicemia etc. Horse: Respiratory tract diseases, bacterial infections. Pigs: Respiratory tract diseases, Metritis-Mastitis-Agalactia (MMA) syndrome.	Contraindications: Contraindicated for use in animals with known hypersensitivity to Cefquinome or cephalosporin group of antibiotics. Side effects: Localized tissue reaction may occur in some cases, but the tissue lesions will resolve 15 days after last administration.	2.5 gm/100 ml Injection	Veterinary Formulary, 5th Edition, P: 154	Abjgr` b Kiv thZ cti /	Abjgr` b Kiv nj /
8.	Acme Laboratories Ltd., Dhamrai, Dhaka	Amoxicillin 400mg + Clavulanic Acid 100 mg Bolus (For Veterinary Use Only)	Amoxicillin Trihydrate BP 460 mg eq. to 400 mg Amoxicillin + Diluted Potassium Clavulanate [As	Antibiotic	Indicated for short-term treatment of bacterial infections at the following sites: Upper respiratory tract infections (including ENT) e.g. tonsillitis, sinusitis, otitis media. Lower respiratory tract infections e.g. acute and chronic	Contraindications: Penicillin hypersensitivity, history of co-amoxiclav-associated or penicillin-associated jaundice or hepatic dysfunction. Side effects: Side effects, as	Amoxicillin 500 mg Bolus, 2 g/vial & 1.5 g/10 ml Injection	Veterinary Formulary, 5th Edition, P: 147	Abjgr` b Kiv thZ cti /	Abjgr` b Kiv nj /

Sl. No	Name of the Manufacturer	Name of the Product	Generic Name	Therpeutic Class	Indication	Contra-indication & Side effect	Status (New Molecule /Existing)	USFDA, BNF or MHRA Reference	তউকীক'জ মে কুগী mfví উমখীশী	mfví উমখীশী
			Potassium Clavulanate and Microcrystalline Cellulose 1:1] BP 238.40 mg eqv. to 100 mg Clavulanic Acid		bronchitis, lobar and bronchopneumonia. Genito-urinary tract infections e.g. cystitis, urethritis, pyelonephritis. Skin and soft tissue infections. Bone and joint infections e.g.osteomyelitis. Other infections e.g. septic abortion, puerperal sepsis, intra-abdominal sepsis etc.	with Amoxicillin, are uncommon and mainly of a mild and transitory nature. Diarrhoea, pseudomembranous colitis, indigestion, nausea, vomiting and candidiasis have been reported. If gastrointestinal side effects occur with oral therapy, that may be reduced by taking Co-amoxiclav at the start of meals. Hepatitis and cholestatic jaundice have been reported rarely but are usually reversible. Urticarial and erythematous rashes sometimes occur. Rarely erythema multiforme, Stevens- Johnson Syndrome and exfoliative dermatitis have been reported. In common with other beta-lactam antibiotics angioedema and anaphylaxix have been reported.				
9.	Acme Laboratories Ltd., Dhamrai, Dhaka	Amoxicillin 800mg + Clavulanic Acid 200 mg Bolus (For Veterinary Use Only)	Amoxicillin Trihydrate BP 920 mg eqv. to 800 mg Amoxicillin + Diluted Potassium Clavulanate [As Potassium Clavulanate and Microcrystalline Cellulose 1:1] BP 476.80 mg eqv. to 200 mg Clavulanic Acid	Antibiotic	Indicated for short-term treatment of bacterial infections at the following sites : Upper respiratory tract infections (including ENT) e.g. tonsillitis, sinusitis, otitis media. Lower respiratory tract infections e.g. acute and chronic bronchitis, lobar and bronchopneumonia. Genito-urinary tract infections e.g. cystitis, urethritis, pyelonephritis. Skin and soft tissue infections. Bone and joint infections e.g.osteomyelitis. Other infections e.g. septic abortion, puerperal sepsis, intra-abdominal sepsis etc.	Contraindications: Penicillin hypersensitivity, history of co-amoxiclav-associated or penicillin-associated jaundice or hepatic dysfunction. Side effects: Side effects, as with Amoxicillin, are uncommon and mainly of a mild and transitory nature. Diarrhoea, pseudomembranous colitis, indigestion, nausea, vomiting and candidiasis have been reported. If gastrointestinal side effects occur with oral therapy, that may be reduced by taking Co-amoxiclav at the start of meals. Hepatitis and cholestatic jaundice have been reported rarely but are usually reversible. Urticarial and erythematous rashes sometimes occur. Rarely erythema multiforme,	Amoxicillin 500mg Bolus, 2gm/Vial & 1.5gm/10ml Injection	Veterinary Formulary, 5th Edition, P: 147	Abjgv`b Kiv thtZ cti /	Abjgv`b Kiv nj /

Sl. No	Name of the Manufacturer	Name of the Product	Generic Name	Therapeutic Class	Indication	Contra-indication & Side effect	Status (New Molecule /Existing)	USFDA, BNF or MHRA Reference	†UKibK'ij me KuglDi mfvi imxıŒı	mfvi imxıŒı
					resistant to gentamicin remain sensitive to amikacin and amikacin also has the advantage of being less toxic to the kidneys.	therapy. In 90 day intramuscular toxicology studies, evidence of muscle damage was detected histologically as well as by elevated creatinine phosphokinase.				
17.	Incepta Pharmaceuticals Ltd (Dhamrai Unit).	Marbofloxacin 10.0gm/100ml Solution	Marbofloxacin BP 10.0gm/100ml	Antibiotic	<p>Cattle Treatment of respiratory infections caused by sensitive strains of Pasteurella multocida, Mannheimia haemolytica and Mycoplasma bovis. Treatment of acute mastitis caused by Echerichia coli strains sensitive to marbofloxacin during the lactation period.</p> <p>Sheeps/Goats: Treatment of Metritis Mastitis Agalactia Syndrome (postpartum dysgalactia syndrome, PDS) caused by bacterial strains sensitive to marbofloxacin.</p>	<p>Contraindications: Do not use in cases where the pathogen involved is resistant to other fluoroquinolones (cross resistance). Do not use in animals with known hypersensitivity to fluoroquinolones or to any of the excipients. The efficacy data showed that the product has insufficient efficacy for the treatment of acute forms of mastitis induced by Gram-positive bacteria.</p> <p>Side effect: The following clinical signs were reported during the course of clinical field studies in dogs receiving marbofloxacin at dosages up to 2.5 mg/lb daily: decreased or loss of appetite (5.4%), decreased activity (4.4%), and vomiting (2.9%). The following signs were reported in less than 1% of cases in dogs: increased thirst, soft stool/diarrhea, behavioral changes, shivering/shaking/tremors, and ataxia. One dog which had a seizure the day before study enrollment experienced a seizure while on marbofloxacin therapy. The following clinical signs were reported during clinical field studies in cats receiving 1.25 mg/lb/day: diarrhea (2.1%) and soft stool (1.4%). Vomiting</p>	New		Abjgr`b Kiv thZ cti /	Abjgr`b Kiv nj /

Sl. No	Name of the Manufacturer	Name of the Product	Generic Name	Therapeutic Class	Indication	Contra-indication & Side effect	Status (New Molecule /Existing)	USFDA, BNF or MHRA Reference	፲፱፻፲፱ ዓ.ም. ገዢ ጽ/ቤት ገዢ ጽ/ቤት	ገዢ ጽ/ቤት
						<p>drugs include theophylline, antacids, iron supplements, sucralfate, cyclosporine and various other antibiotics.</p> <p>Paracetamol If the dog has a liver condition, paracetamol is strictly forbidden. The components of paracetamol influence the liver function and if the liver is damaged, the drug may be fatal. A dog that is under narcotic or analgesic medication shouldn't take paracetamol.</p> <p>Side-effects Ciprofloxacin</p> <ul style="list-style-type: none"> • Loss of appetite • Vomiting • Diarrhea • Lethargy • Convulsions • Seizures in pets with CNS disorders • Cataracts if given long-term <p>Paracetamol</p> <ul style="list-style-type: none"> • While generally safe and effective when recommended by a veterinarian, acetaminophen can cause side effects in some animals. • Acetaminophen should not be used in animals with known hypersensitivity or <u>allergy</u> to the drug. • Acetaminophen should never be 				

Sl. No	Name of the Manufacturer	Name of the Product	Generic Name	Therpeutic Class	Indication	Contra-indication & Side effect	Status (New Molecule /Existing)	USFDA, BNF or MHRA Reference	তউকীক'য় মে কুগী মবি মম'সী	মবি মম'সী
	Pharmaceuticals Limited	Hydrochloride 6.6% Oral Powder (Vet)	Hydrochloride INN 6.6gm/100gm		coccidiosis caused by Eimeria mivati, E. brunette, E. tenella, E. acervulina, E. maxima and E. necatrix in broiler chickens only. Limitation: Feed continuously as the sole ration. Do not feed to chickens producing eggs for food.	Warning: Withdraw 5days prior to slaughter.			ঢ়ী	
21.	Incepta Pharmaceuticals Ltd (Dhamrai Unit).	Glutaraldehyde 25.483gm + Quaternary Ammonium Compound 9.6860gm/100ml Liquid	Glutaraldehyde USP 25.483gm + Quaternary Ammonium Compound BP/Ph. Eur. 9.6860gm/100ml	Disinfectant	<ul style="list-style-type: none"> Active in the presence of organic matter Non-staining DEFRA (Department for Environment, Food & Rural Affairs, UK) Approved (Foot & Mouth, Poultry & General Orders) Prolonged residual activity Rapid acting against bacteria, viruses & fungi 	Contraindications: Glutaraldehyde is contraindicated in conditions like damaged skin. Side-effects: The disinfectant is well tolerated by the animals. At the recommended doses, side effect is relatively nil.	Glutaraldehyde 2.4% Solution		Ab'g' b Kiv thZ ঢ়ী	Ab'g' b Kiv nj
22.	Acme Laboratories Ltd., Dhamrai, Dhaka	Furosemide 2.0gm Bolus (For Veterinary Use Only)	Furosemide BP 2gm	Diuretics	It is indicated in cardiac, pulmonary, hepatic and renal oedema, peripheral oedema and hypertension.	Contraindications: Furosemide is contraindicated in anuria, electrolyte deficiency and pre-comatose states associated with liver cirrhosis. Hypersensitivity to furosemide or sulphonamides. Side effects: Alkalosis, uric acid retention and may rarely produce acute gout. Furosemide may provoke hyperglycemia and glycosuria.	New	USFDA	Ab'g' b Kiv thZ ঢ়ী	Ab'g' b Kiv nj
23.	Incepta Pharmaceuticals Ltd (Dhamrai Unit).	Ambroxol Hydrochloride 0.3gm/100ml Solution	Ambroxol Hydrochloride BP 0.3gm/100ml	Mucolytic expectorant	AMBROXOL is indicated to aid in the treatment of catarrhal inflammation of bronchi and the upper respiratory tract in horses and dogs. Specific indications include: Chest Infections; acute and chronic bronchopneumonia, catarrhal rhinitis, strangles, post-viral cough Uterine Infections: pyometron,	Contraindications: Ambroxol Hydrochloride solution is contraindicated for use in animals with known hypersensitivity or idiosyncratic reaction to Ambroxol Hydrochloride (or any of the other ingredients in the product). Side Effects: Gastrointestinal side	New		ঢ়ী Rb tbB ঞাঐ A'fe`b brgA' Kiv thZ ঢ়ী	ঢ়ী Rb tbB ঞাঐ A'fe`b brgA' Kiv nj

Sl. No	Name of the Manufacturer	Name of the Product	Generic Name	Therapeutic Class	Indication	Contra-indication & Side effect	Status (New Molecule /Existing)	USFDA, BNF or MHRA Reference	তുകিবক'জ মে কৃগুবি মফবি মমখিঈ	মফবি মমখিঈ
					mucometron Ocular Infections: purulent conjunctivitis, hypopion.	effects may occur occasionally with Ambroxol and a transient rise in serum aminotransferase values has been reported. Other reported adverse effect includes sweating, allergic reactions.				
24.	Acme Laboratories Ltd., Dhamrai, Dhaka	Carprofen 500 mg Bolus (For Veterinary Use Only)	Carprofen BP 500 mg	NSAID	For the treatment of inflammation and pain.	Contraindications: Animals with cardiac, renal or hepatic disease, where there is the possibility of gastro-intestinal ulceration or bleeding, hypersensitivity to the drug; treatment with other NSAIDs concurrently or within 24 hours; racehorses prior to racing; pregnant mares. Side effects: Prolonged use may cause gastro-intestinal lesions, inappetance, vomiting and diarrhea.	New	Veterinary Formulary, 5th Edition, P: 471	Abjgv`b Kiv thtZ cti /	Abjgv`b Kiv nj /
25.	Acme Laboratories Ltd., Dhamrai, Dhaka	Carprofen 0.500 g/10 ml Vial Injection (For Veterinary Use Only)	Carprofen BP 0.500 g/10 ml	NSAID	For the treatment of inflammation and pain.	Contraindications: Animals with cardiac, renal or hepatic disease, hypersensitivity to the drug; treatment with other NSAIDs concurrently or within 24 hours; racehorses prior to racing; pregnant mares. Side effects: Inappetance, vomiting and diarrhea.	New	Veterinary Formulary, 5th Edition, P: 471	Abjgv`b Kiv thtZ cti /	Abjgv`b Kiv nj /
26.	Acme Laboratories Ltd., Dhamrai, Dhaka	Carprofen 1.500 g/30 ml Vial Injection (For Veterinary Use Only)	Carprofen BP 1.500 g/30 ml	NSAID	For the treatment of inflammation and pain.	Contraindications: Animals with cardiac, renal or hepatic disease, hypersensitivity to the drug; treatment with other NSAIDs concurrently or within 24 hours; racehorses prior to racing; pregnant mares.	New	Veterinary Formulary, 5th Edition, P: 471	Abjgv`b Kiv thtZ cti /	Abjgv`b Kiv nj /

Sl. No	Name of the Manufacturer	Name of the Product	Generic Name	Therapeutic Class	Indication	Contra-indication & Side effect	Status (New Molecule /Existing)	USFDA, BNF or MHRA Reference	তথ্যসূত্রের নাম	মফবি নম্বর
						Side effects: Inappetance, vomiting and diarrhea.				
27.	Acme Laboratories Ltd., Dhamrai, Dhaka	Meloxicam 0.200g/10ml Vial Injection (For Veterinary Use Only)	Meloxicam BP 0.200 g/10 ml	NSAID	Cattle: Inflammation, pain, fever, lameness, dehorning & castration. It is also used as supportive therapy in acute respiratory infection, diarrhea, acute mastitis etc Dog: Osteoarthritis Pig: Inflammation and locomotor disorders	Contraindications: Contraindicated in- Animals less than six weeks old, animals hypersensitive to Meloxicam and animals with impaired renal, hepatic or cardiac function. Side effects: A slight transient swelling at the injection site following SC injection may be seen. Prolong use may cause Inappetance, vomiting and diarrhea.	50mg/10ml & 150mg/30 ml Injection, 100mg Bolus	-	Abjgr`b Kiv thZ cti	Abjgr`b Kiv nj
28.	Acme Laboratories Ltd., Dhamrai, Dhaka	Meloxicam 0.600g/30 ml Vial Injection (For Veterinary Use Only)	Meloxicam BP 0.600 g/30 ml	NSAID	Cattle: Inflammation, pain, fever, lameness, dehorning & castration. It is also used as supportive therapy in acute respiratory infection, diarrhea, acute mastitis etc Dog: Osteoarthritis Pig: Inflammation and locomotor disorders	Contraindications: Contraindicated in- Animals less than six weeks old, animals hypersensitive to Meloxicam and animals with impaired renal, hepatic or cardiac function. Side effects: A slight transient swelling at the injection site following SC injection may be seen. Prolong use may cause Inappetance, vomiting and diarrhea.	Meloxicam 50 mg/10 ml & 150 mg/30 ml Injection, 100 mg Bolus	-	Abjgr`b Kiv thZ cti	Abjgr`b Kiv nj
29.	Eskayef Pharmaceuticals Limited	Caprofen 0.250gm/Vial SC/IV Injection (Vet)	Caprofen BP 0.250gm/Vial	NSAIDS	It is indicated for the relief of pain and inflammation associated with osteoarthritis and for the control of postoperative pain associated with soft tissue and orthopedic.	Contraindication: Hypersensitivity.	New		Abjgr`b Kiv thZ cti	Abjgr`b Kiv nj
30.	Acme Laboratories Ltd., Dhamrai, Dhaka	Zilpaterol Hydrochloride 75mg + Melengestrol Acetate 0.38 mg	Zilpaterol Hydrochloride INN 75mg + Melengestrol Acetate USP	β 2 Adrenergic Agonist + Steroidal Progestin	For fattening (Body weight gain), improved feed efficiency, quality meat production and suppression of estrus (heat) in heifers fed in confinement for slaughter.	Contraindications: Animals hypersensitive to Zilpaterol Hydrochloride &/or Melengestrol Acetate are contraindicated. This bolus is intended for use only for meat	Zilpaterol Hydrochloride 4.800 g + Melengestrol Acetate		c@qRb tbB weiq Arte`b br gAjy Kiv thZ cti	c@qRb tbB weiq Arte`b br gAjy Kiv nj

Annex-D: Propose Product List for Import (Veterinary)

bs	cŃZKviŃKi big I wKivr	JlŃai big	ŃRibni K big	Ń_i ucDŃJK Km	ibŃ Rbv	Contraindication & Side-effect	Status (New/Existing)	FSC/CPP	ŃŃKŃbK'vj me KŃgŃŃi mFvi mŃxŃŃŃ	mFvi mŃxŃŃŃ
1.	Manufacturer: V.M.D. nv, Belgium Local Agent: Inter Agro BD Ltd. 718/A, 1st Floor, West Nakalpara Tejgoan, Dhaka	Diaziprim-48%S Soluble powder for veterinary use	Sodium sulfadiazine- 420mg + Trimethoprim-80mg	Antibacterial	Treatment of infections caused by microorganisms susceptible to trimethoprim and/or sulfadiazine, such as gastro-intestinal, respiratory and urogenital tract infections and general infections in valves, pigs and poultry.	Contraindications The drug should not be administered to: • commercial laying hens • animals with severe liver and kidney impairment or blood dyscrasia • animals hypersensitive to sulfonamides and • older calves with developed function of rumen, omasus and reticulum. Side Effects: None Reported.	Sulphamethoxazole 400 mg + Trimethoprim 80mg Tablet	Belgium	cŃŃqŃRb ŃbB Ńeavq ArŃe`b bigŃŃj Kiv thŃZ cŃŃi	cŃŃqŃRb ŃbB Ńeavq ArŃe`b bigŃŃj Kiv nj
2.	Manufacturer: Laboratories Biove, France Local Agent: Inter Agro BD Ltd. 718/A, 1st Floor, West Nakalpara Tejgoan, Dhaka	BIOAMOXI 50% Powder for Oral Solution	Amoxicillin 500mg/gm Powder for Oral Solution	Antibiotic	For the treatment and control of Pigs : Infectious Processes caused by Streptococcus suis, except nervous and articular forms. Poultry : Pasteurellosis and colibacillosis, caused by sensitive strains to amoxicillin. Lactating calves : Pasteurellosis and colibacillosis, caused by sensitive strains to amoxicillin and salmonellosis.	Contraindications: The use of amoxicillin is contraindicated in animals with a history of an allergic reaction to penicillin. Adverse Reactions: Amoxicillin is a semisynthetic penicillin and, therefore, has the potential for producing allergic reactions. Epinephrine and/or steroids should be administered if an allergic reaction occurs.	10%, 15% 20%, 30%, 80% Powder	France	cŃŃqŃRb ŃbB Ńeavq ArŃe`b bigŃŃj Kiv thŃZ cŃŃi	cŃŃqŃRb ŃbB Ńeavq ArŃe`b bigŃŃj Kiv nj
3.	Sung-Won Co., Ltd., Korea (ACI Ltd.)	AMOXYPEN Oral Powder 500g, 1Kg & 5 Kg	Amoxicillin Hydrate BP 200 gm(liter) + Acetaminophen BP 200gm /kg	Antibiotic	Treatment of sensitivity bacterial diseases in the amoxicillin like <i>Staphylococcus spp.</i> , <i>Streptococcus spp.</i> , <i>Pasteurella spp.</i> , <i>Escherichia coli</i> , <i>Hemophilus spp.</i> , <i>Actinobacillus pleuropneumoniae</i> .	Contraindication: Do not use in combination with Microlide, Aminoglycoside, Chloramphenic and tetracycline antibiotics. Side Effect: Excessive administration can cause nervous system disorders such as convulsions or seizures or hepatotoxicity.	10%, 15% 20%, 30%, 80% Powder	Korea	cŃŃqŃRb ŃbB Ńeavq ArŃe`b bigŃŃj Kiv thŃZ cŃŃi	cŃŃqŃRb ŃbB Ńeavq ArŃe`b bigŃŃj Kiv nj
4.	Ewhapharmtek Corp. Korea Local Agent: Fahat Trade International	EWHA APMA 250 WSP	Apramycin Sulfate.250g/kg	Antibiotic	Treatment for Diarrhea.	Hypersensitivity to apramycin Administered orally apramycin is well tolerated. Sometimes diarrhea may occur while using the drug at high doses and for a prolonged period of time	New	korea	AbŃŃŃr`b Kiv thŃZ cŃŃi	AbŃŃŃr`b Kiv nj

bs	c0ZKvitiKi big / i/Kubv	Jl'ai big	iRubi K big	i_ iucDitUK Km	ibf` Rbv	Contraindication & Side-effect	Status (New/Existing)	FSC/ CPP	tUKubK'uj me Kuglji mfvi imxisi	mfvi imxisi
	12/2 Purana Palton Line, Dhaka-1000.									
5.	Manufacturer: V.M.D. nv, Belgium Local Agent: Inter Agro BD Ltd. 718/A, 1st Floor, West Nakalpara Tejgoan, Dhaka	L-Spec 5/10 Injectable solution for veterinary use	Lincomycin base 50mg + Spectinomycin 100mg/ml	Antibiotic	Treatment of infections caused by Mycoplasma spp., and gram+ and gram-bacteria in pigs (mycoplasmal pneumonia, swine dysentery, bacterial enteritis, infectious arthritis), nonruminating calves (enteritis and/or pneumonia), sheep and goat (contagious foot rot, respiratory infections), poultry and turkeys (CRD airsacculitis) caused by avian Mycoplasma spp. and coliform infections), dogs (pneumonia, pharyngitis, tonsillitis, laryngitis, bronchitis, dermatitis, abscesses, cystitis, metritis) and cats (cystitis, abscesses, respiratory tract infections)..	<i>Contra indications: Hypersensitivity to lincomycin and/or spectinomycin. Administration to animals with an impaired renal and/or hepatic function. Concurrent administration of penicillins, cephalosporins, quinolones and cycloserine. Side effects: Hypersensitivity reactions. Shortly after injection a slight pain, itching or diarrhoea can occur.</i>	Lincomycin Base 22.2 gm + Spectinomycin 44.4 gm/100 gm Water Soluble Powder	Belgium	Abtgr`b Kiv thZ cti	Abtgr`b Kiv nj
6.	Green Cross Veterinary Products Co. Ltd., Korea (ACI Ltd.)	SKIN CARE Liquid 100ML & 200ML	Lincomycin Hydrochloride BP 10gm + Florfenicol 50gm/Litre	Antibiotic	- Treatment and prevention for topical infections of skin, foot, hoof and etc. caused by organisms sensitive to lincomycin and florfenicol. - Prevention of infection after various surgeries such as castration, tail docking, rumenotomy and other abdominal surgeries.	Contraindication: Avoid spraying in animal's eyes. Side effect: Unknown	Lincomycin Base 22.2 gm + Spectinomycin 44.4 gm/100 gm Water Soluble Powder	Korea	Abtgr`b Kiv thZ cti	Abtgr`b Kiv nj
7.	Ewhapharmtek Corp. Korea Local Agent: Fahat Trade International 12/2 Purana Palton Line, Dhaka-1000	EWHA LINCOSTIN	Lincomycin Hydrochloride Hydrate.....100g + Colistin Sulfate.....500MIU/k g	Antibiotic	For the treatment of the following disease caused by Mycoplasma spp., Clostridium spp., Haemophilus spp., Pasteurella spp.	Contraindications: Lincomycin - This drug is contraindicated in patients previously found to be hypersensitive to lincomycin or clindamycin. Clindamycin may interfere with the attachment and entry of Toxoplasma gondii tachyzoites into host cells. Colistin- COLISTIN is contraindicated in patients with known hypersensitivity to	Lincomycin Base 22.2 gm + Spectinomycin 44.4 gm/100 gm Water Soluble Powder	korea	Abtgr`b Kiv thZ cti	Abtgr`b Kiv nj

bs	c0ZKvifKi big / w/Kubv	Jl'ai big	fRubi K big	t_i ucDitUK Km	ibf` Rbv	Contraindication & Side-effect	Status (New/Existing)	FSC/ CPP	tUKubK'uj me Kuglji mfvi m×iSl	mfvi m×iSl
						colistimethate sodium (colistin) or topolymyxin B and in patients with myasthenia gravis. Side Effects: Not Known.				
8.	Manufacturer: Laboratorios Calier, S.A., Spain Local Agent: NEXUS Distributor House no. 49/K jail Road, Mymensingh, Bangladesh,	YODIMASPEN Powder and solvent for suspension for injection (Vet) 10 gm/Vial (Active) and 30 ml/Vial Solvent	Penethamate hydriodide 10.0 gm/Vial (Eq. to 10 MUI of benzyl penicillin)	Antibiotic	Cattle: Treatment of mastitis caused by <i>Streptococcus uberis</i> , <i>Streptococcus dysgalactiae</i> , <i>Streptococcus agalactiae</i> and <i>Staphylococcus aureus</i> (non-betalactamase-producing bacteria) sensible to benzylpenicillin.	Do not administer to animals presenting a hypersensitivity record to penicillin, cephalosporins and/or some of the excipients.	New	SPAIN	Abtgr`b Kiv thtZ citi	Abtgr`b Kiv nj
9.	Manufacturer: M/s. Laboratorios Maymo S.A., Via Augusta, 302 08017 Barcelona, Spain Local Agent: NEXUS Distributor House no. 49/K jail Road, Mymensingh, Bangladesh	SPIR Soluble Powder	Spiramycin 2070000 IU/g	Antibiotic	Poultry : Chronic Respiratory Disease (CRD) and infectious sinusitis Pigs : Transmissible Gastro-Enteritis (TGE), enzootic pneumonia, atrophic rhinitis and porcine pleuropneumonia	Do not use in case of known hypersensitivity to spiramycin, other macrolides and /or to any excipients Do not use on laying birds Do not use in animals with hepatic insufficiency or biliary obstruction	Spiramycine 500000 IU/gm Powde	spain	c0qRb`tbB wearq Arte`b bigAy Kiv thtZ citi	c0qRb`tbB wearq Arte`b bigAy Kiv nj
10.	Sung-Won Co., Ltd., Korea (ACI Ltd.)	SULFA 500 Oral Powder 500g, 1Kg & 5 Kg	Sulfamethoxazole BP 400gm + Trimethoprim BP 80gm/kg	Antibiotic	Prevention and treatment of bacterial infections susceptible to sulfamethoxazole and trimethoprim like Chronic Respiratory Disease (CRD) and Complicated Chronic Respiratory Disease (CCRD).	Contraindication: Do not use on animals that have been exposed to shock or hypersensitivity to this drug. Side Effect: Allergic reactions, type II and type III hypersensitivity, arthropathy, anemia and thrombocytopenia.	Sulphadiazine 40% + Trimethoprim 8% Powder	Korea	c0qRb`tbB wearq Arte`b bigAy Kiv thtZ citi	c0qRb`tbB wearq Arte`b bigAy Kiv nj
11.	Manufacturer: M/s. Laboratorios Maymo S.A., Via Augusta,	MAYLOSINA Oral Soluble Powder	Tylosin (Tartrate) 1000 mg/gm	Antibiotic	Poultry : Chronic Respiratory Disease (CRD), airsacculitis sinusitis Pigs : Hemorrhagic enteritis and enzootic	Do not use in case of hypersensitivity to the active substance Do not use in cases of known	Tylosin 20% Powder	spain	c0qRb`tbB wearq Arte`b bigAy Kiv thtZ	c0qRb`tbB wearq Arte`b bigAy Kiv nj

bs	cŃZKvřřKi big I w/Kubv	Jlřai big	řRubiřK big	ř_řucDřřK Km	řbř Rbv	Contraindication & Side-effect	Status (New/Existing)	FSC/CPP	řřKřbřř me Křřřřř řřřř řřřřř	řřřř řřřřřř
	302 08017 Barcelona, Spain Local Agent: NEXUS Distributor House no. 49/K jail Road, Mymensingh, Bangladesh				pneumonia Calves : Pneumonias caused by mycoplasma and mannheimia haemolytica	resistance to tylosin or cross- resistance to other macrolides (MLS resistance) Do not use in horses or other equines in which tylosin can be fatal			cřřřřř	
12.	ALFASAN INTERNATIONAL BV, The Netherlands Local Agent: Zenon Agro Pharma Eastern Trade Centre (12/1) 56, Purana Paltan Lane, VIP Road, Dhaka	Tyloxol Extra Water soluble Oral Powder	Tylosine Tartrate 100 gm + Doxycycline hyclate 200 gm/Kg	Antibiotic	Treatment of respiratory infections caused by Gram-negative bacteria such as Bordetella bronchiseptica and Pasteurella spp and which are sensitive to doxycycline, as well as infections of the urinary tract caused by sensitive Gram-positive bacteria. Tylosine is a macrolide with broad spectrum, active mainly against Gram- positive bacteria, Mycoplasma (PPLO), Actinomyces, some Spirochaetes such as Treponema hyodysenterica, Haemophilus, Erysipelothrixinsidosa, Corynebacterium diphtheriae, Vibrio coli, Moraxella bovis, Listeria monocytogenes, Bacteroides, Fusobacterium.	Contraindication : Hypersensitivity to the active ingredients. Kidney or liver problems. Side effects: Tylosine: none known Doxycycline: In calves an acute, sometimes fatal, heart muscle degeneration may occur after one or multiple administrations.	Tylosin 20% Powder	The Netherlan ds	cřřřřř řřřř řřřřř řřřřř řřřřř řřřřř řřřřř řřřřř řřřřř	cřřřřř řřřř řřřřř řřřřř řřřřř řřřřř řřřřř řřřřř řřřřř
13.	Manufacturer: Laboratories Biove, France Local Agent: Inter Agro BD Ltd. 718/A, 1st Floor, West Nakalpara Tejgoan, Dhaka	TYLOLIDE 10,000,0000 IU/Vial Injection	Tyosin as Tartrate 10,000,0000 IU/Vial	Antibiotic	Tylosin Injection is indicated for use in the treatment of bovine respiratory complex (shipping fever, pneumonia) usually associated with Pasteurella multocida and Actinomyces pyogenes; foot-rot (necrotic pododermatitis) and calf diphtheria caused by Fusobacterium necrophorum and metritis caused by Actinomyces pyogenes in beef cattle and nonlactating dairy cattle.	Side Effects: Side effects consisting of edema of the rectal mucosa, anal protrusion, diarrhea, erythema and pruritus have been observed in some hogs following the use of tylosin. Discontinuation of treatment effected an uneventful recovery. Adverse Events: Adverse reactions, including shock and death may result from overdosage in baby pigs. Do not attempt injection into pigs weighing	New	France	cřřřřř řřřř řřřřř řřřřř řřřřř řřřřř řřřřř řřřřř řřřřř	cřřřřř řřřř řřřřř řřřřř řřřřř řřřřř řřřřř řřřřř řřřřř

bs	c0ZKvitiKi big I i/Kubv	Jl'ai big	iRubi K big	i_ iucDitUK Km	ibf` Rbv	Contraindication & Side-effect	Status (New/Existing)	FSC/ CPP	tUKubK'uj me Kugubi m fvi imx'isi	m fvi imx'isi
					In swine, Tylosin Injection is indicated for use in the treatment of swine arthritis caused by Mycoplasma hyosynoviae; swine pneumonia caused by Pasteurella spp.; swine erysipelas caused by Erysipelothrix rhusiopathiae; and acute swine dysentery associated with Brachyspira (formerly Serpulina or Treponema) hyodysenteriae when followed by appropriate medication in the drinking water and/or feed.	less than 25 pounds (0.5 mL). It is recommended that Tylosin Injection 50 mg/mL be used in pigs weighing less than 25 pounds. If tylosin-medicated drinking water is used as follow-up treatment for swine dysentery, the animal should thereafter receive feed containing 40 to 100 grams of tylosin per ton for 2 weeks to assure depletion of tissue residues.				
14.	ALFASAN INTERNATIONAL BV, The Netherlands Local Agent: Zenon Agro Pharma Eastern Trade Centre (12/1) 56, Purana Paltan Lane, VIP Road, Dhaka	Dicox Forte Water soluble Oral Powder	Amprolium HCl 17.50gm + Sulfaquinoxaline sodium 17.50gm + Vitamin A 1,500,000 IU+ Vitamin K 500 mg/100gm	Antibiotic + Vitamin	Treatment of intestinal coccidiosis caused by Eimeria spp susceptible to amprolium and/or Sulfaquinoxaline.	Contraindication : Liver pathologies, blood disorders, hypersensitivity to active ingredients. Side effects: No undesirable effects are to be expected when the prescribed dosage regimen is followed.	Amprolium 10.2% + Mendione Sodium Bisulphite (Vitamin-K) 0.1% + Sulfaquinoxaline Sodium 10.2% Powder	The Netherlands	c0qirB tbB weavq Arte`b bigAj Kiv thtZ citi	c0qirB tbB weavq Arte`b bigAj Kiv nj
15.	ALFASAN INTERNATIONAL BV, The Netherlands Local Agent: Zenon Agro Pharma Eastern Trade Centre (12/1) 56, Purana Paltan Lane, VIP Road, Dhaka	Alfaceryl Water soluble Oral Powder	Erythromycin thiocyanate 3500 mg + Colistin 25,000,000 IU + Oxytetracycline 5,000 mg + Streptomycin Sulphate 3500 mg + Neomycin Sulphate 1,000 mg + Vitamin A 500,000 IU + Vitamin D3 200,000 IU + Vitamin E 200 mg + Vitamin K 200 mg + Vitamin B1 200 mg +	Antibiotic + Vitamin	Poultry: Prevention and treatment of bacterial infections caused by Gram-positive and Gram-negative germs, e.g. CRD, Coryza, Fowl Cholera, Gastro-intestinal infections, etc. in Chicken, turkey, guniea fowl, goat, sheep, cattle, camel	Contraindication : Hypersensitivity to one or several of the ingredients. Side effects: No undesirable effects are to be expected when the prescribed dosage regimen is followed.	Erythromycin Thiocyanate 18 gm + Sulphadiazine 15 gm + Trimethoprim 3 gm/100 gm Powder	The Netherlands	c0qirB tbB weavq Arte`b bigAj Kiv thtZ citi	c0qirB tbB weavq Arte`b bigAj Kiv nj

bs	cŃZKviŃKi big I w/Kubv	JlŃai big	tRubi K big	t_iwcDitUK Km	ibŃ Rbv	Contraindication & Side-effect	Status (New/Existing)	FSC/ CPP	tUKubK'uj me KugŃi mfvi m×iŃl	mfvi m×iŃl
			Vitamin B2 400 mg + Vitamin B6 200 mg + Vitamin B12 1mg+ Vitamin PP (Nicotinamide) 2,000 mg + Vitamin C 2,000 mg + D-Ca- pantothenate 1,000 mg + Inositol: 100 mg/100gm							
16.	Manufacturer: Laboratories Biove, France Local Agent: Inter Agro BD Ltd. 718/A, 1st Floor, West Nakalpara Tejgoan, Dhaka	ACTILIVER Solution for Injection	Menbutone 50mg + Sorbitol 250mg/ml	Choleretic agent + Hyperosmotic laxative	The preparation can be used for all domestic animals whose digestion and all associated secretory processes need assistance. Cattle, sheep, goats Primary indigestions After overfeeding, particularly with easily digestible carbohydrates (ruminal acidosis), with contaminated and spoiled food (ruminal breakdown) and as a result of rapid changes in diet; overloading of the rumen; distension of rumen; constipation. Secondary indigestions Post-Operative use to restore normal digestion, energy metabolic disorders (Acetonaemia in cows, toxaemia of pregnancy in ewes). Stimulation of hepatic function by promoting bile secretion (therapy aimed at protecting the liver). Horses Indigestion after overfeeding with high – protein feed or oats, constipation, intestinal atony, gas colic, feed intoxication,. stimulation of hepatic function by promoting bile secretion. Dogs Constipation, intestinal atony, exocrine pancreatic insufficiency. Stimulation of hepatic function by promoting bile secretion.	Contraindications: The use of Menbutone + Sorbitol is contraindicated in animals with a history of an allergic reaction to its. Adverse Reactions: Anal irritation; diarrhea; gas; nausea; stomach cramps.	New	France	cŃqRb tB weaq Aite`b bigÁy Kiv thtZ cŃi	cŃqRb tB weaq Aite`b bigÁy Kiv nj
17.	WooGene B&G Co., Ltd. Korea (ACI Ltd.)	FLUSON Injectable solution 10ml, 20ml, 50ml &	Flumethasone KVP 0.25mg/ml	Corticosteroid	It is used for the treatment in cattle for Ketosis, milk fever, agalactia, grass-tetany, indigestions, metritis, puerperal infections, puerperal shock, mastitis,	Contraindication: Osteoporosis, injections in infected tissues, bacteriological ophthalmitis and faults of epithelium of the cornea,	New	Korea	cŃqRb tB weaq Aite`b bigÁy Kiv thtZ cŃi	cŃqRb tB weaq Aite`b bigÁy Kiv nj

bs	c0ZKvitiKig I i/Kubv	Jl'ai big	iRubiK big	t_iucDitUK Km	ibf` Rbv	Contraindication & Side-effect	Status (New/Existing)	FSC/ CPP	tUKubK'ij me Kuglji m fvi imxvSI	m fvi imxvSI
		100ml			diarrhea, coliseptisemia, pododermatitis.	pregnancy Side Effect: Symptoms of an overdoses manifest by retension of liquids, loss of potassium, increase of weight etc.				
18.	Zotal Laboratorios Ctra. Nacional 630, km. 809, 41900 CAMAS (Seville) SPAIN Tel: +34954390204 Fax: +34954395516 www.zotal.com Agent: Provet Resources Ltd. Plot # 37, Sonargaon Janapath Road, Sector # 7 Uttara, Dhaka.	Zotal G	(2- Phenylphenol 3% + 4-Chlorophene-2 benzylal 1.5%) / 100ml	Disinfectant Deodorizer	Disinfection against bacteria (Salmonella Typhimurium, Brucella Ovis) and Virus (FMDV, Avian Influenza) Characteristic smell it eliminates unpleasant odours providing a hygienic and clean enviroment	Contraindications: Gastric Lavage, neutralization, activated charcoal. Side effects: Not Known	New	Spain	c0qRb`tbB weavq`Arte`b bigAjy Kiv thtZ citi	c0qRb`tbB weavq`Arte`b bigAjy Kiv nj
19.	Eagle vet. Tech Co. Ltd. 235-34, Chusa-Ro Shinam-myun, Yesan-kun, Chungchongnam-do, Korea Agent: Albion Laboratories Limited House # F2/8, Road # 2, Block # B, Chasndgoan, Chittagong, Bangladesh.	K-2 Solution of Disinfectant	(N-Alkyl dimethyl benzyl ammonium chloride 100g + Citric Acid Monohydrate 200g) / 1000ml	Disinfectant	Disinfection of panthogen that has Product. 1. Bacteria ; General bacteria (Salmonella Typhimurium) Brucella Ovis 2. Virus ; Avian influenza virus (AIV), Newcastle Disease Virus (NDV), Classical Swine Fever Virus (CSFV), Porccine Epidemic Diarrhea virus (PEDV), Foot and Mouth Disease Virus (FMDV) Disinfection of pens and livestock equipment.	Contraindications: Gastric Lavage, neutralization, activated charcoal. Side effects: Not Known	New	korea	Abtgr`b Kiv thtZ citi	Abtgr`b Kiv nj

bs	c0ZKvitKi big I wKubv	Jl'ai big	tRibiiK big	t_iucDitUK Km	ibf` Rbv	Contraindication & Side-effect	Status (New/Existing)	FSC/CPP	tUKubK'uj me Kugubi mfv m×všl	mfvi m×všl
20.	Manufacturer: Laboratories Meriel, France Local Agent: Inter Agro BD Ltd. 718/A, 1st Floor, West Nakalpara Tejgoan, Dhaka	Vulkan Solution	Didecyl Dimethyl Ammonium Chloride 24.50gm + Alkyl Dimethyl Benzyl Ammonium Chloride 238.0gm % + Glutaraldehyde 151.50gm/Liter	Disinfectant	It is used in food industries & Farm breeding, It is efficient against bacteria, fungi and viruses.	Contraindications: None. Adverse Reactions: None	Glutaraldehyde 2.4% Solution	France	Abjgr`b Kiv thZ citi	Abjgr`b Kiv nj
21.	Zotal Laboratorios Ctra. Nacional 630, km. 809, 41900 CAMAS (Seville) SPAIN Tel: +34954390204 Fax: +34954395516 www.zotal.com Agent: Provet Resources Ltd. Plot # 37, Sonargaon Janapath Road, Sector # 7 Uttara, Dhaka.	Arpon Actisan	Glutaraldehyde 10% + Didecyl dimethyl ammonium chloride 7.25% + Alkyl benzyl dimethyl ammonium chloride 15.92% + Cypermethrin 10% + Deltamethrin 1.5%	Disinfectant Insecticide	Disinfection against bacteria (Salmonella Typhimurium, Brucella Ovis), Virus (FMDV, Avian Influenza) and fungi. Ingredients are exceptionally effective against all kind of insects and mites, such as flies, mosquitoes, cockroaches, fleas, ant, spiders ticks.	Contraindications: Gastric Lavage, neutralization, activated charcol. Side effects: Not Known	Benzalkonium Chloride 100 mg + Glutaraldehyde 150 mg/100 ml Suspension	Spain	Abjgr`b Kiv thZ citi	Abjgr`b Kiv nj
22.	Zotal Laboratorios Ctra. Nacional 630, km. 809, 41900 CAMAS (Seville) SPAIN Tel: +34954390204 Fax: +34954395516 www.zotal.com Agent: Provet Resources Ltd., Plot # 37, Sonargaon	Sanitas Forte vet	Glutaraldehyde 14% + Didecyl dimethyl ammonium chloride 10%	Disinfectant	Disinfection against bacteria (Salmonella Typhimurium, Brucella Ovis), Virus (FMDV, Avian Influenza) and fungi.	Contraindications: Gastric Lavage, neutralization, activated charcol. Side effects: Not Known	Benzalkonium Chloride 100 mg + Glutaraldehyde 150 mg/100 ml Suspension	Spain	Abjgr`b Kiv thZ citi	Abjgr`b Kiv nj

bs	c0ZKv#Ki big I #Kubv	Jl'ai big	tRibni K big	t_i ucDitUK Km	ibf` Rbv	Contraindication & Side-effect	Status (New/Existing)	FSC/ CPP	tUKubK'uj me Kuglbi mfvi m×iSl	mfvi m×iSl
	Janapath Road, Sector # 7 Uttara, Dhaka.									
23.	<p>Manufacturer: QUATCHEM LTD, 4 DODGSON STREET, ROCHDALE, UK</p> <p>Owner/Distributor.: GENTRY PHARMACEUTICAL S LTD. House No#39, Road#27, Sector# 07, Uttara, Dhaka-1230 Tel- +880 2 -8931139 Web: pharma@gentryphar ma.com</p>	IODOCLEANS	Iodine - 3.0 % w/w.	Disinfectant	<p>Full Spectrum of Activity: Proven Effectiveness Against Bacteria, Mycobacterium & Spores, Fungi, Yeasts, Moulds & Viruses. Proven activity under high Organic Contamination & hard Water. Odour Free & Non-Tainting, Ideal for use in process plants for Meat & Dairy Products. Suitable For Manual, Machine Applications.</p> <p>For the Daily Cleaning, Sanitizing & Disinfection of Livestock & Agricultural Farming, Dairies, Hatcheries, Aquaculture Farms, Milking Parlours, Veterinary Surgeries, All Food & Dairy Processing, All Transportation Hubs & Vehicles, Public & Municipal Buildings, Canning & Bottling, Abattoirs & Meat Processing Plants, and all Equipment and Utensils associated with the above facilities</p>	<p>Contraindications: No contraindicated incidence in Human & Animal occurred during use. Not a Drug Entity Intended for internal use</p> <p>Side effects: No Side effect which has been independently tested and approved by DEFRA, UK (Department of Fisheries and Rural Affairs, UK)</p> <p>100 % Biodegradable</p>	New	UK	Abjgr` b Kiv thZ citi	Abjgr` b Kiv nj
24.	<p>Manufacturer: QUATCHEM LTD, 4 DODGSON STREET, ROCHDALE, UK</p> <p>Owner/Distributor.: GENTRY PHARMACEUTICAL S LTD. House No#39, Road#27, Sector# 07, Uttara, Dhaka-1230</p>	VIROXIDE SUPER	Peroxy Mono Su lphate - 50 % w/w. Sodium Trichloroisocyanurate (60 % coated) - 10 % w/w.	Disinfectant	<p>Full Spectrum of Activity: Proven Effectiveness Against Bacteria, Mycobacterium & Spores, Fungi, Yeasts, Moulds & Viruses. Proven activity under high Organic Contamination & hard Water. Odour Free & Non-Tainting, Ideal for use in process plants for Meat & Dairy Products. Suitable For Manual, Machine Applications.</p> <p>For the Daily Cleaning, Sanitizing & Disinfection of Livestock & Agricultural Farming, Dairies, Hatcheries,</p>	<p>Contraindications: No contraindicated incidence in Human & Animal occurred during use. Not a Drug Entity Intended for internal use</p> <p>Side effects: No Side effect which has been independently tested and approved by DEFRA, UK (Department of Fisheries and Rural Affairs, UK)</p> <p>100 % Biodegradable</p>	New	UK	Abjgr` b Kiv thZ citi	Abjgr` b Kiv nj

bs	cŃZKviŃKi big I iŃKubv	JlŃai big	iŃRubiŃK big	Ń_iucDitŃK Km	ibŃ Rbv	Contraindication & Side-effect	Status (New/Existing)	FSC/ CPP	ŃŃKubK'uj me KugŃŃi mŃvi m×iŃŃ	mŃvi m×iŃŃ
	Tel- +880 2 -8931139 Web: pharma@gentryphar ma.com				Aquaculture Farms, Milking Parlours, Veterinary Surgeries, All Food & Dairy Processing, All Transportation Hubs & Vehicles, Public & Municipal Buildings, Canning & Bottling, Abattoirs & Meat Processing Plants, and all Equipment and Utensils associated with the above facilities.					
25.	Green Cross Veterinary Products Co. Ltd., Korea (ACI Ltd.)	STERILE DILUENT 18ml, 20ml, 36ml, 80ml & 100ml	Sodium Chloride BP 3.04mg + Anhydrous Sodium phosphate dibasic USP 2.04mg + Sodium phosphate monobasic dihydrate USP 1mg + Phenol Red 0.02mg /1ml	Liquid	It is used as a diluents for injectable products.	Contraindication: Do not administer unless solution is clear. Side effect: None.	New	Korea	cŃqŃRb ŃbB Ńeavq Arte`b bigÁy Kiv thŃZ cŃti	cŃqŃRb ŃbB Ńeavq Arte`b bigÁy Kiv nj
26.	Manufacturer: Laboratories Biove, France Local Agent: Inter Agro BD Ltd. 718/A, 1st Floor, West Nakalpara Tejgoan, Dhaka	CALCIUM BOROGLUCONATE Injectable solution for veterinary use	Calcium gluconate 28.0gm + Magnesium Hypophosphite Hexahydrate 9.0gm/100ml	Mineral	Calcium borogluconate is for treatment of hypocalcemia in cattle, sheep, and goats, and administered at 1 ml/kg.	CAUTIONS: Use only if solution is clear. If no improvement is noticed in the condition being treated after 24 hours or less depending on the severity of the condition, the diagnosis should be reevaluated and a veterinarian consulted. Do not retain partially used vial. Contains no preservative.	New	France	cŃqŃRb ŃbB Ńeavq Arte`b bigÁy Kiv thŃZ cŃti	cŃqŃRb ŃbB Ńeavq Arte`b bigÁy Kiv nj
27.	Manufacturer: Laboratories Biove, France Local Agent: Inter Agro BD Ltd. 718/A, 1st Floor, West Nakalpara Tejgoan, Dhaka	BIOVEINE Calcium GMC Solution for Injection	Calcium (as gluconate monohydrate) 25.04 mg + Magnesium (as hypophosphite hexahydrate) 52.96 mg/ml	Minerals	Prevention and treatment of hypocalcemia and/ or hypomagnesemia and/or hypophosphatemia associated with metabolic and hepatic disorders observed during milk fever, peripartum paresis, grass tetany or eclampsia.	Contraindications: None Adverse Events: Rapid intravenous injection may result in cardiac arrhythmias and in severely toxæmic cows, collapse and death.	New	France	cŃqŃRb ŃbB Ńeavq Arte`b bŃ gÁy Kiv thŃZ cŃti	cŃqŃRb ŃbB Ńeavq Arte`b bigÁy Kiv nj
28.	Green Cross Veterinary Products Co. Ltd., Korea	Canine DHPPV Vaccine 1dose/Vial, 2doses/Vial, 5doses/Vial, 10doses/Vial	A. DHPP Vaccine: Canine distemper attenuated virus (TCO- D strain) ...18% +	Vaccine	Prevention of canine distemper, canine hepatitis (Canine adenovirus type 2), canine parvovirus, canine parainfluenza- 2 virus infection, and leptospirosis by	Contraindication: Pregnant animals might avoid the vaccination.	New	Korea	AbŃgr`b Kiv thŃZ cŃti	AbŃgr`b Kiv nj

bs	c0ZKvitKi big I w/Kubv	Jl'ai big	tRibii K big	t_i ucDitUK Km	ibf` Rbv	Contraindication & Side-effect	Status (New/Existing)	FSC/ CPP	tUKubK'uj me Kuglji m fvi m x i S l	m fvi m x i S l
	(ACI Ltd.)	& 20doses/Vial	Canine infectious hepatitis attenuated virus (TCO-H strain)...10% + Canine parvovirus attenuated virus (CPV-GCV strain) ... 24% + Canine parainfluenza attenuated virus (CPI-GCV)... 18% B. Lepto Vaccine: <i>Leptospira canicola</i> bacterin...10%/ml + <i>Leptospira icterohaemorrhagiae</i> bacterin...10%/ml/dose		stimulating specific immune system.	Side Effect: The vaccinated animals may have transient anorexia, slight fever, which disappeared in time.				
29.	LAPROVET Hungary Veterinary Pharmaceuticals Ltd. Country of Origin : Hungary Navana Pharmaceuticals Ltd.	AVI ND HB 1+IB	<i>Avian Infectious Bronchitis virus Massachusetts type B-48 strain, Newcastle disease virus Hitchner B1 strain.</i>	Vaccine	AVI ND HB 1+IB is recommended for the active immunization of chickens against Newcastle disease and Infectious Bronchitis.	Contra-indications: No contraindications are known. Side effects: Rarely, catarrhal respiratory symptoms may occur on 4 to 6 days following vaccination but disappear in a few days	New		<i>Abjgr` b Kiv thZ cti </i>	<i>Abjgr` b Kiv nj </i>
30.	CevaPhylaxia Veterinary Biologicals Co., Ltd. Hungary (ACI Ltd.)	CEVAC META L Live freeze dried vaccine 1000 ds, 2000 ds, 3000 ds, 4000 ds & 5000 ds/Vial	Avian Metapneumovirus, subtype B, strain CRR126min. 2.5 log10 TCID50 / dose	Vaccine	For the active immunization of chickens in order to reduce clinical respiratory signs associated with avian metapneumovirus infection (Swollen Head Syndrome) and to reduce shedding of the infectious virus to the environment.	Contraindication: No Contraindications are known. Side effects: No undesirable effects are known.	New	Hungary	<i>Abjgr` b Kiv thZ cti </i>	<i>Abjgr` b Kiv nj </i>
31.	LAPROVET Hungary Veterinary Pharmaceuticals Ltd. Country of Origin : Hungary Navana Pharmaceuticals Ltd.	ITA CORYZA ABC GEL Inactivated Vaccine	<i>Avibacterium paragallinarum</i> serotype A, <i>Avibacterium paragallinarum</i> serotype B, <i>Avibacterium paragallinarum</i> serotype C,	Vaccine	ITA CORYZA ABC GEL inactivated vaccine is recommended for the vaccination of breeder and layer type chicken flocks, against infectious coryza caused by <i>Avibacterium paragallinarum</i> .	Contra-indications: No contraindications are known. Side effects: Vaccination does not cause systemic reactions or significant reactions at site of injection.	New		<i>Abjgr` b Kiv thZ cti </i>	<i>Abjgr` b Kiv nj </i>

bs	c0ZKviti big I i/Kubv	Jl tai big	iRubi K big	t_iucDitUK Km	ibf` Rbv	Contraindication & Side-effect	Status (New/Existing)	FSC/CPP	tUKubK'uj me Kuglji m fvi m x i S l	m fvi m x i S l
32.	Green Cross Veterinary Products Co. Ltd., Korea (ACI Ltd.)	BEF Live Vaccine 1dose/Vial, 3doses/Vial, 5doses/Vial & 10doses/Vial	BEF virus (M11 BH23 V5 Strain)...over 10 ^{3.0} TCID50/ml + LPGG... 20%/Dose	Vaccine	BEF Live vaccine is used for the prevention of bovine ephemeral fever in Cattle.	Contraindication: Do not use combined with other medications. Side effect: The cattle may undergo a light fever (under 400C) not lasting more than 3 days.	New	Korea	c0qirB` tbB weaq Arte`b bigAy Kiv thtZ citi	c0qirB` tbB weaq Arte`b bigAy Kiv nj
33.	Manufacturer : Merial, INC 1168, Airport Parkway, SW, Gainesville, GA 30501, USA. Local Agent: Advance Animal Science Co. Ltd. 149/A, DIT Exention Road Motijheel C/A, Dhaka-1000.	Newxxitek HVT + ND	Marek's Disease- Newcastle Disease Vaccine Serotype 3, Live Marek's Disease Vector	Vaccine	This Vaccine is recommended for in ovo vaccination of 18-19 day embryonated chicken eggs. For in ovo vaccination, only healthy embryonated eggs should be use. This vaccine is also recommended for subcutaneous vaccination of healthy one day old chickens.	Contraindications: None Side effects: Vaccination with Newxxitek HVT + ND is satisfactory and has no tendency to revert the virulence after several passages in chicken.	New	USA	Abjgr` b Kiv thtZ citi	Abjgr` b Kiv nj
34.	Manufacturer: SEOUL VET PHARMA CO., LTD. 6F Kofeed B/D, 1581- 13, Seocho 3-dong, Seocho-gu, Seoul, South Korea. Local Agent: UNIVET LIMITED House 1, Road 10/A, Nikunja 1, Khilkhet, Dhaka – 1229, Bangladesh.	NUVIZONE-C 20% Oral Liquid	Vitamin C (Sodium Ascorbate) 200gm/Liter	Vitamin	<ul style="list-style-type: none"> • Prevention of Vitamin C deficiency, • Prevention of stress, • Improvement of egg production and hatching rate, fertility & eggshell quality • Enhancement of immunity • Prevention of leg weakness in broilers. 	Contradiction: Each gram of Sodium Ascorbate contains approximately 5 mEq of sodium, this should be considered when the drug is used in patients on salt-restricted diets. Side effects: Chronic ingestion of mega doses may be a more serious problem. An acute intravenous overdose of Vitamin C has resulted in renal failure.	100% Powder	South Korea	c0qirB` tbB weaq Arte`b bigAy Kiv thtZ citi	c0qirB` tbB weaq Arte`b bigAy Kiv nj

**Annex-D: list of Medical Device adopted by MD Guideline on the basis of risk categories
such as –
Class B (Low moderate risk), Class C (Moderate high risk), Class D (High risk) :**

Sl.	CLASS	Name of the Medical Devices
1.	B	TONOMETER, MANUAL
2.	B	URETHROSCOPE
3.	B	ABERRMETER, OPHTHALMIC
4.	B	DEVICE, ABLATION, VARICOSE VEIN
5.	B	SYSTEM, ABORTION, VACUUM
6.	B	ABSORBENT, CARBON-DIOXIDE
7.	B	ABSORBER, CARBON-DIOXIDE
8.	B	ELECTRODE, PH, STOMACH
9.	B	MATERIALS, FABRICATING PROSTHODONTIC APPLIANCES, DENTAL LAB.
10.	B	ACUPUNCTURE, DIAGNOSTIC, ELECTRIC AL RESISTANCE
11.	B	ADAPTER, A-V SHUNT OR FISTULA
12.	B	ADAPTER, ANESTHESIA
13.	B	ADAPTER, TRACHEAL TUBE
14.	B	ADAPTER, TRACHEOSTOMY TUBE
15.	B	ADAPTOR, BULB, MISCELLANEOUS, FOR ENDOSCOPE
16.	B	ADAPTOR, CABLE, EQUIPMENT
17.	B	ADAPTOR, CATHETER
18.	B	ADAPTOR, ELECTROSURGICAL UNIT CABLE
19.	B	ADAPTOR, LEAD SWITCHING, ELECTROCARDIOGRAPH
20.	B	ADAPTOR, NEEDLE
21.	B	ADAPTOR, STOPCOCK, MANIFOLD, FITTING, CARDIOPULMONARY BYPASS
22.	B	ADAPTOR, SYRINGE
23.	B	ADAPTOR, Y
24.	B	CABLE AND ADAPTER, DEFIBRILLATOR
25.	B	TUBING, CONNECTOR/ADAPTOR
26.	B	BLADE, OSTEOTOME AND OTHER CUTTING INSTRUMENTS (DISPOSABLE)
27.	B	ADHESIVE, BRACKET AND TOOTH CONDITIONER, RESIN
28.	B	ELECTRODE, GEL
29.	B	ATOMIZER AND TIP, ENT
30.	B	MASK, OXYGEN
31.	B	NEBULIZER (DIRECT PATIENT INTERFACE)
32.	B	OCULAR ESTHESIOMETER
33.	B	AIRWAY, ESOPHAGEAL (OBTURATOR)
34.	B	AIRWAY, OROPHARYNGEAL, ANESTHESIOLOGY
35.	B	KIT, CRICOTHYROTOMY
36.	B	KIT, SUCTION, AIRWAY
37.	B	UNIT, CONTINUOUS POSITIVE AIRWAY PRESSURE (CPAP, CPPB)
38.	B	ALARM, ENURESIS, CONDITIONED RESPONSE
39.	B	ALARM, LEAKAGE CURRENT, PORTABLE
40.	B	MONITOR (APNEA DETECTOR), VENTILATORY EFFORT
41.	B	SYSTEM, ALARM, ELECTROSURGICAL
42.	B	ALGESIMETER, POWERED
43.	B	ALIGNMENT SYSTEM, ORTHODONTIC
44.	B	PUMP, INFUSION, ENTERAL
45.	B	CERAMIC, PROSTHODONTIC APPLIANCES
46.	B	SAMPLER, AMNIOTIC FLUID (AMNIOCENTESIS TRAY)
47.	B	ENDOSCOPE, TRANSCERVICAL (AMNIOSCOPE), AND ACCESSORIES
48.	B	AMNIOTOME (DISPOSABLE)

Sl.	CLASS	Name of the Medical Devices
49.	B	AMPLIFIER AND SIGNAL CONDITIONER, BIOPOTENTIAL
50.	B	AMPLIFIER AND SIGNAL CONDITI ONER, TRANSDUCER SIGNAL
51.	B	AMPLIFIER, MICROELECTRODE
52.	B	AMPLIFIER, PHYSIOLOGICAL SIGNAL
53.	B	TUBE, IMAGE AMPLIFIER, X-RAY
54.	B	GAS-MACHINE, ANALGESIA
55.	B	SYSTEM, HEARING- AID ANALYSIS
56.	B	ANALYZER, BODY COMPOSITION
57.	B	ANALYZER, DOPPLER SPECTRUM
58.	B	ANALYZER, ELECTROSURGICAL UNIT
59.	B	ANALYZER, METABOLISM
60.	B	ANALYZER, PACEMAKER, GENERATOR FUNCTION
61.	B	ANALYZER, PULMONARY FUNCTION
62.	B	SYSTEM, GASTROINTESTINAL MOTILITY (ELECTRICAL)
63.	B	DEVICE, ANASTOMOTIC, MICROVASCULAR
64.	B	ANCHOR, PREFORMED
65.	B	ABSORBENT, CARBON-DIOXIDE
66.	B	ANESTHESIA SET, PUDENDAL
67.	B	APPARATUS, GAS-SCAVENGING
68.	B	CALIBRATOR ANESTHESIA UNIT
69.	B	DEVICE, ELECTRICAL DENTAL ANESTHESIA
70.	B	KIT, ANESTHESIA, BRACHIAL PLEXUS
71.	B	KIT, ANESTHESIA, EPIDURAL
72.	B	KIT, ANESTHESIA, SPINAL
73.	B	SET, ANESTHESIA, PARACERVICAL
74.	B	STIMULATOR, NERVE, PERIPHERAL, ELECTRIC
75.	B	ANGIODYNOGRAPH
76.	B	WIRE, GUIDE, ANGIOGRAPHIC AND ACCESSORIES
77.	B	DILATOR, VESSEL, FOR PERCUTANEOUS CATHETERIZATION
78.	B	ANGIOSCOPE
79.	B	ANOSCOPE, NON-POWERED
80.	B	DEVICE, ANTICHOKE, TONGS
81.	B	NEEDLE, ASPIRATION AND INJECTION, DISPOSABLE
82.	B	EQUIPMENT, THERAPY, APNEA
83.	B	MONITOR (APNEA DETECTOR), VENTILATORY EFFORT
84.	B	MONITOR, BREATHING FREQUENCY
85.	B	APPLICATOR (LARYNGO-TRACHEAL), TOPICAL ANESTHESIA
86.	B	APPLICATOR, RESIN
87.	B	SYSTEM, APPLICATOR, RADIONUCLIDE, MANUAL
88.	B	APPLIER, ANEURYSM CLIP
89.	B	APPLIER, SURGICAL, CLIP
90.	B	RADIOGRAPHIC PICTURE ARCHIVING/COMMUNICATION SYSTEM (PACS)
91.	B	ARTHROGRAM KIT
92.	B	ARTHROSCOPE AND ACCESSORIES
93.	B	CATHETER, SUCTION, TRACHEOBRONCHIAL
94.	B	ELECTRODE, FLEXIBLE SUCTION COAGULATOR
95.	B	SYSTEM, ABORTION, VACUUM
96.	B	APPARATUS, SUCTION, PATIENT CARE
97.	B	ASPIRATOR, ENDOCERVICAL
98.	B	ASPIRATOR, ENDOMETRIAL
99.	B	ASPIRATOR, INFANT
100.	B	ASPIRATOR, LOW VOLUME (GASTRIC SUCTION) - UROLOGY USE

Sl.	CLASS	Name of the Medical Devices
101.	B	ASPIRATOR, OPHTHALMIC
102.	B	ASPIRATOR, SURGICAL
103.	B	ASPIRATOR, TRACHEAL
104.	B	ASPIRATOR, ULTRASONIC
105.	B	ASPIRATOR, WOUND SUCTION PUMP
106.	B	EVACUATOR, BLADDER, MANUALLY OPERATED
107.	B	EXTRACTOR, VACUUM, FETAL
108.	B	ATOMIZER AND TIP, ENT
109.	B	NEBULIZER, MEDICINAL, NON-VENTILATORY (ATOMIZER)
110.	B	AUDIOMETER
111.	B	STETHOSCOPE, ELECTRONIC
112.	B	STERILIZER, STEAM (AUTOCLAVE)
113.	B	APPARATUS, AUTOTRANSFUSION
114.	B	HEMOCONCENTRATOR
115.	B	DEVICE, AVERSIVE CONDITIONING
116.	B	AWL
117.	B	BAG, BREATHING
118.	B	BAG, ENTERAL FEEDING
119.	B	BAG, HEMOSTATIC
120.	B	BAG, POLITZER, BAG AND ACCESSORIES
121.	B	CONTAINER, I.V.
122.	B	DEVICE, MEDICATION RECONSTITUTION/TRANSER
123.	B	BALLISTOCARDIOGRAPH
124.	B	BALLOON, RECTAL
125.	B	DEVICE, PERCUTANEOUS RETRIEVAL
126.	B	OCCLUDER, VASCULAR
127.	B	BAND, ELASTIC, ORTHODONTIC
128.	B	BAND, MATERIAL, ORTHODONTIC
129.	B	BAND, PREFORMED, ORTHODONTIC
130.	B	BANDAGE, LIQUID
131.	B	BAR, PREFORMED
132.	B	BASKET, BILIARY STONE RETRIEVAL
133.	B	BATH, PARAFFIN
134.	B	BATTERY, REPLACEMENT, RECHARGEABLE
135.	B	STERILIZER, GLASS BEAD
136.	B	DEVICE, BEAM -LIMITING, X-RAY, DIAGNOSTIC
137.	B	DEVICE, BEAM -LIMITING, X-RAY, THERAPEUTIC
138.	B	BED, AIR FLUIDIZED
139.	B	BED, FLOTATION THERAPY, POWERED
140.	B	BED, PATIENT, ROTATION, POWERED
141.	B	LENS, CONTACT (OTHER MATERIAL) - DAILY
142.	B	LENS, CONTACT, BIFOCAL
143.	B	BILIRUBINOMETER, CUTANEOUS (JAUNDICE METER)
144.	B	DEVICE, BIOFEEDBACK
145.	B	CURETTE, SUCTION, ENDOMETRIAL (AND ACCESSORIES)
146.	B	DEVICE, BIOPSY, ENDOMYOCARDIAL
147.	B	INSTRUMENT, BIOPSY
148.	B	INSTRUMENT, BIOPSY, MECHANICAL, GASTROINTESTINAL
149.	B	KIT, BIOPSY
150.	B	KNIFE, MYRINGOTOMY (DISPOSABLE)
151.	B	BIT, DRILL
152.	B	BIT, SURGICAL

Sl.	CLASS	Name of the Medical Devices
153.	B	BUR, DENTAL
154.	B	BUR, SURGICAL, GENERAL & PLASTIC SURGERY
155.	B	BURR, ORTHOPEDIC
156.	B	BLADE, BONE CUTTING
157.	B	BLADE, LARYNGOSCOPE
158.	B	BLADE, OSTEOTOME AND OTHER CUTTING INSTRUMENTS (DISPOSABLE)
159.	B	BLADE, SCALPEL (DISPOSABLE)
160.	B	BLADE, SURGICAL, SAW, GENERAL & PLASTIC SURGERY
161.	B	RETRACTOR BLADES (DISPOSABLE)
162.	B	BLANKET, HYPO/HYPERThERMIA
163.	B	DEVICE, HYPOTHERMIA (BLANKET, PLUMBING & HEAT EXCHANGER)
164.	B	CONTROLLER, OXYGEN (BLENDER)
165.	B	BLOCK, BEAM -SHAPING, RADIATION THERAPY
166.	B	APPARATUS, AUTOTRANSFUSION
167.	B	KIT, ADMINISTRATION, BLOOD
168.	B	KIT, SAMPLING, ARTERIAL BLOOD
169.	B	KIT, SAMPLING, BLOOD
170.	B	RESERVOIR, BLOOD, CARDIOPULMONARY BYPASS
171.	B	ANALYZER, METABOLISM
172.	B	ADHESIVE, BRACKET AND TOOTH CONDITIONER, RESIN
173.	B	BONE MARROW COLLECTION/TRANSFUSION KIT
174.	B	STIMULATOR, BONE GROWTH, NON -INVASIVE
175.	B	BOUGIE, ESOPHAGEAL, AND GASTROINTESTINAL, GASTRO-UROLOGY
176.	B	BOUGIE, ESOPHAGEAL, ENT
177.	B	BOUGIE, EUSTACHIAN
178.	B	DILATOR, URETHRAL
179.	B	FACE BOW
180.	B	BRACKET, METAL, ORTHODONTIC
181.	B	BRACKET, ORTHODONTIC, OTHER
182.	B	BRACKET, PLASTIC, ORTHODONTIC
183.	B	ATTACHMENT, BREATHING, POSITIVE END EXPIRATORY PRESSURE
184.	B	CIRCUIT, BREATHING (W CONNECTOR, ADAPTOR, Y PIECE)
185.	B	CIRCUIT, BREATHING, VENTILATOR
186.	B	MONITOR (APNEA DETECTOR), VENTILATORY EFFORT
187.	B	TUBE, TRACHEOSTOMY
188.	B	CROWN AND BRIDGE, TEMPORARY, RESIN
189.	B	BRONCHOSCOPE (FLEXIBLE OR RIGID)
190.	B	BRONCHOSCOPE, FLEXIBLE
191.	B	BRUSH, BIOPSY, GENERAL & PLASTIC SURGERY
192.	B	BRUSH, CYTOLOGY, FOR ENDOSCOPE
193.	B	BRUSH, ENDOMETRIAL
194.	B	BRUSH, OPHTHALMIC
195.	B	GRID, RADIOGRAPHIC
196.	B	BULB, INFLATION, FOR ENDOSCOPE
197.	B	IRRIGATING SYRINGE
198.	B	BURN KIT
199.	B	BUR, DENTAL
200.	B	BUR, SURGICAL, GENERAL & PLASTIC SURGERY
201.	B	BURR, CORNEAL, AC -POWERED
202.	B	BURR, CORNEAL, BATTERY-POWERED
203.	B	BURR, ORTHOPEDIC
204.	B	DRILL, DENTAL, INTRAORAL

Sl.	CLASS	Name of the Medical Devices
205.	B	POWERED COMPOUND DRILLS, BURRS, TREPHINES & ACCESSORIES
206.	B	POWERED SIMPLE DRILLS, BURRS, TREPHINES & ACCESSORIES
207.	B	BUTTON, NASAL SEPTUM
208.	B	BUTTON, TRACHEOSTOMY TUBE
209.	B	CABINET, MOIST STEAM
210.	B	CABLE
211.	B	CABLE AND ADAPTER, DEFIBRILLATOR
212.	B	CABLE, ELECTRIC
213.	B	CABLE, ELECTRODE
214.	B	CABLE, ELECTROSURGICAL UNIT
215.	B	CABLE, TRANSDUCER AND ELECTRODE, PATIENT, (INCLUDING CONNECTOR)
216.	B	CABLE/LEAD, EEG
217.	B	CABLE/LEAD, EMG
218.	B	CABLE/LEAD, TENS
219.	B	CONTROLLER, FOOT, HANDPIECE AND CORD
220.	B	CALCULATOR, PULMONARY FUNCTION DATA
221.	B	CALCULATOR, PULMONARY FUNCTION INTERPRETATOR (DIAGNOSTIC)
222.	B	GAS, CALIBRATION (SPECIFIED CONCENTRATION)
223.	B	SOURCE, CALIBRATION, SEALED, NUCLEAR
224.	B	CALIBRATOR ANESTHESIA UNIT
225.	B	CALIBRATOR, BLOOD GAS
226.	B	CALIBRATOR, DOSE, RADIONUCLIDE
227.	B	CALIBRATOR, PRESSURE TRANSDUCER
228.	B	CALIBRATOR, PRESSURE, GAS
229.	B	CALIBRATOR, RESPIRATORY THERAPY UNIT
230.	B	CALIBRATOR, TONOMETER
231.	B	CALIBRATOR, VENTILATOR
232.	B	CAMERA, CINE, ENDOSCOPIC, WITHOUT AUDIO (INVASIVE)
233.	B	CAMERA, FOCAL SPOT, RADIOGRAPHIC
234.	B	CAMERA, OPHTHALMIC, AC -POWERED
235.	B	CAMERA, SCINTILLATION (GAMMA)
236.	B	CAMERA, TELEVISION, ENDOSCOPIC, WITHOUT AUDIO (INVASIVE)
237.	B	CAMERA, X -RAY, FLUOROGRAPHIC, CINE OR SPOT
238.	B	SYSTEM, INTUBATION, LACRIMAL
239.	B	CANNULA AND TROCAR, SUPRAPUBLIC, NON-DISPOSABLE
240.	B	CANNULA, AORTIC
241.	B	CANNULA, ARTERIAL
242.	B	CANNULA, CATHETER
243.	B	CANNULA, CORONARY ARTERY
244.	B	CANNULA, DRAINAGE, ARTHROSCOPY
245.	B	CANNULA, EYE, LACRIMAL
246.	B	CANNULA, HEMODIALYSIS
247.	B	CANNULA, INJECTION
248.	B	CANNULA, INSUFFLATION, UTERINE (AND ACCESSORIES)
249.	B	CANNULA, NASAL OXYGEN, CONTINUOUS POSITIVE AIRWAY PRESSURE
250.	B	CANNULA, NASAL, OXYGEN
251.	B	CANNULA, OPHTHALMIC
252.	B	CANNULA, SINUS
253.	B	CANNULA, SUCTION, UTERINE
254.	B	CANNULA, SURGICAL, GENERAL & PLASTIC SURGERY
255.	B	CANNULA, VENA CAVA
256.	B	CANNULA, VENOUS

Sl.	CLASS	Name of the Medical Devices
257.	B	CANNULA, VENTRICULAR
258.	B	CANNULAE, BRONCHIAL
259.	B	INSTRUMENT, SURGICAL, ENDOSCOPIC/LAPAROSCOPIC (NON-POWERED)
260.	B	SURGICAL INSTRUMENT WITH SUCTION CANNULA
261.	B	SYSTEM, CANNULA, INTRAFALLOPIAN
262.	B	CANNULAT OR, LYMPH DUCT
263.	B	CONTRACEPTIVE CERVICAL CAP
264.	B	SITE, SAMPLING/INJECTION, ASEPTIC
265.	B	PLETHYSMOGRAPH, IMPEDANCE
266.	B	BALLOON CATHETER FOR RETINAL REATTACHMENT
267.	B	CANNULA, CATHETER
268.	B	CATHETER (GASTRIC, COLONIC, ETC.), IRRIGATION AND ASPIRATION
269.	B	CATHETER AND TIP, SUCTION
270.	B	CATHETER, ANGIOGRAPHIC
271.	B	CATHETER, ARTERIAL
272.	B	CATHETER, BALLOON TYPE
273.	B	CATHETER, BALLOON, DILATATION, VESSEL
274.	B	CATHETER, BARTHOLIN GLAND
275.	B	CATHETER, BILIARY, GENERAL & PLASTIC SURGERY (SHORT-TERM)
276.	B	CATHETER, BRONCHOGRAPHY
277.	B	CATHETER, CANNULA AND TUBING, VASCULAR, CARDIOPULMONARY BYPASS
278.	B	CATHETER, CHOLANGIOGRAPHY
279.	B	CATHETER, CONDUCTION, ANESTHETIC
280.	B	CATHETER, CONTINUOUS FLUSH
281.	B	CATHETER, CONTINUOUS IRRIGATION
282.	B	CATHETER, COUDE
283.	B	CATHETER, DEPEZZER
284.	B	CATHETER, DOUBLE LUMEN FEMALE URETHROGRAPHIC
285.	B	CATHETER, EPIDURAL
286.	B	CATHETER, ESOPHAGEAL BALLOON
287.	B	CATHETER, EUSTACHIAN, GENERAL & PLASTIC SURGERY
288.	B	CATHETER, GUIDING
289.	B	CATHETER, HEMODIALYSIS, NON-IMPLANTED
290.	B	CATHETER, HEMOSTATIC
291.	B	CATHETER, INFUSION
292.	B	CATHETER, INTRAMUSCULAR, PRESSURE-MONITORING
293.	B	CATHETER, INTRAUTERINE AND INTRODUCER
294.	B	CATHETER, INTRAVASCULAR, OCCLUDING, TEMPORARY
295.	B	CATHETER, INTRAVASCULAR, SHORT TERM
296.	B	CATHETER, INTRAVENOUS
297.	B	CATHETER, IRRIGATION
298.	B	CATHETER, JEJUNOSTOMY
299.	B	CATHETER, LIGHT, FIBEROPTIC, GLASS, URETERAL
300.	B	CATHETER, MALECOT
301.	B	CATHETER, MULTIPLE LUMEN
302.	B	CATHETER, NASAL, OXYGEN
303.	B	CATHETER, NEPHROSTOMY
304.	B	CATHETER, OXYGEN, TRACHEAL
305.	B	CATHETER, PERITONEAL DIALYSIS, SINGLE USE
306.	B	CATHETER, RADIOGRAPHIC (NON-VASCULAR)
307.	B	CATHETER, RECTAL
308.	B	CATHETER, RETENTION TYPE

Sl.	CLASS	Name of the Medical Devices
309.	B	CATHETER, RETENTION TYPE, BALLOON
310.	B	CATHETER, RETENTION, BARIUM ENEMA WITH BAG
311.	B	CATHETER, SALPINGOGRAPHY
312.	B	CATHETER, SINGLE NEEDLE HEMODIALYSIS
313.	B	CATHETER, STRAIGHT
314.	B	CATHETER, SUBCLAVIAN
315.	B	CATHETER, SUCTION, TRACHEOBRONCHIAL
316.	B	CATHETER, SUPRAPUBIC (AND ACCESSORIES)
317.	B	CATHETER, UMBILICAL ARTERY
318.	B	CATHETER, UPPER URINARY TRACT
319.	B	CATHETER, URETERAL DISPOSABLE (X-RAY)
320.	B	CATHETER, URETERAL, GASTRO-UROLOGY
321.	B	CATHETER, URETHRAL
322.	B	CATHETER, URETHRAL, DIAGNOSTIC
323.	B	CATHETER, URETHROGRAPHIC, MALE
324.	B	CHORIONIC VILLUS SAMPLING CATHETER
325.	B	DEVICE, PERCUTANEOUS RETRIEVAL
326.	B	SCLEROTHERAPY NEEDLE/CATHETER
327.	B	SYSTEM, WATER JET CATHETER, RENAL
328.	B	INJECTOR AND SYRINGE, ANGIOGRAPHIC
329.	B	TRAY, CATHETERIZATION, STERILE URETHRAL, WITH OR WITHOUT CATHETER
330.	B	APPARATUS, AUTOTRANSFUSION
331.	B	SENSOR, OXYGEN
332.	B	CERAMIC, PROSTHODONTIC APPLIANCES
333.	B	CHLORIDIMETER
334.	B	CHOLEDOCHOSCOPE, FLEXIBLE OR RIGID
335.	B	CHRONAXIMETER
336.	B	CIRCUIT, BREATHING (W CONNECTOR, ADAPTOR, Y PIECE)
337.	B	CIRCUIT, BREATHING, VENTILATOR
338.	B	YOKE ASSEMBLY, MEDICAL GAS
339.	B	CIRCULATOR, BREATHING CIRCUIT
340.	B	KIT, CIRCUMCISION, DISPOSABLE TRAY
341.	B	CLAMP, VASCULAR
342.	B	CLAMP, WIRE, ORTHODONTIC
343.	B	INSTRUMENT GUARD
344.	B	CLASP, PREFORMED
345.	B	CLASP, WIRE
346.	B	CLEANER, ULTRASONIC, CONTACT LENS
347.	B	ACCESSORIES TO CONTACT LENSES - CLEANING AND WETTING AGENTS
348.	B	CLIP, REMOVABLE (SKIN)
349.	B	CLIP, SCALP
350.	B	CLIP, WOUND
351.	B	COAGULATOR, LAPAROSCOPIC, UNIPOLAR (AND ACCESSORIES)
352.	B	COAGULATOR-CUTTER, ENDOSCOPIC, BIPOLAR (AND ACCESSORIES)
353.	B	COAGULATOR-CUTTER, ENDOSCOPIC, UNIPOLAR (AND ACCESSORIES)
354.	B	ELECTRODE, FLEXIBLE SUCTION COAGULATOR
355.	B	COATING, DENTURE HYDROPHILIC, RESIN
356.	B	DEVICE, CRYOTHERAPY/COMPRESSION
357.	B	DEVICE, COLIC TREATMENT
358.	B	BONE MARROW COLLECTION/TRANSFUSION KIT
359.	B	KIT, BLOOD COLLECTION, PHLEBOTOMY
360.	B	COLLIMATOR, AUTOMATIC, RADIOGRAPHIC

Sl.	CLASS	Name of the Medical Devices
361.	B	COLLIMATOR, MANUAL, RADIOGRAPHIC
362.	B	COLLIMATOR, THERAUPEUTIC X-RAY, OTHER
363.	B	COLONOSCOPE, GASTRO-UROLOGY
364.	B	COLONOSCOPE, GENERAL & PLASTIC SURGERY
365.	B	COLPOSCOPE (AND COLPOMICROSCOPE)
366.	B	COLUMN, LIFE SUPPORT (ELECTRICAL/GAS)
367.	B	RADIOGRAPHIC PICTURE ARCHIVING/COMMUNICATION SYSTEM (PACS)
368.	B	COMPRESSION UNIT, INTERMITTENT (ANTI-EMBOLISM PUMP)
369.	B	DEVICE, CRYOTHERAPY/COMPRESSION
370.	B	COMPRESSOR, AIR, PORTABLE
371.	B	COMPUTER, AUDIOMETRY
372.	B	COMPUTER, DIAGNOSTIC, PRE-PROGRAMMED, SINGLE FUNCTION
373.	B	COMPUTER, DIAGNOSTIC, PROGRAMMABLE
374.	B	COMPUTER, NUCLEAR MEDICINE
375.	B	COMPUTER, OXYGEN -UPTAKE
376.	B	COMPUTER, PATIENT DATA MANAGEMENT
377.	B	COMPUTER, PULMONARY FUNCTION LABORATORY
378.	B	COMPUTER, RADIOGRAPHIC IMAGE ANALYSIS
379.	B	COMPUTER, STRESS EXERCISE
380.	B	CONDENSER, HEAT AND MOISTURE (ARTIFICIAL NOSE)
381.	B	ADHESIVE, BRACKET AND TOOTH CONDITIONER, RESIN
382.	B	AMPLIFIER AND SIGNAL CONDITIONER, BIOPOTENTIAL
383.	B	AMPLIFIER AND SIGNAL CONDITIONER, TRANSDUCER SIGNAL
384.	B	CONDITIONER, SIGNAL, PHYSIOLOGICAL
385.	B	CONDOMWITH NONOXYNOL-9
386.	B	MICRO-CONDOM
387.	B	PROPHYLACTIC (CONDOM) - LATEX
388.	B	SHEATH, SEMINAL COLLECTION
389.	B	SOLUTION-TEST STANDARD CONDUCTIVITY, DIALYSIS
390.	B	CONE, RADIOGRAPHIC
391.	B	CONFORMER, OPHTHALMIC
392.	B	CONNECTOR, AIRWAY (EXTENSION)
393.	B	CONNECTOR, BLOOD TUBING, INFUSION "T"
394.	B	CONNECTOR, CATHETER
395.	B	CONNECTOR, SHUNT
396.	B	CONNECTOR, TUBING, BLOOD
397.	B	TUBING, CONNECTOR/ADAPTOR
398.	B	TUBING, DIALYSATE (AND CONNECTOR)
399.	B	CONTAINER, EVACUATED
400.	B	CONTAINER, I.V.
401.	B	CONTRACEPTIVE CERVICAL CAP
402.	B	CONTRACEPTIVE SPONGE
403.	B	CONTRACEPTIVE, VAGINAL (FOAM, GEL, SUPPOSITORY)
404.	B	DIAPHRAGM, CONTRACEPTIVE (AND ACCESSORIES)
405.	B	PESSARY, VAGINAL
406.	B	APPARATUS, INFUSION, MANUAL
407.	B	CONTROL, PUMP SPEED, CARDIOPULMONARY BYPASS
408.	B	CONTROLLER, FOOT, HANDPIECE AND CORD
409.	B	CONTROLLER, HEMODIALYSIS UNIT, SINGLE NEEDLE
410.	B	CONTROLLER, INTRAVASCULAR, INFUSION, ELECTRONIC
411.	B	CONTROLLER, OXYGEN (BLENDER)
412.	B	CONTROLLER, TEMPERATURE, CARDIOPULMONARY BYPASS

Sl.	CLASS	Name of the Medical Devices
413.	B	DEVICE, INFLATION CONTROL FOR DILATION BALLOONS
414.	B	GAS CONTROL UNIT, CARDIOPULMONARY BYPASS
415.	B	SUCTION CONTROL, INTRACARDIAC, CARDIOPULMONARY BYPASS
416.	B	UNIT, COOLING, CARDIAC
417.	B	CORD, ELECTRIC, FOR ENDOSCOPE
418.	B	INSTRUMENT, SURGICAL, ORTHOPEDIC, AC -POWERED MOTOR AND
419.	B	ACCESSORY/ATTACHMENT
420.	B	RESPIRATORY MOTION CORRECTOR
421.	B	FINGER COT
422.	B	PADDIE, COTTONOID
423.	B	COUNTER, WHOLE BODY, NUCLEAR
424.	B	PROBE AND COUNTER, ISOTOPE, FOR PHOSPHORUS CB
425.	B	COUNTER-PULSATING DEVICE, EXTERNAL
426.	B	INSTRUMENT GUARD
427.	B	PROTECTOR, TISSUE, HYDROPHILIC POLYMER
428.	B	EXERCISER, PASSIVE, NON-MEASURING
429.	B	KIT, CRICOTHYROTOMY
430.	B	CERAMIC, PROSTHODONTIC APPLIANCES
431.	B	CROWN AND BRIDGE, TEMPORARY, RESIN
432.	B	DEVICE, CRYOTHERAPY/COMPRESSION
433.	B	CUFF, BLOOD PRESSURE
434.	B	CUFF, CATHETER, ANTIMICROBIAL
435.	B	CUFF, INFLATION
436.	B	CUFF, TRACHEAL TUBE, INFLATABLE
437.	B	SYSTEM, MEASUREMENT, BLOOD PRESSURE, NON-INVASIVE
438.	B	CULDOSCOPE (AND ACCESSORIES)
439.	B	CUP, MENSTRUAL
440.	B	CURETTE (DISPOSABLE)
441.	B	CURETTE, ADENOID (DISPOSABLE)
442.	B	CURETTE, DERMAL (DISPOSABLE)
443.	B	CURETTE, EAR (DISPOSABLE)
444.	B	CURETTE, ETHMOID (DISPOSABLE)
445.	B	CURETTE, NASAL (DISPOSABLE)
446.	B	CURETTE, OPERATIVE (DISPOSABLE)
447.	B	CURETTE, OPHTHALMIC (DISPOSABLE)
448.	B	CURETTE, SALPINGEAL (DISPOSABLE)
449.	B	CURETTE, SUCTION, ENDOMETRIAL (AND ACCESSORIES)
450.	B	CURETTE, SURGICAL (DISPOSABLE)
451.	B	CURETTE, UTERINE (DISPOSABLE)
452.	B	DEVICE, THERAPY, DIRECT CURRENT, LOW INTENSITY
453.	B	THERAPY, INTERFERENTIAL CURRENT
454.	B	AMNIOTOME (DISPOSABLE)
455.	B	COAGULATOR-CUTTER, ENDOSCOPIC, BIPOLAR (AND ACCESSORIES)
456.	B	COAGULATOR-CUTTER, ENDOSCOPIC, UNIPOLAR (AND ACCESSORIES)
457.	B	CUTTER, BONE
458.	B	CUTTER, SURGICAL
459.	B	CUTTER, SUTURE
460.	B	CYSTOTOME (DISPOSABLE)
461.	B	DERMATOME
462.	B	KERATOME, AC -POWERED
463.	B	KERATOME, BATTERY-POWERED
464.	B	PAPILLOTOME/SPHINCTEROTOME

Sl.	CLASS	Name of the Medical Devices
465.	B	VALVULOTOME
466.	B	INSTRUMENT, CUTTING, ORTHOPEDIC
467.	B	SAW
468.	B	SYSTEM, DIAGNOSTIC, CYSTIC FIBROSIS
469.	B	CYSTOURETHROSCOPE
470.	B	CYSTOMETER, ELECTRICAL RECORDING
471.	B	CYSTOMETRIC GAS (CARBON-DIOXIDE) ON HYDRAULIC DEVICE
472.	B	DEVICE, CYSTOMETRIC, AIR
473.	B	CYSTOSCOPE, DIAGNOSTIC
474.	B	CYSTOTOME (DISPOSABLE)
475.	B	CYSTOURETHROSCOPE
476.	B	SET, I.V. FLUID TRANSFER
477.	B	TRAY, DECLOTTING (INCLUDING CONTENTS)
478.	B	RHINOANEMOMETER (MEASUREMENT OF NASAL DECONGESTION)
479.	B	BED, AIR FLUIDIZED
480.	B	BED, FLOTATION THERAPY, POWERED
481.	B	DEFOAMER, CARDIOPULMONARY BYPASS
482.	B	DENSITOMETER
483.	B	DENSITOMETER, RADIOGRAPHIC
484.	B	UNIT, OPERATIVE DENTAL
485.	B	DENTOSCOPE
486.	B	DENTURE PREFORMED (PARTIALLY PREFABRICATED DENTURE)
487.	B	DENTURE, PLASTIC, TEETH
488.	B	KIT, DENTURE REPAIR
489.	B	KIT, DENTURE REPAIR, OTC
490.	B	MATERIALS, FABRICATING PROSTHODONTIC APPLIANCES, DENTAL LAB.
491.	B	RELINER, DENTURE, OTC
492.	B	RESIN, DENTURE, RELINING, REPAIRING, REBASING
493.	B	TEETH, ARTIFICIAL, BACKING AND FACING
494.	B	TEETH, ARTIFICIAL, POSTERIOR WITH METAL INSERT
495.	B	TEETH, PORCELAIN
496.	B	TEETH, PREFORMED GOLD DENTURE
497.	B	LIGHT, THERAPY, SEASONAL AFFECTIVE DISORDER (SAD)
498.	B	UNIT, DERMABRASION
499.	B	BLADE, OSTEOTOME AND OTHER CUTTING INSTRUMENTS (DISPOSABLE)
500.	B	DERMATOME
501.	B	DEVICE, CARIES DETECTION
502.	B	LASER, FLUORESCENCE CARIES DETECTION
503.	B	DETECTOR, DEEP VEIN THROMBOSIS
504.	B	MONITOR (APNEA DETECTOR), VENTILATORY EFFORT
505.	B	TUBING, DIALYSATE (AND CONNECTOR)
506.	B	SET, ADMINISTRATION, FOR PERITONEAL DIALYSIS, DISPOSABLE
507.	B	SET, DIALYSIS, SINGLE NEEDLE WITH UNI-DIRECTIONAL PUMP
508.	B	SET, TUBING, BLOOD WITH AND WITHOUT ANTI-REGURGITATION VALVE
509.	B	UNIT, DIALYSIS, PERITONEAL (CAPD)
510.	B	REPROCESSING UNIT, DIALYZER
511.	B	DIAPHRAGM, CONTRACEPTIVE (AND ACCESSORIES)
512.	B	DIATHERMY, MICROWAVE, FOR USE IN APPLYING THERAPEUTIC DEEP HEAT
513.	B	DIATHERMY, MICROWAVE, FOR USE OTHER THAN APPLYING THERAPEUTIC DEEP HEAT
514.	B	DIATHERMY, SHORTWAVE, FOR USE IN APPLYING THERAPEUTIC DEEP HEAT
515.	B	DIATHERMY, ULTRASONIC, FOR USE IN APPLYING THERAPEUTIC DEEP HEAT

Sl.	CLASS	Name of the Medical Devices
516.	B	BOUGIE, ESOPHAGEAL, AND GASTROINTESTINAL, GASTRO-UROLOGY
517.	B	BOUGIE, ESOPHAGEAL, ENT
518.	B	DILATOR, CATHETER
519.	B	DILATOR, CATHETER, URETERAL
520.	B	DILATOR, CERVICAL, FIXED SIZE
521.	B	DILATOR, CERVICAL, HYGROSCOPIC -LAMINARIA
522.	B	DILATOR, COMMON DUCT
523.	B	DILATOR, ESOPHAGEAL
524.	B	DILATOR, ESOPHAGEAL, ENT
525.	B	DILATOR, LACHRYMAL
526.	B	DILATOR, RECTAL
527.	B	DILATOR, URETHRAL
528.	B	DILATOR, VAGINAL
529.	B	DILATOR, VESSEL, FOR PERCUTANEOUS CATHETERIZATION
530.	B	DILATOR, VESSEL, SURGICAL
531.	B	FILLIFORM AND FILIFORM FOLLOWER
532.	B	GUIDE, SURGICAL, NEEDLE
533.	B	WASHER/DISINFECTOR
534.	B	DISLODGER, STONE, BASKET, URETERAL, METAL
535.	B	DISLODGER, STONE, BILIARY
536.	B	DISLODGER, STONE, FLEXIBLE
537.	B	DISPENSER, CEMENT
538.	B	DEVICE, MEDICATION RECONSTITUTION/TRANSER DEVICE
539.	B	DISPLAY, CATHODE-RAY TUBE, MEDICAL
540.	B	DISSECTOR, SURGICAL, GENERAL & PLASTIC SURGERY
541.	B	DISSECTOR, TONSIL
542.	B	NEBULIZER PUMP, ELECTRICALLY POWERED
543.	B	DOUCHE, UTERINE
544.	B	DOUCHE-APPARATUS, VAGINAL, THERAPEUTIC
545.	B	NOZZLE, DOUCHE
546.	B	DRAIN, CERVICAL
547.	B	DRAIN, PENROSE
548.	B	DRAIN, SUMP
549.	B	DRAIN, T
550.	B	DRAIN, TEE (WATER TRAP)
551.	B	DRAIN, THORACIC (CHEST)
552.	B	DRAIN, VENT
553.	B	KIT, CHEST DRAINAGE (THORACENTESIS TRAY)
554.	B	KIT, INCISION AND DRAINAGE
555.	B	KIT, WOUND DRAINAGE
556.	B	KIT, WOUND DRAINAGE, CLOSED, CRANIOTOMY
557.	B	TUBING, RUBBER
558.	B	DRAPE, PURE LATEX SHEET, WITH SELF RETAINING FINGER COT
559.	B	DRESSING, BURN
560.	B	DRESSING, GEL
561.	B	DRESSING, PERMEABLE, MOISTURE
562.	B	DRESSING, TRACHEOSTOMY TUBE
563.	B	DRESSING, WOUND AND BURN, HYDROGEL
564.	B	DRESSING, WOUND AND BURN, OCCLUSIVE
565.	B	BIT, DRILL
566.	B	BUR, DENTAL
567.	B	BUR, SURGICAL, GENERAL & PLASTIC SURGERY

Sl.	CLASS	Name of the Medical Devices
568.	B	BURR, ORTHOPEDIC
569.	B	DRILL, BONE
570.	B	DRILL, BONE CEMENT
571.	B	DRILL, CANNULATED
572.	B	DRILL, CHUCK
573.	B	DRILL, DENTAL, INTRAORAL
574.	B	DRILL, FINGERNAIL
575.	B	DRILL, MIDDLE EAR SURGERY
576.	B	DRILL, ORAL SURGERY
577.	B	DRILL, SURGICAL, ENT (ELECTRIC OR PNEUMATIC) INCLUDING HANDPIECE
578.	B	PERFORATOR, DRILL
579.	B	POWERED COMPOUND DRILLS, BURRS, TREPHINES & ACCESSORIES
580.	B	POWERED SIMPLE DRILLS, BURRS, TREPHINES & ACCESSORIES
581.	B	DRIVER/EXTRACTOR, BONE NAIL/PIN
582.	B	DRIVER/EXTRACTOR, BONE PLATE
583.	B	ESOPHAGO GASTRO DUODENOSCOPE
584.	B	DYNAMOMETER
585.	B	DYNAMOMETER, PHYSICAL MEDICINE
586.	B	VIBRATOR FOR THERAPEUTIC USE, GENITAL
587.	B	ECHOCARDIOGRAPH
588.	B	ECHOENCEPHALOGRAPH
589.	B	ECHOOPHTHALMOGRAPH (ULTRASONIC SCANNER)
590.	B	ELECTROCARDIOGRAPH
591.	B	MONITOR, ECG, AMBULATORY, REAL -TIME
592.	B	RECORDER, LONG TERM, ECG, PORTABLE (HOLTER MONITOR)
593.	B	SYNCHRONIZER, ECG/RESPIRATOR, RADIOGRAPHIC
594.	B	CUTANEOUS ELECTRODE
595.	B	ELECTRODE, BIOPOTENTIAL, SURFACE, METALLIC
596.	B	ELECTRODE, BLOOD GAS, CARBON -DIOXIDE
597.	B	ELECTRODE, CLIP, FETAL SCALP (AND APPLICATOR)
598.	B	ELECTRODE, CORNEAL
599.	B	ELECTRODE, CORTICAL
600.	B	ELECTRODE, ELECTROCARDIOGRAPH
601.	B	ELECTRODE, ELECTROENCEPHALOGRAPHIC
602.	B	ELECTRODE, ELECTROMYOGRAPHIC
603.	B	ELECTRODE, ELECTRONYSTAGMOGRAPHIC
604.	B	ELECTRODE, ELECTROSURGICAL
605.	B	ELECTRODE, ELECTROSURGICAL, ACTIVE, UROLOGICAL
606.	B	ELECTRODE, ESOPHAGEAL
607.	B	ELECTRODE, FLEXIBLE SUCTION COAGULATOR
608.	B	ELECTRODE, GEL
609.	B	ELECTRODE, GEL, ELECTROSURGICAL
610.	B	ELECTRODE, METALLIC WITH SOFT PAD COVERING
611.	B	ELECTRODE, NASOPHARYNGEAL
612.	B	ELECTRODE, NEEDLE
613.	B	ELECTRODE, NEEDLE, DIAGNOSTIC ELECTROMYOGRAPH
614.	B	ELECTRODE, NEUROLOGICAL
615.	B	ELECTRODE, NEUROMUSCULAR STIMULATOR
616.	B	ELECTRODE, PACEMAKER, EXTERNAL
617.	B	ELECTRODE, PH, STOMACH
618.	B	ELECTRODE, SKIN SURFACE, OPHTHALMIC
619.	B	ELECTRODE, TENS

Sl.	CLASS	Name of the Medical Devices
620.	B	ELECTRODE, TRANSCUTANEOUS, OXYGEN
621.	B	GEL, ELECTRODE
622.	B	ELECTROENCEPHALOGRAPH
623.	B	STIMULATOR, MUSCLE, POWERED
624.	B	UNIT, ELECTROLYSIS, AC -POWERED, OPHTHALMIC
625.	B	ELECTROMYOGRAPH
626.	B	ELECTRONYSTAGMOGRAPH (ENG)
627.	B	COAGULATOR, LAPAROSCOPIC, UNIPOLAR (AND ACCESSORIES)
628.	B	COAGULATOR-CUTTER, ENDOSCOPIC, BIPOLAR (AND ACCESSORIES)
629.	B	COAGULATOR-CUTTER, ENDOSCOPIC, UNIPOLAR (AND ACCESSORIES)
630.	B	UNIT, ELECTROTHERAPEUTIC
631.	B	ECHOENCEPHALOGRAPH
632.	B	ELECTROENCEPHALOGRAPH
633.	B	INSTRUMENT, ENDODONTIC
634.	B	ENDOILLUMINATOR
635.	B	ANOSCOPE, NON-POWERED
636.	B	CANNULA AND TROCAR, SUPRAPUBLIC, NON-DISPOSABLE
637.	B	CHOLEDOCHOSCOPE, FLEXIBLE OR RIGID
638.	B	CYSTOURETHROSCOPE
639.	B	ENDOSCOPE AND/OR ACCESSORIES
640.	B	ENDOSCOPE, FIBER OPTIC
641.	B	ENDOSCOPE, FLEXIBLE
642.	B	ENDOSCOPE, NEUROLOGICAL
643.	B	ENDOSCOPE, RIGID
644.	B	ENDOSCOPE, TRANSCERVICAL (AMNIOSCOPE), AND ACCESSORIES
645.	B	ESOPHAGO GASTRO DUODENOSCOPE
646.	B	ESOPHAGOSCOPE, GENERAL & PLASTIC SURGERY
647.	B	GASTROSCOPE, GASTRO-UROLOGY
648.	B	HYSTEROSCOPE (AND ACCESSORIES)
649.	B	INSTRUMENT, SURGICAL, ENDOSCOPIC/L APAROSCOPIC (NON-POWERED)
650.	B	LAPAROSCOPE, GENERAL & PLASTIC SURGERY
651.	B	MEDIASTINOSCOPE
652.	B	PANENDOSCOPE (GASTRODUODENOSCOPE)
653.	B	PERITONEOSCOPE
654.	B	PROCTOSCOPE
655.	B	RESECTOSCOPE
656.	B	SCOPE, FIBEROPTIC INTUBATION
657.	B	SET, NEPHROSCOPE
658.	B	SIGMOIDOSCOPE, FLEXIBLE
659.	B	SPHYNCTEROSCOPE
660.	B	TELESCOPE, RIGID, ENDOSCOPE
661.	B	KIT, BARIUM ENEMA, DISPOSABLE
662.	B	KIT, ENEMA, (FOR CLEANING PURPOSE)
663.	B	ENTEROSCOPE
664.	B	ERGOMETER, TREADMILL
665.	B	ESOPHAGOSCOPE, GENERAL & PLASTIC SURGERY
666.	B	OCULAR ESTHESIOMETER
667.	B	EVACUATOR, BLADDER, MANUALLY OPERATED
668.	B	TUBE, STOMACH EVACUATOR (GASTRIC LAVAGE)
669.	B	EXCHANGE DEVICE, PERCUTANEOUS TRANSLUMINAL CATHETER
670.	B	FILTER, BLOOD, CARDIOPULMONARY BYPASS, ARTERIAL LINE
671.	B	FILTER, BLOOD, CARDIOTOMY SUCTION LINE, CARDIOPULMONARY BYPASS

Sl.	CLASS	Name of the Medical Devices
672.	B	DEVICE, HYPOTHERMIA (BLANKET, PLUMBING & HEAT EXCHANGER)
673.	B	HEAT-EXCHANGER, CARDIOPULMONARY BYPASS
674.	B	EXERCISER, FINGER, POWERED
675.	B	EXERCISER, NUCLEAR DIAGNOSTIC (CARDIAC STRESS TABLE)
676.	B	EXERCISER, PASSIVE, NON-MEASURING
677.	B	EXOPHTHALMOMETER
678.	B	DRIVER/EXTRACTOR, BONE NAIL/PIN
679.	B	DRIVER/EXTRACTOR, BONE PLATE
680.	B	EXTRACTOR
681.	B	EXTRACTOR, VACUUM, FETAL
682.	B	DEVICE, THERAPY, DIRECT CURRENT, LOW INTENSITY
683.	B	UNIT, MAGNETIC, THERAPEUTIC
684.	B	CANNULA, INSUFFLATION, UTERINE (AND ACCESSORIES)
685.	B	FALLOPOSCOPE
686.	B	KIT, FEEDING, ADULT (ENTERAL)
687.	B	PUMP, INFUSION, ENTERAL
688.	B	SET, GAVAGE, INFANT, STERILE
689.	B	FERTILITY DIAGNOSTIC DEVICE
690.	B	FILE, PULP CANAL, ENDODONTIC
691.	B	FILLIFORM AND FILIFORM FOLLOWER
692.	B	FILLING, TEMPORARY, OTC
693.	B	FILTER, BACTERIAL, BREATHING CIRCUIT
694.	B	FILTER, BLOOD, CARDIOPULMONARY BYPASS, ARTERIAL LINE
695.	B	FILTER, BLOOD, CARDIOTOMY SUCTION LINE, CARDIOPULMONARY
696.	B	FILTER, BLOOD, DIALYSIS
697.	B	FILTER, CONDUCTION, ANESTHETIC
698.	B	FILTER, GAS
699.	B	FILTER, INFUSION LINE
700.	B	FILTER, PREBYPASS, CARDIOPULMONARY BYPASS
701.	B	FILTER, RADIOGRAPHIC
702.	B	FILTER, SYRINGE
703.	B	FILTER, VENTILATOR
704.	B	NEEDLE, FILTER
705.	B	FITTING, LUER
706.	B	LOCALIZER & FIXATOR, LESION, BREAST
707.	B	FLASHER, AFTER -IMAGE
708.	B	FLOWMETER, ANESTHESIA
709.	B	FLOWMETER, BLOOD, CARDIOVASCULAR
710.	B	FLOWMETER, CALIBRATION, GAS
711.	B	FLOWMETER, NONBACK-PRESSURE COMPENSATED, BOURDON GAUGE
712.	B	FLOWMETER, TUBE, THORPE, BACK -PRESSURE COMPENSATED
713.	B	CONTAINER, I.V.
714.	B	INFUSION FLUID THERMAL WARMER
715.	B	DEVICE, FLUSHING, AUTOMATIC
716.	B	FOIL, DENTAL
717.	B	CATHETER, BALLOON TYPE
718.	B	TRAY, CATHETERIZATION, STERILE URETHRAL, WITH OR WITHOUT CATHETER
719.	B	FILLIFORM AND FILIFORM FOLLOWER
720.	B	FORCEPS, BIOPSY
721.	B	FORCEPS, BIOPSY, BRONCHOSCOPE (RIGID) (DISPOSABLE)
722.	B	FORCEPS, BIOPSY, ELECTRIC
723.	B	FORCEPS, BIOPSY, NON-ELECTRIC

Sl.	CLASS	Name of the Medical Devices
724.	B	FORCEPS, ELECTROSURGICAL
725.	B	FORCEPS, GRASPING, FLEXIBLE ENDOSCOPIC
726.	B	FORCEPS, OPHTHALMIC (DISPOSABLE)
727.	B	FORCEPS, STONE MANIPULATION
728.	B	FORCEPS, TUBE INTRODUCTION
729.	B	INSTRUMENT GUARD
730.	B	INSTRUMENT, SURGICAL, ENDOSCOPIC/LAPAROSCOPIC (NON-POWERED)
731.	B	CAMERA, OPHTHALMIC, AC -POWERED
732.	B	SOLDER, PROSTHODONTIC APPLIANCES
733.	B	STIMULATOR, MUSCLE, POWERED
734.	B	PANENDOSCOPE (GASTRODUODENOSCOPE)
735.	B	GASTROSCOPE, GASTRO-UROLOGY
736.	B	CATHETER, MALECOT
737.	B	GAUGE, GAS PRESSURE, CYLINDER/PIPELINE
738.	B	GAUGE, PRESSURE
739.	B	GAUZE, NONABSORBABLE, MEDICATED (INTERNAL SPONGE)
740.	B	GAUZE, NONABSORBABLE, NON-MEDICATED, (INTERNAL SPONGE)
741.	B	GAUZE, NONABSORBABLE, X-RAY DETECTABLE (INTERNAL SPONGE)
742.	B	SET, GAVAGE, INFANT, STERILE
743.	B	JELLY, LUBRICATING, FOR TRANSURETHRAL SURGICAL INSTRUMENT
744.	B	GENERATOR, AEROSOL
745.	B	GENERATOR, OXYGEN, PORTABLE
746.	B	GENERATOR, SHOCK-WAVE (FOR PAIN RELIEF)
747.	B	MASKER, TINNITIS
748.	B	VALVE, SPEAKING, TRACHEAL
749.	B	GLOVE, PATIENT EXAMINATION
750.	B	GLOVE, SURGICAL
751.	B	CURETTE, NASAL (DISPOSABLE)
752.	B	GRID, RADIOGRAPHIC
753.	B	INSTRUMENT GUARD
754.	B	GUIDE
755.	B	GUIDE, CATHETER
756.	B	GUIDE, DRILL
757.	B	GUIDE, GIGLI SAW
758.	B	GUIDE, NEEDLE
759.	B	GUIDE, SURGICAL, INSTRUMENT
760.	B	GUIDE, SURGICAL, NEEDLE
761.	B	INTRAOCULAR LENS GUIDE
762.	B	DEVICE, HAIR REGROWTH
763.	B	INSTRUMENT HANDLE, ORTHOPEDIC
764.	B	INSTRUMENT, SURGICAL, ENDOSCOPIC/LAPAROSCOPIC (NON-POWERED)
765.	B	ACCESSORIES, PHACOFAGMENTATION/EMULSIFICATION UNIT
766.	B	HANDPIECE, AIR -POWERED, DENTAL
767.	B	HANDPIECE, BELT AND/OR GEAR DRIVEN, DENTAL
768.	B	HANDPIECE, CONTRA-AND RIGHT-ANGLE ATTACHMENT, DENTAL
769.	B	HANDPIECE, DIRECT DRIVE, AC -POWERED
770.	B	HEADGEAR, EXTRAORAL, ORTHODONTIC
771.	B	HEARING AID, GROUP AND AUDITORY TRAINER
772.	B	HEARING-AID, AIR-CONDUCTION
773.	B	HEAT SOURCE FOR BLEACHING TEETH
774.	B	HEATER, BREATHING SYSTEM W/VO CONTROLLER (NOT HUMIDIFIER OR NEBULIZER)

Sl.	CLASS	Name of the Medical Devices
775.	B	HEATER, PERINEAL, RADIANT, NON CONTACT
776.	B	HEMOCONCENTRATOR
777.	B	FILTER, BLOOD, DIALYSIS
778.	B	PROTECTOR, TRANSDUCER, DIALYSIS
779.	B	SINGLE NEEDLE DIALYSIS SET (CO-AXIAL FLOW)
780.	B	SOLUTION-TEST STANDARD CONDUCTIVITY, DIALYSIS
781.	B	TEST EQUIPMENT, DIALYSIS UNIT
782.	B	TRAY, START/STOP (INCLUDING CONTENTS), DIALYSIS
783.	B	TUBING, DIALYSATE (AND CONNECTOR)
784.	B	ACCESSORY, BLOOD CIRCUIT, HEMODIALYSIS
785.	B	ACCESSORY, BLOOD CIRCUIT, HEMODIALYSIS
786.	B	HOLDER, HEART VALVE, PROSTHESIS
787.	B	RECORDER, LONG TERM, ECG, PORTABLE (HOLTER MONITOR)
788.	B	HOOD, OXYGEN, INFANT
789.	B	HOOK, OPHTHALMIC
790.	B	HUMIDIFIER, HEAT/MOISTURE EXCHANGE
791.	B	HUMIDIFIER, HEATED
792.	B	HUMIDIFIER, NON-HEATED
793.	B	HUMIDIFIER, RESPIRATORY GAS, (D IRECT PATIENT INTERFACE)
794.	B	INSTRUMENT, SHUNT SYSTEM IMPLANTATION
795.	B	NEEDLE, ASPIRATION AND INJECTION, DISPOSABLE
796.	B	NEEDLE, ASPIRATION AND INJECTION, REUSABLE
797.	B	DEVICE, HYPOTHERMIA (BLANKET, PLUMBING & HEAT EXCHANGER)
798.	B	DEVICE, HYPOTHERMIA THERAPY - INHALATION REWARMING
799.	B	DEVICE, TESTICULAR HYPOTHERMIA
800.	B	HEART INSULATION/PROTECTION POUCH
801.	B	HYSTEROSCOPE (AND ACCESSORIES)
802.	B	ILLUMINATOR, FIBEROPTIC, SURGICAL FIELD
803.	B	SYSTEM, IMAGE INTENSIFICATION
804.	B	IMAGING, GASTROINTESTINAL, WIRELESS, CAPSULE CAMERA
805.	B	SCANNER, WHOLE BODY, NUCLEAR
806.	B	SYSTEM, IMAGING, DENTAL, DIGITAL - FILMLESS
807.	B	SYSTEM, NUCLEAR MAGNETIC RESONANCE IMAGIN G
808.	B	UNIT, IMAGING, THERMAL
809.	B	STIMULATOR, FUNCTIONAL NEUROMUSCULAR, SCOLIOSIS
810.	B	DRIVER/EXTRACTOR, BONE PLATE
811.	B	INSTRUMENT, SHUNT SYSTEM IMPLANTATION
812.	B	DRAIN, PENROSE
813.	B	KIT, INCISION AND DRAINAGE
814.	B	DEVICE, INCONTINENCE, INFLATABLE, FEMALE
815.	B	APPARATUS, INFUSION, MANUAL
816.	B	BONE MARROW COLLECTION/TRANSFUSION KIT
817.	B	CATHETER, RADIOGRAPHIC (NON-VASCULAR)
818.	B	NEBULIZER, MEDICINAL
819.	B	KIT, DRUG INJECTION, HOME USE
820.	B	SET, LARYNGEAL INJECTION
821.	B	SITE, SAMPLING/INJECTION, ASEPTIC
822.	B	INJECTOR & ACCESSORIES, UTERINE MANIPULATOR
823.	B	INJECTOR AND SYRINGE, ANGIOGRAPHIC
824.	B	INJECTOR, INSULIN
825.	B	INJECTOR, JET, MECHANICAL -POWERED
826.	B	INJECTOR, MEDICATION (INOCULATOR)

Sl.	CLASS	Name of the Medical Devices
827.	B	INJECTOR, SYRINGE
828.	B	INJECTOR, MEDICATION (INOCULATOR)
829.	B	EQUIPMENT, IN -VITRO FERTILIZATION/EMBRYO TRANSFER
830.	B	INSERT, DRY EYE
831.	B	INTRAOCULAR LENS GUIDE
832.	B	INSTRUMENT, DIAMOND, DENTAL
833.	B	INSTRUMENT, SURGICAL, CARDIOVASCULAR
834.	B	INSTRUMENT, SURGICAL, ORTHOPEDIC, AC -POWERED MOTOR AND
835.	B	ACCESSORY/ATTACHMENT
836.	B	INSTRUMENT, SURGICAL, ORTHOPEDIC, PNEUMATIC POWERED &
837.	B	ACCESSORY/ATTACHMENT
838.	B	INSTRUMENT, SURGICAL, SONIC AND ACCESSORY/ATTACHMENT
839.	B	SURGICAL INSTRUMENT KIT, DISPOSABLE
840.	B	SURGICAL INSTRUMENT, DISPOSABLE
841.	B	INSUFFLATOR, AUTOMATIC CARBON-DIOXIDE FOR ENDOSCOPE
842.	B	INSUFFLATOR, CARBON-DIOXIDE, UTEROTUBAL (AND ACCESSORIES)
843.	B	INSUFFLATOR, HYSTEROSCOPIC
844.	B	INSUFFLATOR, LAPAROSCOPIC
845.	B	CONTAINER, I.V.
846.	B	FLOWMETER, BLOOD, CARDIOVASCULAR
847.	B	I.V. START KIT
848.	B	INTRAVASCULAR (I.V.) ADMINISTRATION SET
849.	B	SET, I.V. FLUID TRANSFER
850.	B	STOPCOCK, I.V. SET
851.	B	GUIDE, CATHETER
852.	B	INTRODUCER, CATHETER
853.	B	INTRODUCER, CONTRACEPTIVE DIAPHRAGM
854.	B	INTRODUCER, NEEDLE
855.	B	INTRODUCER, SPINAL NEEDLE
856.	B	KIT, INTRODUCER, PACEMAKER, LEAD
857.	B	SET, INTUBATION
858.	B	SYSTEM, INTUBATION, LACRIMAL
859.	B	DEVICE, IONTOPHORESIS
860.	B	DEVICE, IONTOPHORESIS, OTHER USES
861.	B	SYSTEM, DIAGNOSTIC, CYSTIC FIBROSIS
862.	B	DEVICE, IRRIGATION, OCULAR SURGERY
863.	B	EQUIPMENT, SUCTION/IRRIGATION, ENDOSCOPIC
864.	B	KIT, IRRIGATION, EYE
865.	B	KIT, IRRIGATION, WOUND
866.	B	STIMULATOR, CALORIC -WATER
867.	B	TRAY, IRRIGATION, STERILE
868.	B	IRRIGATOR, OCULAR, EMERGENCY
869.	B	IRRIGATOR, ORAL
870.	B	IRRIGATOR, OSTOMY
871.	B	IRRIGATOR, SUCTION
872.	B	SYSTEM, IRRIGATOR, COLONIC
873.	B	ISOMETER
874.	B	JELLY, LUBRICATING, FOR TRANSURETHRAL SURGICAL INSTRUMENT
875.	B	KERATOME, AC -POWERED
876.	B	KERATOME, BATTERY-POWERED
877.	B	KNIFE, KERATOME (DISPOSABLE)
878.	B	KERATOMETER

Sl.	CLASS	Name of the Medical Devices
879.	B	KNIFE, CATARACT
880.	B	KNIFE, CERVICAL CONE
881.	B	KNIFE, DURA HOOK
882.	B	KNIFE, EAR
883.	B	KNIFE, KERATOME (DISPOSABLE)
884.	B	KNIFE, LARYNGEAL
885.	B	KNIFE, MARGIN FINISHING, OPERATIVE
886.	B	KNIFE, MENISCUS
887.	B	KNIFE, MYRINGOTOMY (DISPOSABLE)
888.	B	KNIFE, NASAL
889.	B	KNIFE, OPHTHALMIC
890.	B	KNIFE, ORTHOPEDIC
891.	B	KNIFE, PERIODONTIC
892.	B	KNIFE, SCALPEL (DISPOSABLE)
893.	B	KNIFE, SKIN GRAFTING
894.	B	KNIFE, SURGICAL
895.	B	KNIFE, TONSIL
896.	B	SCALPEL, ONE-PIECE (DISPOSABLE)
897.	B	LAMP, HEAT
898.	B	LAMP, INFRARED
899.	B	LAMP, ULTRAVIOLET, PHYSICAL MEDICINE
900.	B	LIGHT, ULTRAVIOLET, DERMATOLOGICAL
901.	B	LANCET, BLOOD
902.	B	INSTRUMENT, SURGICAL, ENDOSCOPIC/LAPAROSCOPIC (NON-POWERED)
903.	B	LAPAROSCOPE, GENERAL & PLASTIC SURGERY
904.	B	LAPAROSCOPE, GYNECOLOGIC (AND ACCESSORIES)
905.	B	SET, LAPAROSCOPY
906.	B	LARYNGOSCOPE
907.	B	LARYNGOSCOPE, NON-RIGID
908.	B	LARYNGOSCOPE, RIGID
909.	B	LARYNX, ARTIFICIAL, BATTERY POWERED
910.	B	INSTRUMENT, VISUAL FIELD, LASER
911.	B	LASER FOR WOUND HEALING (CLASS A-CA)
912.	B	LASER, FLUORESCENCE CARIES DETECTION
913.	B	SYSTEM, SMOKE EVACUATION, LASER
914.	B	LAVAGE, JET
915.	B	TUBE, STOMACH EVACUATOR (GASTRIC LAVAGE)
916.	B	ELECTRODE, ELECTROCARDIOGRAPH
917.	B	LENS, CONTACT (OTHER MATERIAL) - DAILY
918.	B	LENS, CONTACT (POLYMETHYLMETHACRYLATE)
919.	B	LENS, CONTACT, BIFOCAL
920.	B	LENS, CONTACT, DISPOSABLE
921.	B	LENS, CONTACT, GAS-PERMEABLE
922.	B	LENS, CONTACT, POLYMETHYLMETH ACRYLATE, DIAGNOSTIC
923.	B	LENS, CONTACT, TINTED
924.	B	LENS, SURGICAL, LASER
925.	B	LENSES, SOFT CONTACT, DAILY WEAR
926.	B	LENSES, SOFT CONTACT, EXTENDED WEAR (LESS THAN C0 DAYS)
927.	B	LIGATOR, HEMORRHOIDAL
928.	B	LIGHT, THERAPY, SEASONAL AFFECTIVE DISORDER (SAD)
929.	B	LIGHT, ULTRAVIOLET, DERMATOLOGICAL
930.	B	MAXWELL SPOT, AC -POWERED

Sl.	CLASS	Name of the Medical Devices
931.	B	LOCALIZER & FIXATOR, LESION, BREAST
932.	B	LOCATOR, ACUPUNCTURE POINT
933.	B	LOCATOR, EPIDURAL SPACE
934.	B	LOCATOR, METAL, ELECTRONIC
935.	B	LOCATOR, ROOT APEX
936.	B	LOOP, IDENTIFICATION, SURGICAL
937.	B	SITE, SAMPLING/INJECTION, ASEPTIC
938.	B	LOOP, ENDARTERECTOMY
939.	B	LOOP, IDENTIFICATION, SURGICAL
940.	B	LOOP, VASCULAR
941.	B	JELLY, LUBRICATING, FOR TRANSURETHRAL SURGICAL INSTRUMENT
942.	B	PATIENT LUBRICANT
943.	B	HEAT-EXCHANGER, CARDIOPULMONARY BYPASS
944.	B	MAGNET, AC -POWERED
945.	B	MAGNET, TEST, PACEMAKER
946.	B	SCANNER, WHOLE BODY, NUCLEAR
947.	B	UNIT, MAGNETIC, THERAPEUTIC
948.	B	MAINTAINER, SPACE PREFORMED, ORTHODONTIC
949.	B	INJECTOR & ACCESSORIES, UTERINE MANIPULATOR
950.	B	MANOMETER, BLOOD PRESSURE, VENOUS
951.	B	MANOMETER, SPINAL FLUID
952.	B	SPHYGMOMANOMETER, ELECTRONIC (ARTERIAL PRESSURE)
953.	B	LOOP, IDENTIFICATION, SURGICAL
954.	B	MARKER, OCULAR
955.	B	MARKER, SCLERA
956.	B	PEN, MARKING, SURGICAL
957.	B	MASK, AEROSOL ADMINISTRATION
958.	B	MASK, GAS, ANESTHESIA
959.	B	MASK, OXYGEN
960.	B	MASK, OXYGEN, LOW CONCENTRATION, VENTURI
961.	B	MASK, OXYGEN, NON-REBREATHING
962.	B	MASK, TRACHEOSTOMY
963.	B	MASKER, TINNITIS
964.	B	MASSAGER, BATTERY-POWERED
965.	B	MASSAGER, POWERED INFLATABLE TUBE
966.	B	MASSAGER, THERAPEUTIC, ELECTRIC
967.	B	TAB LE, PHYSICAL THERAPY, MULTI FUNCTION
968.	B	MATTRESS, AIR FLOTATION, ALTERNATING PRESSURE
969.	B	MATTRESS, ALTERNATING PRESSURE
970.	B	TEMPERATURE REGULATED WATER MATTRESS
971.	B	MAXWELL SPOT, AC -POWERED
972.	B	DEVICE, SKIN POTENTIAL MEASUREMENT
973.	B	SYSTEM, MEASUREMENT, BLOOD PRESSURE, NON-INVASIVE
974.	B	SYSTEM, MEASUREMENT, URODYNAMIC
975.	B	MEDIA, REPRODUCTIVE
976.	B	MEDIASTINOSCOPE
977.	B	BILIRUBINOMETER, CUTANEOUS (JAUNDICE METER)
978.	B	METER, AIRWAY PRESSURE (INSPIRATORY FORCE)
979.	B	METER, DIALYSATE CONDUCTIVITY
980.	B	METER, PEAK FLOW, SPIROMETRY
981.	B	METER, SKIN RESISTANCE, BATTERY POWERED
982.	B	MICROFILTER, BLOOD TRANSFUSION

Sl.	CLASS	Name of the Medical Devices
983.	B	DIATHERMY, MICROWAVE, FOR USE IN APPLYING THERAPEUTIC DEEP HEAT
984.	B	DIATHERMY, MICROWAVE, FOR USE OTHER THAN APPLYING THERAPEUTIC DEEP HEAT
985.	B	MIXER, BREATHING GASES, ANESTHESIA INHALATION
986.	B	MOLD, VAGINAL
987.	B	MANOMETER, BLOOD PRESSURE, VENOUS
988.	B	METER, AIRWAY PRESSURE (INSPIRATORY FORCE)
989.	B	METER, PEAK FLOW, SPIROMETRY
990.	B	MONITOR (APNEA DETECTOR), VENTILATORY EFFORT
991.	B	MONITOR, BLOOD PRESSURE, NON-INDWELLING
992.	B	MONITOR, BLOOD PRESSURE, TRANSDUCER, NON-INDWELLING
993.	B	MONITOR, BREATHING FREQUENCY
994.	B	MONITOR, ECG, AMBULATORY, REAL -TIME
995.	B	MONITOR, ELECTROMYOGRAPHIC
996.	B	MONITOR, ESOPHAGEAL MOTILITY, AND TUBE
997.	B	MONITOR, ESOPHAGEAL PRESSURE
998.	B	MONITOR, EYE MOVEMENT
999.	B	MONITOR, EYE MOVEMENT, DIAGNOSTIC
1000.	B	MONITOR, IMPEDANCE PNEUMOGRAPH
1001.	B	MONITOR, PATIENT POSITION, LIGHT BEAM
1002.	B	MONITOR, PERIODONTAL TISSUE
1003.	B	MONITOR, TEMPERATURE, GENERAL & PLASTIC SURGERY
1004.	B	PENILE TUMESCENCE MONITOR
1005.	B	PLETHYSMOGRAPH, VOLUME
1006.	B	RECORDER, LONG TERM, ECG, PORTABLE (HOLTHER MONITOR)
1007.	B	SYSTEM, THERMAL REGULATING
1008.	B	DEVICE, MONITORING, BALLOON/CUFF PRESSURE
1009.	B	KIT, PRESSURE MONITORING (AIR/GAS)
1010.	B	CUTTER, SURGICAL
1011.	B	SYSTEM, GASTROINTESTINAL MOTILITY (ELECTRICAL)
1012.	B	MOTOR, DRILL, PNEUMATIC
1013.	B	MOTOR, SURGICAL INSTRUMENT, AC -POWERED
1014.	B	MOTOR, SURGICAL INSTRUMENT, PNEUMATIC POWERED
1015.	B	MOUTHPIECE, BREATHING
1016.	B	SCANNER, WHOLE BODY, NUCLEAR
1017.	B	DEVICE, THERAPY, DIRECT CURRENT, LOW INTENSITY
1018.	B	DYNAMOMETER
1019.	B	DYNAMOMETER, PHYSICAL MEDICINE
1020.	B	KIT, MYELOGRAM
1021.	B	MYOMETER, MUSCLE FORCE MEASUREMENT
1022.	B	NASOPHARYNGOSCOPE (FLEXIBLE OR RIGID)
1023.	B	NEBULIZER (DIRECT PATIENT INTERFACE)
1024.	B	NEBULIZER NON-HEATED
1025.	B	NEBULIZER, HEATED
1026.	B	NEBULIZER, MEDICINAL
1027.	B	NEBULIZER, MEDICINAL, NON-VENTILATORY (ATOMIZER)
1028.	B	NEBULIZER, ULTRASONIC
1029.	B	DEVICE, MEDIC ATION RECONSTITUTION/TRANSER
1030.	B	KIT, BIOPSY NEEDLE
1031.	B	KIT, CRICOTHYROTOMY
1032.	B	LOCATOR, ACUPUNCTURE POINT
1033.	B	NEEDLE, ACUPUNCTURE

Sl.	CLASS	Name of the Medical Devices
1034.	B	NEEDLE, ANGIOGRAPHIC
1035.	B	NEEDLE, ASPIRATION AND INJECTION, DISPOSABLE
1036.	B	NEEDLE, ASPIRATION AND INJECTION, REUSABLE
1037.	B	NEEDLE, BIOPSY, MAMMARY
1038.	B	NEEDLE, BLOOD COLLECTING
1039.	B	NEEDLE, BONE MARROW
1040.	B	NEEDLE, CARDIAC
1041.	B	NEEDLE, CATHETER
1042.	B	NEEDLE, CERCLAGE, GYNECOLOGICAL
1043.	B	NEEDLE, CHOLANGIOGRAPHY
1044.	B	NEEDLE, CONDUCTION, ANESTHETIC (W/WO INTRODUCER)
1045.	B	NEEDLE, DENTAL
1046.	B	NEEDLE, EMERGENCY AIRWAY
1047.	B	NEEDLE, ENDOSCOPIC (DISPOSABLE)
1048.	B	NEEDLE, FILTER
1049.	B	NEEDLE, FISTULA
1050.	B	NEEDLE, GASTRO-UROLOGY
1051.	B	NEEDLE, HYPODERMIC, SINGLE LUMEN
1052.	B	NEEDLE, INTRA- ARTERIAL
1053.	B	NEEDLE, INTRAVENOUS
1054.	B	NEEDLE, NEUROSURGICAL SUTURE
1055.	B	NEEDLE, OOCYTE ASPIRATION
1056.	B	NEEDLE, OPHTHALMIC (DISPOSABLE)
1057.	B	NEEDLE, OPHTHALMIC SUTURIN G
1058.	B	NEEDLE, PNEUMOPERITONEUM, SIMPLE
1059.	B	NEEDLE, PNEUMOPERITONEUM, SPRING LOADED
1060.	B	NEEDLE, RADIOGRAPHIC
1061.	B	NEEDLE, SPINAL, SHORT TERM
1062.	B	NEEDLE, SUTURING, DISPOSABLE
1063.	B	NEEDLE, SUTURING, REUSABLE
1064.	B	NEEDLE, SYRINGE, PUNCTURE PROTECTIVE
1065.	B	NEEDLE, TONSIL SUTURING
1066.	B	SCLEROTHERAPY NEEDLE/CATHETER
1067.	B	SET, NEPHROSCOPE
1068.	B	SCANNER, WHOLE BODY, NUCLEAR
1069.	B	NOZZLE, DOUCHE
1070.	B	NYSTAGMOGRAPH
1071.	B	AIRWAY, ESOPHAGEAL (OBTURATOR)
1072.	B	OBTURATOR, FOR ENDOSCOPE
1073.	B	OCCLUDER, CATHETER TIP
1074.	B	OCCLUDER, VASCULAR
1075.	B	OPHTHALMODYNAMOMETER
1076.	B	OPHTHALMOSCOPE, LASER
1077.	B	ADHESIVE, BRACKET AND TOOTH CONDITIONER, RESIN
1078.	B	STIMULATOR, SCOLIOSIS (ORTHOSIS)
1079.	B	OSCILLOMETER
1080.	B	OSCILLOSCOPE
1081.	B	STIMULATOR, BONE GROWTH, NON -INVASIVE
1082.	B	BLADE, OSTEOTOME AND OTHER CUTTING INSTRUMENTS (DISPOSABLE)
1083.	B	KIT, ADMINISTRATION, OXYGEN
1084.	B	UNIT, EMERGENCY OXYGEN AND RESUSCITATION
1085.	B	UNIT, LIQUID OXYGEN, PORTABLE

Sl.	CLASS	Name of the Medical Devices
1086.	B	UNIT, OXYGEN THERAPY, PORTABLE
1087.	B	PACHYMETER
1088.	B	PACKING, SURGICAL (NASAL, VAGINAL)
1089.	B	RADIOGRAPHIC PICTURE ARCHIVING/COMMUNICATION SYSTEM (PACS)
1090.	B	PAD, DEFIBRILLATOR PADDLE
1091.	B	PADDIE, COTTONOID
1092.	B	PADDLE, PAD, ELECTRODE, DEFIBRILLATOR (EXTERNAL)
1093.	B	PANCREATOSCOPE, BILIARY
1094.	B	PANENDOSCOPE (GASTRODUODENOSCOPE)
1095.	B	URETHROSCOPE
1096.	B	KIT, PAP SMEAR
1097.	B	KIT, ADMINISTRATION, PARENTERAL
1098.	B	PASSER, WIRE, ORTHOPEDIC
1099.	B	INSTRUMENT, LIGATURE PASSING AND KNOT TYING
1100.	B	INTERNAL PELVIMETER
1101.	B	INJECTOR, INSULIN
1102.	B	PEN, MARKING, SURGICAL
1103.	B	PENETROMETER
1104.	B	PERCUSSOR, POWERED -ELECTRIC
1105.	B	PERFORATOR, DRILL
1106.	B	SET, PERFUSION, KIDNEY, DISPOSABLE
1107.	B	SYSTEM, PERFUSION, KIDNEY
1108.	B	TUBING, FLUID DELIVERY
1109.	B	PERINEOMETER
1110.	B	SCREW, DECLOTTING
1111.	B	PERITONEOSCOPE
1112.	B	PESSARY, VAGINAL
1113.	B	ACCESSORIES, PHACOFAGMENTATION/EMULSIFICATION UNIT
1114.	B	ACCESSORIES, PHACOFAGMENTATION/EMULSIFICATION UNIT
1115.	B	PHANEROSCOPE
1116.	B	PHANTOM, ANTHROPOMORPHIC, NUCLEAR
1117.	B	PHANTOM, ANTHROPOMORPHIC, RADIOGRAPHIC
1118.	B	PHANTOM, DIGITAL SUBTRACTION ANGIOGRAPHY (DSA)
1119.	B	PHANTOM, FLOOD SOURCE, NUCLEAR
1120.	B	PHANTOM, TEST-PATTERN, RADIONUCLIDE
1121.	B	TEST PATTERN, RADIOGRAPHIC
1122.	B	PHLEBOGRAPH, IMPEDANCE
1123.	B	PHONOCARDIOGRAPH
1124.	B	PHOTOSTIMULATOR
1125.	B	DEVICE, MEDICATION RECONSTITUTION/TRANSER
1126.	B	PIPETTE, VAGINAL POOL SMEAR
1127.	B	DEVICE, INFLATION CONTROL FOR DILATION BALLOONS
1128.	B	PLETHYSMOGRAPH, IMPEDANCE
1129.	B	PLETHYSMOGRAPH, PHOTOELECTRIC, PNEUMATIC OR HYDRAULIC
1130.	B	PLETHYSMOGRAPH, PRESSURE
1131.	B	PLETHYSMOGRAPH, VOLUME
1132.	B	PLOTTER, PATIENT CONTOUR
1133.	B	BUTTON, TRACHEOSTOMY TUBE
1134.	B	PLUG, SCLERAL
1135.	B	APPARATUS, PNEUMOPERITONEUM, AUTOMATIC
1136.	B	PNEUMOTACHOMETER
1137.	B	APPARATUS, PNEUMOTHORAX

Sl.	CLASS	Name of the Medical Devices
1138.	B	POINT, PAPER, ENDODONTIC
1139.	B	POLISHER, EXTRACAPSULAR EXTRACTION PROCEDURE
1140.	B	POLYGRAPH
1141.	B	SNARE, FLEXIBLE (DISPOSABLE)
1142.	B	SITE, SAMPLING/INJECTION, ASEPTIC
1143.	B	INSTRUMENT, STEREOTAXIC
1144.	B	POSITIONER, ELECTRODE, ELECTROENCEPHALOGRAPH
1145.	B	HEART INSULATION/PROTECTION POUCH
1146.	B	ATTACHMENT, PRECISION, ALL
1147.	B	CUFF, INFLATION
1148.	B	DEVICE, CRYOTHERAPY/COMPRESSION
1149.	B	UNIT, CONTINUOUS POSITIVE AIRWAY PRESSURE (CPAP, CPPB)
1150.	B	PRISM, GONIOSCOPIC
1151.	B	ACCESSORIES, PHACOFAGMENTATION/EMULSIFICATION UNIT
1152.	B	PROBE AND COUNTER, ISOTOPE, FOR PHOSPHORUS CB
1153.	B	PROBE, HEATING, TISSUE, LAPAROSCOPE
1154.	B	PROBE, LASER
1155.	B	PROBE, PH CATHETER
1156.	B	PROBE, RADIOFREQUENCY LESION
1157.	B	PROBE, TEMPERATURE
1158.	B	PROBE, UPTAKE, NUCLEAR
1159.	B	SOUND, UTERINE (DISPOSABLE)
1160.	B	PROCTOSCOPE
1161.	B	ULTRASONIC PROPHYLAXIS UNIT,DENTAL
1162.	B	MATERIALS, FABRICATING PROSTHODONTIC APPLIANCES, DENTAL LAB.
1163.	B	INSTRUMENT GUARD
1164.	B	PROTECTOR, TISSUE, HYDROPHILIC POLYMER
1165.	B	PROTECTOR, TRANSDUCER, DIALYSIS
1166.	B	ANALYZER, PULMONARY FUNCTION
1167.	B	CALCULATOR, PULMONARY FUNCTION DATA
1168.	B	CALCULATOR, PULMONARY FUNCTION INTERPRETATOR (D IAGNOSTIC)
1169.	B	COMPUTER, PULMONARY FUNCTION LABORATORY
1170.	B	COMPRESSION UNIT, INTERMITTENT (ANTI-EMBOLISM PUMP)
1171.	B	COUNTER-PULSATING DEVICE, EXTERNAL
1172.	B	NEBULIZER PUMP, ELECTRICALLY POWERED
1173.	B	PUMP, AIR, NON-MANUAL, FOR ENDOSCOPE
1174.	B	PUMP, ALTERNATING PRESSURE PAD
1175.	B	PUMP, BLOOD, CARDIOPULMONARY BYPASS, ROLLER TYPE
1176.	B	PUMP, BLOOD, EXTRA LUMINAL
1177.	B	PUMP, BREAST, POWERED
1178.	B	PUMP, EXTRACORPOREAL PERFUSION
1179.	B	PUMP, INFUSION, ELASTOMERIC
1180.	B	PUMP, INFUSION, ENTERAL
1181.	B	PUMP, NEBULIZER, MANUAL
1182.	B	PUMP, PORTABLE, ASPIRATION (MANUAL OR POWERED)
1183.	B	SYSTEM, ABORTION, VACUUM
1184.	B	UNIT, SUCTION OPERATORY
1185.	B	INSTRUMENT, SURGICAL, ENDOSCOPIC/LAPAROSCOPIC (NON-POWERED)
1186.	B	PUNCH, AORTIC (DISPOSABLE)
1187.	B	PUNCH, BIOPSY
1188.	B	KIT, LUMBAR PUNCTURE
1189.	B	SYSTEM, X-RAY, TOMOGRAPHIC

Sl.	CLASS	Name of the Medical Devices
1190.	B	UNIT, RADIOGRAPHIC, DIAGNOSTIC, DENTAL (X-RAY)
1191.	B	SYSTEM, X-RAY, ANGIOGRAPHIC
1192.	B	SYSTEM, X-RAY, FLUOROSCOPIC, IMAGE-INTENSIFIED
1193.	B	SYSTEM, X-RAY, FLUOROSCOPIC, NON-IMAGE-INTENSIFIED
1194.	B	SYSTEM, X-RAY, MAMMOGRAPHIC
1195.	B	SYSTEM, X-RAY, MOBILE, FLUOROSCOPIC
1196.	B	UNIT, X-RAY, MOBILE, EXPLOSION-SAFE
1197.	B	RADIOMETER, PHOTOTHERAPY
1198.	B	RASP, BONE
1199.	B	REAMER
1200.	B	DEVICE, REBREATHING
1201.	B	SYSTEM, REBREATHING, RADIONUCLIDE
1202.	B	TRANSMITTER AND RECEIVER, ELECTROCARDIOGRAPH, TELEPHONE
1203.	B	TRANSMITTER AND RECEIVER, PHYSIOLOGICAL SIGNAL, RADIOFREQUENCY
1204.	B	TRANSMITTER/RECEIVER SYSTEM, FETAL MONITOR, TELEPHONE
1205.	B	RECORDER, LONG TERM, ECG, PORTABLE (HOLTER MONITOR)
1206.	B	RECORDER, LONG TERM, RESPIRATION
1207.	B	RECORDER, PAPER CHART
1208.	B	RECORDER, PRESSURE, INTRAUTERINE
1209.	B	VENTILATORY EFFORT RECORDER
1210.	B	REFRACTOMETER, OPHTHALMIC
1211.	B	REGULATOR, OXYGEN, MECHANICAL
1212.	B	REGULATOR, PRESSURE, GAS CYLINDER
1213.	B	REGULATOR, SUCTION (W GAUGE)
1214.	B	REGULATOR, SUCTION, LOW VOLUME (GASTRIC)
1215.	B	REGULATOR, SUCTION, SURGICAL
1216.	B	REGULATOR, VACUUM
1217.	B	SYSTEM, THERMAL REGULATING
1218.	B	RELINER, DENTURE, OTC
1219.	B	KIT, CATHETER REPAIR, NON-BALLOON
1220.	B	KIT, DENTURE REPAIR
1221.	B	KIT, DENTURE REPAIR, OTC
1222.	B	REPROCESSING UNIT, DIALYZER
1223.	B	RESECTOSCOPE
1224.	B	WORKING ELEMENT OF RESECTOSCOPE
1225.	B	DEVICE, MEDICATION RECONSTITUTION/TRANSER
1226.	B	RESERVOIR, BLOOD, CARDIOPULMONARY BYPASS
1227.	B	ADHESIVE, BRACKET AND CONDITIONER, RESIN
1228.	B	RESIN, DENTURE, RELINING, REPAIRING, REBASING
1229.	B	RESIN, ORTHODONTIC
1230.	B	UNIT, EVOKED RESPONSE
1231.	B	UNIT, EMERGENCY OXYGEN AND RESUSCITATION
1232.	B	VENTILATOR, EMERGENCY, MANUAL (RESUSCITATOR)
1233.	B	RETAINER, DENTAL
1234.	B	RETAINER, SCREW EXPANSION, ORTHODONTIC
1235.	B	RETAINER, VISCERAL
1236.	B	RETRACTOR, OPHTHALMIC (DISPOSABLE)
1237.	B	RETRACTOR, SURGICAL, GENERAL & PLASTIC SURGERY (DISPOSABLE)
1238.	B	RETRACTOR, VESSEL
1239.	B	DEVICE, PERCUTANEOUS RETRIEVAL
1240.	B	RETRIEVER, ENDOMAGNETIC
1241.	B	SNARE, FLEXIBLE (DISPOSABLE)

Sl.	CLASS	Name of the Medical Devices
1242.	B	RHINOANEMOMETER (MEASUREMENT OF NASAL DECONGESTION)
1243.	B	RONGEUR, POWERED
1244.	B	SAMPLER, AMNIOTIC FLUID (AMNIOCENTESIS TRAY)
1245.	B	SAMPLER, BLOOD, FETAL
1246.	B	KIT, SAMPLING, ARTERIAL BLOOD
1247.	B	KIT, SAMPLING, BLOOD
1248.	B	KIT, SAMPLING, ENDOMETRIAL
1249.	B	SITE, SAMPLING/INJECTION, ASEPTIC
1250.	B	BLADE, SURGICAL, SAW, GENERAL & PLASTIC SURGERY
1251.	B	SAW
1252.	B	SAW, BONE, PNEUMATIC
1253.	B	SAW, HANDPIECE
1254.	B	SAW, POWERED, AND ACCESSORIES
1255.	B	SAW, SURGICAL, ENT (ELECTRIC OR PNEUMATIC)
1256.	B	SCALER, ROTARY
1257.	B	SCALER, ULTRASONIC
1258.	B	BLADE, SCALPEL (DISPOSABLE)
1259.	B	KNIFE, SCALPEL (DISPOSABLE)
1260.	B	SCALPEL, ONE-PIECE (DISPOSABLE)
1261.	B	CAMERA, SCINTILLATION (GAMMA)
1262.	B	ECHOCARDIOGRAPH
1263.	B	ECHOENCEPHALOGRAPH
1264.	B	SCANNER, FLUORESCENT
1265.	B	SCANNER, RECTILINEAR, NUCLEAR
1266.	B	SCANNER, WHOLE BODY, NUCLEAR
1267.	B	SYSTEM, TOMOGRAPHIC, NUCLEAR
1268.	B	APPARATUS, GAS-SCAVENGING
1269.	B	INSTRUMENT, SURGICAL, ENDOSCOPIC/LAPAROSCOPIC (NON-POWERED)
1270.	B	SCISSORS, OPHTHALMIC (DISPOSABLE)
1271.	B	SCOPE, FIBEROPTIC INTUBATION
1272.	B	SCRAPER, CYTOLOGY (CERVICAL)
1273.	B	UNIT, SCREENING, AUDITORY FUNCTION
1274.	B	SCREW, DECLOTTING
1275.	B	SCREW, FIBROID, GYNECOLOGICAL
1276.	B	SCREWDRIVER (BATTERY-POWERED)
1277.	B	MATERIALS, FABRICATING PROSTHODONTIC APPLIANCES, DENTAL LAB.
1278.	B	SENSOR, BLOOD GAS, IN -LINE, CARDIOPULMONARY BYPASS
1279.	B	SENSOR, OXYGEN
1280.	B	SHEATH, FOR ENDOSCOPE
1281.	B	SHEATH, SEMINAL COLLECTION
1282.	B	DRAPE, PURE LATEX SHEET, WITH SELF RETAINING FINGER COT
1283.	B	INSTRUMENT GUARD
1284.	B	SHIELD, CORNEAL
1285.	B	LOOP, ENDARTERECTOMY
1286.	B	CATHETER, RADIOGRAPHIC (NON-VASCULAR)
1287.	B	SIGMOIDOSCOPE, FLEXIBLE
1288.	B	SIMULATOR, LUNG
1289.	B	DRAIN, TEE (WATER TRAP)
1290.	B	SIZER, HEART VALVE PROSTHESIS
1291.	B	SIZER, MAMMARY
1292.	B	TUBE, CALIBRATION, GASTROPLASTY
1293.	B	INSTRUMENT GUARD

Sl.	CLASS	Name of the Medical Devices
1294.	B	SLEEVE, COMPRESSIBLE LIMB
1295.	B	SYSTEM, SMOKE EVACUATION, LASER
1296.	B	SNARE, ENDOSCOPIC
1297.	B	SNARE, FLEXIBLE (DISPOSABLE)
1298.	B	SNARE, POLYP
1299.	B	COMPUTER, DIAGNOSTIC, PROGRAMMABLE
1300.	B	COMPUTER, PATIENT DATA MANAGEMENT
1301.	B	RADIOGRAPHIC PICTURE ARCHIVING/COMMUNICATION SYSTEM (PACS)
1302.	B	SOLDER, PROSTHODONTIC APPLIANCES
1303.	B	ACCESSORIES TO CONTACT LENSES - CLEANING AND WETTING AGENTS
1304.	B	KIT, ADMINISTRATION, CARDIOPLEGIA SOLUTION
1305.	B	SOLUTION, CARRIES REMOVAL
1306.	B	SOLUTION, INSTRUMENT, LAPROSCOPIC, ANTI-FOG
1307.	B	SOLUTIONS, STERILE, PATIENT CARE
1308.	B	SOUND, URETHRAL, METAL OR PLASTIC (DISPOSABLE)
1309.	B	SOUND, UTERINE (DISPOSABLE)
1310.	B	SPECULUM, OPHTHALMIC (DISPOSABLE)
1311.	B	SPECULUM, VAGINAL, NONMETAL (DISPOSABLE)
1312.	B	SPECULUM, VAGINAL, NONMETAL, FIBEROPTIC
1313.	B	CONDOM WITH NONOXYNOL-9
1314.	B	CONTRACEPTIVE, VAGINAL (FOAM, GEL, SUPPOSITORY)
1315.	B	SPHYNCTEROSCOPE
1316.	B	PAPILLOTOME/SPHINCTEROTOME
1317.	B	SPHYGMOMANOMETER, ELECTRONIC (ARTERIAL PRESSURE)
1318.	B	SPIROMETER, DIAGNOSTIC
1319.	B	CONTRACEPTIVE SPONGE
1320.	B	SPONGE FOR INTERNAL USE
1321.	B	SPONGE, OPHTHALMIC
1322.	B	SPRING, ORTHODONTIC
1323.	B	DEVICE, STABILIZER, HEART
1324.	B	SUPPORT, INTERNAL ORGAN, SURGICAL
1325.	B	STAPLE, REMOVABLE (SKIN)
1326.	B	STAPLER, SURGICAL
1327.	B	STENT, LARYNGEAL
1328.	B	STENT, VAGINAL
1329.	B	INSTRUMENT, STEREOTAXIC
1330.	B	STERILIZER, BOILING WATER
1331.	B	STERILIZER, CHEMICAL
1332.	B	STERILIZER, DRY HEAT
1333.	B	STERILIZER, ETHYLENE OXIDE GAS
1334.	B	STERILIZER, FORMALDEHYDE
1335.	B	STERILIZER, GLASS BEAD
1336.	B	STERILIZER, OTHER
1337.	B	STERILIZER, SOFT LENS, THERMAL AC POWERED
1338.	B	STERILIZER, STEAM (AUTOCLAVE)
1339.	B	STERILIZER, TONOMETER
1340.	B	STERILIZER, ULTRAVIOLET
1341.	B	STERILIZER/WASHER, ENDOSCOPE
1342.	B	STETHOSCOPE, DIRECT (ACOUSTIC)
1343.	B	STETHOSCOPE, ELECTRONIC
1344.	B	STETHOSCOPE, ELECTRONIC -AMPLIFIED
1345.	B	STETHOSCOPE, ESOPHAGEAL

Sl.	CLASS	Name of the Medical Devices
1346.	B	DEVICE, COLIC TREATMENT
1347.	B	DEVICE, THERAPY, DIRECT CURRENT, LOW INTENSITY
1348.	B	PHOTOSTIMULATOR
1349.	B	STIMULATOR, AUDITORY, EVOKED RESPONSE
1350.	B	STIMULATOR, BONE GROWTH, NON -INVASIVE
1351.	B	STIMULATOR, CALORIC -WATER
1352.	B	STIMULATOR, ELECTRICAL, EVOKED RESPONSE
1353.	B	STIMULATOR, ELECTRICAL, INCONTINENCE (NON-IMPLANTABLE)
1354.	B	STIMULATOR, ELECTRO- ACUPUNCTURE
1355.	B	STIMULATOR, ELECTRO- ANALGESIC
1356.	B	STIMULATOR, FUNCTIONAL NEUROMUSCULAR, SCOLIOSIS
1357.	B	STIMULATOR, MUSCLE, DIAGNOSTIC
1358.	B	STIMULATOR, MUSCLE, POWERED
1359.	B	STIMULATOR, NERVE
1360.	B	STIMULATOR, NERVE LOCATING, FACIAL
1361.	B	STIMULATOR, NERVE, AC -POWERED
1362.	B	STIMULATOR, NERVE, BATTERY POWERED
1363.	B	STIMULATOR, NERVE, PERIPHERAL, ELECTRIC
1364.	B	STIMULATOR, NERVE, TRANSCUTANEOUS, FOR PAIN RELIEF
1365.	B	STIMULATOR, NEUROMUSCULAR, EXTERNAL FUNCTIONAL
1366.	B	STIMULATOR, PHOTIC, EVOKED RESPONSE
1367.	B	STIMULATOR, SCOLIOSIS (ORTHOISIS)
1368.	B	STIMULATOR, ULTRASOUND AND MUSCLE, FOR USE IN APPLYING THERAPEUTIC DEEP HEAT
1369.	B	STIMULATOR, WOUND HEALING
1370.	B	STIMULATOR, SALIVARY SYSTEM
1371.	B	STOPCOCK, I.V. SET
1372.	B	SITE, SAMPLING/INJECTION, ASEPTIC
1373.	B	STRIP, SCHIRMER
1374.	B	STRIPPER, VEIN, DISPOSABLE
1375.	B	STYLET FOR CATHETER, GASTRO-UROLOGY
1376.	B	STYLET, CATHETER
1377.	B	STYLET, NEEDLE
1378.	B	STYLET, TRACHEAL TUBE
1379.	B	SUCKER, CARDIOTOMY RETURN, CARDIOPULMONARY BYPASS
1380.	B	APPARATUS, SUCTION, OPERATING ROOM, WALL VACUUM POWERED
1381.	B	APPARATUS, SUCTION, PATIENT CARE
1382.	B	APPARATUS, SUCTION, SINGLE PATIENT USE, PORTABLE, NONPOWERED
1383.	B	APPARATUS, SUCTION, WARD USE, PORTABLE, AC-POWERED
1384.	B	EQUIPMENT, SUCTION/IRRIGATION, ENDOSCOPIC
1385.	B	FISTULOGRAPHY INSTRUMENT, VACUUM SUCTION
1386.	B	INSTRUMENT, BIOPSY, SUCTION
1387.	B	KIT, SUCTION, AIRWAY
1388.	B	PUMP, PORTABLE, ASPIRATION (MANUAL OR POWERED)
1389.	B	SUCTION SNAKE BITE KIT
1390.	B	UNIT, SUCTION OPERATORY
1391.	B	SUPPORT, INTERNAL ORGAN, SURGICAL
1392.	B	KIT, SUTURE
1393.	B	SWAB, SPECIMEN COLLECTION
1394.	B	SYNCHRONIZER, ECG/RESPIRATOR, RADIOGRAPHIC
1395.	B	INJECTOR AND SYRINGE, ANGIOGRAPHIC
1396.	B	INJECTOR, SYRINGE

Sl.	CLASS	Name of the Medical Devices
1397.	B	IRRIGATING SYRINGE
1398.	B	STERILE IRRIGATING SYRINGE
1399.	B	SYRINGE, ANESTHESIA
1400.	B	SYRINGE, ANGIOGRAPHIC
1401.	B	SYRINGE, BALLOON INFLATION
1402.	B	SYRINGE, BULB
1403.	B	SYRINGE, BULB, AIR OR WATER
1404.	B	SYRINGE, CARTRIDGE
1405.	B	SYRINGE, DENTAL
1406.	B	SYRINGE, DISPOSABLE, WITH/WITHOUT NEEDLE
1407.	B	SYRINGE, DRUG, LUER -LOCK
1408.	B	SYRINGE, ENT
1409.	B	SYRINGE, HYPODERMIC
1410.	B	SYRINGE, INSULIN
1411.	B	SYRINGE, IRRIGATING
1412.	B	SYRINGE, OPHTHALMIC
1413.	B	SYRINGE, PERIODONTIC, ENDODONTIC, IRRIGATING
1414.	B	SYRINGE, PISTON
1415.	B	SYRINGE, RESTORATIVE AND IMPRESSION MATERIAL
1416.	B	SYRINGE, TUBERCULIN
1417.	B	UNIT, SYRINGE, AIR AND/OR WATER
1418.	B	EXERCISER, NUCLEAR DIAGNOSTIC (CARDIAC STRESS TABLE)
1419.	B	TABLE, PHYSICAL THERAPY, MULTI FUNCTION
1420.	B	TAMPON, MENSTRUAL, SCENTED, DEODORIZED
1421.	B	TAMPON, MENSTRUAL, UNSCENTED
1422.	B	TANK, HOLDING, DIALYSIS
1423.	B	TAP, BONE
1424.	B	STRIP, SCHIRMER
1425.	B	SYSTEM, INTUBATION, LACRIMAL
1426.	B	TELEMETRY UNIT, PHYSIOLOGICAL, MULTIPLE CHANNEL
1427.	B	TELEMETRY UNIT, PHYSIOLOGICAL, TEMPERATURE
1428.	B	TELESCOPE, LARYNGEAL-BRONCHIAL
1429.	B	TELESCOPE, RIGID, ENDOSCOPE
1430.	B	HOOD, OXYGEN, INFANT
1431.	B	TENT, MIST
1432.	B	TENT, OXYGEN
1433.	B	TENT, OXYGEN, ELECTRICALLY POWERED
1434.	B	TENT, PEDIATRIC AEROSOL
1435.	B	KIT, TEST, PERIODONTAL
1436.	B	MAGNET, TEST, PACEMAKER
1437.	B	PHANTOM, TEST-PATTERN, RADIONUCLIDE
1438.	B	SOLUTION-TEST STANDARD CONDUCTIVITY, DIALYSIS
1439.	B	TEST PATTERN, RADIOGRAPHIC
1440.	B	METER, DIALYSATE CONDUCTIVITY
1441.	B	TEST EQUIPMENT, DIALYSIS UNIT
1442.	B	TESTER, AUDITORY IMPEDANCE
1443.	B	TESTER, BRIGHTNESS ACUITY
1444.	B	TESTER, DEFIBRILLATOR
1445.	B	TESTER, ELECTROCARDIOGRAPH CABLE
1446.	B	TESTER, ELECTRODE/LEAD, ELECTROENCEPHALOGRAPH
1447.	B	TESTER, PACEMAKER ELECTRODE FUNCTION
1448.	B	TESTER, PULP

Sl.	CLASS	Name of the Medical Devices
1449.	B	TESTER, RADIOLOGY QUALITY ASSURANCE
1450.	B	SYSTEM, ISOKINETIC TESTING AND EVALUATION
1451.	B	INFUSION FLUID THERMAL WARMER
1452.	B	SYSTEM, THERMAL REGULATING
1453.	B	THERMAL DEVICE FOR HEMORRHOIDS
1454.	B	THERMOMETER, CHEMICAL COLOR CHANGE
1455.	B	THERMOMETER, ELECTRONIC
1456.	B	THERMOMETER, ELECTRONIC, CLINICAL
1457.	B	THERMOMETER, INFRARED
1458.	B	THORACOSCOPE
1459.	B	LOOP, IDENTIFICATION, SURGICAL
1460.	B	TIMER, FLOW
1461.	B	TIMER, PHOTOTHERAPY
1462.	B	ATOMIZER AND TIP, ENT
1463.	B	CATHETER AND TIP, SUCTION
1464.	B	TIP, ENEMA
1465.	B	TIP, SUCTION TUBE (YANKAUER, POOLE, ETC.)
1466.	B	TIP, SUCTION, ELECTROSURGICAL
1467.	B	SYSTEM, TOMOGRAPHIC, NUCLEAR
1468.	B	SYSTEM, X-RAY, TOMOGRAPHIC
1469.	B	DEVICE, ANTICHOKE, TONGS
1470.	B	SKULL TONG FOR TRACTION
1471.	B	TONOGRAPH
1472.	B	TONOMETER, AC -POWERED
1473.	B	TOOTHBRUSH, POWERED
1474.	B	TOURNIQUET, AIR PRESSURE
1475.	B	TOURNIQUET, PNEUMATIC
1476.	B	KIT, TRACHEOTOMY
1477.	B	EQUIPMENT, TRACTION, POWERED
1478.	B	UNIT, TRACTION, POWERED
1479.	B	DOME, PRESSURE TRANSDUCER
1480.	B	TRANSDUCER, APEX CARDIOGRAPHIC
1481.	B	TRANSDUCER, BLOOD FLOW, NON-INDWELLING
1482.	B	TRANSDUCER, BLOOD PRESSURE
1483.	B	TRANSDUCER, BLOOD PRESSURE, EXTRAVASCULAR
1484.	B	TRANSDUCER, FORCE
1485.	B	TRANSDUCER, GAS FLOW
1486.	B	TRANSDUCER, GAS PRESSURE
1487.	B	TRANSDUCER, GAS PRESSURE, DIFFERENTIAL
1488.	B	TRANSDUCER, HEART SOUND
1489.	B	TRANSDUCER, MINIATURE PRESSURE
1490.	B	TRANSDUCER, PRESSURE, INTRAUTERINE
1491.	B	TRANSDUCER, RESPIRATION RATE
1492.	B	TRANSDUCER, TREMOR
1493.	B	EQUIPMENT, IN -VITRO FERTILIZATION/EMBRYO TRANSFER
1494.	B	SET, I.V. FLUID TRANSFER
1495.	B	TRANSFORMER, ENDOSCOPE
1496.	B	APPARATUS, AUTOTRANSFUSION
1497.	B	BONE MARROW COLLECTION/TRANSFUSION KIT
1498.	B	KIT, TRANSFUSION
1499.	B	PHANEROSCOPE
1500.	B	TRANSMITTER AND RECEIVER, ELECTROCARDIOGRAPH, TELEPHONE

Sl.	CLASS	Name of the Medical Devices
1501.	B	TRANSMITTER AND RECEIVER, PHYSIOLOGICAL SIGNAL, RADIOFREQUENCY
1502.	B	TRANSMITTER/RECEIVER SYSTEM, FETAL MONITOR, TELEPHONE
1503.	B	DRAIN, TEE (WATER TRAP)
1504.	B	TRAP, BUBBLE
1505.	B	TRAY, SURGICAL, CUSTOM/SPECIAL PROCEDURE
1506.	B	ENGINE, TREPHINE, ACCESSORIES, AC -POWERED
1507.	B	POWERED COMPOUND DRILLS, BURRS, TREPHINES & ACCESSORIES
1508.	B	POWERED SIMPLE DRILLS, BURRS, TREPHINES & ACCESSORIES
1509.	B	TREPHINE (DISPOSABLE)
1510.	B	TREPHINE, MANUAL, OPHTHALMIC (DISPOSABLE)
1511.	B	TRIPSOR, STONE, BLADDER
1512.	B	CANNULA AND TROCAR, SUPRAPUBLIC, NON-DISPOSABLE
1513.	B	TROCAR
1514.	B	TROCAR, ABDOMINAL
1515.	B	TROCAR, ANTRUM
1516.	B	TROCAR, ENT
1517.	B	TROCAR, GALLBLADDER
1518.	B	TROCAR, GASTRO-UROLOGY
1519.	B	TROCAR, LARYNGEAL
1520.	B	TROCAR, OVARIAN
1521.	B	TROCAR, SINUS
1522.	B	TROCAR, THORACIC
1523.	B	DRAIN, THORACIC (CHEST)
1524.	B	KIT, CATHETER REPAIR, NON-BALLOON
1525.	B	SET, GAVAGE, INFANT, STERILE
1526.	B	TUBE, ASPIRATING, BRONCHOSCOPE, RIGID
1527.	B	TUBE, ASPIRATING, FLEXIBLE, CONNECTING
1528.	B	TUBE, BRONCHIAL (W/WO CONNECTOR)
1529.	B	TUBE, CALIBRATION, GASTROPLASTY
1530.	B	TUBE, COLON
1531.	B	TUBE, CONNECTING
1532.	B	TUBE, DECOMPRESSION
1533.	B	TUBE, DOUBLE LUMEN FOR INTESTINAL DECOMPRESSION AND/OR INTUBATION
1534.	B	TUBE, DRAINAGE
1535.	B	TUBE, ESOPHAGEAL, BLAKEMORE
1536.	B	TUBE, ESOPHAGEAL, SENGSTAK EN
1537.	B	TUBE, FEEDING
1538.	B	TUBE, GASTRO-ENTEROSTOMY
1539.	B	TUBE, GASTROINTESTINAL (AND ACCESSORIES)
1540.	B	TUBE, HEART-LUNG BYPASS UNIT
1541.	B	TUBE, IMAGE AMPLIFIER, X-RAY
1542.	B	TUBE, LARYNGECTOMY
1543.	B	TUBE, LEVINE
1544.	B	TUBE, NASOGASTRIC
1545.	B	TUBE, NEPHROSTOMY
1546.	B	TUBE, ORTHODONTIC
1547.	B	TUBE, RECTAL
1548.	B	TUBE, SINGLE LUMEN, W MERCURY WT BALLOON FOR INTES. INTUB. &/OR DECOMPRESSION
1549.	B	TUBE, STOMACH EVACUATOR (GASTRIC LAVAGE)
1550.	B	TUBE, TONSIL SUCTION

Sl.	CLASS	Name of the Medical Devices
1551.	B	TUBE, TRACHEAL (ENDOTRACHEAL) (W/WO CONNECTOR)
1552.	B	TUBE, TRACHEAL/BRONCHIAL, DIFFERENTIAL VENTILATION
1553.	B	TUBE, TRACHEOSTOMY
1554.	B	CATHETER, CANNULA AND TUBING, VASCULAR, CARDIOPULMONARY BYPASS
1555.	B	KIT, INTRAVENOUS EXTENSION TUBING
1556.	B	KIT, TUBING HEMODIALYSIS, HEMOPERFUSION, HEMOFILTRATION
1557.	B	SET, TUBING AND SUPPORT, VENTILATOR (W HARNESS)
1558.	B	SET, TUBING, BLOOD WITH AND WITHOUT ANTI-REGURGITATION VALVE
1559.	B	TUBING, CONDUCTIVE
1560.	B	TUBING, CONNECTOR/ADAPTOR
1561.	B	TUBING, CORRUGATED
1562.	B	TUBING, DIALYSATE (AND CONNECTOR)
1563.	B	TUBING, FLUID DELIVERY
1564.	B	TUBING, INSTRUMENTATION, BRONCHOSCOPE (BRUSH SHEATH A/O ASPIRATING)
1565.	B	TUBING, LATEX
1566.	B	TUBING, NON-CONDUCTIVE
1567.	B	TUBING, OXYGEN CONNECTING
1568.	B	TUBING, POLYETHYLENE
1569.	B	TUBING, POLYVINYL, CHLORIDE
1570.	B	TUBING, PRESSURE AND ACCESSORIES
1571.	B	TUBING, PUMP, CARDIOPULMONARY BYPASS
1572.	B	TUBING, REPLACEMENT, PHACOFRAGMENTATION UNIT
1573.	B	TUBING, RUBBER
1574.	B	TUBING, SILICONE
1575.	B	TUBING, VINYL
1576.	B	TUNNELER, SURGICAL (DISPOSABLE)
1577.	B	INSTRUMENT, LIGATURE PASSING AND KNOT TYING
1578.	B	ECHOCARDIOGRAPH
1579.	B	ECHOENCEPHALOGRAPH
1580.	B	STETHOSCOPE, DIRECT (ACOUSTIC)
1581.	B	WASHER/DISINFECTOR
1582.	B	STIMULATOR, BONE GROWTH, NON -INVASIVE
1583.	B	URETEROSCOPE
1584.	B	URETHROMETER
1585.	B	CYSTOURETHROSCOPE
1586.	B	CATHETER, NEPHROSTOMY
1587.	B	TRAY, CATHETERIZATION, STERILE URETHRAL, WITH OR WITHOUT CATHETER
1588.	B	URINOMETER, ELECTRICAL
1589.	B	DEVICE, CYSTOMETRIC, HYDRAULIC
1590.	B	UROFLOWMETER
1591.	B	GAUGE, PRESSURE
1592.	B	SYSTEM, ABORTION, VACUUM
1593.	B	VAGINOSCOPE AND ACCESSORIES
1594.	B	VALVE, BREATHING
1595.	B	VALVE, CATHETER FLUSH, CONTINUOUS
1596.	B	VALVE, CATHETER, FLUSH
1597.	B	VALVE, NON -REBREATHING
1598.	B	VALVE, POSITIVE END EXPIRATORY PRESSURE (PEEP)
1599.	B	VALVE, PRESSURE RELIEF, CARDIOPULMONARY BYPASS
1600.	B	VALVE, SPEAKING, TRACHEAL
1601.	B	VALVE, SWITCHING

Sl.	CLASS	Name of the Medical Devices
1602.	B	VALVE, SWITCHING (PLOSS)
1603.	B	VALVULOTOME
1604.	B	KIT, SURGICAL, VASECTOMY
1605.	B	CAMERA, TELEVISION, ENDOSCOPIC, WITHOUT AUDIO (INVASIVE)
1606.	B	SYSTEM, THERMAL REGULATING
1607.	B	VECTORCARDIOGRAPH
1608.	B	ATTACHMENT, INTERMITENT MANDATORY VENTILATION (IMV)
1609.	B	CIRCUIT, BREATHING, VENTILATOR
1610.	B	VENTILATOR, EMERGENCY, MANUAL (RESUSCITATOR)
1611.	B	DEVICE, COLIC TREATMENT
1612.	B	MASSAGER, BATTERY-POWERED
1613.	B	MASSAGER, THERAPEUTIC, ELECTRIC
1614.	B	VIBRATOR FOR THERAPEUTIC USE, GENITAL
1615.	B	VIBRATOR, THERAPEUTIC
1616.	B	TESTER, BRIGHTNESS ACUITY
1617.	B	LARYNX, ARTIFICIAL, BATTERY POWERED
1618.	B	VALVE, SPEAKING, TRACHEAL
1619.	B	SPIROMETER, MONITORING (W/WO ALARM)
1620.	B	INFUSION FLUID THERMAL WARMER
1621.	B	APPARATUS, AUTOTRANSFUSION
1622.	B	STERILIZER/WASHER, ENDOSCOPE
1623.	B	WASHER/DISINFECTOR
1624.	B	TEMPERATURE REGULATED WATER MATTRESS
1625.	B	BATH, PARAFFIN
1626.	B	EXTERNAL DEVICE FOR WEIGHT MANAGEMENT
1627.	B	ACCESSORIES TO CONTACT LENSES - CLEANING AND WETTING AGENTS
1628.	B	GUIDE, CATHETER
1629.	B	WIRE, GUIDE, ANGIOGRAPHIC AND ACCESSORIES
1630.	B	WIRE, GUIDE, CATHETER
1631.	B	WIRE, ORTHODONTIC
1632.	B	DEVICE, CRYOTHERAPY/COMPRESSION
1633.	B	SYSTEM, IMAGING, DENTAL, DIGITAL - FILMLESS
1634.	B	SYSTEM, X-RAY, TOMOGRAPHIC
1635.	B	UNIT, RADIOGRAPHIC, DIAGNOSTIC, DENTAL (X-RAY)
1636.	B	YOKE ASSEMBLY, MEDICAL GAS
1637.	C	DEVICE, ABLATION, THERMAL, ENDOMETRIAL
1638.	C	SYSTEM, GALLBLADDER THERMAL ABLATION
1639.	C	ABUTMENT, IMPLANT, DENTAL ENDOSSEOUS
1640.	C	ACCELERATOR, LINEAR, MEDICAL
1641.	C	MATERIAL, ACRYLIC, DENTAL
1642.	C	ACTUATOR, SYRINGE, INJECTOR TYPE
1643.	C	CEMENT, DENTAL
1644.	C	DENTAL ADHESIVE SYSTEM (ETCHANT, PRIMER, ADHESIVE)
1645.	C	GLUE, SURGICAL TISSUE
1646.	C	KIT, DIAGNOSTIC, PULMONARY, RADIO AEROSOL
1647.	C	ALARM, BLOOD PRESSURE
1648.	C	ALARM, BREATHING CIRCUIT
1649.	C	DETECTOR AND ALARM, ARRHYTHMIA
1650.	C	SKIN EXPANDER, INFLATABLE
1651.	C	ALLOY, AMALGAM
1652.	C	ALLOY, PRECIOUS METAL, FOR CLINICAL USE
1653.	C	ALLOY, AMALGAM

Sl.	CLASS	Name of the Medical Devices
1654.	C	SYSTEM, ECG ANALYSIS
1655.	C	ANALYZER, DATA, OBSTETRIC
1656.	C	ANALYZER, GAS, CARBON-DIOXIDE, GASEOUS PHASE
1657.	C	ANALYZER, GAS, CARBON-MONOXIDE, GASEOUS PHASE
1658.	C	ANALYZER, GAS, HALOTHANE, GASEOUS PHASE (ANESTHETIC CONC.)
1659.	C	ANALYZER, GAS, MULTIPLE, GASEOUS PHASE (ANESTHETIC CONC.)
1660.	C	ANALYZER, GAS, NITROGEN, GASEOUS PHASE
1661.	C	ANALYZER, GAS, NITROUS-OXIDE, GASEOUS PHASE (ANESTHETIC CONC.)
1662.	C	ANALYZER, GAS, OXYGEN, CONTINUOUS MONITOR
1663.	C	ANALYZER, GAS, OXYGEN, GASEOUS PHASE
1664.	C	ANALYZER, OXYHEMOGLOBIN CONCENTRATION, BLOOD PHASE, INDWELLING
1665.	C	ANASTOMOSIS DEVICE FOR GASTROENTEROLOGY-UROLOGY USE
1666.	C	ANASTOMOSIS DEVICE FOR MICROVASCULAR SURGERY
1667.	C	APPARATUS, ELECTRONANESTHESIA
1668.	C	GAS-MACHINE, ANESTHESIA
1669.	C	KIT, CONDUCTION ANESTHETIC
1670.	C	PROSTHESIS, ANKLE, SEMI-CONSTRAINED, CEMENTED, METAL/POLYMER
1671.	C	PROSTHESIS, ANKLE, TALAR COMPONENT
1672.	C	PROSTHESIS, ANKLE, TIBIAL COMPONENT
1673.	C	DEVICE, ANTICHOKE, SUCTION
1674.	C	SYSTEM, APPLICATOR, RADIONUCLIDE, REMOTE-CONTROLLED
1675.	C	OPHTHALMIC LASER
1676.	C	DEVICE, ANTICHOKE, SUCTION
1677.	C	INSTRUMENT, VITREOUS ASPIRATION AND CUTTING, AC -POWERED
1678.	C	MATERIAL, PERIODONTAL TISSUE AUGMENTATION/REGENERATION
1679.	C	BAG, POLYMERIC MESH, PACEMAKER
1680.	C	INTRAGASTRIC IMPLANT FOR MORBID OBESITY
1681.	C	BAND OR BELT, PELVIC SUPPORT
1682.	C	MATRIX, DENTAL
1683.	C	BAND, GASTRIC, IMPLANTED
1684.	C	DEVICE, OCCLUSION, TUBAL (TOD), CONTRACEPTIVE
1685.	C	EXPANSION BANDS, SCLERAL
1686.	C	BARRIER, ABSORBABLE, ADHESION
1687.	C	BARRIER, STD, ORAL SEX
1688.	C	BED, ROCKING, BREATHING ASSIST
1689.	C	RECONSTRUCTION BLOCK, PLASTIC SURGERY
1690.	C	WASHER, BOLT, NUT
1691.	C	AGENT, TOOTH BONDING, RESIN
1692.	C	BONE GRAFT, SUBSTITUTE
1693.	C	CAP, BONE
1694.	C	CEMENT, BONE
1695.	C	GRANULES, TRICALCIUM PHOSPHATE FOR DENTAL BONE REPAIR
1696.	C	IMPLANT, ENDOSSEOUS FOR BONE FILLING AND/OR AUGMENTATION
1697.	C	STIMULATOR, OSTEOGENESIS, ELECTRIC, BATTERY-OPERATED, INVASIVE
1698.	C	SYSTEM, THERMOGRAPHIC, LIQUID CRYSTAL
1699.	C	THERMOGRAPHIC DEVICE, INFRARED
1700.	C	DETECTOR, AIR OR FOAM
1701.	C	INTRAGASTRIC IMPLANT FOR MORBID OBESITY
1702.	C	INJECTABLE BULKING AGENT FOR GASTROENTEROLOGY
1703.	C	CAMERA, MULTI-IMAGE
1704.	C	CANNULA, A-V SHUNT
1705.	C	CAP, BONE

Sl.	CLASS	Name of the Medical Devices
1706.	C	CAP, LEAD, PACEMAKER
1707.	C	ANALYZER, GAS, CARBON-DIOXIDE, GASEOUS PHASE
1708.	C	CARDIAC OUTPUT UNIT, DIRECT FICK
1709.	C	CARDIAC OUTPUT UNIT, DYE DILUTION
1710.	C	CARDIAC OUTPUT UNIT, INDICATOR DILUTION (THERMAL)
1711.	C	RADIOGRAPHIC/FLUROSCOPIC UNIT, ANGIOGRAPHIC, DIGITAL
1712.	C	CARDIOTACHOMETER, FETAL, WITH SENSORS
1713.	C	MONITOR, CARDIAC (INCL. CARDIOTACHOMETER & RATE ALARM)
1714.	C	IMPLANT, CARTILAGE, FOR ARTICULAR CARTILAGE REPAIR
1715.	C	SCANNER, COMPUTED TOMOGRAPH Y, X-RAY
1716.	C	CATHETER, HEMODIALYSIS (LONG-TERM)
1717.	C	CATHETER, PERCUTANEOUS, INTRAVASCULAR, LONG TERM
1718.	C	CATHETER, PERCUTANEOUS, LONG -TERM, INTRASPINAL
1719.	C	CATHETER, PERITONEAL, LONG-TERM INDWELLING
1720.	C	PORT & CATHETER, IMPLANTED, SUBCUTANEOUS, INTRAVASCULAR
1721.	C	PORT & CATHETER, SUBCUTANEOUS, INTRASPINAL
1722.	C	PORT AND CATHETER, INFUSION, IMPLANTED, SUBCUTANEOUS,
1723.	C	SYSTEM, CATHETER CONTROL, STEERABLE
1724.	C	CEMENT, BONE
1725.	C	CEMENT, DENTAL
1726.	C	CHAMBER, DECOMPRESSION, ABDOMINAL
1727.	C	CHAMBER, HYPERBARIC
1728.	C	CHARGER, PACEMAKER
1729.	C	PROSTHESIS, CHIN, INTERNAL
1730.	C	CLAMP, TUBING, BLOOD, AUTOMATIC
1731.	C	CLIP, HEMOSTATIC
1732.	C	CLIP, IMPLANTABLE
1733.	C	CLIP, LIGATING ABSORBABLE
1734.	C	CLIP, SUTURE
1735.	C	CLIP, TANTALUM, OPHTHALMIC
1736.	C	DEVICE, OCCLUSION, TUBAL (TOD), CONTRACEPTIVE
1737.	C	ELECTROSURGICAL CUTTING & COAGULATION DEVICE & ACCESSORIES
1738.	C	COATING, FILLING MATERIAL, RESIN
1739.	C	COCHLEAR IMPLANT
1740.	C	UNIT, CRYOTHERAPY, OPHTHALMIC
1741.	C	INJECTABLE BULKING AGENT FOR GASTROENTEROLOGY
1742.	C	PASTE, INJECTABLE FOR VOCAL CORD AUGMENTATION
1743.	C	MATERIAL, TOOTH SHADE, RESIN
1744.	C	CARDIAC OUTPUT UNIT, DYE DILUTION
1745.	C	CARDIAC OUTPUT UNIT, INDICATOR DILUTION (THERMAL)
1746.	C	COMPUTER, BLOOD PRESSURE
1747.	C	COMPUTER, BRAIN MAPPING
1748.	C	COMPUTER, CARDIAC CATHETERIZATION
1749.	C	COMPUTER, ULTRASOUND
1750.	C	SYSTEM, MANAGEMENT, RADIOTHERAPY
1751.	C	GENERATOR, RADIOGRAPHIC, CAPACITOR DISCHARGE
1752.	C	SEALANT, PIT AND FISSURE, AND CONDITIONER, RESIN
1753.	C	CONDOM, NON-LATEX
1754.	C	POUCH, INTRAVAGINAL (FEMALE CONDOM)
1755.	C	CONSOLE, HEART LUNG MACHINE, CARDIOPULMONARY BYPASS
1756.	C	DEVICE, OCCLUSION, TUBAL (TOD), CONTRACEPTIVE
1757.	C	INTRAUTERINE, DEVICE, CONTRACEPTIVE (IUD) AND INTRODUCER

Sl.	CLASS	Name of the Medical Devices
1758.	C	CONVERTER, HEMODIALYSIS UNIT, SINGLE PASS
1759.	C	ANASTOMOSIS DEVICE FOR MICROVASCULAR SURGERY
1760.	C	COVER, BURR HOLE
1761.	C	PACEMAKER COVER
1762.	C	CROWN, PREFORMED
1763.	C	CRYOPHTHALMIC UNIT
1764.	C	CRYOSURGICAL UNIT & ACCESSORIES
1765.	C	UNIT, CRYOTHERAPY, OPHTHALMIC
1766.	C	CUFF, NERVE
1767.	C	VENTILATOR, EXTERNAL BODY, NEGATIVE PRESSURE, ADULT (CUIRASS)
1768.	C	CUTTER, VITREOUS INFUSION SUCTION
1769.	C	ELECTROSURGICAL CUTTING & COAGULATION DEVICE & ACCESSORIES
1770.	C	INSTRUMENT, VITREOUS ASPIRATION AND CUTTING, AC -POWERED
1771.	C	LASER, NEODYMIUM:YAG, OPHTHALMIC FOR POSTERIOR CAPSULOTOMY
1772.	C	DEVICE, CYCLODESTRUCTIVE ULTRASOUND
1773.	C	SUTURE, NONABSORBABLE, SYNTHETIC, POLYESTER
1774.	C	BARRIER, STD, ORAL SEX
1775.	C	RADIOGRAPHIC/FLUROSCOPIC UNIT, ANGIOGRAPHIC, DIGITAL
1776.	C	CHAMBER, HYPERBARIC
1777.	C	DC-DEFIBRILLATOR, HIGH ENERGY, (INCLUDING PADDLES)
1778.	C	DEFIBRILLATOR, BATTERY POWERED
1779.	C	DEFIBRILLATOR, TRANSTELEPHONIC
1780.	C	DEFIBRILLATOR/MONITOR, BATTERY POWERED
1781.	C	DEFIBRILLATOR/MONITOR, LINE POWERED
1782.	C	APPARATUS, NITRIC OXIDE DELIVERY
1783.	C	DENSITOMETER, BONE
1784.	C	DENSITOMETER, BONE, DUAL PHOTON
1785.	C	SONOMETER, BONE
1786.	C	UNIT, ELECTROSURGICAL, AND ACCESSORIES
1787.	C	INSTRUMENT, SURGICAL, POWERED, LASER
1788.	C	IMPLANT, DERMAL, OTHER, FOR AESTHETIC USE
1789.	C	DESENSITIZER, TOOTH
1790.	C	DETECTOR AND ALARM, ARRHYTHMIA
1791.	C	DETECTOR, AIR OR FOAM
1792.	C	DETECTOR, BLOOD FLOW, ULTRASONIC (DOPPLER)
1793.	C	DETECTOR, BLOOD LEAK
1794.	C	DETECTOR, BLOOD LEVEL
1795.	C	DETECTOR, FETAL HEART, ULTRASONIC (DOPPLER)
1796.	C	SEMI-AUTOMATIC PERITONEAL DIALYSATE DELIVERY SYSTEM
1797.	C	SYSTEM, DIALYSATE DELIVERY, CENTRAL MULTIPLE PATIENT
1798.	C	SYSTEM, DIALYSATE DELIVERY, SINGLE PATIENT
1799.	C	SYSTEM, DIALYSATE DELIVERY, SORBENT REGENERATED
1800.	C	SYSTEM, PERITONEAL, AUTOMATIC DELIVERY
1801.	C	STATION, DIALYSIS CONTROL, NEGATIVE PRESSURE TYPE
1802.	C	SUBSYSTEM, WATER PURIFICATION
1803.	C	SYSTEM, PERITONEAL, AUTOMATIC DELIVERY
1804.	C	DIALYZER, CAPILLARY, HOLLOW FIBER
1805.	C	DIALYZER, COMPOSITE, HEMODIALYSIS/HEMOPERFUSION
1806.	C	DIALYZER, DISPOSABLE
1807.	C	DIALYZER, HIGH PERMEABILITY WITH OR WITHOUT SEALED DIALYSATE
1808.	C	DIALYZER, PARALLEL FLOW
1809.	C	DIALYZER, SINGLE COIL

Sl.	CLASS	Name of the Medical Devices
1810.	C	DIATHERMY ULTRASONIC, FOR USE OTHER THAN APPLYING THERAPEUTIC DEEP HEAT
1811.	C	EXTERNAL MANDIBULAR FIXATOR AND/OR DISTRACTOR
1812.	C	DOPPLER ULTRASOUND FOR FETAL EVALUATION
1813.	C	DOPPLER, BLOOD FLOW, TRANSCRANIAL
1814.	C	MONITOR, ULTRASONIC, NON-FETAL
1815.	C	DOSIMETER, RADIATION
1816.	C	TUBE, TYMPANOSTOMY
1817.	C	MATERIAL, DRESSING, SURGICAL, POLYLACTIC ACID
1818.	C	DRILL, CRANIAL
1819.	C	PROSTHESIS, EAR, INTERNAL
1820.	C	PROSTHESIS, PARTIAL OSSICULAR REPLACEMENT
1821.	C	REPLACEMENT, OSSICULAR PROSTHESIS, TOTAL
1822.	C	REPLACEMENT, TYMPANIC MEMBRANE
1823.	C	PROSTHESIS, ELBOW, CONSTRAINED, CEMENTED
1824.	C	PROSTHESIS, ELBOW, HUMERAL COMPONENT
1825.	C	PROSTHESIS, ELBOW, NON -CONSTRAINED, UNIPOLAR
1826.	C	PROSTHESIS, ELBOW, RADIAL COMPONENT
1827.	C	PROSTHESIS, ELBOW, TOTAL
1828.	C	PROSTHESIS, ELBOW, ULNAR COMPONENT
1829.	C	MONITOR, HEART RATE, R-WAVE (ECG)
1830.	C	SYSTEM, ECG ANALYSIS
1831.	C	TELEMETRY UNIT, PHYSIOLOGICAL, ECG
1832.	C	CAUTERY, OPHTHALMIC
1833.	C	ELECTROCAUTERY UNIT, BATTERY POWERED
1834.	C	ELECTROCAUTERY UNIT, LINE POWERED
1835.	C	ELECTROCAUTERY, GYNECOLOGIC (AND ACCESSORIES)
1836.	C	DEVICE, ELECTROCONVULSIVE THERAPY
1837.	C	DEVICE, ELECTROCONVULSIVE THERAPY
1838.	C	EQUIPMENT, ELECTROSURGICAL, SPECIAL PURPOSE
1839.	C	UNIT, ELECTROSURGICAL, AND ACCESSORIES
1840.	C	KIT, DIAGNOSTIC, PULMONARY, RADIO AEROSOL
1841.	C	UNIT, EMERGENCY CARE, NEONATAL
1842.	C	IMPLANT, ENDOSSEOUS
1843.	C	IMPLANT, ENDOSSEOUS FOR BONE FILLING AND/OR AUGMENTATION
1844.	C	PROSTHESIS, ESOPHAGEAL
1845.	C	AGENT, TOOTH BONDING, RESIN
1846.	C	ZINC OXIDE EUGENOL
1847.	C	SKIN EXPANDER, INFLATABLE
1848.	C	IMPLANT, EYE SPHERE
1849.	C	IMPLANT, EYE VALVE
1850.	C	PROSTHESIS, EYE, INTERNAL
1851.	C	PROSTHESIS, EYELID
1852.	C	PROSTHESIS, CRANIOFACIAL
1853.	C	PROSTHESIS, FACIAL, MANDIBULAR IMPLANT
1854.	C	DEVICE, OCCLUSION, TUBAL (TOD), CONTRACEPTIVE
1855.	C	PROSTHESIS, FALLOPIAN TUBE
1856.	C	FASTENER, CRANIOPLASTY PLATE
1857.	C	FASTENER, FIXATION, BIODEGRADABLE, HARD TISSUE
1858.	C	FASTENER, FIXATION, BIODEGRADABLE, SOFT TISSUE
1859.	C	FASTENER, FIXATION, NONDEGRADABLE, SOFT TISSUE
1860.	C	PROSTHESIS, FEMORAL HEAD

Sl.	CLASS	Name of the Medical Devices
1861.	C	PROSTHESIS, FEMOROTIBIAL, CONSTRAINED (METAL -ON-POLYMER)
1862.	C	PROSTHESIS, UPPER FEMORAL
1863.	C	FILLER, BONE VOID, OSTEOINDUCTION
1864.	C	FILLER, CALCIUM SULPHATE PREFORMED PELLETS
1865.	C	COATING, FILLING MATERIAL, RESIN
1866.	C	LINER, CAVITY, CALCIUM HYDROXIDE
1867.	C	MATERIAL, DENTAL FILLING
1868.	C	RESIN, ROOT CANAL FILLING
1869.	C	PROSTHESIS, FINGER, CONSTRAINED, METAL, CEMENTED
1870.	C	PROSTHESIS, FINGER, CONSTRAINED, POLYMER
1871.	C	PROSTHESIS, FINGER, TOTAL
1872.	C	CERCLAGE FIXATION
1873.	C	DEVICE, FIXATION, PROXIMAL FEMORAL, IMPLANT
1874.	C	FIXATION DEVICE, JAW FRACTURE
1875.	C	FIXATION DEVICE, SPINAL, EXTERNAL
1876.	C	IMPLANT, FIXATION DEVICE, CONDYLAR PLATE
1877.	C	IMPLANT, FIXATION DEVICE, SPINAL
1878.	C	NAIL, FIXATION, BONE
1879.	C	EXTERNAL MANDIBULAR FIXATOR AND/OR DISTRATOR
1880.	C	FLOWMETER, BLOOD, LASER
1881.	C	FLOWMETER, BLOOD, NON-INVASIVE ELECTROMAGNETIC OR DOPPLER
1882.	C	FLOWMETER, BLOOD, ULTRASONIC
1883.	C	FLUID, INTRAOCULAR
1884.	C	FLUID, JOINT LUBRICATING
1885.	C	RADIOGRAPHIC/FLUOROSCOPIC UNIT FIXED
1886.	C	RADIOGRAPHIC/FLUOROSCOPIC UNIT, MOBILE C -ARM
1887.	C	RADIOGRAPHIC/FLUROSCOPIC UNIT, ANGIOGRAPHIC, DIGITAL
1888.	C	SYSTEM, X-RAY, ANGIOGRAPHIC
1889.	C	ABSORBABLE HEMOSTATIC AGENTS NON-COLLAGEN BASED
1890.	C	PROSTHESIS, FOOT ARCH
1891.	C	CRYOSURGICAL UNIT & ACCESSORIES
1892.	C	GAUGE, PRESSURE, CORONARY, CARDIOPULMONARY BYPASS
1893.	C	ABSORBABLE HEMOSTATIC AGENTS NON-COLLAGEN BASED
1894.	C	GENERATOR, ELECTROSURGICAL, COAGULATION, CANCER
1895.	C	GENERATOR, HIGH VOLTAGE X-RAY THERAPEUTIC
1896.	C	GENERATOR, HIGH-VOLTAGE, X-RAY, DIAGNOSTIC
1897.	C	GENERATOR, LESION, RADIOFREQUENCY
1898.	C	GENERATOR, LOW VOLTAGE, THERAPEUTIC X-RAY
1899.	C	GENERATOR, ORTHOVOLTAGE, THERAPEUTIC X-RAY
1900.	C	GENERATOR, PULSALITE FLOW, CARDIOPULMONARY BYPASS
1901.	C	GENERATOR, RADIOGRAPHIC, CAPACITOR DISCHARGE
1902.	C	MONITOR, BLOOD GLUCOSE (TEST)
1903.	C	GLUE, SURGICAL TISSUE
1904.	C	BONE GRAFT, SUBSTITUTE
1905.	C	GRAFT, VASCULAR ACCESS
1906.	C	GRANULES, TRICALCIUM PHOSPHATE FOR DENTAL BONE REPAIR
1907.	C	STIMULATOR, OSTEOGENESIS, ELECTRIC, BATTERY-OPERATED, INVASIVE
1908.	C	MATERIAL, PERIODONTAL TISSUE AUGMENTATION/REGENERATION
1909.	C	GUTTA PERCHA
1910.	C	INSTRUMENT, SURGICAL, POWERED , LASER
1911.	C	TERMINAL HEADER OR PLUG FOR PULSE GENERAT OR
1912.	C	HEARING AID, IMPLANTED BONE CONDUCTION

Sl.	CLASS	Name of the Medical Devices
1913.	C	WARMER, INFANT RADIANT
1914.	C	APPARATUS, HEMOPERFUSION, SORBENT
1915.	C	GRAFT, VASCULAR ACCESS
1916.	C	HEMOFILTRATION UNIT
1917.	C	MONITOR, TEMPERATURE, DIALYSIS
1918.	C	SUBSYSTEM, PROPORTIONING
1919.	C	UNIT, HEMODIALYSIS (KIDNEY MACHINE)
1920.	C	HEMOFILTRATION UNIT
1921.	C	APPARATUS, HEMOPERFUSION, SORBENT
1922.	C	ABSORBABLE HEMOSTATIC AGENTS NON-COLLAGEN BASED
1923.	C	MESH, SURGICAL, POLYMERIC
1924.	C	PROSTHESIS, HIP CUP INSERT
1925.	C	PROSTHESIS, HIP, ACETABULAR COMPONENT, METAL, NON -CEMENTED
1926.	C	PROSTHESIS, HIP, ACETABULAR COMPONENT, POLYETHYLENE
1927.	C	PROSTHESIS, HIP, ACETABULAR MESH
1928.	C	PROSTHESIS, HIP, CEMENT RESTRICTOR
1929.	C	PROSTHESIS, HIP, CONSTRAINED, CEMENTED OR UNCEMENTED, METAL/ POLYMER
1930.	C	PROSTHESIS, HIP, FEMORAL COMPONENT, CEMENTED, METAL
1931.	C	PROSTHESIS, HIP, HEMI-, ACETABULAR, CEMENTED, METAL
1932.	C	PROSTHESIS, HIP, HEMI-, FEMORAL, METAL, NON-CEMENTED
1933.	C	PROSTHESIS, HIP, HEMI-, FEMORAL, METAL/POLYMER, CEMENTED OR UNCEMENTED
1934.	C	PROSTHESIS, HIP, METAL STEM/CERAMIC SELF-LOCKING BALL
1935.	C	PROSTHESIS, HIP, SEMI-CONSTRAINED (METAL CEMENTED ACETABULAR COMPONENT)
1936.	C	PROSTHESIS, HIP, SEMI-CONSTRAINED METAL/CERAMIC/POLYMER
1937.	C	PROSTHESIS, HIP, SEMI-CONSTRAINED OR HEMI-, METAL/PTFE
1938.	C	PROSTHESIS, HIP, SEMI-CONSTRAINED, METAL/CERAMIC/CERAMIC
1939.	C	PROSTHESIS, HIP, SEMI-CONSTRAINED, METAL/CERAMIC/CERAMIC, CEMENTED
1940.	C	PROSTHESIS, HIP, SEMI-CONSTRAINED, METAL/POLYMER, CEMENTED
1941.	C	PROSTHESIS, HIP, SEMI-CONSTRAINED, METAL/POLYMER, NON-POROUS, CALCIUM-
1942.	C	PHOSPHATE
1943.	C	PROSTHESIS, HIP, SEMI-CONSTRAINED, METAL/POLYMER, POROUS UNCEMENTED
1944.	C	PROSTHESIS, HIP, SEMI-CONSTRAINED, METAL/POLYMER, UNCEMENTED
1945.	C	PROSTHESIS, HIP, SEMI-CONSTRAINED, POROUS COATED
1946.	C	PROSTHESIS, HIP, SEMI-CONSTRAINED, UNCEMENTED, POROUS, METAL/POLYMER
1947.	C	FLUID, INTRAOCULAR
1948.	C	SYSTEM, HYPERTHERMIA, RF/MICROWAVE (BENIGN PROSTATIC HYPERPLASIA)
1949.	C	RADIOGRAPHIC/FLUROSCOPIC UNIT, ANGIOGRAPHIC, DIGITAL
1950.	C	SYSTEM IMAGING, PULSED DOPPLER, ULTRASONIC
1951.	C	SYSTEM, IMAGING, PULSED ECHO, ULTRASONIC
1952.	C	SYSTEM, IMAGING, ULTRASONIC, OPHTHALMIC
1953.	C	SYSTEM, IMAGING, X-RAY, ELECTROSTATIC
1954.	C	CARBON-FIBER IMPLANT FOR ARTHROPLASTY
1955.	C	COCHLEAR IMPLANT
1956.	C	FASTENER, FIXATION, BIODEGRADABLE, SOFT TISSUE
1957.	C	IMPLANT (FOR FEMALE INCONTINENCE)
1958.	C	IMPLANT, ABSORBABLE (SCLERAL BUCKLING METHOD)

Sl.	CLASS	Name of the Medical Devices
1959.	C	IMPLANT, CARTILAGE, FOR ARTICULAR CARTILAGE REPAIR
1960.	C	IMPLANT, DERMAL, OTHER, FOR AESTHETIC USE
1961.	C	IMPLANT, ENDOSSEOUS
1962.	C	IMPLANT, ENDOSSEOUS FOR BONE FILLING AND/OR AUGMENTATION
1963.	C	IMPLANT, EYE SPHERE
1964.	C	IMPLANT, EYE VALVE
1965.	C	IMPLANT, MUSCLE, PECTORALIS
1966.	C	IMPLANT, ORBITAL, EXTRA-OCULAR
1967.	C	IMPLANT, REFLUX, ANTI-GASTROESOPHAGEAL
1968.	C	IMPLANT, RETINAL
1969.	C	IMPLANT, SUBPERIOSTEAL
1970.	C	IMPLANTED SUBCUTANEOUS PERITONEAL ACCESS DEVICE
1971.	C	INJECTABLE BULKING AGENT FOR GASTROENTEROLOGY
1972.	C	INTRAGASTRIC IMPLANT FOR MORBID OBESITY
1973.	C	JOINT, TEMPOROMANDIBULAR, IMPLANT
1974.	C	MALAR IMPLANT
1975.	C	MESH, SURGICAL, POLYMERIC
1976.	C	POLYMER, ENT COMPOSITE SYNTHETIC PTFE WITH CARBON -FIBRE ENT
1977.	C	POLYMER, ENT SYNTHETIC-PIFE, SILICONE ELASTOMER, POLYETHYLENE, POLYURETHANE
1978.	C	POLYMER, ENT, SYNTHETIC, POROUS POLYETHYLENE
1979.	C	PORT & CATHETER, SUBCUTANEOUS, INTRASPINAL
1980.	C	REPLACEMENT, TYMPANIC MEMBRANE
1981.	C	DEVICE, IMPOTENCE, MECHANICAL/HYDRAULIC
1982.	C	DEVICE, FECAL INCONTINENCE, IMPLANTED
1983.	C	DEVICE, INCONTINENCE, MECHANICAL/HYDRAULIC
1984.	C	IMPLANT (FOR FEMALE INCONTINENCE)
1985.	C	INJECTABLE BULKING AGENT FOR GASTROENTEROLOGY
1986.	C	INCUBATOR, NEONATAL
1987.	C	INCUBATOR, NEONATAL, TRANSPORT
1988.	C	INFUSION SYSTEM, IMPLANTABLE, DRUG ADMINISTRATION
1989.	C	SYSTEM, RADIONUCLIDE INFUSION
1990.	C	INHIBITOR, POSTOPERATIVE FIBROSIS, TENOLYSIS
1991.	C	IMPLANT, DERMAL, OTHER, FOR AESTHETIC USE
1992.	C	INJECTOR, CONTRAST MEDIUM, AUTOMATIC
1993.	C	INJECTOR, THERMAL DILUTION
1994.	C	INTRAGASTRIC IMPLANT FOR MORBID OBESITY
1995.	C	SYSTEM, RADIONUCLIDE INFUSION
1996.	C	INTRAUTERINE, DEVICE, CONTRACEPTIVE (IUD) AND INTRODUCER
1997.	C	SOURCE, WIRE, IRIIDIUM, RADIOACTIVE
1998.	C	IRRADIATOR, BLOOD, EXTRACORPOREAL
1999.	C	INSTRUMENT, VITREOUS ASPIRATION AND CUTTING, AC -POWERED
2000.	C	SOURCE, ISOTOPE, SEALED, GOLD, TITANIUM, PLATINUM
2001.	C	KERATOPROSTHESIS, NON-CUSTOM
2002.	C	PROSTHESIS, KNEE PATELLOFEMOROTIBIAL CONSTRAINED, CEMENTED, POLYMER/METAL
2003.	C	PROSTHESIS, KNEE, FEMOROTIBIAL, CONSTRAINED, CEMENTED, METAL
2004.	C	PROSTHESIS, KNEE, FEMOROTIBIAL, NON-CONSTRAINED, CEMENTED, METAL/POLYMER
2005.	C	PROSTHESIS, KNEE, FEMOROTIBIAL, SEMI-CONSTRAINED, CEMENTED, METAL/POLYMER
2006.	C	PROSTHESIS, KNEE, HEMI-, FEMORAL

Sl.	CLASS	Name of the Medical Devices
2007.	C	PROSTHESIS, KNEE, HEMI-, PATELLAR RESURFACING, UNCEMENTED
2008.	C	PROSTHESIS, KNEE, HEMI-, TIBIAL RESURFACING, U NCEMENTED
2009.	C	PROSTHESIS, KNEE, HINGED (METAL -METAL)
2010.	C	PROSTHESIS, KNEE, PATELLAR
2011.	C	PROSTHESIS, KNEE, PATELLOFEMORAL, SEMI-CONSTRAINED, CEMENTED, METAL/POLYMER
2012.	C	PROSTHESIS, KNEE, PATELLOFEMOROTIBIAL, SEMI-CONSTRAINED, CEMENTED , POLYMER
2013.	C	PROSTHESIS, KNEE, TIBIAL
2014.	C	PROSTHESIS, KNEE, TOTAL
2015.	C	PROSTHESIS, KNEE, UNICOMPARTMENTAL, CEMENTED
2016.	C	OPHTHALMIC LASER
2017.	C	PROSTHESIS, LACRIMAL DUCT
2018.	C	PROSTHESIS, LARYNX
2019.	C	INSTRUMENT, SURGICAL, POWERED, LASER
2020.	C	LASER, COPPER VAPOR
2021.	C	LASER, DENTAL
2022.	C	LASER, LITHOTRIPTOR
2023.	C	LASER, NEODYMIUM:YAG, OPHTHALMIC FOR POSTERIOR CAPSULOTOMY
2024.	C	LASER, OPHTHALIMC, PHOTOCOAGULATOR
2025.	C	LASER, PHOTODYNAMIC THERAPY (PDT)
2026.	C	LASER, Q-SWITCHED
2027.	C	LASER, SURGICAL, CARBON -DIOXIDE
2028.	C	LASER, SURGICAL, DYE
2029.	C	LASER, SURGICAL, GYNECOLOGIC
2030.	C	LASER, SURGICAL, HOLMIUM
2031.	C	LASER, SURGICAL, NEODYMIUM, YAG
2032.	C	LASER, SYSTEM, EXCIMER
2033.	C	LASER, THERAPEUTIC
2034.	C	OPHTHALMIC LASER
2035.	C	SYSTEM, LASER, PHOTODYNAMIC THERAPY
2036.	C	LEAD, ANCHORING SLEEVE, IMPLANTABLE
2037.	C	LENS, INTRAOCULAR
2038.	C	LENS, MULTIFOCAL INTRAOCULAR
2039.	C	PROSTHESIS, LIGAMENT
2040.	C	LOCK, WIRE, AND LIGATURE, INTRAORAL
2041.	C	LIGHT, BILIRUBIN (PHOTOTHERAPY)
2042.	C	ACCELERATOR, LINEAR, MEDICAL
2043.	C	LINER, CAVITY, CALCIUM HYDROXIDE
2044.	C	LIN ER, CAVITY, OTHER
2045.	C	PROSTHESIS, HIP CUP INSERT
2046.	C	DEVICE, LIPECTOMY, SUCTION
2047.	C	LITHOTRIPTOR
2048.	C	LITHOTRIPTOR, ELECTRO-HYDRAULIC
2049.	C	LITHOTRIPTOR, EXTRAC ORPOREAL, SHOCKWAVE
2050.	C	LITHOTRIPTOR, ULTRASONIC
2051.	C	LOCK, WIRE, AND LIGATURE, INTRAORAL
2052.	C	FLUID, JOINT LUBRICATING
2053.	C	KIT, DIAGNOSTIC, PULMONARY, RADIO AEROSOL
2054.	C	MEMBRANE, LUNG (FOR LONG-TERM RESPIRATORY SUPPORT)
2055.	C	VENTILATOR, EXTERNAL BODY, NEGATIVE PRESSURE, ADULT (CUIRASS)
2056.	C	MALAR IMPLANT

Sl.	CLASS	Name of the Medical Devices
2057.	C	SYSTEM, X-RAY, MAMMOGRAPHIC
2058.	C	SYSTEM, MANAGEMENT, RADIOTHERAPY
2059.	C	MARKER, RADIOGRAPHIC, IMPLANTABLE
2060.	C	MEMBRANE, LUNG (FOR LONG-TERM RESPIRATORY SUPPORT)
2061.	C	FASTENER, FIXATION, NONDEGRADABLE, SOFT TISSUE
2062.	C	MESH, METAL
2063.	C	MESH, SURGICAL
2064.	C	MESH, SURGICAL, POLYMERIC
2065.	C	METAL, BASE
2066.	C	METER, CONDUCTIVITY, NON-REMOTE
2067.	C	METHYL METACRYLATE FOR CRANIOPLASTY
2068.	C	SYSTEM, HYPERTHERMIA, RF/MICROWAVE (BENIGN PROSTATIC HYPERPLASIA)
2069.	C	SYSTEM, THERMOTHERAPY, RF/MICROWAVE (BENIGN PROSTATIC HYPERPLASIA)
2070.	C	SYSTEM, PATIENT MONITORING - MULTI-FUNCTION COMPONENTS
2071.	C	MOLD, MIDDLE EAR
2072.	C	BLOOD PRESSURE/OXYGEN SATURATION IN THE BLOOD MONITOR
2073.	C	BLOOD PRESSURE/TEMPERATURE MONITOR
2074.	C	DEFIBRILLATOR/MONITOR, BATTERY POWERED
2075.	C	DEFIBRILLATOR/MONITOR, LINE POWERED
2076.	C	MONITOR AND/OR CONTROL, LEVEL SENSING, CARDIOPULMONARY
2077.	C	MONITOR, AIRWAY PRESSURE (INCLUDES GAUGE AND/OR ALARM)
2078.	C	MONITOR, BLOOD FLOW, ULTRASONIC
2079.	C	MONITOR, BLOOD GAS, ON-LINE, CARDIOPULMONARY BYPASS
2080.	C	MONITOR, BLOOD GAS, TRANSCUTANEOUS OXYGEN
2081.	C	MONITOR, BLOOD GLUCOSE (TEST)
2082.	C	MONITOR, BLOOD PRESSURE, INDWELLING
2083.	C	MONITOR, BLOOD PRESSURE, TRANSDUCER, INDWELLING
2084.	C	MONITOR, BLOOD-PRESSURE, NEONATAL, ULTRASONIC/DOPPLER
2085.	C	MONITOR, CARDIAC (INCL. CARDIOTACHOMETER & RATE ALARM)
2086.	C	MONITOR, CARDIAC OUTPUT, THERMAL (BALLOON TYPE CATHETER)
2087.	C	MONITOR, CARDIAC OUTPUT, TREND (ARTERIAL PRESSURE PULSE)
2088.	C	MONITOR, CEREBRAL FUNCTION
2089.	C	MONITOR, ELECTROCARDIOGRAPH
2090.	C	MONITOR, ELECTROENCEPHALOGRAPHIC, FETAL (AND ACCESSORIES)
2091.	C	MONITOR, ELECTROENCEPHALOGRAPHIC, GENERAL & PLASTIC SURGERY
2092.	C	MONITOR, HEART RATE, FETAL, ULTRASONIC
2093.	C	MONITOR, HEART RATE, NEONATAL
2094.	C	MONITOR, HEART RATE, R-WAVE (ECG)
2095.	C	MONITOR, HEMODYNAMIC
2096.	C	MONITOR, HEMOFILTRATION
2097.	C	MONITOR, LESION TEMPERATURE
2098.	C	MONITOR, LUNG WATER MEASUREMENT
2099.	C	MONITOR, NEONATAL, PHYSIOLOGICAL
2100.	C	MONITOR, OXYGEN (VENTILATORY) W/WO ALARM
2101.	C	MONITOR, OXYGEN, BRAIN
2102.	C	MONITOR, PHYSIOLOGICAL, PATIENT
2103.	C	MONITOR, POB, CONTINUOUS
2104.	C	MONITOR, PRESSURE, HEMODIALYSIS, EXTRACORPOREAL
2105.	C	MONITOR, PULSE RATE
2106.	C	MONITOR, RESPIRATORY
2107.	C	MONITOR, SPINAL-FLUID PRESSURE

Sl.	CLASS	Name of the Medical Devices
2108.	C	MONITOR, TEMPERATURE (WITH PROBE)
2109.	C	MONITOR, TEMPERATURE, DIALYSIS
2110.	C	MONITOR, ULTRAFILTRATION
2111.	C	MONITOR, ULTRASONIC, FETAL
2112.	C	MONITOR, ULTRASONIC, NON-FETAL
2113.	C	MONITOR, UTERINE CONTRACTION, EXTERNAL
2114.	C	MONITOR, VENTILATION
2115.	C	PATIENT MONITORING SYSTEM, MAINFRAME
2116.	C	SYSTEM, PATIENT MONITORING - CENTRAL STATION
2117.	C	SYSTEM, PATIENT MONITORING - MULTI-FUNCTION COMPONENTS
2118.	C	IMPLANT, MUSCLE, PECTORALIS
2119.	C	PROSTHESIS, RHINOPLASTY/NASAL DORSAL IMPLANT
2120.	C	NEEDLE, ISOTOPE, GOLD, TITANIUM, PLATINUM
2121.	C	SUTURE/NEEDLE COMBINATION
2122.	C	APPARATUS, NITRIC OXIDE DELIVERY
2123.	C	PROSTHESIS, NOSE, INTERNAL
2124.	C	WASHER, BOLT, NUT
2125.	C	DEVICE, OCCLUSION, TUBAL (TOD), CONTRACEPTIVE
2126.	C	LASER, THERAPEUTIC
2127.	C	IMPLANT, ORBITAL, EXTRA-OCULAR
2128.	C	PLATE, BONE
2129.	C	ORTHOSIS, SPINAL PEDICLE FIXATION
2130.	C	PROSTHESIS, PARTIAL OSSICULAR REPLACEMENT
2131.	C	REPLACEMENT, OCCICULAR, POROUS POLYETHYLENE
2132.	C	REPLACEMENT, OSSICULAR PROSTHESIS, TOTAL
2133.	C	BLOOD PRESSURE/OXYGEN SATURATION IN THE BLOOD MONITOR
2134.	C	OXIMETER, EAR
2135.	C	OXIMETER, FINGER
2136.	C	OXIMETER, PULSE
2137.	C	OXYGENATOR, CARDIOPULMONARY BYPASS
2138.	C	CAP, LEAD, PACEMAKER
2139.	C	LEAD, ANCHORING SLEEVE, IMPLANTABLE
2140.	C	PACEMAKER, CARDIAC, EXTERNAL TRANSCUTANEOUS (NON-INVASIVE)
2141.	C	PASTE, INJECTABLE FOR VOCAL CORD AUGMENTATION
2142.	C	MESH, SURGICAL, POLYMERIC
2143.	C	PROSTHESIS, PENILE
2144.	C	PROSTHESIS, PENIS, INFLATABLE
2145.	C	PROSTHESIS, PENIS, RIGID ROD
2146.	C	PUMP, INFUSION
2147.	C	SYSTEM, DIALYSATE DELIVERY, SINGLE PATIENT
2148.	C	SYSTEM, PERITONEAL, AUTOMATIC DELIVERY
2149.	C	INJECTABLE BULKING AGENT FOR GASTROENTEROLOGY
2150.	C	SYSTEM, PHACOEMULSIFICATION & ACCESSORIES
2151.	C	UNIT, PHACOFRAGMENTATION AND ACCESSORIES
2152.	C	SYSTEM, LASER, PHOTODYNAMIC THERAPY
2153.	C	PHOTOCOAGULATOR AND ACCESSORIES
2154.	C	EXTRACORPOREAL PHOTOPHERSIS SYSTEM
2155.	C	PHOTOTHERAPY UNIT, NEONATAL
2156.	C	PIN, FIXATION, SMOOTH
2157.	C	PIN, FIXATION, THREADED
2158.	C	PIN, RETENTIVE AND SPLINTING, AND ACCESSORY INSTRUMENTS
2159.	C	STEREOTAXIC PLANNING SOFTWARE

Sl.	CLASS	Name of the Medical Devices
2160.	C	SYSTEM, PLANNING, RADIATION THERAPY TREATMENT
2161.	C	COMPRESSION PLATE AND INSTRUMENT SET
2162.	C	PLATE, BONE
2163.	C	PLATE, BONE, SKULL (CRANIOPLASTY)
2164.	C	PLATE, FIXATION, BONE
2165.	C	SET, BONE PLATE & SCREW
2166.	C	PLUG, PUNCTUM
2167.	C	TERMINAL HEADER OR PLUG FOR PULSE GENERATOR
2168.	C	POINT, SILVER, ENDODONTIC
2169.	C	POLYMER, ENT COMPOSITE SYNTHETIC PTFE WITH CARBON -FIBRE
2170.	C	POLYMER, ENT SYNTHETIC-PIFE, SILICONE ELASTOMER,
2171.	C	POLYMER, ENT, SYNTHETIC, POROUS POLYETHYLENE
2172.	C	PORT & CATHETER, IMPLANTED, SUBCUTANEOUS, INTRAVASCULAR
2173.	C	PORT & CATHETER, SUBCUTANEOUS, INTRASPINAL
2174.	C	PORT AND CATHETER, INFUSION, IMPLANTED, SUBCUTANEOUS
2175.	C	PORT, GASTROSTOMY FEED
2176.	C	POST, ROOT CANAL
2177.	C	POUCH, INTRAVAGINAL (FEMALE CONDOM)
2178.	C	POWDER, PORCELAIN
2179.	C	PRIMER, CAVITY, RESIN
2180.	C	VARNISH, CAVITY
2181.	C	PROBE, BLOOD FLOW, EXTRAVASCULAR
2182.	C	PROBE, ULTRASONIC
2183.	C	SUBSYSTEM, PROPORTIONING
2184.	C	PROSTHESIS, ANKLE, SEMI-CONSTRAINED, CEMENTED, METAL/POLYMER
2185.	C	PROSTHESIS, ANKLE, TALAR COMPONENT
2186.	C	PROSTHESIS, ANKLE, TIBIAL COMPONENT
2187.	C	PROSTHESIS, CARPAL
2188.	C	PROSTHESIS, CHIN, INTERNAL
2189.	C	PROSTHESIS, CRANIOFACIAL
2190.	C	PROSTHESIS, EAR, INTERNAL
2191.	C	PROSTHESIS, ELBOW, CONSTRAINED, CEMENTED
2192.	C	PROSTHESIS, ELBOW, HUMERAL COMPONENT
2193.	C	PROSTHESIS, ELBOW, NON -CONSTRAINED, UNIPOL AR
2194.	C	PROSTHESIS, ELBOW, RADIAL COMPONENT
2195.	C	PROSTHESIS, ELBOW, TOTAL
2196.	C	PROSTHESIS, ELBOW, ULNAR COMPONENT
2197.	C	PROSTHESIS, ESOPHAGEAL
2198.	C	PROSTHESIS, EYE, INTERNAL
2199.	C	PROSTHESIS, EYELID
2200.	C	PROSTHESIS, FACIAL, MANDIBULAR IMPLANT
2201.	C	PROSTHESIS, FALLOPIAN TUBE
2202.	C	PROSTHESIS, FEMORAL HEAD
2203.	C	PROSTHESIS, FEMOROTIBIAL, CONSTRAINED (METAL -ON-POLYMER)
2204.	C	PROSTHESIS, FINGER, CONSTRAINED, METAL, CEMENTED
2205.	C	PROSTHESIS, FINGER, CONSTRAINED, POLYMER
2206.	C	PROSTHESIS, FINGER, TOTAL
2207.	C	PROSTHESIS, FOOT ARCH
2208.	C	PROSTHESIS, HIP CUP INSERT
2209.	C	PROSTHESIS, HIP, ACETABULAR COMPONENT, METAL, NON -CEMENTED
2210.	C	PROSTHESIS, HIP, ACETABULAR COMPONENT, POLYETHYLENE
2211.	C	PROSTHESIS, HIP, ACETABULAR MESH

Sl.	CLASS	Name of the Medical Devices
2212.	C	PROSTHESIS, HIP, CEMENT RESTRICTOR
2213.	C	PROSTHESIS, HIP, CONSTRAINED, CEMENTED OR UNCEMENTED, METAL/ POLYMER
2214.	C	PROSTHESIS, HIP, FEMORAL COMPONENT, CEMENTED, METAL
2215.	C	PROSTHESIS, HIP, HEMI-, ACETABULAR, CEMENTED, METAL
2216.	C	PROSTHESIS, HIP, HEMI-, FEMORAL, METAL, NON-CEMENTED
2217.	C	PROSTHESIS, HIP, HEMI-, FEMORAL, METAL/POLYMER, CEMENTED OR UNCEMENTED
2218.	C	PROSTHESIS, HIP, METAL STEM/CERAMIC SELF-LOCKING BALL
2219.	C	PROSTHESIS, HIP, SEMI-CONSTRAINED (METAL CEMENTED ACETABULAR COMPONENT)
2220.	C	PROSTHESIS, HIP, SEMI-CONSTRAINED METAL/CERAMIC/POLYMER
2221.	C	PROSTHESIS, HIP, SEMI-CONSTRAINED OR HEMI-, METAL/PTFE
2222.	C	PROSTHESIS, HIP, SEMI-CONSTRAINED, METAL/CERAMIC/CERAMIC
2223.	C	PROSTHESIS, HIP, SEMI-CONSTRAINED, METAL/CERAMIC/CERAMIC, CEMENTED
2224.	C	PROSTHESIS, HIP, SEMI-CONSTRAINED, METAL/POLYMER, CEMENTED
2225.	C	PROSTHESIS, HIP, SEMI-CONSTRAINED, METAL/POLYMER, NON-POROUS, CALCIUM-
2226.	C	PHOSPHATE
2227.	C	PROSTHESIS, HIP, SEMI-CONSTRAINED, METAL/POLYMER, POROUS UNCEMENTED
2228.	C	PROSTHESIS, HIP, SEMI-CONSTRAINED, METAL/POLYMER, UNCEMENTED
2229.	C	PROSTHESIS, HIP, SEMI-CONSTRAINED, POROUS COATED
2230.	C	PROSTHESIS, HIP, SEMI-CONSTRAINED, UNCEMENTED, POROUS, METAL/POLYMER
2231.	C	PROSTHESIS, JOINT, OTHER
2232.	C	PROSTHESIS, KNEE PATELLOFEMOROTIBIAL CONSTRAINED, CEMENTED, POLYMER/METAL
2233.	C	PROSTHESIS, KNEE, FEMOROTIBIAL, CONSTRAINED, CEMENTED, METAL
2234.	C	PROSTHESIS, KNEE, FEMOROTIBIAL, NON-CONSTRAINED, CEMENTED, METAL/POLYMER
2235.	C	PROSTHESIS, KNEE, FEMOROTIBIAL, SEMI-CONSTRAINED, CEMENTED, METAL/POLYMER
2236.	C	PROSTHESIS, KNEE, HEMI-, FEMORAL
2237.	C	PROSTHESIS, KNEE, HEMI-, PATELLAR RESURFACING, UNCEMENTED
2238.	C	PROSTHESIS, KNEE, HEMI-, TIBIAL RESURFACING, UNCEMENTED
2239.	C	PROSTHESIS, KNEE, HINGED (METAL -METAL)
2240.	C	PROSTHESIS, KNEE, PATELLAR
2241.	C	PROSTHESIS, KNEE, PATELLOFEMORAL, SEMI-CONSTRAINED, CEMENTED, METAL/POLYMER
2242.	C	PROSTHESIS, KNEE, PATELLOFEMOROTIBIAL, SEMI-CONSTRAINED, CEMENTED, POLYMER
2243.	C	PROSTHESIS, KNEE, TIBIAL
2244.	C	PROSTHESIS, KNEE, TOTAL
2245.	C	PROSTHESIS, KNEE, UNICOMPARTMENTAL, CEMENTED
2246.	C	PROSTHESIS, LACRIMAL DUCT
2247.	C	PROSTHESIS, LARYNX
2248.	C	PROSTHESIS, LIGAMENT
2249.	C	PROSTHESIS, NOSE, INTERNAL
2250.	C	PROSTHESIS, PARTIAL OSSICULAR REPLACEMENT
2251.	C	PROSTHESIS, PENILE
2252.	C	PROSTHESIS, PENIS, INFLATABLE
2253.	C	PROSTHESIS, PENIS, RIGID ROD

Sl.	CLASS	Name of the Medical Devices
2254.	C	PROSTHESIS, RHINOPLASTY/NASAL DORSAL IMPLANT
2255.	C	PROSTHESIS, SHOULDER
2256.	C	PROSTHESIS, SHOULDER, HEMI-, GLENOID, METALLIC CEMENTED
2257.	C	PROSTHESIS, SHOULDER, HEMI-, HUMERAL, METALLIC UNCEMENTED
2258.	C	PROSTHESIS, SHOULDER, HUMERAL (BIPOLAR HEMI-SHOULDER) METAL/POLYMER
2259.	C	PROSTHESIS, TENDON
2260.	C	PROSTHESIS, TENDON, PASSIVE
2261.	C	PROSTHESIS, TESTICULAR
2262.	C	PROSTHESIS, TOE
2263.	C	PROSTHESIS, TRACHEAL
2264.	C	PROSTHESIS, UPPER FEMORAL
2265.	C	PROSTHESIS, URETHRAL SPHINCTER
2266.	C	PROSTHESIS, WRIST, B PART METAL -PLASTIC ARTICULATION, SEMI - CONSTRAINED
2267.	C	PROSTHESIS, WRIST, C PART METAL -PLASTIC -METAL ARTICULATION, SEMI- CONSTRAINED
2268.	C	PROSTHESIS, WRIST, CARPAL SCAPHOID
2269.	C	PROSTHESIS, WRIST, CARPAL TRAPEZIUM
2270.	C	PROSTHESIS, WRIST, CARPAL, LUNATE
2271.	C	PROSTHESIS, WRIST, HEMI-, ULNAR
2272.	C	INJECTABLE BULKING AGENT FOR GASTROENTEROLOGY
2273.	C	PASTE, INJECTABLE FOR VOCAL CORD AUGMENTATION
2274.	C	KIT, DIAGNOSTIC, PULMONARY, RADIO AEROSOL
2275.	C	PUMP, BLOOD, CARDIOPULMONARY BYPASS, NON-ROLLER TYPE
2276.	C	PUMP, INFUSION
2277.	C	PUMP, INFUSION, AMBULATORY
2278.	C	PUMP, INFUSION, IMPLANTED
2279.	C	PUMP, INFUSION, INSULIN
2280.	C	PUMP, INFUSION, PATIENT CONTROLLED ANALGESIA
2281.	C	PUMP, WITHDRAWAL/INFUSION
2282.	C	SUBSYSTEM, WATER PURIFICATION
2283.	C	SYSTEM, PLANNING, RADIATION THERAPY TREATMENT
2284.	C	SYSTEM, SIMULATION, RADIATION THERAPY
2285.	C	UNIT, BETA, RADIATION, OPHTHALMIC
2286.	C	SOURCE, BRACHYTHERAPY, RADIONUCLIDE
2287.	C	SOURCE, TELETHERAPY, RADIONUCLIDE
2288.	C	SYSTEM, RADIATION THERAPY, RADIONUCLIDE
2289.	C	MATERIAL, PERIODONTAL TISSUE AUGMENTATION/REGENERATION
2290.	C	MESH, SURGICAL, POLYMERIC
2291.	C	MATERIAL, TOOTH SHADE, RESIN
2292.	C	RESIN, ROOT CANAL FILLING
2293.	C	VARNISH, CAVITY
2294.	C	RESINOUS COMPOUND
2295.	C	AGENT, TOOTH BONDING, RESIN
2296.	C	DENTAL RESTORATIVE SYSTEM (ETCHANT, PRIMER, ADHESIVE)
2297.	C	MATERIAL, TOOTH SHADE, RESIN
2298.	C	VENTILATOR, EMERGENCY, POWERED (RESUSCITATOR)
2299.	C	IMPLANT, RETINAL
2300.	C	DEVICE, OCCLUSION, TUBAL (TOD), CONTRACEPTIVE
2301.	C	RING/SHELL, PROTRUSIO
2302.	C	RING, CAPSULAR TENSION, IRIS DIAPHRAGM

Sl.	CLASS	Name of the Medical Devices
2303.	C	ROD, FIXATION, INTRAMEDULLARY AND ACCESSORIES
2304.	C	SCANNER, COMPUTED TOMOGRAPHY, X-RAY
2305.	C	SCANNER, ULTRASONIC, GENERAL PURPOSE
2306.	C	SYSTEM, IMAGING, PULSED ECHO, ULTRASONIC
2307.	C	SYSTEM, IMAGING, ULTRASONIC, OPHTHALMIC
2308.	C	FASTENER, FIXATION, BIODEGRADABLE, SOFT TISSUE
2309.	C	FASTENER, FIXATION, NONDEGRADABLE, SOFT TISSUE
2310.	C	IMPLANT, FIXATION DEVICE, CONDYLAR PLATE
2311.	C	IMPLANT, FIXATION DEVICE, SPINAL
2312.	C	ORTHOSIS, SPINAL PEDICLE FIXATION
2313.	C	SCREW, CRANIOPLASTY PLATE
2314.	C	SCREW, FIXATION, BONE
2315.	C	SCREW, FIXATION, INTRAOSSEOUS
2316.	C	SET, BONE PLATE & SCREW
2317.	C	SEALANT, PIT AND FISSURE, AND CONDITIONER, RESIN
2318.	C	SEED, ISOTOPE IAB5
2319.	C	SEED, ISOTOPE, GOLD, TITANIUM, PLATINUM
2320.	C	SEPARATOR, AUTOMATED, BLOOD CELL AND PLASMA, THERAPEUTIC USE
2321.	C	RECONSTRUCTIVE SHEETING, PLASTIC SURGERY
2322.	C	RING/SHELL, PROTRUSIO
2323.	C	PROSTHESIS, SHOULDER
2324.	C	PROSTHESIS, SHOULDER, HEMI-, GLENOID, METALLIC CEMENTED
2325.	C	PROSTHESIS, SHOULDER, HEMI-, HUMERAL, METALLIC UNCEMENTED
2326.	C	PROSTHESIS, SHOULDER, HUMERAL (BIPOLAR HEMI-SHOULDER) METAL/POLYMER
2327.	C	SHUNT, INTRAOCULAR
2328.	C	SHUNT, PERITONEAL (PERITONEO-VEIN)
2329.	C	SHUNT, PLEURO-PERITONEAL
2330.	C	SYSTEM, SIMULATION, RADIATION THERAPY
2331.	C	STEREOTAXIC PLANNING SOFTWARE
2332.	C	SONOMETER, BONE
2333.	C	SPACER, CEMENT
2334.	C	PROSTHESIS, URETHRAL SPHINCTER
2335.	C	SPLINT, ENDODONTIC STABILIZER
2336.	C	SPLINT, URETERAL
2337.	C	POWDER/LIQUID/STAIN, PORCELAIN
2338.	C	STAPLE, ABSORBABLE
2339.	C	STAPLE, FIXATION, BONE
2340.	C	STAPLE, IMPLANTABLE
2341.	C	SUTURE UNIT, AUTOMATIC (STAPLER)
2342.	C	STAPLING SET
2343.	C	MATERIAL, METALLIC -STAINLESS STEEL, TANTALUM, PLATINUM, VITALLIUM
2344.	C	STENT, BILIARY
2345.	C	STENT, COLONIC, METALLIC, EXPANDABLE
2346.	C	STENT, ESOPHAGEAL
2347.	C	STENT, METALLIC, EXPANDABLE
2348.	C	STENT, PANCREATIC
2349.	C	STENT, URETERAL
2350.	C	STENT, URETHRAL, BULBOUS, PERMANENT OR SEMI-PERMANENT
2351.	C	STENT, URETHRAL, PROSTATIC, PERMANENT OR SEMI-PERMANENT
2352.	C	DETECTOR, FETAL HEART, ULTRASONIC (DOPPLER)
2353.	C	INTESTINAL STIMULATOR

Sl.	CLASS	Name of the Medical Devices
2354.	C	STIMULATOR, CRANIAL ELECTROTHERAPY
2355.	C	STIMULATOR, ELECTRICAL FOR INCONTINENCE (IMPLANTABLE)
2356.	C	STIMULATOR, ELECTRICAL, IMPLANTED FOR GASTROPARESIS
2357.	C	STIMULATOR, OSTEOGENESIS, ELECTRIC, BATTERY-OPERATED,
2358.	C	STIMULATOR, PERIPHERAL NERVE, IMPLANTED (PAIN RELIEF)
2359.	C	STRIP, CRANIOSYNOSTOSIS, PREFORMED
2360.	C	IMPLANT, SUBPERIOSTEAL
2361.	C	DEVICE, ANTICHOKE, SUCTION
2362.	C	DEVICE, LIPECTOMY, SUCTION
2363.	C	SUTURE UNIT, AUTOMATIC (STAPLER)
2364.	C	SUTURE, ABSORBABLE
2365.	C	SUTURE, ABSORBABLE, SYNTHETIC, POLYGLYCOLIC ACID
2366.	C	SUTURE, DENTAL
2367.	C	SUTURE, NONABSORBABLE
2368.	C	SUTURE, NONABSORBABLE, STEEL, MONOFILAMENT AND MULTIFILAMENT
2369.	C	SUTURE, NONABSORBABLE, SYNTHETIC, POLYAMIDE
2370.	C	SUTURE, NONABSORBABLE, SYNTHETIC, POLYESTER
2371.	C	SUTURE, NONABSORBABLE, SYNTHETIC, POLYETHYLENE
2372.	C	SUTURE, NONABSORBABLE, SYNTHETIC, POLYPROPYLENE
2373.	C	SUTURE, SURGICAL, NONABSORBABLE, POLYBUTESTER
2374.	C	SUTURE/NEEDLE COMBINATION
2375.	C	FLUID, JOINT LUBRICATING
2376.	C	TACK, SACCULOTOMY (CODY TACK)
2377.	C	INJECTABLE BULKING AGENT FOR GASTROENTEROLOGY
2378.	C	PASTE, INJECTABLE FOR VOCAL CORD AUGMENTATION
2379.	C	TELEMETRY UNIT, PHYSIOLOGICAL, ECG
2380.	C	SYSTEM, RADIATION THERAPY, RADIONUCLIDE
2381.	C	PROSTHESIS, TENDON
2382.	C	PROSTHESIS, TENDON, PASSIVE
2383.	C	PROSTHESIS, TESTICULAR
2384.	C	SYSTEM, THERMOGRAPHIC, LIQUID CRYSTAL
2385.	C	THERMOGRAPHIC DEVICE, INFRARED
2386.	C	SYSTEM, THERMOTHERAPY, RF/MICROWAVE (BENIGN PROSTATIC HYPERPLASIA)
2387.	C	TIP, VESSEL
2388.	C	PROSTHESIS, TOE
2389.	C	TOURNIQUET, AUTOMATIC ROTATING
2390.	C	PROSTHESIS, TRACHEAL
2391.	C	COMPONENT, TRACTION, INVASIVE
2392.	C	TRANSDUCER, ULTRASONIC
2393.	C	TRANSDUCER, ULTRASONIC, DIAGNOSTIC
2394.	C	TRANSDUCER, ULTRASONIC, OBSTETRIC
2395.	C	GRANULES, TRICALCIUM PHOSPHATE FOR DENTAL BONE REPAIR
2396.	C	ASSEMBLY, TUBE HOUSING, X-RAY, DIAGNOSTIC
2397.	C	ASSEMBLY, TUBE HOUSING, X-RAY, THERAPEUTIC
2398.	C	TUBE, ANASTOMOSIS BYPASS
2399.	C	TUBE, FEEDING, GASTROSOTOMY/JEJUNOSTOMY
2400.	C	TUBE, SHUNT, ENDOLYMPHATIC
2401.	C	TUBE, SHUNT, ENDOLYMPHATIC WITH VALVE
2402.	C	TUBE, TYMPANOSTOMY
2403.	C	TUBE, X-RAY
2404.	C	DETECTOR, BLOOD FLOW, ULTRASONIC (DOPPLER)

Sl.	CLASS	Name of the Medical Devices
2405.	C	DETECTOR, FETAL HEART, ULTRASONIC (DOPPLER)
2406.	C	MONITOR, BLOOD-PRESSURE, NEONATAL, ULTRASONIC/DOPPLER
2407.	C	SCANNER, ULTRASONIC, GENERAL PURPOSE
2408.	C	SYSTEM IMAGING, PULSED DOPPLER, ULTRASONIC
2409.	C	SYSTEM, MAGING, PULSED ECHO, ULTRASONIC
2410.	C	SYSTEM, IMAGING, ULTRASONIC, OPHTHALMIC
2411.	C	DOPPLER ULTRASOUND FOR FETAL EVALUATION
2412.	C	FLOWMETER, BLOOD, NON-INVASIVE ELECTROMAGNETIC OR DOPPLER
2413.	C	SONOMETER, BONE
2414.	C	UNIT, PHACOFRAGMENTATION AND ACCESSORIES
2415.	C	DEVICE, OCCLUSION, TUBAL (TOD), CONTRACEPTIVE
2416.	C	VAPORIZER, ANESTHESIA, NON-HEATED
2417.	C	VARNISH, CAVITY
2418.	C	VENEER, DENTAL
2419.	C	TUBE, TYMPANOSTOMY
2420.	C	RESPIRATOR, NEONATAL VENTILATOR
2421.	C	VENTILATOR, ANESTHESIA UNIT
2422.	C	VENTILATOR, CONTINUOUS (RESPIRATOR)
2423.	C	VENTILATOR, CONTINUOUS, HYPERBARIC
2424.	C	VENTILATOR, CONTINUOUS, NON-LIFE-SUPPORTING
2425.	C	VENTILATOR, EMERGENCY, POWERED (RESUSCITATOR)
2426.	C	VENTILATOR, EXTERNAL BODY, NEGATIVE PRESSURE, ADULT (CUIRASS)
2427.	C	VENTILATOR, NON-CONTINUOUS (RESPIRATOR)
2428.	C	VEN TILATOR, PRESSURE CYCLED (IPPB MACHINE)
2429.	C	VENTILATOR, VOLUME (CRITICAL CARE)
2430.	C	TACK, SACCULOTOMY (CODY TACK)
2431.	C	FLUID, INTRAOCULAR
2432.	C	PROSTHESIS, LARYNX
2433.	C	WARMER, INFANT RADIANT
2434.	C	WARMER, RADIANT, ADULT
2435.	C	WASHER, BOLT, NUT
2436.	C	WAX, BONE
2437.	C	LOCK, WIRE, AND LIGATURE, INTRAORAL
2438.	C	SOURCE, WIRE, IRIIDIUM, RADIOACTIVE
2439.	C	SUTURE, NONABSORBABLE, STEEL, MONOFILAMENT AND MULTIFI LAMENT
2440.	C	WIRE, BONE
2441.	C	WIRE, FIXATION, INTRAOSSEOUS
2442.	C	WIRE, LIGATURE
2443.	C	WIRE, SURIGICAL
2444.	C	PROSTHESIS, CARPAL
2445.	C	PROSTHESIS, WRIST, B PART METAL -PLASTIC ARTICULATION, SEMI - CONSTRAINED
2446.	C	PROSTHESIS, WRIST, C PART METAL -PLASTIC -METAL ARTICULATION, SEMI- CONSTRAINED
2447.	C	PROSTHESIS, WRIST, CARPAL SCAPHOID
2448.	C	PROSTHESIS, WRIST, CARPAL TRAPEZIUM
2449.	C	PROSTHESIS, WRIST, CARPAL, LUNATE
2450.	C	PROSTHESIS, WRIST, HEMI-, ULNAR
2451.	C	XENON SYSTEM
2452.	C	ASSEMBLY, TUBE HOUSING, X-RAY, DIAGNOSITC
2453.	C	ASSEMBLY, TUBE HOUSING, X-RAY, THERAPEUTIC
2454.	C	CAMERA, MULTI-IMAGE

Sl.	CLASS	Name of the Medical Devices
2455.	C	SYSTEM, IMAGING, X-RAY, ELECTROSTATIC
2456.	C	SYSTEM, THERAPEUTIC, X-RAY
2457.	C	SYSTEM, X-RAY, ANGIOGRAPHIC
2458.	C	SYSTEM, X-RAY, FLUOROSCOPIC, IMAGE-INTENSIFIED
2459.	C	SYSTEM, X-RAY, FLUOROSCOPIC, NON-IMAGE-INTENSIFIED
2460.	C	SYSTEM, X-RAY, MAMMOGRAPHIC
2461.	C	SYSTEM, X-RAY, MOBILE, FLUOROSCO PIC
2462.	C	SYSTEM, X-RAY, STATIONARY
2463.	C	TUBE, X-RAY
2464.	C	UNIT, X-RAY, MOBILE, EXPLOSION-SAFE
2465.	D	ELECTRODE, PERCUTANEOUS CONDUCTION TISSUE ABLATION
2466.	D	SUCTION ABLATION CATHETER SYSTEM (SAC)
2467.	D	SYSTEM, ABLATION, RADIOFREQUENCY
2468.	D	CATHETER, OXIMETER, FIBEROPTIC
2469.	D	ADAPTOR, LEAD, PACEMAKER
2470.	D	TISSUE ADHESIVE FOR ANEURSMORRHAPHY
2471.	D	AMNIOSCOPE, TRANSABDOMINAL (FETOSCOPE) (AND ACCESSORIES)
2472.	D	KIT, ANGIOGRAPHIC, DIGITAL
2473.	D	KIT, CATHETERIZATION, CARDIAC
2474.	D	PATCH, PLEDGET AND INTRACARDIAC, PETP, PTFE, POLYPROPYLENE
2475.	D	DEVICE, LASER, ANGIOPLASTY, CORONARY
2476.	D	DEVICE, NEUROSURGICAL, FRAGMENTATION AND ASPIRATION
2477.	D	BALLOON FOR CEREBROVASCULAR OCCLUSION
2478.	D	SYSTEM, BALLOON, INTRA-AORTIC AND CONTROL
2479.	D	BAND, PULMONARY ARTERY
2480.	D	BATTERY, PACEMAKER
2481.	D	DEVICE, EMBOLIZATION, ARTERIAL
2482.	D	GRAFT, BONE
2483.	D	PROSTHESIS, BREAST, INFLATABLE, INTERNAL, SALINE
2484.	D	PROSTHESIS, BREAST, NONINFLATABLE, INTERNAL, SALINE
2485.	D	PROSTHESIS, BREAST, NONINFLATABLE, INTERNAL, SILICONE GEL-FILLED
2486.	D	SUCTION ABLATION CATHETER SYSTEM (SAC)
2487.	D	CATHETER, CORONARY PERFUSION
2488.	D	CATHETER, ANGIOPLASTY, PERIPHERAL, TRANSLUMINAL
2489.	D	CATHETER, CARDIAC THERMODILUTION
2490.	D	CATHETER, CARDIOVASCULAR
2491.	D	CATHETER, CARDIOVASCULAR, BALLOON TYPE
2492.	D	CATHETER, CEREBROSPINAL
2493.	D	CATHETER, CORONARY PERFUSION
2494.	D	CATHETER, CORONARY, ATHERECTOMY
2495.	D	CATHETER, ELECTRODE RECORDING, OR PROBE, ELECTRODE RECORDING
2496.	D	CATHETER, EMBOLECTOMY
2497.	D	CATHETER, FLOW D IRECTED
2498.	D	CATHETER, IMAGING, ULTRASONIC
2499.	D	CATHETER, INTRA- AORTIC BALLOON
2500.	D	CATHETER, INTRACARDIAC MAPPING, HIGH DENSITY ARRAY
2501.	D	CATHETER, INTRAVASCULAR OCCLUDING
2502.	D	CATHETER, INTRAVASCULAR, DIAGNOSTIC
2503.	D	CATHETER, INTRAVENOUS, CENTRAL
2504.	D	CATHETER, LASER, MYOPLASTY, CORONARY
2505.	D	CATHETER, OCCLUDING, CARDIOVASCULAR, IMPLANTABLE
2506.	D	CATHETER, OCCLUSION

Sl.	CLASS	Name of the Medical Devices
2507.	D	CATHETER, OXIMETER, FIBEROPTIC
2508.	D	CATHETER, PERCUTANEOUS
2509.	D	CATHETER, PERCUTANEOUS (VALVULOPLASTY)
2510.	D	CATHETER, PERFUSION
2511.	D	CATHETER, PERICARDIUM DRAINAGE
2512.	D	CATHETER, PERIPHERAL, ATHERECTOMY
2513.	D	CATHETER, SEPTOSTOMY
2514.	D	CATHETER, STEERABLE
2515.	D	CATHETER, THROMBECTOMY
2516.	D	CATHETER, TRANSLUMINAL, CORONARY ANGIOPLASTY, PERCUTANEOUS
2517.	D	CATHETER, VENTRICULAR
2518.	D	KIT, BALLOON REPAIR, CATHETER
2519.	D	LEAD, PACEMAKER (CATHETER)
2520.	D	SHUNT, CENTRAL NERVOUS SYSTEM AND COMPONENTS
2521.	D	SUCTION ABLATION CATHETER SYSTEM (SAC)
2522.	D	KIT, CATHETERIZATION, CARDIAC
2523.	D	DEVICE, BYPASS, VENTRICULAR (ASSIST)
2524.	D	CLIP, ANEURYSM
2525.	D	CLIP, IMPLANTED MALLEABLE
2526.	D	CLIP, VASCULAR
2527.	D	CLIP, VENA CAVA
2528.	D	COLLAGEN IMPLANTS FOR NON- AESTHETIC USE
2529.	D	IMPLANT, RESORBABLE BOVINE COLLAGEN, MENISCAL REPAIR
2530.	D	TOTALLY IMPLANTED SPINAL CORD STIMULATOR FOR PAIN RELIEF
2531.	D	CONDOM - NATURAL MEMBRANE
2532.	D	CLOSED -LOOP BLOOD GLUCOSE CONTROLLER
2533.	D	CATHETER, CEREBROSPINAL
2534.	D	PATCH, PLEDGET AND INTRACARDIAC, PETP, PTFE, POLYPROPYLENE
2535.	D	DEFIBRILLATOR, AUTOMATIC IMPLANTABLE CARDIOVERTER
2536.	D	DEFIBRILLATOR, EXTERNAL, AUTOMATIC
2537.	D	LEAD, ELECTRODE, CARDIOVERTER, DEFIBRILLATOR, PERMANENT
2538.	D	DERMAL IMPLANTS OF COLLAGEN FOR AESTHETIC USE
2539.	D	DEVICE, DERMAL REPLACEMENT
2540.	D	DETECTOR, HIS BUNDLE
2541.	D	DEVICE, INTRACRANIAL PRESSURE MONITORING
2542.	D	DURA SUBSTITUTE
2543.	D	LYOPHILIZED HUMAN DURA MATER
2544.	D	STIMULATOR, SPINAL CORD, IMPLANTED, FOR BLADDER EVACUATION
2545.	D	ELECTRODE, DEFIBRILLATOR (INTERNAL, NON-IMPLANTED)
2546.	D	ELECTRODE, DEPTH
2547.	D	ELECTRODE, PACEMAKER, TEMPORARY
2548.	D	ELECTRODE, PACEMAKER, TRANSTHORACIC
2549.	D	ELECTRODE, PERCUTANEOUS CONDUCTION TISSUE ABLATION
2550.	D	LEAD, ELECTRODE, CARDIOVERTER, DEFIBRILLATOR, PERMANENT
2551.	D	LEAD, ELECTRODE, PACEMAKER, PERMANENT
2552.	D	STABILIZED EPIDURAL SPINAL ELECTRODE
2553.	D	EMBOLIC PROTECTION DEVICE
2554.	D	ARTIFICIAL EMBOLIZATION DEVICE
2555.	D	DEVICE, EMBOLIZATION, ARTERIAL
2556.	D	ENDOSCOPE, FETAL BLOOD SAMPLING (AND ACCESSORIES)
2557.	D	DEVICE, LASER, ANGIOPLASTY, CORONARY

Sl.	CLASS	Name of the Medical Devices
2558.	D	AMNIOSCOPE, TRANSABDOMINAL (FETOSCOPE) (AND ACCESSORIES)
2559.	D	FILTER, INTRAVASCULAR, CARDIOVASCULAR
2560.	D	CATHETER, EMBOLECTOMY
2561.	D	DEVICE, NEUROSURGICAL, FRAGMENTATION AND ASPIRATION
2562.	D	MATERIALS, REPAIR OR REPLACEMENT, PACEMAKER
2563.	D	PROGRAMMER, PACEMAKER
2564.	D	PULSE-GENERATOR, PACEMAKER, EXTERNAL
2565.	D	PULSE-GENERATOR, PACEMAKER, EXTERNAL, PROGRAMMABLE
2566.	D	PULSE-GENERATOR, PACEMAKER, IMPLANTABLE
2567.	D	PULSE-GENERATOR, PROGRAM MODULE
2568.	D	GRAFT, BONE
2569.	D	GRAFT, SKIN
2570.	D	GRAFT, VASCULAR, BIOLOGICAL
2571.	D	PROSTHESIS, ARTERIAL GRAFT, BOVINE CAROTID ARTERY
2572.	D	PROSTHESIS, VASCULAR GRAFT, OF 6MM AND GREATER DIAMETER
2573.	D	PROSTHESIS, VASCULAR GRAFT, OF LESS THAN 6MM DIAMETER
2574.	D	SYSTEM, ENDOVASCULAR GRAFT, AORTIC ANEURYSM TREATMENT
2575.	D	HEART, ARTIFICIAL
2576.	D	ABSORBABLE HEMOSTATIC AGENTS, COLLAGEN BASED
2577.	D	SHUNT, CENTRAL NERVOUS SYSTEM AND COMPONENTS
2578.	D	DERMAL IMPLANTS OF COLLAGEN FOR AESTHETIC USE
2579.	D	IMPLANT, RESORBABLE BOVINE COLLAGEN, MENISCAL REPAIR
2580.	D	PATCH, PLEDGET AND INTRACARDIAC, PETP, PTFE, POLYPROPYLENE
2581.	D	CLOSED -LOOP BLOOD GLUCOSE CONTROLLER
2582.	D	CATHETER, OXIMETER, FIBEROPTIC
2583.	D	CLOSED -LOOP BLOOD GLUCOSE CONTROLLER
2584.	D	DEVICE, LASER, ANGIOPLASTY, CORONARY
2585.	D	ELECTRODE, PACEMAKER, TEMPORARY
2586.	D	LEAD, ELECTRODE, CARディオVERTER, DEFIBRILLATOR, PERMANENT
2587.	D	LEAD, ELECTRODE, PACEMAKER, PERMANENT
2588.	D	LEAD, EXTENDER, PACEMAKER, IMPLANTABLE
2589.	D	LEAD, PACEMAKER (CATHETER)
2590.	D	LEAD, PACEMAKER , IMPLANTABLE, INDIFFERENT
2591.	D	CLOSED -LOOP BLOOD GLUCOSE CONTROLLER
2592.	D	FETAL PH MONITOR
2593.	D	IMPLANTED INTRACRANIAL PRESSURE MONITOR
2594.	D	MONITOR, CEREBRAL BLOOD FLOW, THERMAL DIFFUSION
2595.	D	MONITOR, PRESSURE, CARDIAC, ARTERIAL
2596.	D	DEVICE, INTRACRANIAL PRESSURE MONITORING
2597.	D	OCCLUDEUR, PATENT DUCTUS, ARTERIOSUS
2598.	D	CATHETER, OXIMETER, FIBEROPTIC
2599.	D	OXIMETER, INTRACARDIAC
2600.	D	MATERIALS, REPAIR OR REPLACEMENT, PACEMAKER
2601.	D	PACEMAKER, HEART, IMPLANTABLE, ANTI -TACHYCARDIA
2602.	D	PACEMAKER, HEART, IMPLANTABLE, DUAL CHAMBER
2603.	D	PACEMAKER, HEART, IMPLANTABLE, NON-PROGRAMMABLE
2604.	D	PACEMAKER, HEART, IMPLANTABLE, RATE RESPONSIVE
2605.	D	PULSE-GENERATOR, PROGRAM MODULE
2606.	D	TEMPORARY PACING SYSTEM, ACUTE, INTERNAL, ATRIAL
2607.	D	LEAD, ELECTRODE, CARディオVERTER, DEFIBRILLATOR, PERMANENT
2608.	D	PATCH, PERICARDIAL
2609.	D	PATCH, PLEDGET AND INTRACARDIAC, PETP, PTFE, POLYPROPYLENE

Sl.	CLASS	Name of the Medical Devices
2610.	D	PATCH, PLEDGET AND INTRACARDIAC, PETP, PTFE, POLYPROPYLENE
2611.	D	PLEDGET, DACRON, TEFLON, POLYPROPYLENE
2612.	D	KIT, BLOOD PRESSURE, CENTRAL VENOUS
2613.	D	CATHETER, ELECTRODE RECORDING, OR PROBE, ELECTRODE RECORDING
2614.	D	PROBE, THERMODILUTION
2615.	D	PROGRAMMER, PACEMAKER
2616.	D	HEART, ARTIFICIAL
2617.	D	PROSTHESIS, ARTERIAL GRAFT, BOVINE CAROTID ARTERY
2618.	D	PROSTHESIS, BREAST, INFLATABLE, INTERNAL, SALINE
2619.	D	PROSTHESIS, BREAST, NONINFLATABLE, INTERNAL, SALINE
2620.	D	PROSTHESIS, BREAST, NONINFLATABLE, INTERNAL, SILICONE GEL-FILLED
2621.	D	PROSTHESIS, VASCULAR GRAFT, OF 6MM AND GREATER DIAMETER
2622.	D	PROSTHESIS, VASCULAR GRAFT, OF LESS THAN 6MM DIAMETER
2623.	D	EMBOLIC PROTECTION DEVICE
2624.	D	BAND, PULMONARY ARTERY
2625.	D	KIT, BALLOON REPAIR, CATHETER
2626.	D	RING, ANNULOPLASTY
2627.	D	COLLAGEN CORNEAL SHIELD
2628.	D	SHUNT, CENTRAL NERVOUS SYSTEM AND COMPONENTS
2629.	D	PULSE-GENERATOR, PROGRAM MODULE
2630.	D	STENT, CARDIOVASCULAR
2631.	D	IMPLANTED AUTONOMIC NERVE STIMULATOR FOR EPILEPSY
2632.	D	STABILIZED EPIDURAL SPINAL ELECTRODE
2633.	D	STIMULATOR, CEREBELLAR, IMPLANTED
2634.	D	STIMULATOR, DIAPHRAGMATIC/PHRENIC NERVE, IMPLANTED
2635.	D	STIMULATOR, INTRACEREBRAL/SUBCORTICAL, IMPLANTED
2636.	D	STIMULATOR, NEUROMUSCULAR, IMPLANTED
2637.	D	STIMULATOR, SPINAL CORD, IMPLANTED (PAIN RELIEF)
2638.	D	STIMULATOR, SPINAL CORD, IMPLANTED, FOR BLADDER EVACUATION
2639.	D	STIMULATOR, VEGUS NERVE, IMPLANTED, EPILEPSY
2640.	D	TOTALLY IMPLANTED SPINAL CORD STIMULATOR FOR PAIN RELIEF
2641.	D	SUTURE, ABSORBABLE, NATURAL
2642.	D	SUTURE, CARDIOVASCULAR
2643.	D	SUTURE, NON ABSORBABLE SILK
2644.	D	PATCH, PLEDGET AND INTRACARDIAC, PETP, PTFE, POLYPROPYLENE
2645.	D	TISSUE, HEART VALVE
2646.	D	TRANSDUCER, PRESSURE, CATHETER TIP
2647.	D	TRANSDUCER, VESSEL OCCLUSION
2648.	D	HEART-VALVE, MECHANICAL
2649.	D	SHUNT, CENTRAL NERVOUS SYSTEM AND COMPONENTS
2650.	D	TISSUE, HEART VALVE
2651.	D	DEVICE, BYPASS, VENTRICULAR (ASSIST)
2652.	D	WRAP, IMPLANT, ORBITAL

Annex-E: Proposed Product for Local Production (IVD Reagent)

SI No	cŪZKviŧKi big	ewŪR`K big	AuBŪfiŪŪ ūiŧqŧRŧŪi big	KŪm	Intended use	ŧŪKŪb`ŧj me-KŪgŪŪ mŧvi ūm×ŪŧŪ	mŧvi ūm×ŪŧŪ
1.	Incepta Pharmaceuticals Ltd.; Zirabo, Savar, Dhaka	Cholkit (Cholera Kit)	Mouse Anti LPS VCO1 IgG gor gold conjugation and test line 7.66µg + Goat Anti Mouse IgG 1.5 µg + Nitrocellulose membrane 6 cm X 3mm + Adsorbent pad 3 cm X 3mm + Sample pad 1.8 cm X 3mm + Gold conjugate pad 3 X 6mm, 2pcs + Masking pad 1.8 X 3mm + Tris 0.0031µg + NaCl 0.0037µg + WFI	B	Cholkit is used for specific and sensitive diagnosis of Cholera (without any cross reactivity with other bacterial disease) from the stool sample collected or received from patient.	ŧŪKŪb`ŧj Ūŧqŧj i mŧŧŪŪ RbK ūiŧcŪŪ cŪBi ūfiŪŪZ AbŧgŪ b Kiv ŧŧZ cŪŧi	ŧŪKŪb`ŧj Ūŧqŧj i mŧŧŪŪ RbK ūiŧcŪŪ cŪBi ūfiŪŪZ AbŧgŪ b Kivnj
2.	OMC Healthcare Pvt.Ltd.Plot # 44,Rupnagar Industrial Area ,Block -K Road # Mirpur -2 Dhaka 1216,	TPHA Test	Teponema Palidum(TP) Antibody Test	C	It is a rapid and convenient Immunochromatographic in vitro assay in the diagnosis of syphilis. It is used for qualitative determination of TP IgG and IgM antibodies in human serum or plasma. This assay provides only a preliminary result.	ŧiŪRŧŧkŧbi cŧe cŪi`kŧ kŧZ`AbŧgŪ b Kiv ŧŧZ cŪŧi	ŧiŪRŧŧkŧbi cŧe cŪi`kŧ kŧZ`AbŧgŪ b Kivnj
3.	OMC Healthcare Pvt.Ltd.Plot # 44,Rupnagar Industrial Area ,Block -K Road # Mirpur -2 Dhaka 1216,	HIV 1 & 2	Human Immunodeficiency Virus 1/2 Test.	C	Human Immunodeficiency Virus 1 and 2 (HIV-1/2) Antibody Test kit is a rapid and convenient immunochromatographic in vitro assay. It is used to for detection of antibodies to HIV- ½ in human seram and plasma. This assay provides only a preliminary result. Clinical expertise and professional judgment should be sought to further evaluate the result of the test .It is intended for professional use as an aid in the diagnosis of HIV.	ŧiŪRŧŧkŧbi cŧe cŪi`kŧ kŧZ`AbŧgŪ b Kiv ŧŧZ cŪŧi	ŧiŪRŧŧkŧbi cŧe cŪi`kŧ kŧZ`AbŧgŪ b Kivnj
4.	OMC Healthcare Pvt.Ltd.Plot # 44,Rupnagar Industrial Area ,Block -K Road # Mirpur -2 Dhaka 1216,	Malaria Test kit	Malaria Antigen Test	B	It is a rapid and convenient immunochromatographic assay for qualitative detection of <i>Plasmodium Falciparum</i> and <i>Plasmodium Vivax</i> in whole blood sample. It is intended for professional use as an in diagnosis of malarial infection. This assay provides only a preliminary result and all positive specimen should be confirmed with other qualified assay	ŧiŪRŧŧkŧbi cŧe cŪi`kŧ kŧZ`AbŧgŪ b Kiv ŧŧZ cŪŧi	ŧiŪRŧŧkŧbi cŧe cŪi`kŧ kŧZ`AbŧgŪ b Kivnj

SI No	cŌZKviŧKi big	ewŨrK big	AŨBŨfŨŨ ŨiŧŧRŧŨi big	KŨm	Intended use	ŧŨKŨbK'Ũj me-KŨgŨŨ mfvi Ũm×ŨŨŨŨ	mfvi Ũm×ŨŨŨŨ
5.	OMC Healthcare Pvt.Ltd.Plot # 44,Rupnagar Industrial Area ,Block –K Road # Mirpur -2 Dhaka 1216,	Hepatitis Panel Test kit	Hepatitis Panel (Hepatitis A, Hepatitis B, Hepatitis C	C	It is an immunochromatographic strip assay for qualitative detection of Antigen /antibody in human serum for Hepatitis A, Hepatitis B & Hepatitis C.	ŧŨRŧŧŧŧbi cŧe© cŨi `kŧ kŧZ'Abŧŧŧ' b Kiv ŧŧZ cŨi	ŧŨRŧŧŧŧbi cŧe©cŨi `kŧ kŧZ'Abŧŧŧ' b Kiv nj
6.	Get Well Limited Olipur, Shaistaganj, Habiganj	Getwell HBsAg Test Kit (Cassette)	Acrylonitrile Butadine Styrene (ABS) Medical Grade 5.20 gm + Masterbatch Medical Grade 0.05 gm + Desiccant Pharma. Grade 1 Pc + Sample Dropper Medical Grade 1 Pc + Strip Medical Grade 1 Pc + Foil Pouch Pharma. Grade 1 Pc	C	It is immunoassay designed for the qualitative detection of Hepatitis B Surface Antigen (HBsAg) in serum or plasma or blood	ŧŨRŧŧŧŧbi cŧe© cŨi `kŧ kŧZ'Abŧŧŧ' b Kiv ŧŧZ cŨi	ŧŨRŧŧŧŧbi cŧe©cŨi `kŧ kŧZ'Abŧŧŧ' b Kiv nj
7.	Get Well Limited Olipur, Shaistaganj, Habiganj	Getwell HIV Test Kit (Cassette)	Acrylonitrile Butadine Styrene (ABS) Medical Grade 5.20 gm + Masterbatch Medical Grade 0.05 gm + Desiccant Pharma. Grade 1 Pc + Sample Dropper Medical Grade 1 Pc + Strip Medical Grade 1 Pc + Foil Pouch Pharma. Grade 1 Pc	C	It is immunoassay designed for the qualitative detection of HIV (Human Immunodeficiency Virus) in serum or plasma or blood .	ŧŨRŧŧŧŧbi cŧe© cŨi `kŧ kŧZ'Abŧŧŧ' b Kiv ŧŧZ cŨi	ŧŨRŧŧŧŧbi cŧe©cŨi `kŧ kŧZ'Abŧŧŧ' b Kiv nj
8.	Get Well Limited Olipur, Shaistaganj, Habiganj	Getwell LH (Ovulation) Test Kit (Cassette)	Acrylonitrile Butadine Styrene (ABS) Medical Grade 5.20 gm + Masterbatch Medical Grade 0.05 gm + Desiccant Pharma. Grade 1 Pc + Sample Dropper Medical Grade 1 Pc + Strip Medical Grade 1 Pc + Foil Pouch Pharma. Grade 1 Pc	B	It is a self-performing immunoassay designed for the qualitative detection of LH (luteinizing hormone). The LH Urine Ovulation Test is fast and easy to use. It is a qualitative test that can predict when there is a LH (luteinizing hormone) surge, and in turn, when you are likely to ovulate.	ŧŨRŧŧŧŧbi cŧe© cŨi `kŧ kŧZ'Abŧŧŧ' b Kiv ŧŧZ cŨi	ŧŨRŧŧŧŧbi cŧe©cŨi `kŧ kŧZ'Abŧŧŧ' b Kiv nj

SI No	Name of the Manufacturer & Importer	Brand Name	IVD Reagent Name	Class	Intended Uses	FSC/ CPP	তുകিবক'য় মে কুগ'লি ম'বি ম'ব'সি	ম'বি ম'ব'সি
	Yeongtong-gu, Suwon-si, Gyeonggi-do, 16690, REPUBLIC OF KOREA Local Agent: LAB Traders 1512/A, O.R Nizam Road, Panchlaish, Chittagong				strip is intended to use outside the body (in vitro diagnostic use) in home.		FSC/ CPP / c'q'Rbxq WK'gU `mLj i k'Z° Ab'g' b Kiv th'Z c'vi	FSC/ CPP / c'q'Rbxq WK'gU `mLj i k'Z° Ab'g' b Kiv nj
7.	SD Biosensor, Inc. C 4th&5th, 16, Deogyong-daero, 1556beon-gil, Yeongtong-gu, Suwon-si, Gyeonggi-do, 16690, REPUBLIC OF KOREA Local Agent: LAB Traders 1512/A, O.R Nizam Road, Panchlaish, Chittagong	GlucNavii NFC Blood Glucose Monitoring System	Blood Glucose Monitoring System	C	Your new SD GlucoNavii® NFC Blood Glucose Meter and accessories work together to measure the amount of glucose (sugar) in your blood. Your SD GlucoNavii® NFC Blood Glucose Monitoring System is indicated for monitoring glucose in fresh capillary whole blood or fresh venous blood. Testing is done outside the body. (in vitro diagnostic use). This system is indicated for home (over-the-counter or OTC) by person with diabetes, or in clinical settings by healthcare professionals, as an aid to monitor the effectiveness of diabetes control. This system should not be used for the diagnosis of diabetes. SD GlucoNavii® NFC Blood Glucose Monitoring System is suitable for self-testing.	South Korea	ti m'R'okb m'bwj vBb Ab'g'q FSC/ CPP / c'q'Rbxq WK'gU `mLj i k'Z° Ab'g' b Kiv th'Z c'vi	ti m'R'okb m'bwj vBb Ab'g'q FSC/ CPP / c'q'Rbxq WK'gU `mLj i k'Z° Ab'g' b Kiv nj
8.	SD Biosensor, Inc. C 4th&5th, 16, Deogyong-daero, 1556beon-gil, Yeongtong-gu, Suwon-si, Gyeonggi-do, 16690, REPUBLIC OF KOREA Local Agent: LAB Traders 1512/A, O.R Nizam Road, Panchlaish, Chittagong	GlucNavii NFC Blood Glucose Test Strip	NFC Blood Glucose Test Strip	C	SD GlucoNavii® NFC Blood Glucose Test Strip is designed for self testing blood glucose using fresh capillary whole blood or fresh venous blood. This strip is intended to use outside the body (in vitro diagnostic use) and only with SD GlucoNavii® NFC Blood Glucose Meter.	South Korea	ti m'R'okb m'bwj vBb Ab'g'q FSC/ CPP / c'q'Rbxq WK'gU `mLj i k'Z° Ab'g' b Kiv th'Z c'vi	ti m'R'okb m'bwj vBb Ab'g'q FSC/ CPP / c'q'Rbxq WK'gU `mLj i k'Z° Ab'g' b Kiv nj
9.	SD Biosensor, Inc. C 4th&5th, 16, Deogyong-daero, 1556beon-gil, Yeongtong-gu, Suwon-si,	SD A1cCare Analyzer	SD A1cCare Analyzer	C	SD A1cCare analyzer works to measure the quantitative measurement of the glycated hemoglobin(hereafter HbA1c) in the blood. The analyzer is intended for monitoring the HbA1c in fresh capillary or venous whole	South Korea	ti m'R'okb m'bwj vBb Ab'g'q FSC/ CPP / c'q'Rbxq	ti m'R'okb m'bwj vBb Ab'g'q FSC/ CPP / c'q'Rbxq

SI No	Name of the Manufacturer & Importer	Brand Name	IVD Reagent Name	Class	Intended Uses	FSC/ CPP	তുകিবক'য় মে কুগুদি মফবি মমবিসি	মফবি মমবিসি
	Local Agent: LAB Traders 1512/A, O.R Nizam Road, Panchlaish, Chittagong						কতZ° আব্য়গ'ব কিব তহZ চটি	কতZ° আব্য়গ'ব কিব ন
13.	SD Biosensor, Inc. C 4th&5th, 16, Deogyong-daero, 1556beon-gil, Yeongtong-gu, Suwon-si, Gyeonggi-do, 16690, REPUBLIC OF KOREA Local Agent: LAB Traders 1512/A, O.R Nizam Road, Panchlaish, Chittagong	SD Multicare CRP Test Kit	SD Multicar CRP Test Kit	C	It is an in vitro diagnostic use to measure the C - reactive protein (CRP) in the human blood sample (Capillary, Venous whole blood/Serum/Plasma). The measurement of CRP provides information for the detection and evaluation of infection, tissue injury, inflammatory disorders and associated diseases.	South Korea	তিনিRতোকব মিBমিB আব্য়গ'ব FSC/ CPP I চটিRবি মকতZ° আব্য়গ'ব কিব তহZ চটি	তিনিRতোকব মিBমিB আব্য়গ'ব FSC/ CPP I চটিRবি মকতZ° আব্য়গ'ব কিব ন
14.	SD Biosensor, Inc. C 4th&5th, 16, Deogyong-daero, 1556beon-gil, Yeongtong-gu, Suwon-si, Gyeonggi-do, 16690, REPUBLIC OF KOREA Local Agent: LAB Traders 1512/A, O.R Nizam Road, Panchlaish, Chittagong	<u>STANDARD E: Zika IgM ELISA</u>	Zika IgM ELISA	C	It is an enzyme linked immunosorbent assay for the detection of Zika IgM in human serum or plasma. This test is for in vitro professional diagnostic use and intended as an aid to early diagnosis of Zika virus infection in patient with clinical symptoms. It provides only an initial screening test result. More specific alternative diagnosis methods such as viral culture test or Plaque Reduction Neutralization Test (PRNT) should be performed in order to obtain the confirmation of Zika virus infection.	South Korea	তিনিRতোকব মিBমিB আব্য়গ'ব FSC/ CPP I চটিRবি মকতZ° আব্য়গ'ব কিব তহZ চটি	তিনিRতোকব মিBমিB আব্য়গ'ব FSC/ CPP I চটিRবি মকতZ° আব্য়গ'ব কিব ন
15.	SD Biosensor, Inc. C 4th&5th, 16, Deogyong-daero, 1556beon-gil, Yeongtong-gu, Suwon-si, Gyeonggi-do, 16690, REPUBLIC OF KOREA.	STANDARD E: Zika IgG ELISA	Zika IgG ELISA	C	STANDARD E Zika IgG ELISA Test is an enzyme linked immunosorbent assay for the detection of Zika IgG in human serum or plasma. This test is for in vitro professional diagnostic use and intended as an aid to early diagnosis of Zika virus infection in patient with clinical symptoms. It Provides only an initial screening test result. More specific alternative diagnosis methods	South Korea	তিনিRতোকব মিBমিB আব্য়গ'ব FSC/ CPP I চটিRবি মকতZ° আব্য়গ'ব	তিনিRতোকব মিBমিB আব্য়গ'ব FSC/ CPP I চটিRবি মকতZ° আব্য়গ'ব

SI No	Name of the Manufacturer & Importer	Brand Name	IVD Reagent Name	Class	Intended Uses	FSC/ CPP	꺆UK¼bK`ij me Kug¼li mfvi ¼¼¼¼	mfvi ¼¼¼¼
	Local Agent: LAB Traders 1512/A, O.R Nizam Road, Panchlaish, Chittagong				such as viral culture test or Plaque Reduction Neutralization Test (PRNT) should be performed in order to obtain the confirmation of Zika virus infection		Kiv thZ c¼ti	Kiv nj
16.	SD Biosensor, Inc. C 4th&5th, 16, Deogyong-daero, 1556beon-gil, Yeongtong-gu, Suwon-si, Gyeonggi-do, 16690, REPUBLIC OF KOREA. Local Agent: LAB Traders 1512/A, O.R Nizam Road, Panchlaish, Chittagong	STANDARD F: RSV Ag FIA	STANDARD F RSV Ag FIA	C	STANDARD F RSV Ag FIA is the fluorescence immunoassay to detect RSV antigen present in nasopharyngeal swab or nasopharyngeal aspirate/wash specimens from patients with symptoms of a viral respiratory infection. This test is for in vitro professional diagnostic use and intended as an aid to early diagnosis of RSV infection. It provides only an initial screening test result. Specific alternative diagnosis method should be performed in order to obtain the confirmation of the infection.	South Korea	꺆¼R¼¼kb M¼B¼j ¼Bb Ab¼y¼q¼ FSC/ CPP I c¼¼q¼R¼b¼q W¼K¼g¼U `¼L¼j i k¼Z° Ab¼j¼v`b Kiv thZ c¼ti	꺆¼R¼¼kb M¼B¼j ¼Bb Ab¼y¼q¼ FSC/ CPP I c¼¼q¼R¼b¼q W¼K¼g¼U `¼L¼j i k¼Z° Ab¼j¼v`b Kiv nj
17.	SD Biosensor, Inc. C 4th&5th, 16, Deogyong-daero, 1556beon-gil, Yeongtong-gu, Suwon-si, Gyeonggi-do, 16690, REPUBLIC OF KOREA. Local Agent: LAB Traders 1512/A, O.R Nizam Road, Panchlaish, Chittagong	STANDARD F: Strep A Ag FIA	STANDARD F Strep A Ag FIA	C	STANDARD F Strep A Ag FIA is the fluorescence immunoassay to detect group A streptococcal (Strep A) antigen present in throat specimens from patients with clinical symptoms. This test is for in vitro professional diagnostic use and intended as an aid to early diagnosis of group A streptococcal infection. It provides only an initial screening test result. Specific alternative diagnosis method should be performed in order to obtain the confirmation of group A streptococcal infection.	South Korea	꺆¼R¼¼kb M¼B¼j ¼Bb Ab¼y¼q¼ FSC/ CPP I c¼¼q¼R¼b¼q W¼K¼g¼U `¼L¼j i k¼Z° Ab¼j¼v`b Kiv thZ c¼ti	꺆¼R¼¼kb M¼B¼j ¼Bb Ab¼y¼q¼ FSC/ CPP I c¼¼q¼R¼b¼q W¼K¼g¼U `¼L¼j i k¼Z° Ab¼j¼v`b Kiv nj
18.	SD Biosensor, Inc. C 4th&5th, 16, Gyeonggi-do, 16690, REPUBLIC OF KOREA. Local Agent: LAB Traders 1512/A, O.R Nizam Road, Panchlaish, Chittagong	STANDARD F: Legionella Ag FIA	STANDARD F Legionella Ag FIA	C	STANDARD F Legionella Ag FIA is a fluorescence immunoassay for the qualitative detection of Legionella pneumophila serogroup 1 antigen present in urine samples from patients with symptoms of pneumonia. This test is for in vitro diagnostic use and intended for professional use, only for an initial screening test. STANDARD F Legionella Ag FIA should be used with the appropriate analyzer, STANDARD F Analyzers.	South Korea	꺆¼R¼¼kb M¼B¼j ¼Bb Ab¼y¼q¼ FSC/ CPP I c¼¼q¼R¼b¼q W¼K¼g¼U `¼L¼j i k¼Z° Ab¼j¼v`b Kiv thZ c¼ti	꺆¼R¼¼kb M¼B¼j ¼Bb Ab¼y¼q¼ FSC/ CPP I c¼¼q¼R¼b¼q W¼K¼g¼U `¼L¼j i k¼Z° Ab¼j¼v`b Kiv nj
19.	SD Biosensor, Inc.	STANDARD F: S.pneumoniae Ag FIA	STANDARD F S.	C	STANDARD F S. pneumoniae Ag FIA is a fluorescence	South	꺆¼R¼¼kb	꺆¼R¼¼kb

SI No	Name of the Manufacturer & Importer	Brand Name	IVD Reagent Name	Class	Intended Uses	FSC/ CPP	தகவல் கிடைக்க முடியும்	மேலும் கிடைக்க முடியும்
	C 4th&5th, 16, Deogyong-daero, 1556beon-gil, Yeongtong-gu, Suwon-si, Gyeonggi-do, 16690, REPUBLIC OF KOREA Local Agent: LAB Traders 1512/A, O.R Nizam Road, Panchlaish, Chittagong		pneumoniae Ag FIA		immunoassay for the qualitative detection of S.pneumoniae CPS Ag present in urine samples from patients with respiratory symptoms. This test is for in vitro professional diagnostic use and intended as an aid to early diagnosis of S.pneumoniae infection. It provides only an initial screening test result. Specific alternative diagnosis method should be performed in order to obtain the confirmation of S.pneumoniae infection.	Korea	MbWj vBb Ablyqx FSC/ CPP / c@qvRbxq WKtgU `mLj i ktZ° Abjgv`b Kiv thtZ c@ti	MbWj vBb Ablyqx FSC/ CPP / c@qvRbxq WKtgU `mLj i ktZ° Abjgv`b Kiv nj
20.	SD Biosensor, Inc. C 4th&5th, 16, Deogyong-daero, 1556beon-gil, Yeongtong-gu, Suwon-si, Gyeonggi-do, 16690, REPUBLIC OF KOREA. Local Agent: LAB Traders 1512/A, O.R Nizam Road, Panchlaish, Chittagong	STANDARD F: HbA1c FIA	STANDARD F HbA1c FIA	C	STANDARD F HbA1c FIA is an in vitro diagnostic system for quantitative measurement of HbA1c in human capillary or venous whole blood. This test is for professional use to monitor glycemic control in people with diabetes. STANDARD F HbA1c FIA should be used with the appropriate analyzer, STANDARD F Analyzers, manufactured by SD BIOSENSOR.	South Korea	ti mRtokb MbWj vBb Ablyqx FSC/ CPP / c@qvRbxq WKtgU `mLj i ktZ° Abjgv`b Kiv thtZ c@ti	ti mRtokb MbWj vBb Ablyqx FSC/ CPP / c@qvRbxq WKtgU `mLj i ktZ° Abjgv`b Kiv nj
21.	SD Biosensor, Inc. C 4th&5th, 16, Deogyong-daero, 1556beon-gil, Yeongtong-gu, Suwon-si, Gyeonggi-do, 16690, REPUBLIC OF KOREA. Local Agent: LAB Traders 1512/A, O.R Nizam Road, Panchlaish, Chittagong	STANDARD F: CRP FIA	STANDARD F CRP FIA	C	STANDARD F CRP FIA is an in vitro diagnostic use to measures the CRP in the human serum, plasma, and whole blood sample. The measurement of CRP provides information for the detection and evaluation of infection, tissue injury, inflammatory disorders and associated diseases. STANDARD F CRP FIA should be used with the appropriate analyzer, STANDARD F Analyzers.	South Korea	ti mRtokb MbWj vBb Ablyqx FSC/ CPP / c@qvRbxq WKtgU `mLj i ktZ° Abjgv`b Kiv thtZ c@ti	ti mRtokb MbWj vBb Ablyqx FSC/ CPP / c@qvRbxq WKtgU `mLj i ktZ° Abjgv`b Kiv nj
22.	SD Biosensor, Inc.	STANDARD F: PCT FIA (Serum)	STANDARD F PCT	C	The STANDARD F PCT FIA (Serum) is an in vitro	South	ti mRtokb	ti mRtokb

SI No	Name of the Manufacturer & Importer	Brand Name	IVD Reagent Name	Class	Intended Uses	FSC/ CPP	தகவல் கிடைக்க முடியும்	மேலும் கிடைக்க முடியும்
	C 4th&5th, 16, Deogyong-daero, 1556beon-gil, Yeongtong-gu, Suwon-si, Gyeonggi-do, 16690, REPUBLIC OF KOREA Local Agent: LAB Traders 1512/A, O.R Nizam Road, Panchlaish, Chittagong		FIA (Serum)		diagnostic use to measures the PCT in the serum from the human. The quantity measurement of the PCT is useful in the diagnosis of bacterial infection and sepsis.	Korea	MiBwj vBb Abjyqx FSC/ CPP / c@qvRbxq WKzU `mLj i kZ° Abjy`b Kiv thZ cti	MiBwj vBb Abjyqx FSC/ CPP / c@qvRbxq WKzU `mLj i kZ° Abjy`b Kiv nj
23.	SD Biosensor, Inc. C 4th&5th, 16, Deogyong-daero, 1556beon-gil, Yeongtong-gu, Suwon-si, Gyeonggi-do, 16690, REPUBLIC OF KOREA. Local Agent: LAB Traders 1512/A, O.R Nizam Road, Panchlaish, Chittagong	STANDARD Q: Influenza A/B FIA	STANDARD Q Influenza A/B FIA	C	The STANDARD Q Influenza A/B Test is for an in vitro diagnostic use to detect influenza infection in human nasal swab and nasopharyngeal swab, wash, or aspirate specimens, identifying existence of influenza virus type A and B. STANDARD Q Influenza A/B Test can be used with the appropriate analyzer.	South Korea	tiRtokb MiBwj vBb Abjyqx FSC/ CPP / c@qvRbxq WKzU `mLj i kZ° Abjy`b Kiv thZ cti	tiRtokb MiBwj vBb Abjyqx FSC/ CPP / c@qvRbxq WKzU `mLj i kZ° Abjy`b Kiv nj
24.	SD Biosensor, Inc. C 4th&5th, 16, Deogyong-daero, 1556beon-gil, Yeongtong-gu, Suwon-si, Gyeonggi-do, 16690, REPUBLIC OF KOREA. Local Agent: LAB Traders 1512/A, O.R Nizam Road, Panchlaish, Chittagong	STANDARD Q: RSV Ag Test	STANDARD Q RSV Ag Test	C	STANDARD Q RSV Ag Test is a rapid chromatographic immunoassay for the qualitative detection of RSV antigen present in nasopharyngeal swab or nasopharyngeal aspirate/wash specimens from patients with symptoms of a viral respiratory infection. This test is for in vitro professional diagnostic use and intended as an aid to early diagnosis of RSV infection. It provides only an initial screening test result.	South Korea	tiRtokb MiBwj vBb Abjyqx FSC/ CPP / c@qvRbxq WKzU `mLj i kZ° Abjy`b Kiv thZ cti	tiRtokb MiBwj vBb Abjyqx FSC/ CPP / c@qvRbxq WKzU `mLj i kZ° Abjy`b Kiv nj
25.	SD Biosensor, Inc. C 4th&5th, 16, Deogyong-	STANDARD Q: Legionella Ag Test	STANDARD Q Legionella Ag Test	C	It is a rapid chromatographic immunoassay for the qualitative detection of Legionella pneumophila	South Korea	tiRtokb MiBwj vBb	tiRtokb MiBwj vBb

SI No	Name of the Manufacturer & Importer	Brand Name	IVD Reagent Name	Class	Intended Uses	FSC/ CPP	தகவல்கள் மேலும் மேலும்	மேலும் மேலும்
	daero, 1556beon-gil, Yeongtong-gu, Suwon-si, Gyeonggi-do, 16690, REPUBLIC OF KOREA. Local Agent: LAB Traders 1512/A, O.R Nizam Road, Panchlaish, Chittagong				serogroup 1 antigen present in urine specimen from patients with symptoms of pneumonia. This test is for in vitro professional diagnostic use and intended as an aid to early diagnosis of Legionella infection . It provides only an initial screening test result. Specific alternative diagnosis method should be performed in order to obtain the confirmation of Legionella infection.		Ablyq FSC/ CPP / c0qRbx WKtU `mLj i ktZ° Abjg`b Kiv thZ cti	Ablyq FSC/ CPP / c0qRbx WKtU `mLj i ktZ° Abjg`b Kiv nj
26.	SD Biosensor, Inc. C 4th&5th, 16, Deogyong-daero, 1556beon-gil, Yeongtong-gu, Suwon-si, Gyeonggi-do, 16690, REPUBLIC OF KOREA. Local Agent: LAB Traders 1512/A, O.R Nizam Road, Panchlaish, Chittagong	STANDARD Q: S.pneumoniae Ag Test	S.pneumoniae Ag Test	C	STANDARD Q S.pneumoniae Ag Test is a rapid chromatographic immunoassay for the qualitative detection of S.pneumoniae CPS Ag present in urine samples from patients with respiratory symptoms. This test is for in vitro professional diagnostic use and intended as an aid to early diagnosis of S.pneumoniae infection. It provides only an initial screening test result. Specific alternative diagnosis method should be performed in order to obtain the confirmation of S.pneumoniae infection.	South Korea	tiRt0kb MvWj vBb Ablyq FSC/ CPP / c0qRbx WKtU `mLj i ktZ° Abjg`b Kiv thZ cti	tiRt0kb MvWj vBb Ablyq FSC/ CPP / c0qRbx WKtU `mLj i ktZ° Abjg`b Kiv nj
27.	SD Biosensor, Inc. C 4th&5th, 16, Deogyong-daero, 1556beon-gil, Yeongtong-gu, Suwon-si, Gyeonggi-do, 16690, REPUBLIC OF KOREA. Local Agent: LAB Traders 1512/A, O.R Nizam Road, Panchlaish, Chittagong	STANDARD Q: Strep A Ag Test	Strep A Ag Test	C	It is a rapid chromatographic immunoassay for the qualitative detection of group A streptococcal (Strep A) antigen present in throat specimen from patients with clinical symptoms. This test is for in vitro professional diagnostic use and intended as an aid to early diagnosis of group A streptococcal infection. It provides only an initial screening test result. Specific alternative diagnosis method should be performed in order to obtain the confirmation of group A streptococcal infection.	South Korea	tiRt0kb MvWj vBb Ablyq FSC/ CPP / c0qRbx WKtU `mLj i ktZ° Abjg`b Kiv thZ cti	tiRt0kb MvWj vBb Ablyq FSC/ CPP / c0qRbx WKtU `mLj i ktZ° Abjg`b Kiv nj
28.	SD Biosensor, Inc. C 4th&5th, 16, Deogyong-daero, 1556beon-gil, Yeongtong-gu, Suwon-si,	SD A1c Control – Level 1 & Level 2	SD A1C Control – Level 1 & Level 2	C	SD A1C Control is intended for use as a quality control material to check the performance of SD MultiCare™ System for HbA1c testing.	South Korea	tiRt0kb MvWj vBb Ablyq FSC/ CPP /	tiRt0kb MvWj vBb Ablyq FSC/ CPP /

SI No	Name of the Manufacturer & Importer	Brand Name	IVD Reagent Name	Class	Intended Uses	FSC/ CPP	তുകিবক'য় মে কুগু'লি ম'ফি ম'ব'স'লি	ম'ফি ম'ব'স'লি
	Gyeonggi-do, 16690, REPUBLIC OF KOREA. Local Agent: LAB Traders 1512/A, O.R Nizam Road, Panchlaish, Chittagong						চ'ল'ক'ব'ক'য় ম'ক'গ'ল'য় ক'ত'ক'য় ক'ব'ক'য়	চ'ল'ক'ব'ক'য় ম'ক'গ'ল'য় ক'ত'ক'য় ক'ব'ক'য়
29.	SD Biosensor, Inc. C 4th&5th, 16, Deogyong-daero, 1556beon-gil, Yeongtong-gu, Suwon-si, Gyeonggi-do, 16690, REPUBLIC OF KOREA. Local Agent: LAB Traders 1512/A, O.R Nizam Road, Panchlaish, Chittagong	SD CRP control- Level 1 & Level 2	SD CRP Control – Level 1 & Level 2	C	SD CRP Control is intended for use as a quality control material to check the performance of SD MultiCare™ System for CRP testing.	South Korea	সি'ম'ব'স'লি ম'ব'স'লি অ'ব'স'লি ফ'স'স'লি চ'ল'ক'ব'ক'য় ম'ক'গ'ল'য় ক'ত'ক'য় ক'ব'ক'য়	সি'ম'ব'স'লি ম'ব'স'লি অ'ব'স'লি ফ'স'স'লি চ'ল'ক'ব'ক'য় ম'ক'গ'ল'য় ক'ত'ক'য় ক'ব'ক'য়
30.	Manufacturer: Siemens Healthcare Diagnostics Inc. 511 Benedict Avenue Tarrytown, New York 10591-5097, USA Local Agent: Siemens Healthcare Ltd. Laila Tower (6th Floor) 8 Gulshan Avenue Gulshan-1, Dhaka	Anti TG – Auto antibodies against Thyroglobulin Part no. 10492398, Anti TG 100 Test Part no. 10492399, Anti TG 500 Test Part No. LKTG1, 10381641 Anti TG 100 Test Part No. L2KTG2, 10381659 Anti TG 200 Test Part No. L2KTG6, 10381655 Anti TG 600 Test "Accessory" to Anti TG Reagent: Part No. 10630915 CAL 1(ATG) Part No. 9348261, 10310430 ATG DILUENT ANCILLARY Part No. 10630917 ATG CONTROL SET Part No. LAACM, 10385381 Autoantibody CONTROL MODULE Part No. LSUBX, 10385394 Substrate Module	Anti TG – (Auto antibodies against Thyroglobulin) Reagent	B	Quantitative determination of Auto antibodies against Thyroglobulin (Anti TG) from Human Blood Serum or Plasma Samples in Automated Chemiluminescence Immunoassay. Measurement of Auto antibodies against Thyroglobulin (Anti TG) are used to aid in the differential diagnosis of Hashimoto's and Graves disease which are autoimmune disease affecting the Human Thyroid Gland.	USA	অ'ব'স'লি ক'ব'ক'য় ক'ত'ক'য়	অ'ব'স'লি ক'ব'ক'য় ক'ত'ক'য়

SI No	Name of the Manufacturer & Importer	Brand Name	IVD Reagent Name	Class	Intended Uses	FSC/ CPP	তথ্যসূত্রের নাম কিভাবে মফবি মখসি	মফবি মখসি
		Part No. LPWS2, 10385393 Probe Wash Module Part No. LKPM, 10385332 PROBE CLEANING Part No. LCH1-50, 10385360 SAMPLE CUP HOLDER SET Part No. LSCP, 10380037 SAMPLE CUPS Part No. L2SUBM, 10385232 SUBSTRATE MODULE Part No. L2PWSM, 10385231 PROBE WASH MODUL Part No. L2KPM, 10385229 PROBE CLEANING KIT Part No. LRXT, 10385206 REACTION TUBES						
31.	Manufacturer: Siemens Healthcare Diagnostics Inc. 511 Benedict Avenue Tarrytown, New York 10591-5097, USA Local Agent: Siemens Healthcare Ltd. Laila Tower (6th Floor) 8 Gulshan Avenue Gulshan-1, Dhaka	Anti TPO – Auto antibodies against Thyroid Peroxidase Part no. 10630886 Anti TPO 100 Test Part no. 10630887 Anti TPO 500 Test Part No. LKTO1, 10381618 Anti TPO 100 Test Part No. L2KTO2, 10381650 Anti TPO 200 Test Part No. L2KTO6, 10381649 Anti TPO 600 Test "Accessory" to ATPO Reagent: Part No. 10630932 CAL O (Cal Anti TPO) Part No. 6975850, 10310391 Anti TPO Diluent ANCLRY Part No. 10630936 Anti TPO QC KIT Part No. LAACM, 10385381 Autoantibody CONTROL MODULE	Anti TPO – (Auto antibodies against Thyroid Peroxidase) Reagent	B	Quantitative determination of Auto antibodies against Thyroid Peroxidase (Anti TPO) from Human Blood Serum or Plasma Samples in Automated Chemiluminescence Immunoassay Instrument Platform specially manufactured and designed by Manufacturer. Measurement of Autoantibodies against Thyroid Peroxidase (Anti TPO) are used in the diagnosis of of Thyroid Disease.	USA	Abtgr`b Kiv thz crti	Abtgr`b Kiv nj

SI No	Name of the Manufacturer & Importer	Brand Name	IVD Reagent Name	Class	Intended Uses	FSC/ CPP	তുകিবক'ij me Kug'li mfvi imx'is'	mfvi imx'is'
		Part No. LSUBX, 10385394 Substrate Module Part No. LPWS2, 10385393 Probe Wash Module Part No. LKPM, 10385332 PROBE CLEANING Part No. LCH1-50, 10385360 SAMPLE CUP HOLDER SET Part No. LSCP, 10380037 SAMPLE CUPS Part No. L2SUBM, 10385232 SUBSTRATE MODULE Part No. L2PWSM, 10385231 PROBE WASH MODUL Part No. L2KPM, 10385229 PROBE CLEANING KIT Part No. LRXT, 10385206 REACTION TUBES						
32.	Manufacturer: Siemens Healthcare Diagnostics Inc. 511 Benedict Avenue Tarrytown, New York 10591-5097, USA Local Agent: Siemens Healthcare Ltd. Laila Tower (6th Floor) 8 Gulshan Avenue Gulshan-1, Dhaka	Intact PTH – Intact Parathyroid Hormone Part no. 10492368 Intact PTH 100 Test Part no. 10492369 Intact PTH 500 Test Part No. 10699154 Intact PTH 100 Test Part No. 10699155 Intact PTH 500 Test Part No. LKPP1, 10381399 Intact PTH 100 Test Part No. L2KPP2 10381441 Intact PTH 200 Test Part No. L2KPP6 10381442 Intact PTH 600 Test "Accessory" to Intact PTH: Part No. 10492387 IPTH CAL 56 Part No. 10492394 IPTH CAL 56	Intact PTH – (Intact Parathyroid Hormone) Reagent	B	Quantitative determination of Intact Parathyroid Hormone (Intact PTH) from Human Blood Serum or Plasma Samples in Automated Chemiluminescence Immunoassay Instrument Platform specially manufactured and designed by Manufacturer. The Assay Intended to be used to aid in the differential diagnosis of Hyperthyroidism, Hypothyroidism, or Hypocalcaemia of Malignancy.	USA	Ab'gr`b Kiv th'Z c'ri	Ab'gr`b Kiv nj

SI No	Name of the Manufacturer & Importer	Brand Name	IVD Reagent Name	Class	Intended Uses	FSC/CPP	ՀԱՅԱՍՏԱՆԻ ՀԱՆՐԱՊԵՏՈՒԹՅԱՆ ԱՍԻՄԻԼԱԿՆԵՐԻ ԿՐԴՈՒՄԻ ՄԱՍԻՆ	մֆվի մաքսի
		Part No. 5699280, 10310281 MULTI-DILUENT 11 Part No. 10492364 MULTIDIL 13 Part No. 10699156 Intact PTH Control Part No. 10492378 IPTH Control SET Part No. 1137199, 10310032 WASH 1 REAGENT Part No. 3773025 10319550 WASH 1 REAGENT Part No. L2PHZ, 10387060 Intact PTH SMPLE Diluent Part No. LSUBX, 10385394 Substrate Module Part No. LPWS2, 10385393 Probe Wash Module Part No. LKPM, 10385332 PROBE CLEANING Part No. LCH1-50, 10385360 SAMPLE CUP HOLDER SET Part No. LSCP, 10380037 SAMPLE CUPS Part No. L2SUBM, 10385232 SUBSTRATE MODULE Part No. L2PWSM, 10385231 PROBE WASH MODUL Part No. L2KPM, 10385229 PROBE CLEANING KIT Part No. LRXT, 10385206 REACTION TUBES Part No. LPHCM, 10385354 Intact PTH CONTROL MODULE Part No. LPHZ, 10283037 Intact PTH						

SI No	Name of the Manufacturer & Importer	Brand Name	IVD Reagent Name	Class	Intended Uses	FSC/PPP	তথ্যসূত্র Kugli mvi মসি	মবি মসি
		SAMPLE DILUENT						
33.	<p>Manufacturer: Siemens Healthcare Diagnostics Inc. 511 Benedict Avenue Tarrytown, New York 10591-5097, USA</p> <p>Local Agent: Siemens Healthcare Ltd. Laila Tower (6th Floor) 8 Gulshan Avenue Gulshan-1, Dhaka</p>	<p>Total T3 – Triiodothyronin (including Accessory)</p> <p>Part no. 4779663, 10285732 Total T3 400 Test Part no. 4779671, 10285733 Total T3 80 Test Part No LKT31, 10381630 Total T3 100 Test Part No L2KT32, 10381654 Total T3 200 Test Part No L2KT36, 10381657 Total T3 600 Test</p> <p>"Accessory" For Total T3: Part No. 4800646, 10285903 CAL A Part No. 4800735, 10285904 CAL A Part No. 1514596, 10309954 T3/T4/VB12 ANC RGT Part No. 3644012, 10319315 T3/T4/VB12 ANC RGT Part No 6998311 10311588 T3 DILUENT Part No. LT3Z, 10387578 T3 SAMPLE DILUENT Part No. L2M1Z, 10387057 MULTI-DILUENT 1 Part No. LSUBX, 10385394 Substrate Module Part No. LPWS2, 10385393 Probe Wash Module Part No. LKPM, 10385332 PROBE CLEANING Part No. LCH1-50, 10385360 SAMPLE CUP HOLDER SET Part No. LSCP, 10380037 SAMPLE CUPS Part No. L2SUBM, 10385232 SUBSTRATE MODULE Part No. L2PWSM, 10385231 PROBE WASH MODUL Part No. L2KPM, 10385229 PROBE CLEANING KIT Part No. LRXT, 10385206 REACTION TUBES</p>	Total T3 – (Triiodothyronin) Reagent	B	Quantitative determination of Triiodothyronin (Total T3) from Human Blood Serum or Plasma Sample in Automated Chemiluminescence Immunoassay Instrument Platform specially manufactured and designed by manufacturer. Measurement of Triiodothyronin (Total T3) are used in the diagnosis of Human Thyroid Disease.	USA	Abtgr`b Kiv thZ crti	Abtgr`b Kiv nj
34.	<p>Manufacturer: Siemens Healthcare Diagnostics Inc. 511 Benedict Avenue Tarrytown, New York 10591-5097, USA</p> <p>Local Agent: Siemens Healthcare Ltd. Laila Tower (6th Floor) 8 Gulshan Avenue</p>	<p>Total T4 – Thyroxine (Including Accessory)</p> <p>Part no. 9236439, 10309961 Total T4 500 Test Part no. 8074354, 10309960 Total T4 100 Test Part No. LKT41, 10381633 Total T4 100 Test Part No. LKT45, 10381635 Total T4 500 Test</p>	Total T4 – (Thyroxine) Reagent	B	Quantitative determination of Thyroxine (Total T4) from Human Blood Serum or Plasma Sample in Automated Chemiluminescence Immunoassay Instrument Platform specially manufactured and designed by manufacturer. Measurement of Thyroxine (Total T4) are used in the diagnosis of Human Thyroid Disease.	USA	Abtgr`b Kiv thZ crti	Abtgr`b Kiv nj

SI No	Name of the Manufacturer & Importer	Brand Name	IVD Reagent Name	Class	Intended Uses	FSC/CPP	তথ্যক'র্জ মে কৃষ্টি ম'বি ম'র্শ	ম'বি ম'র্শ
	Gulshan-1, Dhaka	Part No L2KT42, 10381685 Total T4 200 Test Part No. L2KT46, 10381664 Total T4 600 Test Part No. DF65, 10444908 Total T4 120 Test "Accessory" to Total T4 Reagent: Part No. 4800646, 10285903 CAL A Part No. 4800735, 10285904 CAL A Part No. DC13, 10445029 T4 CALIBRATOR Part No. 1514596, 10309954 T3/T4/VB12 ANC RGT Part No. 3644012, 10319315 T3/T4/VB12 ANC RGT Part No. 4889086, 10311585 T4 DILUENT Part No. LT4Z 10387587 TOTAL T4 SAMPLE DILUE Part No. L2M1Z, 10387057 MULTI-DILUENT 1 Part No. LSUBX, 10385394 Substrate Module Part No. LPWS2, 10385393 Probe Wash Module Part No. LKPM, 10385332 PROBE CLEANING Part No. LCH1-50, 10385360 SAMPLE CUP HOLDER SET Part No. LSCP, 10380037 SAMPLE CUPS						

SI No	Name of the Manufacturer & Importer	Brand Name	IVD Reagent Name	Class	Intended Uses	FSC/CP	তথ্যক'য় মে ক'য় মে ম'য়	ম'য়
		Part No. L2SUBM, 10385232 SUBSTRATE MODULE Part No. L2PWSM, 10385231 PROBE WASH MODUL Part No. L2KPM, 10385229 PROBE CLEANING KIT Part No. LRXT, 10385206 REACTION TUBES						
35.	Manufacturer: Siemens Healthcare Diagnostics Inc. 511 Benedict Avenue Tarrytown, New York 10591-5097, USA Local Agent: Siemens Healthcare Ltd. Laila Tower (6th Floor) 8 Gulshan Avenue Gulshan-1, Dhaka	TSH – Thyroid Stimulating Hormone (Including Accessory) Part No. LKTS1, 10381620 TSH 100 Test Part No. LKTS5, 10381627 TSH 500 Test Part No. L2KTS2, 10381665 TSH 200 Test Part No. L2KTS6, 10381667 TSH 600 Test Part No. 6491072, 10282378 TSH 100 Test Part No. 6491080, 10282379 TSH 500 Test Part No. 8700387, 10309959 TSH 500 Test Part No. 4911359, 10309958 TSH 100 Test Part No. RF412, 10444911 TSH 200 Test Part No. RF612, 10464524 TSH 200 Test	TSH (Thyroid Stimulating Hormone) Reagent	B	Quantitative determination of Thyroid Stimulating Hormone (TSH, Thyrotropin) from Human Blood Serum or Plasma Sample in Automated Chemiluminescence. Immunoassay Instrument Platform specially manufactured and designed by manufacturer. Measurement of Thyroid Stimulating Hormone (TSH) are used in the diagnosis of Human Thyroid Disease	USA	Ab'gr`b Kiv thZ cv'i	Ab'gr`b Kiv nj

SI No	Name of the Manufacturer & Importer	Brand Name	IVD Reagent Name	Class	Intended Uses	FSC/CPP	ՀԱՅԱՍՏԱՆԻ ՀԱՆՐԱՊԵՏՈՒԹՅԱՆ ԱՍԻՄԻԼԱԿՆԵՐԻ ՄԻՋՈՒԹՅԱՆ ԿՈՄԻՏԵ	միջազգային կոդեր
		"Accessory" to TSH Reagent: Part No. 652707, 10331729 Calibrator B Part No. 649625, 10308986 Calibrator B Part No. LTSZ, 10386996 TSH SAMPLE DILUENT Part No. L2TSZ, 10387061 TSH SAMPLE DILUE Part No. LSUBX, 10385394 Substrate Module Part No. LPWS2, 10385393 Probe Wash Module Part No. LKPM, 10385332 PROBE CLEANING Part No. LCH1-50, 10385360 SAMPLE CUP HOLDER SET Part No. LSCP, 10380037 SAMPLE CUPS Part No. 1137199, 10310032 WASH 1 REAGENT Part No. 3773025, 10319550 WASH 1 REAGENT Part No. 7907174, 10309942 MULTIDIL 1 6PK Part No. 7293184, 10309941 MULTIDIL 1 2PK Part No. L2SUBM, 10385232 SUBSTRATE MODULE Part No. L2PWSM, 10385231 PROBE WASH MODUL Part No. L2KPM, 10385229 PROBE CLEANING KIT Part No. LRXT, 10385206 REACTION						

SI No	Name of the Manufacturer & Importer	Brand Name	IVD Reagent Name	Class	Intended Uses	FSC/ CPP	তുകিবক'ij me Kug'bi mfvi imx'is'	mfvi imx'is'
		TUBES Part No. RXV1A, 10445044 HM REACTION VESSELS Part No. RD701, 10445052 CHEMISTRY WASH Part No. RD702, 10445036 PROBE CLEANER Part No. RD703, 10445035 SAMPLE PROBE CLEANER Part No. 791092901, 10444875 SAMPLE DILUENT Part No. RC410, 10445018 Thyroid Calibrator Part No. RC610, 10464335 THYROID CAL BOX ASSY Part No. KD694, 10483586 MULTI 2 SAMPLE DILUENT						
36.	SD Biosensor, Inc. C 4th&5th, 16, Deogyong-daero, 1556beon-gil, Yeongtong-gu, Suwon-si, Gyeonggi-do, 16690, REPUBLIC OF KOREA. Local Agent: LAB Traders 1512/A, O.R Nizam Road, Panchlaish, Chittagong	<u>STANDARD Q;</u> Malaria P.f/P.v Ag Test	Malaria P.f/P.v Ag Test	B	It is a rapid and membrane based immunochromatography for the qualitative detection of Plasmodium falciparum (P. falciparum) specific Histidine Rich Protein 2 (HRP-2) and Plasmodium vivax specific Plasmodium lactate dehydrogenase (pLDH) in human whole blood specimen. This test is in vitro professional diagnostic use and intended as an aid to diagnosis of the infection in patient with suspected malaria before treatment is administered. It provides only an initial screening test. Therefore, any reactive specimen with this test should be confirmed with alternative testing method such as microscopic examination of thin blood smear and clinical findings.	South Korea	Ab'gr`b Kiv th'Z c'ri	Ab'gr`b Kiv nj
37.	SD Biosensor, Inc. C 4th&5th, 16, Deogyong-daero, 1556beon-gil,	<u>STANDARD Q;</u> Malaria P.f/Pan Ag Test	Malaria P.f/Pan Ag Test	B	It is a rapid and membrane based immunochromatography for the qualitative detection of Plasmodium falciparum (P. falciparum) specific Histidine	South Korea	Ab'gr`b Kiv th'Z c'ri	Ab'gr`b Kiv nj

SI No	Name of the Manufacturer & Importer	Brand Name	IVD Reagent Name	Class	Intended Uses	FSC/ CPP	ᠲᠤᠬᠤᠨᠢᠪᠠᠨᠠᠵᠢ ᠮᠡᠮᠡᠮᠤᠨᠠᠵᠢ	ᠮᠡᠮᠡᠮᠤᠨᠠᠵᠢ
	Yeongtong-gu, Suwon-si, Gyeonggi-do, 16690, REPUBLIC OF KOREA. Local Agent: LAB Traders 1512/A, O.R Nizam Road, Panchlaish, Chittagong				Rich Protein 2 (HRP-2) and Plasmodium species (P. falciparum, vivax, ovale and malariae) specific Plasmodium lactate dehydrogenase (pLDH) in human whole blood specimen. This test is in vitro professional diagnostic use and intended as an aid to diagnosis of the infection in patient with suspected malaria before treatment is administered. It provides only an initial screening test. Therefore, any reactive specimen with this test should be confirmed with alternative testing method such as microscopic examination of thin blood smear and clinical findings.			
38.	SD Biosensor, Inc. C 4th&5th, 16, Deogyong-daero, 1556beon-gil, Yeongtong-gu, Suwon-si, Gyeonggi-do, 16690, REPUBLIC OF KOREA Local Agent: LAB Traders 1512/A, O.R Nizam Road, Panchlaish, Chittagong	<u>STANDARD Q:</u> Dengue IgM/IgG Test	Dengue IgM/IgG Test	B	It is an immunochromatographic assay for the detection of IgM/IgG antibodies against Dengue virus in human serum, plasma, or whole blood samples. This test kit is for in vitro use only. This is intended for professional use, only for an initial screening test.	South Korea	ᠠᠪᠲᠦᠭᠦᠷᠪᠠᠨᠠᠵᠢ ᠬᠢᠪᠠᠨᠠᠵᠢ	ᠠᠪᠲᠦᠭᠦᠷᠪᠠᠨᠠᠵᠢ ᠬᠢᠪᠠᠨᠠᠵᠢ
39.	SD Biosensor, Inc. C 4th&5th, 16, Deogyong-daero, 1556beon-gil, Yeongtong-gu, Suwon-si, Gyeonggi-do, 16690, REPUBLIC OF KOREA Local Agent: LAB Traders 1512/A, O.R Nizam Road, Panchlaish, Chittagong	<u>STANDARD Q:</u> Dengue NS1 Ag Test	Dengue NS1 Ag Test	B	It is an immunochromatographic assay for the detection of Dengue NS1 antigens in human serum, plasma, or whole blood samples. This test kit is for in vitro use only. This is intended for professional use, only for an initial screening test.	South Korea	ᠠᠪᠲᠦᠭᠦᠷᠪᠠᠨᠠᠵᠢ ᠬᠢᠪᠠᠨᠠᠵᠢ	ᠠᠪᠲᠦᠭᠦᠷᠪᠠᠨᠠᠵᠢ ᠬᠢᠪᠠᠨᠠᠵᠢ
40.	SD Biosensor, Inc. C 4th&5th, 16, Deogyong-daero, 1556beon-gil,	<u>STANDARD Q:</u> Dengue Ag/Ab Duo Test	Dengue Ag/Ab Duo Test	B	It is an immunochromatographic assay for the detection of Dengue NS1 antigens and IgM/IgG antibodies against Dengue virus in human serum, plasma, or whole blood	South Korea	ᠠᠪᠲᠦᠭᠦᠷᠪᠠᠨᠠᠵᠢ ᠬᠢᠪᠠᠨᠠᠵᠢ	ᠠᠪᠲᠦᠭᠦᠷᠪᠠᠨᠠᠵᠢ ᠬᠢᠪᠠᠨᠠᠵᠢ

SI No	Name of the Manufacturer & Importer	Brand Name	IVD Reagent Name	Class	Intended Uses	FSC/PPP	তുകিবক'য় মে কুগ'লি ম'বি ম'ব'স'ি	ম'বি ম'ব'স'ি
	Yeongtong-gu, Suwon-si, Gyeonggi-do, 16690, REPUBLIC OF KOREA.				samples. This test kit is for in vitro use only. This is intended for professional use, only for an initial screening test.			
41.	SD Biosensor, Inc. C 4th&5th, 16, Deogyong-daero, REPUBLIC OF KOREA Local Agent: LAB Traders 1512/A, O.R Nizam Road, Panchlaish, Chittagong	<u>STANDARD Q: Zika/Dengue Trio Test</u>	Zika/Dengue Trio Test	B	It is a rapid chromatographic immunoassay for the detection of Zika IgM/IgG, Dengue IgM/IgG or Dengue NS1 in human serum, plasma or whole blood. This test is for in vitro professional diagnostic use and intended as an aid to early diagnosis of Zika and/or Dengue virus infection in patient with clinical symptoms. It provides only an initial screening test result. Alternative diagnosis methods recommended by the WHO algorithm, the CDC guideline or laboratory testing from the regulatory authorities should be performed in order to obtain the confirmation of the virus infection.	South Korea	Ab'gr`b Kiv th'Z c'ri	Ab'gr`b Kiv nj
42.	SD Biosensor, Inc. C 4th&5th, 16, Deogyong-daero, 1556beon-gil, Yeongtong-gu, Suwon-si, Gyeonggi-do, 16690, REPUBLIC OF KOREA Local Agent: LAB Traders 1512/A, O.R Nizam Road, Panchlaish, Chittagong	<u>STANDARD Q: ZikaIgM/IgG Test</u>	Zika IgM/IgG Test	B	It is a rapid chromatographic immunoassay for the simultaneous detection of Zika IgM/IgG present in serum, plasma or whole blood and differentiation between them. This test is for in vitro professional diagnostic use and intended as an aid to early diagnosis of Zika virus infection in patient with clinical symptoms. It provides only an initial screening test result. Alternative diagnosis methods recommended by the WHO algorithm, the CDC guideline or laboratory testing from the regulatory authorities should be performed in order to obtain the confirmation of Zika virus infection.	South Korea	Ab'gr`b Kiv th'Z c'ri	Ab'gr`b Kiv nj
43.	SD Biosensor, Inc. C 4th&5th, 16, Deogyong-daero, 1556beon-gil, Yeongtong-gu, Suwon-si, Gyeonggi-do, 16690, REPUBLIC OF KOREA Local Agent: LAB Traders	<u>STANDARD Q: Malaria P.f Ag Test</u>	Malaria P.f Ag Test	B	It is a rapid and membrane based immunochromatography for the qualitative detection of Plasmodium falciparum (P. falciparum) specific Histidine Rich Protein 2 (HRP-2) in human whole blood specimen. This test is in vitro professional diagnostic use and intended as an aid to diagnosis of the infection in patient with suspected malaria before treatment is administered. It provides only an initial screening test. Therefore, any reactive specimen with this test should be confirmed	South Korea	Ab'gr`b Kiv th'Z c'ri	Ab'gr`b Kiv nj

SI No	Name of the Manufacturer & Importer	Brand Name	IVD Reagent Name	Class	Intended Uses	FSC/ CPP	তുകিবক'য় মে কিউবি মবি ম×বিসি	মবি ম×বিসি
	1512/A, O.R Nizam Road, Panchlaish, Chittagong				with alternative testing method such as microscopic examination of thin blood smear and clinical findings.			
44.	SD Biosensor, Inc. C 4th&5th, 16, Deogyong-daero, 1556beon-gil, Yeongtong-gu, Suwon-si, Gyeonggi-do, 16690, REPUBLIC OF KOREA Local Agent: LAB Traders 1512/A, O.R Nizam Road, Panchlaish, Chittagong	<u>STANDARD F:</u> Influenza A/B FIA	Influenza A/B FIA	B	It is the fluorescence immunoassay to detect influenza infection in human nasal swab and nasopharyngeal swab, wash, or aspirate specimens, identifying existence of influenza virus type A and B. STANDARD F Influenza A/B FIA should be used with the STANDARD F Analyzers manufactured by SD BIOSENSOR. This is intended for professional use, only for an initial screening test.	South Korea	Abjgr`b Kiv thtZ cxti	Abjgr`b Kiv nj
45.	SD Biosensor, Inc. C 4th&5th, 16, Deogyong-daero, 1556beon-gil, Yeongtong-gu, Suwon-si, Gyeonggi-do, 16690, REPUBLIC OF KOREA Local Agent: LAB Traders 1512/A, O.R Nizam Road, Panchlaish, Chittagong	<u>STANDARD F:</u> F200 Analyzer	STANDARD F200 Analyzer	B	The STANDARD F200 Analyzer works for measuring quantitative or qualitative biomarker with body fluid such as blood, urine, nasal mucus, and so on based in vitro diagnostic assays in laboratory and point-of-care settings. The analyzer is indicated for monitoring and diagnosing from the body fluid parameter in clinical settings by healthcare professionals.	South Korea	Abjgr`b Kiv thtZ cxti	Abjgr`b Kiv nj
46.	SD Biosensor, Inc. C 4th&5th, 16, Deogyong-daero, 1556beon-gil, Yeongtong-gu, Suwon-si, Gyeonggi-do, 16690, REPUBLIC OF KOREA. Local Agent: LAB Traders 1512/A, O.R Nizam Road, Panchlaish, Chittagong	SD Multicare Analyzer	SD MultiCare Analyzer	B	The SD MultiCare™ System is a reflectometry immunoassay instrument for the quantitative measurement in human blood, urine and other specimens. This system is for in vitro diagnostic use and professional use in hospital and clinic.	South Korea	Abjgr`b Kiv thtZ cxti	Abjgr`b Kiv nj

SI No	Name of the Manufacturer & Importer	Brand Name	IVD Reagent Name	Class	Intended Uses	FSC/ CPP	তുകিবক'য় মে কিউবি মবি মখি	মবি মখি
	C 4th&5th, 16, Deogyong-daero, 1556beon-gil, Yeongtong-gu, Suwon-si, Gyeonggi-do, 16690, REPUBLIC OF KOREA Local Agent: LAB Traders 1512/A, O.R Nizam Road, Panchlaish, Chittagong		Dengue IgG ELISA		detection of anti-Dengue IgGs in human serum or plasma. This test is intended for professional use as an aid to diagnosis of Dengue virus infection. This test kit is for in vitro use only.	Korea	thZ cti	nj
51.	SD Biosensor, Inc. C 4th&5th, 16, Deogyong-daero, 1556beon-gil, Yeongtong-gu, Suwon-si, Gyeonggi-do, 16690, REPUBLIC OF KOREA. Local Agent: LAB Traders 1512/A, O.R Nizam Road, Panchlaish, Chittagong	STANDARD G6PD Analyzer	STANDARD G6PD Analyzer	B	It is designed to measure the quantitative determination of total-hemoglobin concentration and G6PD enzymatic activity in fresh human whole blood specimen based on reflectometry assays. The test is intended to aid in the identification of people with G6PD deficiency providing point-of care access and allowing prompt treatment decisions. The analyzer is for in vitro diagnostic use and professional use only. The analyzer should be used exclusively with the STANDARD G6PD test device and STANDARD G6PD check strip manufactured by SD BIOSENSOR. Kindly refer to STANDARD G6PD Test Instructions for Use for details on the test.	South Korea	Abjgr`b Kiv thZ cti	Abjgr`b Kiv nj
52.	SD Biosensor, Inc. C 4th&5th, 16, Deogyong-daero, 1556beon-gil, Yeongtong-gu, Suwon-si, Gyeonggi-do, 16690, REPUBLIC OF KOREA Local Agent: LAB Traders 1512/A, O.R Nizam Road, Panchlaish, Chittagong	STANDARD G6PD Test	STANDARD G6PD Test	B	It is an in vitro enzymatic colorimetric method for the quantitative measurement of total-hemoglobin concentration and G6PD enzymatic activity in human fresh whole blood specimen. The test is intended to aid in the identification of people with G6PD deficiency providing point-of-care access and allowing prompt treatment decisions. The STANDARD G6PD Test can also be applicable to neonatal screening for G6PD deficiency. This STANDARD G6PD Test is for professional use only. Specimens which generate deficient results should be considered with other clinical history available to the physician and confirmatory test methods to verify the deficiency.	South Korea	Abjgr`b Kiv thZ cti	Abjgr`b Kiv nj
53.	SD Biosensor, Inc. C 4th&5th, 16, Deogyong-daero, 1556beon-gil,	<u>STANDARD F:</u> U-Albumin FIA	STANDARD F U-Albumin FIA	B	The STANDARD F U-Albumin FIA is an in vitro diagnostic use to measure the albumin in the urine from the human. This test is for professional use to measure	South Korea	Abjgr`b Kiv thZ cti	Abjgr`b Kiv nj

SI No	Name of the Manufacturer & Importer	Brand Name	IVD Reagent Name	Class	Intended Uses	FSC/ CPP	†UKibK`ij me Kuglji mfvi m×všf	mfvi m×vš
	Yeongtong-gu, Suwon-si, Gyeonggi-do, 16690, REPUBLIC OF KOREA Local Agent: LAB Traders 1512/A, O.R Nizam Road, Panchlaish, Chittagong				U-Albumin to aid to predict the diabetic nephropathy and cardiovascular diseases (CVD). STANDARD F U-Albumin FIA should be used with the appropriate analyzer, STANDARD F Analyzers, manufactured by SD BIOSENSOR.			
54.	SD Biosensor, Inc. C 4th&5th, 16, Deogyong-daero, 1556beon-gil, Yeongtong-gu, Suwon-si, Gyeonggi-do, 16690, REPUBLIC OF KOREA. Local Agent: LAB Traders 1512/A, O.R Nizam Road, Panchlaish, Chittagong	SD U-Albumin control- Level 1 & Level 2	SD U-Albumin Control – Level 1 & Level 2	B	SD U-Albumin Control is intended for use as a quality control material to check the performance of SD MultiCare™ System for U-Albumin testing.	South Korea	Abjgr`b Kiv thtZ citi	Abjgr`b Kiv nj

Annex-G: Proposed Product for Import (Medical Devices)

SI No	cŪZKviŕKi big	ewŕŕK big	ŕgŕŕKj ŕŕŕBŕmi big	Kŕm	ŕbŕ Rbv	Contraindication & Side-effect	FSC/CPP	ŕUKŕbK'ij me Kŕgŕŕi mŕŕi ŕŕŕŕŕ	mŕŕi ŕŕŕŕŕ
9.	<p>Medtronic SofamorDanek USA , INC, 1800 Pyramid, USA</p> <p>Local Agent: Medtronic Bangladesh Pvt. Ltd, Santa Western tower , Tejgaon, Dhaka</p>	Mastergraft Granules	Resorbable calcium salt bone void filler	B	<p>Dental: MASTERGRAFT® Granules may be used alone or in combination with autograft to provide a bone void filler that is resorbed/ remodeled and is replaced by host bone during the healing process. MASTERGRAFT® Granules is packed into bony voids or gaps to fill and/or augment dental oral/maxillofacial bony tissue.</p> <p>specific to MASTERGRAFT® Mini Granules include:</p> <ul style="list-style-type: none"> • Filling of periodontal defects • Sinus lifts • Alveolar ridge augmentation • Filling of dental extraction sockets 	<p>CONTRAINDICATIONS: This product is not intended to provide structural support during the healing process, therefore, MASTERGRAFT® is contraindicated where the device is intended as structural support in the skeletal system. Conditions representing relative contraindications include: 1. Severe neurological or vascular disease. 2. Uncontrolled diabetes. 3. Hypercalcemia. 4. Pregnancy. 5. Where stabilization of fracture is not possible. 6. Segmental defects. 7. Where there is significant vascular impairment proximal to the graft site. 8. When there are systemic and/or metabolic disorders that affect the bone or wound healing. 9. Any patient unwilling to follow postoperative instructions. 10. Any case not described in the indications.</p> <p>POTENTIAL ADVERSE EVENTS A listing of potential adverse events includes, but is not limited to: 1. Deformity of the bone at the surgical site. 2. Fracture or extrusion of the MASTERGRAFT® GRANULES, with or without generation of particulate debris. 3. Wound complications including hematoma, site damage, infection, bone fracture, and other complications common to any surgical procedure. 4. Incomplete, or lack of, osseous ingrowth into bone void, as possible with any bone filler.</p>	CFG-USA	Abŕgŕ b Kŕv thŕZ cŕŕi	Abŕgŕ b Kŕv nj
10.	<p>M/s Medtronic Ireland , park more Business park west , Galway, Ireland</p> <p>Local Agent: Medtronic Bangladesh Pvt. Ltd, Santa Western tower , Tejgaon, Dhaka</p>	Valiant thoracic stent graft with Captivia delivery system	Thoracic Aortic Aneurysm (TAA) stent graft	C	<p>The Valiant thoracic stent graft with the Captivia delivery system is indicated for the endovascular repair of all lesions of the descending thoracic aorta (DTA) in patients having the appropriate anatomy including: • Iliac or femoral artery access vessel morphology that is compatible with vascular access techniques, devices, or accessories; • nonaneurysmal aortic diameter in the range of 18 mm to 42 mm (fusiform and saccular aneurysms/penetrating ulcers), or 18 mm to 44 mm (blunt traumatic aortic injuries), or 20 mm to 44 mm (dissections); and • nonaneurysmal aortic proximal and distal neck lengths \geq20 mm (fusiform and saccular</p>	<p>Contraindications: The Valiant thoracic stent graft with the Captivia delivery system is contraindicated in the following patient populations: • patients who have a condition that threatens to infect the graft • patients with known sensitivities or allergies to the device materials</p> <p>Adverse Events: Potential Adverse Events Adverse events or complications associated with the use of the Valiant thoracic stent graft with the Captivia delivery system that may occur or require intervention include, but are</p>	CFG -USA, CE	Abŕgŕ b Kŕv thŕZ cŕŕi	Abŕgŕ b Kŕv nj

SI No	cŃZKviŃKi big	ewŃrŃK big	ŃgŃŃKj ŃŃfŃŃi big	KŃm	ŃbŃ Rbv	Contraindication & Side-effect	FSC/CPP	ŃUKŃK'vj me KugŃŃi mŃvi ŃmŃŃŃŃ	mŃvi ŃmŃŃŃŃ
					aneurysms/penetrating ulcers), landing zone ≥ 20 mm proximal to the primary entry tear (blunt traumatic aortic injuries, dissections). The proximal extent of the landing zone must not be dissected.	not limited to: • Access failure • Embolism • Post-procedural bleeding • Access site complications (eg, spasm, trauma, bleeding, rupture, dissection) • Endoleaks • Procedural bleeding • Adynamic Ileus • Excessive or inappropriate radiation exposure • Prosthesis dilatation • Allergic reaction (to contrast, antiplatelet therapy, stent graft material) • Extrusion/erosion • Prosthesis infection • Amputation • Failure to deliver the stent graft • Prosthesis rupture • Anesthetic complications • Femoral neuropathy • Prosthesis thrombosis • Aortic expansion (e.g. aneurysm, false lumen) • Fistula (aortobronchia, aortoenteric, aortoosophogeal, arteriovenous, lymph) • Pseudoaneurysm • Aneurysm rupture • Gastrointestinal bleeding/complications • Pulmonary edema • Angina • Genitourinary complications • Pulmonary embolism • Aortic vessel rupture • Hematoma • Reaction to anaesthesia • Arrhythmia • Hemorrhage/bleeding • Renal failure • Arterial stenosis • Hypotension/hypertension • Renal insufficiency • Atelectasis • Infection or fever • Reoperation • Blindness • Insertion or removal difficulty • Respiratory depression or failure • Bowel ischemia/infarction • Intercostal pain • Retrograde Type A dissection • Bowel necrosis • Intramural hematoma • Sepsis • Bowel obstruction • Leg edema/foot edema • Seroma • Branch vessel occlusion • Lymphocele • Shock • Buttock claudication • Myocardial infarction • Spinal neurological deficit • Cardiac tamponade • Neuropathy • Stent graft material failure (including breakage of metal portion of device) • Catheter breakage • Occlusion – Venous or Arterial • Stent graft migration •			

SI No	cŌZKviŧKi big	ewŨr`K big	ŧgŨŧKj ŨfŨBŧmi big	KŨm	Ũbŧ`Rbv	Contraindication & Side-effect	FSC/ CPP	ŧUKŨbK`vj me KugŨŨi mfvi Ũm×vŨŧ	mfvi Ũm×vŨŧ
						Cerebrovascular accident (CVA)/Stroke • Pain/Reaction at catheter insertion site • Stent graft misplacement • Change in mental status • Paralysis • Stent graft occlusion • Coagulopathy • Paraparesis • Stent graft twisting or kinking • Congestive heart failure • Paraplegia • Transient ischemic attack (TIA) • Contrast toxicity • Paresthesia • Thrombosis • Conversion to surgical repair • Perfusion of the false lumen • Tissue necrosis • Death • Peripheral ischemia • Vascular ischemia • Deployment difficulties/ failures • Peripheral nerve injury • Vascular trauma • Dissection, perforation, or rupture of the aortic vessel & surrounding vasculature • Pneumonia • Wound dehiscence • Post-implant syndrome • Wound healing complications			
11.	Medtronic Heart Valves Division, 1851 E. Deere Avenue, Santa Ana, CA 92705, USA Local Agent: Medtronic Bangladesh Pvt. Ltd, Santa Western tower , Tejgaon, Dhaka	CG Future Annuplasty Devices	Annuplasty Devices	C	The CG Ring is indicated for the reconstruction and/or remodeling of pathological mitral valves. Valvular insufficiency and/or stenosis may be corrected by appropriate repair and annular remodeling.	Heavily calcified valves, valvular retraction with severely reduced mobility, active bacterial endocarditis.	CFG-USA, EC Certificate	Abŧgv`b Kiv thŧZ cŧŧi	Abŧgv`b Kiv nj
12.	Medtronic Heart Valves Division, 1851 E. Deere Avenue, Santa Ana, CA 92705, USA Local Agent: Medtronic Bangladesh Pvt. Ltd, Santa Western tower , Tejgaon, Dhaka	Contour 3D	Annuplasty Ring	C	The Contour 3D™ Ring is indicated for the reconstruction and/or remodeling of pathological tricuspid valves.	Contraindications: The Contour 3D™ Ring is contraindicated for patients presenting with any of the following conditions: • Heavily calcified valves • Valvular retraction with severely reduced mobility • Active bacterial endocarditis	CFG-USA, EC Certificate	Abŧgv`b Kiv thŧZ cŧŧi	Abŧgv`b Kiv nj

SI No	cŃZKviŃKi big	ewŃrŃK big	ŃgŃŃŃKj ŃŃŃBŃmi big	KŃm	ŃbŃŃ Rbv	Contraindication & Side-effect	FSC/CPP	ŃUKŃbKŃvj me KugŃŃi mŃvi ŃmŃŃŃŃ	mŃvi ŃmŃŃŃŃ
13.	Medtronic Heart Valves Division, 1851 E. Deere Avenue, Santa Ana, CA 92705, USA Local Agent: Medtronic Bangladesh Pvt. Ltd, Santa Western tower , Tejgaon, Dhaka	Profile 3D	Annuplasty Ring	C	This device is indicated for the reconstruction and/or remodeling of pathological mitral valves. Valvular insufficiency and/or stenosis may be corrected by appropriate repair and annular remodeling. Heavily calcified valves, valvular retraction with severely reduced mobility, active bacterial endocarditis	Contraindications: It is contraindicated for patients presenting with any of the following conditions: • Heavily calcified valves • Valvular retraction with severely reduced mobility • Active bacterial endocarditis	CFG-USA, EC Certificate	AbŃgrŃ b Kiv thiZ cŃti	AbŃgrŃ b Kiv nj
14.	Manufacturer: CEFALY Technology, Rue Louis Plescia 34, 4102 Seraing, Belgium Local Agent: Hema Enterprises Dhaka Trade Centre 99, Kazi Nazrul Islam Avenue, Kawran Bazar C/A, Dhaka-1215	Cefaly	Cefaly Anti-Migraine Device	B	The Cefaly® device is an external cranial neurostimulator designed for supraorbital neurostimulation (also known as external trigeminal nerve stimulation). Trigeminal nerve stimulation induces a neuromodulation of the trigeminal system in order to reduce the frequency of migraine attacks. This is a great confirmation that the Cefaly® is a better solution than medications for migraine prophylaxis. Cefaly®device, uses tiny electrical impulses to stimulate the trigeminal nerve to reduce the frequency and intensity of migraines.	Contraindications 1. Recent brain or facial trauma (less than 3 months). 2. Skin abrasion on the forehead in the area of application of the electrode. 3. Allergy to acrylate. 4. Cutaneous hypersensitivity: +/- 5% of people present a hypersensitivity of the forehead skin and do not tolerate the sensation induced by the Cefaly®. 5. Implanted electronic device in the head. Side effects 1) Sedative effect During a Cefaly® treatment session, there is a sedative effect which is accompanied by a reduction in vigilance and a tendency to fall asleep. This prohibits the use of Cefaly® while driving or during a dangerous activity that needs to be alert and focused. 2) Skin reaction At the end of the session, the skin on the forehead may become reddened where the electrode was placed. This is caused by stimulation of the blood circulation. Depending on the individual, this redness can last for a few minutes or more after the session.	Belgium	AbŃgrŃ b Kiv thiZ cŃti	AbŃgrŃ b Kiv nj

SI No	cŃZKviŃKi big	ewŃrK big	ŃgŃŃKj ŃŃfBŃmi big	KŃm	ŃbŃ Rbv	Contraindication & Side-effect	FSC/ CPP	ŃUKŃK'vj me KŃgŃŃi m fvi ŃŃŃŃŃŃ	m fvi ŃŃŃŃŃŃ
						<p>In very rare cases an allergy to the acrylate of the electrode gel can arise. A temporary rash gradually develops on the forehead. If this should occur, stop using Cefaly® and contact the manufacturer CEFALY Technology to order special electrodes. The skin rash will gradually disappear within in a few days. The use of an anti-inflammatory cream can accelerate the disappearance of the rash.</p> <p>3) Pain during the session A portion of people may perceive the sensation produced by the Cefaly® during the session as painful. In most cases habituation and tolerance to the feeling settle in a few days or weeks. However, there is still a small percentage of subjects for whom the feeling is painful despite regular use.</p> <p>4) Headache after the session Very rarely a headache can occur at the end of a session. This is casual and fleeting but prevents some patients from making effective use of Cefaly®.</p> <p>5) Persistence of sensation The perceived sensation during the session may extend beyond it. In most subjects tingling quickly disappears within the tens of minutes after the session. But for some subjects the feeling persists for several hours or even more. While this may be perceived as unpleasant, it is harmless and inconsequential.</p> <p>6) Neck pain Some subjects, especially in the early stages of use, tend to unconsciously contract neck muscles during a session. It can then lead to</p>			

SI No	cŃZKviŃKi big	ewŃrŃK big	ŃgŃŃKj ŃŃfŃŃmi big	KŃm	ŃbŃŃ Rbv	Contraindication & Side-effect	FSC/ CPP	ŃUKŃKŃvj mve KŃgŃŃŃi mŃvi ŃmŃŃŃŃŃ	mŃvi ŃmŃŃŃŃŃ
						<p>Proper sizing of the device is the responsibility of the physician. The aortic stent graft component should be over-sized approximately 10% to 20% from the vessel inner diameter, and the Endurant stent graft components cover aortic diameters ranging from 19 mm to 32 mm. The recommended overall length of multiple deployed in situ assembled modular components of the Endurant Stent Graft System should extend from the lowest renal artery to just above the internal iliac (hypogastric) artery bifurcation. All lengths and diameters of the stent graft components necessary to complete the procedure should be available to the physician, especially when pre-operative case planning measurements (treatment diameters/lengths) are not certain. Using this approach allows for greater intraoperative flexibility to achieve optimal procedural outcomes. Medtronic Vascular may consult with physicians in their efforts to determine proper stent graft component dimensions based on the physician's assessment of the patient's anatomical measurements. The risks and benefits previously described in Section 4.3 should be carefully considered for each patient before use of the Endurant Stent Graft System. Patient selection factors to be assessed should include: ■ Patient's age and life expectancy ■ Co-morbidities (e.g. cardiac, pulmonary or renal insufficiency prior to surgery) ■ Patient morphologic suitability for endovascular repair NOTE: Due to the nature of the design and the flexibility of the Endurant Stent Graft System, the overall length of each stent graft component may be shorter when deployed than expected due to compression during</p>			

SI No	cŃZKviŃKi big	ewŃR`K big	ŃgŃŃKj ŃŃfŃŃmi big	KŃm	ŃbŃ`Rbv	Contraindication & Side-effect	FSC/CPP	ŃUKŃK`vj mve KugŃŃi mŃvi ŃmŃŃŃŃ	mŃvi ŃmŃŃŃŃ
						<p>deployment or tortuous anatomy. Table 1. Potential Risks Associated with Use of the Endurant Stent Graft System ■ Access failure ■ Allergic reaction (to contrast, anti-platelet therapy, stent graft material) ■ Anastomotic false aneurysm ■ Anemia ■ Anesthesia-related complications ■ Aneurysm expansion ■ Aneurysm rupture ■ Angina ■ Aortic vessel rupture ■ Aortoenteric fistula ■ Arrhythmia ■ Arteriovenous fistula ■ Atelectasis ■ Atherosclerotic ulcer ■ Bowel ischemia ■ Bowel necrosis ■ Bowel obstruction ■ Branch vessel occlusion ■ Buttock claudication ■ Cardiac tamponade ■ Catheter breakage ■ Cerebrovascular accident ■ Change in mental status ■ Coagulopathy ■ Congestive heart failure ■ Contrast toxicity ■ Conversion to surgical repair ■ Damage to the vessel which may require a conversion to open repair ■ Death ■ Dehiscence ■ Deployment failures ■ Device malfunction ■ Dissection, perforation, or rupture of the aortic vessel & surrounding vasculature ■ Embolism ■ Endoleaks ■ Excessive or inappropriate radiation exposure ■ Extrusion/erosion ■ Failure to deliver the stent graft ■ Fem-Fem bypass occlusion ■ Femoral neuropathy ■ Fever ■ Gastrointestinal bleeding ■ Genitourinary complications ■ Hematoma ■ Hypotension/hypertension ■ Ileus ■ Infection ■ Intramural hematoma ■ Lower limb edema ■ Loss of stent graft integrity ■ Loss of stent graft patency ■ Lymphocele/lymph fistula ■ Myocardial infarction ■ Neck enlargement (aneurysmal) ■ Neoplasm ■ Nerve injury ■ Pain/reaction at catheter insertion site ■ Paraplegia ■ Pericarditis ■ Peripheral</p>			

SI No	cŃZKviŃKi big	ewŃrŃK big	ŃgŃŃKj ŃŃfŃBŃmi big	KŃm	ŃbŃŃ Rbv	Contraindication & Side-effect	FSC/CPP	ŃUKŃbKŃvj me KŃgŃŃŃi mŃfvi ŃmŃŃŃŃŃ	mŃfvi ŃmŃŃŃŃŃ
						ischemia ■ Peripheral nerve injury ■ Pleural effusion ■ Pneumonia ■ Pneumothorax ■ Post-implant syndrome ■ Post-procedural bleeding ■ Procedural bleeding ■ Pseudoaneurysm ■ Pulmonary edema ■ Pulmonary embolism ■ Renal failure ■ Renal insufficiency ■ Respiratory depression or failure ■ Retroperitoneal bleeding ■ Sepsis ■ Seroma ■ Sexual dysfunction ■ Shock ■ Spinal neurological deficit ■ Stenosis ■ Stent graft dilatation ■ Stent graft infection ■ Stent graft kinking ■ Stent graft migration ■ Stent graft misplacement ■ Stent graft rupture ■ Stent graft thrombosis ■ Transient-ischemic attack ■ Vascular trauma ■ Vessel occlusion ■ Wound infection			
17.	Medtronic Heart Valves Division, 1851 E. Deere Avenue, Santa Ana, CA 92705, USA Local Agent: Medtronic Bangladesh Pvt. Ltd, Santa Western tower , Tejgaon, Dhaka	Medtronic Aortic Punch	Aortic Bioprosthesis	C	The CARDIOPUNCH™ Single Use Aortic Punch is indicated for use in creating a circular opening in the aortic wall to facilitate vascular anastomosis during coronary artery bypass grafting.	Contraindication: None Side Effect: None	CFG-USA, EC Certificate	AbŃgŃŃ b Kiv thŃZ cŃŃi	AbŃgŃŃ b Kiv nj
18.	M/S. ev3, incorporation , 4600, Nathan Lane North, Polymouth MN, USA Local Agent: Medtronic Bangladesh Pvt. Ltd, Santa Western tower , Tejgaon, Dhaka	TurbohawkPeripheral Plaque Excision system	Peripheral Plaque Excision system (athrectomy)	C	The TurboHawk™ Peripheral Plaque Excision System is intended for use in atherectomy of the peripheral vasculature.		CFG –USA, CE	AbŃgŃŃ b Kiv thŃZ cŃŃi	AbŃgŃŃ b Kiv nj
19.	Manufactured by:	Freestyle Optium Neo	Blood Glucose and Ketone Monitoring	C	To measure Blood glucose and Ketone in fresh blood outside the body.	Contraindications: None Side Effects: None	UK EC	AbŃgŃŃ b Kiv thŃZ cŃŃi	AbŃgŃŃ b Kiv nj

SI No	cŌZKviŃKi big	ewŃr`K big	ŃgŃŃKj ŃŃfBŃmi big	KŃm	ŃbŃ`Rbv	Contraindication & Side-effect	FSC/CPP	ŃUKŃK`vj mve KugŃŃi mfvŃ Ńm×vŃŃ	mfvŃ Ńm×vŃŃ
	<p>Legal Manufacturer: Boston Scientific Corporation 300 Boson Scientific Way Marlborough MA 01752 USA</p> <p>Local Agent: Medi Graphic Trading Ltd , 14 Purana Paltan, Dar Us Salam Arcade, 3rd Floor, Dhaka</p>				procedures.	<p>constitute a threat to patient safety. The contraindications also include the following: Bacteremia or sepsis, Major coagulation system abnormalities, Patients diagnosed with coronary artery spasm, Patients disqualified for CABG surgery, Patients disqualified for PTCA, Severe hemodynamic instability or shock, Use of the imaging catheter to cross a total occlusion</p> <p>ADVERSE EVENTS: The risks and discomforts involved in vascular imaging include those associated with all catheterization procedures. These risks or discomforts may occur at any time with varying frequency or severity. Additionally, these complications may necessitate additional medical treatment including surgical intervention and, in rare instances, result in death. Allergic reaction, Angina, Cardiac arrest, Cardiac arrhythmias including, but not limited to ventricular tachycardia, atrial/ventricular fibrillation and complete heart block, Cardiac tamponade/Pericardial effusion, Death, Device entrapment requiring surgical intervention, Embolism (air, foreign body, tissue or thrombus), Hemorrhage/Hematoma, Hypotension, Infection, Myocardial infarction, Myocardial Ischemia, Stroke and Transient Ischemic Attack, Thrombosis, Vessel occlusion and abrupt closure, Vessel trauma including, but not limited to dissection and perforation</p>			
24.	Manufacturer: Boston Scientific Corporation, Costa Rica	Opticross X 40 MHz coronary imaging Catheter	Coronary Imaging catheter	D	This catheter is intended for ultrasound examination of coronary intravascular pathology only. Intravascular ultrasound imaging is indicated in patients who are candidates for transluminal coronary interventional	Contraindications: Use of this imaging catheter is contraindicated where introduction of any catheter would	USA EC Certificate	AbŃgr`b Kiv thŃZ cvŃi	AbŃgr`b Kiv nj

SI No	cŌZKvi:Ki big	ewM/R`K big	tgM:Kj M/FiB:mi big	Km	ib: Rb	Contraindication & Side-effect	FSC/CP	Abgvr`b Kiv me Kuglji mfvi m×vš	mfvi m×vš
	<p>Legal Manufacturer: Boston Scientific Corporation 300 Bosc Scientific Way Marlborough MA 01752 USA</p> <p>Local Agent: Medi Graphic Trading Ltd , 14 Purana Paltan, Dar Us Salam Arcade, 3rd Floor, Dhaka</p>				procedures.	<p>constitute a threat to patient safety. The contraindications also include the following: Bacteremia or sepsis, Major coagulation system abnormalities, Patients diagnosed with coronary artery spasm, Patients disqualified for CABG surgery, Patients disqualified for PTCA, Severe hemodynamic instability or shock, Use of the imaging catheter to cross a total occlusion</p> <p>ADVERSE EVENTS: The risks and discomforts involved in vascular imaging include those associated with all catheterization procedures. These risks or discomforts may occur at any time with varying frequency or severity. Additionally, these complications may necessitate additional medical treatment including surgical intervention and, in rare instances, result in death. Allergic reaction, Angina, Cardiac arrest, Cardiac arrhythmias including, but not limited to ventricular tachycardia, atrial/ventricular fibrillation and complete heart block, Cardiac tamponade/Pericardial effusion, Death, Device entrapment requiring surgical intervention, Embolism (air, foreign body, tissue or thrombus), Hemorrhage/Hematoma, Hypotension, Infection, Myocardial infarction, Myocardial Ischemia, Stroke and Transient Ischemic Attack, Thrombosis, Vessel occlusion and abrupt closure, Vessel trauma including, but not limited to dissection and perforation</p>			
25.	<p>Manufacturer: Micro Therapeutics, Inc. dba ev3 eurovascular, 9775</p>	Marksman Catheter	Delivery Catheter	C	It is intended for the introduction of interventional devices and infusion of diagnostic or therapeutic agents into the neuro, peripheral, and coronary vasculature	Potential complications include, but are not limited to, the following: • Distal emboli (air, foreign material, tissue, or thrombus) • Hematoma • Hemorrhage • Infection •	CFG-USA, CE	Abgvr`b Kiv thiZ cti	Abgvr`b Kiv nj

SI No	cŃZKviŃKi big	ewŃR`K big	ŃgŃŃKj ŃŃŃBŃmi big	KŃm	ŃbŃ`Rbv	Contraindication & Side-effect	FSC/CEP	ŃUKŃbK`vj mve KugŃŃi mŃvi ŃmŃŃŃŃ	mŃvi ŃmŃŃŃŃ
	Germany. Local Agent : Vision Poly Tech 196,Green Road, 1 st Floor, Dhaka- 1205.	dilator .			entire length of the balloon dilator is inserted into the vagina. 3. Distilled water is injected from the device into the balloon dilator by squeezing the trigger in cycles (with forefinger and middle finger); approximately 22 squeezes are necessary to inject the required amount of water, that is to obtain the required pressure that will dilate the cervical canal to the defined diameter. 4. Once the desired pressure and dilatation have been achieved, the check valve prevents further increasing of pressure in the balloon. 5. After the dilatation, the safety device on the upper side of the handle, which serves to prevent possible blockage of the instrument, is removed. 6. By pressing the button on the upper side of the handle (with thumb), the water is discharged from the balloon back to the reservoir. Also, by pressing this button the device is automatically blocked and may no longer be used. The entire dilatation procedure lasts 30 seconds. 7. The balloon dilator is taken out from the cervical canal. 8. Used dilator is disposed of in the container for medical waste.				
31.	M/s Micro Therapeutics, Inc. dba ev3 Neurovascular, 9775 Toledo Way, Irvine, CA 92618,USA Local Agent: Medtronic Bangladesh Pvt. Ltd, Santa Western tower , Tejgaon, Dhaka	Axium Detachable Coil System	Detachable Coil System	D	The Axium™ Detachable Coils are intended for endovascular embolization of intracranial aneurysms. The Axium Detachable coils are also intended for the embolization of other neurovascular abnormalities, such as arteriovenous malformations and arteriovenous fistulae.	Potential complications include, but are not limited to: • Puncture site hematoma • Vessel perforation • Vasospasm • Hemorrhage • Thromboembolic episodes • Neurological deficits including stroke and death • Vascular thrombosis • Ischemia	CFG-USA, CE	AbŃgr`b Kiv thŃZ cŃti	AbŃgr`b Kiv nj
32.	M/s Micro Therapeutics, Inc. dba ev3 Neurovascular, 9775 Toledo Way,	Axium Prime Detachable Coil System	Detachable Coil system	D	The Axium Prime Detachable Coils are intended for the endovascular embolization of intracranial aneurysms. It is also intended for the embolization of other neurovascular abnormalities such as arteriovenous	Potential complications include, but are not limited to: • Puncture site hematoma • Vessel perforation • Vasospasm • Hemorrhage • Thromboembolic episodes • Neurological	CFG-USA, CE	AbŃgr`b Kiv thŃZ cŃti	AbŃgr`b Kiv nj

SI No	cŌZKviŧKi big	ewŮr`K big	ŧgŮŮŧKj ŮŮfBŧmi big	KŮm	Ůbŧ`RbŮ	Contraindication & Side-effect	FSC/ CPP	ŧiŮRŧŏkb mŮBŮj vBb AbŮŮqŮ FSC/ CPP I cŧŧqŮRbŮq ŮKŧŧŮU `ŮLŧj i kŧZ ^Ů AbŮŮgŮ`b Kiv thŧZ cŮŧi	mŮfvi ŮmŮvŮŧŮ
	Irvine, CA 92618,USA Local Agent: Medtronic Bangladesh Pvt. Ltd, Santa Western tower , Tejgaon, Dhaka				malformations and arteriovenous fistulae.	deficits including stroke and death • Vascular thrombosis • Ischemia			
33.	Manufacturer: BAUSCH & LOMB INC, 1400 N , Goodman St. Rochester ,NY,14609 USA Local agent : Janata Traders TCB Vhabon 1 kawranbazar, Dhaka	Soft Corrective Contact Lens	Contact Lens	C	It is indicated for the daily wear correction of refractive ametropia (myopia and hyperopia) in aphakic and/or not-aphakic persons with non-diseased eyes. The lens may be prescribed in spherical powers ranging from +20.00D to -20.00D. The Lens is to be prescribed for single use disposable wear, and is to be discarded after each removal.	DO NOT USE the Visibility Tinted Contact Lens when any of the following conditions exist: • Acute and sub acute inflammation or infection of the anterior chamber of the eye • Any eye disease, injury, or abnormality that affects the cornea, conjunctiva, or eyelids		ŧiŮRŧŏkb mŮBŮj vBb AbŮŮqŮ FSC/ CPP I cŧŧqŮRbŮq ŮKŧŧŮU `ŮLŧj i kŧZ ^Ů AbŮŮgŮ`b Kiv thŧZ cŮŧi	ŧiŮRŧŏkb mŮBŮj vBb AbŮŮqŮ FSC/ CPP I cŧŧqŮRbŮq ŮKŧŧŮU `ŮLŧj i kŧZ ^Ů AbŮŮgŮ`b Kiv nj
34.	Manufacturer: Bescon Co., Ltd 1024-24 Cheon-daero, Seobuk-gu, Cheonan-si, Chungcheongnam-do, Republic of Korea . Local agent : Janata Traders TCB Bhabon , 1 kawranbazar,Dhaka	Lacelle Contact Lens	Soft Contact Lenses-Daily Wear	C	It's disposable single focus lens to be worn directly in human eye for cosmetics and vision correction.	Any eye disease, injury or abnormality or allergic reactions that may be induced or exaggerated by contact lenses. Must dispose daily wear contact lenses after use. Confirm with a eye care professional in case of any systematic disease that may affect the eyes. Use the appropriate cleaning and re-wetting solutions. If eyes become irritated or cause severe pain, stop the use and seek care immediately.		ŧiŮRŧŏkb mŮBŮj vBb AbŮŮqŮ FSC/ CPP I cŧŧqŮRbŮq ŮKŧŧŮU `ŮLŧj i kŧZ ^Ů AbŮŮgŮ`b Kiv thŧZ cŮŧi	ŧiŮRŧŏkb mŮBŮj vBb AbŮŮqŮ FSC/ CPP I cŧŧqŮRbŮq ŮKŧŧŮU `ŮLŧj i kŧZ ^Ů AbŮŮgŮ`b Kiv nj
35.	Manufacturer: BMC Medical Company Limited, China	RESmart Auto CPAP System Model: RESmart Auto	Auto CPAP System	B	The CPAP (Continuous Positive Airway Pressure) device designed for the treatment of Obstructive Sleep Apnea (OSA) only	Absolute Contraindications: Pneumothorax, mediastinal emphysema, cerebrospinal fluid leak, traumatic brain injury, or pneumocephalus; shock caused by	China	AbŮŮgŮ`b Kiv thŧZ cŮŧi	AbŮŮgŮ`b Kiv nj

SI No	cŌZKviŕKi big	ewŕR`K big	ŕgŕŕŕKj ŕŕfŕBŕmi big	Kŕm	ŕbŕ`Rbv	Contraindication & Side-effect	FSC/ CPP	ŕUKŕbK`vj mve Kŕgŕŕŕi mŕvi ŕmŕŕŕŕ	mŕvi ŕmŕŕŕŕ
	Local Agent: Trade Bangladesh Dhaka Trade Centre 99, Kazi Nazrul Islam Avenue, Kawran Bazar C/A, Dhaka				<p>It is used to remove Sleep Apnea; Hypopnea & Respiration related Disorder as well.</p> <p>The device is to be used only on the instruction of a licensed health care professional. Several accessories are available to make the OSA treatment with this device for its convenient and comfortable use.</p>	<p>a variety of conditions before treatment' active epistaxis; upper gastrointestinal bleeding before treatment; coma or impaired consciousness making the use of mask during therapy impossible; liant vocal fold polyp, etc</p> <p>Relative Contraindications: Severe coronary heart disease complicated with left ventricular failure, acute otitis media, excessive respiratory secretions and week cough, weak spontaneous breathing, nasal or oral tracheal intubation and tracheotomy, severe nasal congestion caused by a variety of conditions, lung bullae, and allergies to breathing masks, etc.</p> <p>Side Effects: The following side effects may occur during treatment: - Dryness of the mouth, nose and throat - Abdominal bloating - Ear or sinus discomfort - Eye irritation - Skin Irritation due to the use of a mask - Chest discomfort</p> <p>Adverse Effects You should report unusual chest pain, severe headache or increased breathlessness to your physician. An acute upper respiratory tract infection may require temporary discontinuation of treatment.</p> <p>The following side effects may arise during the course of therapy:</p> <ul style="list-style-type: none"> • Drying of the nose, mouth or throat • Bloating • Ear or sinus discomfort 			

SI No	cŃZKviŃKi big	ewŃrK big	ŃgŃŃKj ŃŃfBŃmi big	Km	ŃbŃ Rbv	Contraindication & Side-effect	FSC/CP	ŃUKŃK'vj me KŃgŃŃi mŃvi ŃŃŃŃŃŃ	mŃvi ŃŃŃŃŃŃ
						<ul style="list-style-type: none"> • Eye irritation • Mask-related skin irritations • Chest discomfort. Contraindications: The device should not be used if you have severe respiratory failure without a spontaneous respiratory drive. If any of the following conditions applies to you, consult your physician before using the device: If you have any of the following conditions, tell your doctor before using the CPAP: <ul style="list-style-type: none"> • Acute sinusitis or otitis media. 			
36.	Medtronic MiniMed, 18000 Devonshire Street, Northridge, CA91325, USA Local Agent: Medtronic Bangladesh Pvt. Ltd, Santa Western tower , Tejgaon, Dhaka	Guardian 2 Link transmitter system	Data transmitter system of continuous glucose monitoring	B	Guardian™ 2 Link transmitter is a component of the continuous glucose monitoring system for the insulin pump. The transmitter collects data from the glucose sensor. The transmitter then wirelessly sends the data to the insulin pump.	Precautions: It must only be used for interrogating compatible Medtronic implantable devices.	CFG-USA	AbŃgv b Kiv thŃZ cŃŃi	AbŃgv b Kiv nj
37.	Manufacturer: Alpha Dent Implants Ltd. Carl-Zeiss- StraBe 4, 71229 Leonberg, Germany Local Agent: Zas Corporation 80/22 Mymensingh Road , Nurjehan Tower (3 rd Floor) Dhaka	Alpha Dent Dental Implants	Dental Implant System and related Products.	C	Alpha dent Implants are Designed for surgical placement in the upper of lower jaw and serve as a replacement of the tooth root providing the basis for the tooth restoration. Alpha dent implants system is intended for surgical placement in the maxillary and the mandibular arch to support crowns, bridges or over dentures in edentulous patients.	Contra-indication: Debilitating or uncontrolled disease. Pregnancy, hemophilia, granulocytopenia, or other bleeding problems, Conditions , diseases, treatment that severely compromise, Side-Effect: Immediate anesthetic and surgical risks. Psychological and psychiatric risks, medical threats to long-term retention, long term deleterious effects of implants on health. Neurological disorders apoplectic , attack, Parkinson, disease and mental retardation.	FSC-Germany EC Certificate	AbŃgv b Kiv thŃZ cŃŃi	AbŃgv b Kiv nj
38.	Nippon Covidien Ltd. Fukuroi Plant, 1217-1, Tomonaga, Fukuroi, Shizuoka, 437-0004	Argyle Safety Fistula Cannula with Anti-Reflux Valve	Dialysis Cannula	B	Argyle Fistula Cannula is used for gaining vascular access for blood removal and blood reinfusion during dialysis. The needle-stick prevention feature is intended to minimize accidental needle-stick injuries.	Effective prevention • Integrated safety feature reduces the risk of accidental needle puncture and leads to improved safety in the workplace •		ŃiŃRŃŃkb MŃBŃj vBb AbŃgvqŃ FSC/CP I	ŃiŃRŃŃkb MŃBŃj vBb AbŃgvqŃ FSC/CP I

SI No	cŌZKviŧKi big	ewŮR`K big	ŧgŮŮŧKj ŮŮŮBŧmi big	Km	Ůbŧ`Rbv	Contraindication & Side-effect	FSC/CE	ŧŮKŮbK`vj me KŮgŮŮi mŮvi Ům`vŮŧ	mŮvi Ům`vŮŧ
	Japan Local Agent: Medtronic Bangladesh Pvt. Ltd, Santa Western tower , Tejgaon, Dhaka					Compliance with new needle guard legislation • Reduced risk of needlestick injury resulting in potential cost savings		cŮŮqŮRbŮq ŮKŧŮŮ ŮmLŧj i kŧZ© AbŮgŮ`b Kiv thŧZ cŮŧi	cŮŮqŮRbŮq ŮKŧŮŮ ŮmLŧj i kŧZ© AbŮgŮ`b Kiv nj
39.	Xcellance Medical Technologies pvt. Ltd. W-239, rabale , navi Mumbai - 400701, India. Local Agent: Zas Corporation80/22 Mymensingh Road , Nurjehan Tower (3 rd Floor) Dhaka-1000. Bangladesh	SHALYA VISTA	Electrosurgical unit (Diathermy)	B	Electrosurgical unit (Diathermy) for cutting and coagulation of body tissue.	Contra-indication: Anatomical location and the presence of an implantable electronic device are the two main considerations when evaluating for possible contraindications to electro surgery. Side-Effect: Slight bleeding , Infection antibiotics may Given to reduce this risk. Pain or mild discomfort.	FSC-India CE	AbŮgŮ`b Kiv thŧZ cŮŧi	AbŮgŮ`b Kiv nj
40.	Medtronic Neurosurgery, 125 Cremona Drive, Goleta, CA 93117 USA Florida USA Local Agent: Medtronic Bangladesh Pvt. Ltd, Santa Western tower , Tejgaon, Dhaka	EDMS (External Drainage and Monitoring System)	Drainage and Monitoring Kit	B	It is used to drain and monitor CSF flow from the patient's lateral ventricles or the lumbar subarachnoid space to reduce intracranial pressure. The system can be used preoperatively, intraoperatively and postoperatively to monitor CSF chemistry, cytology and physiology, and to provide temporary CSF drainage.	Contraindications : None Side effects : None	CFG-USA, CE	AbŮgŮ`b Kiv thŧZ cŮŧi	AbŮgŮ`b Kiv nj
41.	Medtronic Neurosurgery, 125 Cremona Drive, Goleta, CA 93117 USA	EDM Lumber	External Drainage and Monitoring lumber drainage Kit	C	External Drainage and Monitoring System catheters are either translucent or fabricated of radiopaque (barium impregnated) silicone tubing. They feature larger diameter flow holes and larger inside diameter to	Contraindications : None Side effects : None	CFG-USA	AbŮgŮ`b Kiv thŧZ cŮŧi	AbŮgŮ`b Kiv nj

SI No	cŃZKviŃKi big	ewŃR`K big	ŃgŃŃŃKj ŃŃfŃBŃmi big	KŃm	ŃbŃ`Rbv	Contraindication & Side-effect	FSC/CPP	ŃŃKŃbK`vj mve KŃgŃŃŃi mŃfvi Ńm`vŃŃŃ	mŃfvi Ńm`vŃŃŃ
	Saratoga CA 95070, USA Local Agent : Vastech Limited, Nurjehan Tower (6th Floor), 80/22 Mymensingh Road Dhaka				computer, simply place the capsule into the CapsoAccess® system and close the lid..				
48.	Manufacturer : Shaili Endoscopy, Plot No. 210 & 213, Padra Jambusar Road, Village : Dabhasa, Tal : Padara, Dist. : Vadodara-391440, Gujarat, India Local Agent : Panorama Corporation, Nurjehan Tower, (2nd Floor) 80/22, Mymensingh Road, Bangla Motor, Dhaka-1000	Esophageal Dilator	Esophageal Dilator	B	Used for Endoscopically Biliary Stent placement to reduce time and easier stent placement.	Contraindication Contraindications include those specific to the Gastrointestinal endoscopic procedure, ERCP and Biliary stenting. Patients with lesions, inappropriate for stenting.	FSC-India FSC-Egypt EC Certificate	AbŃgv`b Kiv thŃZ cŃti	AbŃgv`b Kiv nj
49.	Manufacturer : Chetan Meditech Pvt. Ltd., (BIOTEK); India Local Agent : Vastech Limited, Nurjehan Tower (6th Floor), 80/22 Mymensingh Road Dhaka	On Button CL	Fixation Button with Loop	C	It is used for fixation of tendons and ligaments during orthopedic reconstruction procedures such as anterior cruciate ligament (ACL) and posterior cruciate ligament (PCL) reconstruction.	Contraindication: Known hypersensitivity to the implant material. Where material sensitivity is suspected, appropriate tests should be made and sensitivity ruled out prior to implantation. . Insufficient quantity or quality of the bone. . Blood Supply and previous infections which may tend to retard healing. . Active infection. . Conditions which tend to limit the patient's ability or willingness to restrict activities or follow directions during the healing period. Adverse Reaction: Complications are those seen with any method of internal fixation.	FSC-India EC Certificate	ŃiŃRŃŃkb ŃŃBŃŃj vBb AbŃgv`b FSC/CPP I cŃŃqŃRbŃq ŃŃKŃgŃU `ŃŃŃŃŃ i kŃZ® AbŃgv`b Kiv thŃZ cŃti	ŃiŃRŃŃkb ŃŃBŃŃj vBb AbŃgv`b FSC/CPP I cŃŃqŃRbŃq ŃŃKŃgŃU `ŃŃŃŃŃ i kŃZ® AbŃgv`b Kiv nj

SI No	cŌZKviŧKi big	ewŨr`K big	ŧgŨŧKj ŨfŨBŧmi big	KŨm	Ũbŧ`Rbv	Contraindication & Side-effect	FSC/CPP	ŧŨKŨbK`vj mve KŨgŨŨi mfvŨ Ũm×ŨŧŨ	mfvŨ Ũm×ŨŧŨ
						Ischemia			
58.	M/s Micro Therapeutics, Inc. dba ev3 Neurovascular, 9775 Toledo Way, Irvine, CA 92618,USA Local Agent: Medtronic Bangladesh Pvt. Ltd, Santa Western tower , Tejgaon, Dhaka	SilverSpeed Hydrophilic Guide wire	Hydrophilic Guide wire	C	Silver speed guide wire is indicated for general intravascular use to aid in the selective placement of catheters in the peripheral, visceral and cerebral vasculature during diagnostic and/or therapeutic procedures.	CONTRAINDICATIONS • The .014" wire with distal polymer jacket is not DMSO compatible. POTENTIAL COMPLICATIONS Procedures requiring percutaneous catheter introduction should not be attempted by physicians unfamiliar with the possible complications, which may occur during or after the procedure. Possible complications include, but are not limited, to the following: •Perforation of vessel arterial wall •Thrombus formation •Puncturesite hematoma • Vasospasm • Infection • Ischemia	CFG- USA, CE	Abŧgr`b Kiv thŧZ cŨti	Abŧgr`b Kiv nj
59.	M/s Micro Therapeutics, Inc. dba ev3 Neurovascular, 9775 Toledo Way, Irvine, CA 92618,USA Local Agent: Medtronic Bangladesh Pvt. Ltd, Santa Western tower , Tejgaon, Dhaka	X-Pedion Hydrophilic Guide wire	Hydrophilic Guide wire	C	X-Pedion guidewire is indicated for general intravascular use to aid in the selective placement of catheters in the peripheral, visceral and cerebral vasculature during diagnostic and/or therapeutic procedures	CONTRAINDICATIONS • The .014" wire with distal polymer jacket is not DMSO compatible. POTENTIAL COMPLICATIONS Procedures requiring percutaneous catheter introduction should not be attempted by physicians unfamiliar with the possible complications, which may occur during or after the procedure. Possible complications include, but are not limited, to the following: •Perforation of vessel arterial wall •Thrombus formation •Puncturesite hematoma • Vasospasm • Infection • Ischemia	CFG- USA, CE	Abŧgr`b Kiv thŧZ cŨti	Abŧgr`b Kiv nj
60.	M/s Micro Therapeutics, Inc. dba ev3 Neurovascular, 9775 Toledo Way,	Mirage 0.008 Hydrophilic Guide wire	Hydrophilic Guide wire	C	Mirage guidewire is indicated for general intravascular use to aid in the selective placement of catheters in the peripheral, visceral and cerebral vasculature during diagnostic and/or therapeutic procedures.	CONTRAINDICATIONS • The .014" wire with distal polymer jacket is not DMSO compatible.	CFG- USA, CE	Abŧgr`b Kiv thŧZ cŨti	Abŧgr`b Kiv nj

SI No	cŃZKviŃKi big	ewŃrŃK big	ŃgŃŃŃKj ŃŃfŃBŃmi big	KŃm	ŃbŃŃ Rbv	Contraindication & Side-effect	FSC/CPP	ŃUKŃbKŃvj mve KŃgŃŃŃi mŃvi ŃmŃŃŃŃŃ	mŃvi ŃmŃŃŃŃŃ
	Irvine, CA 92618,USA Local Agent: Medtronic Bangladesh Pvt. Ltd, Santa Western tower , Tejgaon, Dhaka					POTENTIAL COMPLICATIONS Procedures requiring percutaneous catheter introduction should not be attempted by physicians unfamiliar with the possible complications, which may occur during or after the procedure. Possible complications include, but are not limited, to the following: •Perforation of vessel or arterial wall •Thrombus formation •Puncture site hematoma • Vasospasm • Infection • Ischemia			
61.	Manufacturer: Lake Region Medical 340 Lake Hazeltine Drive Chaska, Minnesota 55318 USA Local Agent: Medi Graphic Trading Ltd., 14 Purana Paltan, Dar Us Salam Arcade, 3rd Floor, Dhaka-1000	ZIPwire™ Hydrophilic Guidewire	Hydrophilic Guidewire	B	It is intended to facilitate the placement of endourological instruments during diagnostic or interventional procedures. It is not intended for coronary artery, vascular or neurological use.	Contraindication: None known. Potential Complications: Complications which can result from the use of guidewires in urological applications include: Hemorrhage, Tissue Trauma, Perforation, Inability to access target site, False passage, Infection, Pain, Dislodged catheter or stent, Hematuria, Vesicoureteral Reflux, Iatrogenic lesions, Urine leakage, Urine retention, Stricture, Hematoma	USA EC Certificate	AbŃgŃŃ b KŃiv thŃZ cŃŃi	AbŃgŃŃ b KŃiv nj
62.	Manufacturer: Boston Scientific Corporation, Costa Rica Legal Manufacturer: Boston Scientific Corporation 300 Boston Scientific Way Marlborough MA 01752 USA Local Agent: Medi Graphic Trading Ltd, 14 Purana Paltan, Dar Us Salam Arcade, 3rd Floor, Dhaka-1000	Zebra™ Guide wires	Urological Guide Wires	B	It is intended to facilitate the placement of endourological instruments during diagnostic or interventional Procedures. These guidewires are not intended for coronary artery, vascular or neurological use.	Contraindication: None known Adverse Event: Complications which can result from the use of guide wires in urological applications include: Perforation of the urinary tract, Acute Bleeding, Hemorrhage, Tissue Trauma, Edema, Foreign Object in Body, Infection, Hemoglobinuria, Peritonitis, Ureter Avulsion	USA EC Certificate	AbŃgŃŃ b KŃiv thŃZ cŃŃi	AbŃgŃŃ b KŃiv nj

SI No	cŌZKviŧKi big	ewŮr`K big	ŧgŮŮŧKj ŮŮŮBŧmi big	KŮm	Ůbŧ`RbŮ	Contraindication & Side-effect	FSC/CEP	ŧŮKŮbK`yj mve KŮgŮŮi mŮvi ŮmŮŮŮŮŮ	mŮvi ŮmŮŮŮŮŮ
63.	Manufacturer : Boston Scientific Corporation, USA Local Agent : Vastech Limited, Nurjehan Tower (6th Floor), 80/22 Mymensingh Road Dhaka	Alliance Inflation Syringe	Inflation Syringe	B	It is indicated for inflation and deflation of balloon dilatation catheters while simultaneously monitoring balloon catheter pressures and for the crushing of biliary calculi when used with the Trapezoid RX Wire guided Retrieval Basket.	Contraindications: Non Known Adverse events: Damage to endoscope, Significant mucosal damage, Hemorrhage, Perforation, Bacteremia, Sepsis	USA	AbŷgŮ`b Kiv thŷZ cŷti	AbŷgŮ`b Kiv nj
64.	Manufacturer: Micro Therapeutics, Inc. dba ev3 Neurovascular, 9775 Toledo Way, Irvine, CA 92618,USA Local Agent: Medtronic Bangladesh Pvt. Ltd, Santa Western tower , Tejgaon, Dhaka	ProStream Multiple Side hole Infusion Wire	Multiple Side hole Infusion wire	C	It is intended for the controlled selective infusion of physician-specified pharmacological agents or radiopaque contrast media into the general vasculature. All pharmacologic agents utilized with the infusion wire should be fully prepared and used according to instructions for use of the specific pharmacologic agent.		CFG-USA, CE	AbŷgŮ`b Kiv thŷZ cŷti	AbŷgŮ`b Kiv nj
65.	M/s. Unomedical A/S. Mexico Local Agent: Medtronic Bangladesh Pvt. Ltd, Santa Western tower , Tejgaon, Dhaka	I-port Advanced	Injection port	C	I-Port advance is indicated for both adults and children requiring daily subcutaneous injections	Contra-indication: N/A Side-Effects: N/A	FSC-Denmark, CE	AbŷgŮ`b Kiv thŷZ cŷti	AbŷgŮ`b Kiv nj
66.	Micro Therapeutics, Inc. dba ev3 Neurovascular, 9775 Toledo Way, Irvine, CA	Cadence Threaded syringes	Precision Injector Thread Syringe	B	The Cadence precision injector in intended for the controlled delivery of fluids in the inflation and deflation of temporary occlusion balloons		CFG-USA, CE	AbŷgŮ`b Kiv thŷZ cŷti	AbŷgŮ`b Kiv nj

SI No	cŌZKviŧKi big	ewŨr`K big	ŧqŨŨŧKj ŨŨfBŧmi big	KŨm	Ũbŧ`Rbv	Contraindication & Side-effect	FSC/ CPP	ŧUKŨbK`vj mve KŨqŨŨi mŨvi Ũm`vŨŧŨ	mŨvi Ũm`vŨŧŨ
	Rochester ,NY,14609 USA Local agent : Janata Traders TCB Vhabon 1 kawranbazar, Dhaka							cŧŧqŨRbŨq ŨKŧŧŧU `ŨLŧj i kŧZ© Abŧŧŧv`b Kiv thŧZ cŨti	cŧŧqŨRbŨq ŨKŧŧŧU `ŨLŧj i kŧZ© Abŧŧŧv`b Kiv nj
71.	Manufacturer: FertiPro N.V. Industriepark Noord 32 8730 Beernem - Belgium Local Agent: Zas Corporation 80/22 Mymensingh Road , Nurjehan Tower (3 rd Floor) Dhaka	IVF Culture Media	IVF diagnostic media	B	It is used in Human IVF .	Contraindication: N/A Side Effect: Occasional lower abdominal discomfort and bloating, Mild nausea and vomiting, Diarrhea, and Abdominal swelling.		ŧiŨRŧŧŧkb ŨbŨWj vBb AbŧŧŧŨq FSC/ CPP I cŧŧqŨRbŨq ŨKŧŧŧU `ŨLŧj i kŧZ© Abŧŧŧv`b Kiv thŧZ cŨti	ŧiŨRŧŧŧkb ŨbŨWj vBb AbŧŧŧŨq FSC/ CPP I cŧŧqŨRbŨq ŨKŧŧŧU `ŨLŧj i kŧZ© Abŧŧŧv`b Kiv nj
72.	Manufacturer: VITROLIFE Sweden AB; Sweden Local Agent: Zas Corporation 80/22 Mymensingh Road , Nurjehan Tower (3 rd Floor) Dhaka	IVF Fertilization system	IVF-10086	D	It is used in Human IVF .	Contraindication: None Side Effect: None	FSC- Sweden	Abŧŧŧv`b Kiv thŧZ cŨti	Abŧŧŧv`b Kiv nj
73.	Manufactured by: Owen Mumford, Brook	Freestyle Lancing Device	FreeStyle Lancing Device 11	B	It is used as a puncture for collecting of blood for blood glucose monitor.	Contraindications: None Side Effects: None	MHRA	Abŧŧŧv`b Kiv thŧZ cŨti	Abŧŧŧv`b Kiv nj

SI No	cŌZKviŧKi big	ewŨr`K big	ŧgŨŨŧKj ŨŨŨBŧmi big	KŨm	Ũbŧ`Rbv	Contraindication & Side-effect	FSC/CEP	ŧUKŨbK`vj mve KŨgŨŨi mfvi Ũm`vŨŨŨ	mfvi Ũm`vŨŨŨ
	Renata Limited Mirpur, Dhaka								
83.	Manufacturer: Laboratories Gilbert France Local Agent : Renata Limited Mirpur, Dhaka	Marimar-Isotonic Sea Water Solution, Nasal Spray	Isotonic Sea Water Solution, Nasal Spray	B	It is recommended for daily hygiene of the nasal airways, for the humidification of the dried nasal mucous membrane and as a complement to the treatment of ENT disorders.	Unexpected Effects: Some prickling or some transitory irritating sensations can be felt at the beginning of use	France EC Certificate	Abŧgv`b Kiv thŧZ cŨŧi	Abŧgv`b Kiv nj
84.	Medtronic Neurosurgery, 125 Cremona Drive, Goleta, CA 93117 USA Florida USA Local Agent: Medtronic Bangladesh Pvt. Ltd, Santa Western tower , Tejgaon, Dhaka	DELTA	Neonatal Shunt Assembly	B	DELTA® valves minimize over drainage of cerebrospinal fluid (CSF). They're part of a shunt system used to treat the symptoms of hydrocephalus. A shunt redirects excess CSF in the brain to another part of the body, allowing the brain's enlarged ventricles to return to a more normal size.	Contraindications : None Side effects : None	CFG-USA, CE	Abŧgv`b Kiv thŧZ cŨŧi	Abŧgv`b Kiv nj
85.	Meran tip urunleri teknoloji san tic. Istanbul , Turkey. Local Agent: Zas Corporation 80/22 Mymensingh Road , Nurjehan Tower (3rd Floor) Dhaka	Silicon Oil	Ophthalmic Silicon Oil	B	Silicon Oil is being used with increased frequency for retinal tamponade during vitreous surgery for complicated retinal detachment.	Contra-indication: Known hypersensitivity to silicon. Mersilicon should not be used in seudophakic patients who have been fitted with a silicon IOL. Side-Effect: Pre and post operative hyponoty or hypernoty, post operative choroidal detachment, corneal epithelium edema, secondary retinal detachment.	FSC - Turkey CE	Abŧgv`b Kiv thŧZ cŨŧi	Abŧgv`b Kiv nj
86.	Manufacturer: BMG PHARMA S.R.L, Italy Local agent: Radiant	GelX Oral Gel 300ml	Zinc Gluconate EP 0.5% w/v + Taurine EP 1% w/v + PVP (Polyvinylpyrrolidone) EP 8% w/v	B	Symptomatic treatment of pain of oral cavity lesions such as mucositis, stomatitis due to radiotherapy, chemotherapy, pharmacological therapy, and labial mucosa lesions.	There are no known contraindications and Side Effects.	Italy	Abŧgv`b Kiv thŧZ cŨŧi	Abŧgv`b Kiv nj

SI No	cŃZKviŃKi big	ewŃr`K big	ŃgŃŃKj ŃŃfBŃmi big	KŃm	ŃbŃ`RbŃ	Contraindication & Side-effect	FSC/CPP	ŃUKŃbK`vj mŃe KŃgŃŃi mŃvi ŃŃŃŃŃŃŃ	mŃvi ŃŃŃŃŃŃŃ
	Export Import Enterprise. Uttara, Dhaka.								
87.	Manufacturer: BMG PHARMA S.R.L, Italy Local agent: Radiant Export Import Enterprise. Uttara, Dhaka.	GelX Oral Spray 100ml	Zinc Gluconate EP 0.5% w/v + Taurine EP 1% w/v + PVP (Polyvinylpyrrolidone) EP 6% w/v	B	Symptomatic treatment of pain of oral cavity lesions such as mucositis, stomatitis due to radiotherapy, chemotherapy, pharmacological therapy, and labial mucosa lesions.	There are no known contraindications and Side Effects.	Italy	AbŃgŃ`b Kiv thŃZ cŃŃi	AbŃgŃ`b Kiv nj
88.	Medtronic SofamorDanek USA , INC, 2500 Warsaw, USA Local Agent: Medtronic Bangladesh Pvt. Ltd, Santa Western tower , Tejgaon, Dhaka	Prestige LP cervical disc system	Artificial cervical disc	B	The PRESTIGE® Cervical Disc is generally indicated for use at any level from C2/C3 to C7/T1: for cervical degenerative discopathy and instability	Contraindications: If you are experiencing or have been diagnosed with any of the following conditions or symptoms, you should not have cervical disc surgery: » active systemic (whole body) infection or infection at the operating site, as undergoing surgery could interfere with your ability to heal or increase the chance of worsening the infection » allergy to titanium, aluminum, or vanadium, as the PRESTIGE® LP Disc contains titanium, aluminum and vanadium and could cause an allergic reaction » weak or brittle bones (osteoporosis or osteopenia) because this could increase the risk of bone fracture or cause the implant to loosen; » stiffness of the spinal joints due to disc degeneration (spondylosis), as this could limit motion; » unstable cervical spine as seen on x-ray, as the removal of the diseased disc could lead to additional instability; » diseased disc has much more movement than adjoining discs, as this could lead to instability; » deformed cervical spine or spinal column bones that are not healthy, as this could limit movement or increase the risk of device loosening; » significant loss of the normal curvature of your neck (lordosis) or change in the curve of your neck	CFG USA	AbŃgŃ`b Kiv thŃZ cŃŃi	AbŃgŃ`b Kiv nj

SI No	cŃZKviŃKi big	ewŃrŃK big	ŃgŃŃKj ŃŃfŃBŃmi big	KŃm	ŃbŃŃ Rbv	Contraindication & Side-effect	FSC/ CPP	ŃUKŃbKŃvj mve KugŃŃi mŃvi ŃmŃŃŃŃ	mŃvi ŃmŃŃŃŃ
						(kyphosis), as this could limit any motion that could be achieved » more than one cervical disc that needs treatment, as the device has only been studied in patients requiring one cervical level of surgical treatment Precautions: Below is a list of precautions to be aware of as the safety and effectiveness of the PRESTIGE® LP device has not been established in patients with the following conditions: » Neck pain alone without arm pain; » Patients who are not skeletally mature (under the age of 21 or over the age of 78); » Previous cervical spine surgery, including a repeat surgery at the level requiring treatment; » Previous cervical fusion at a level above or below the level of the spine requiring treatment; » Disease or damage of the facet joint at the level of the spine requiring treatment; » Spinal metastases (spreading of cancer); » Diseases of the bone caused by low mineral levels or genetic problems such as Paget's disease, osteomalacia, osteopenia, or other metabolic bone disease; » Local or systemic bacterial infection; » Kidney failure or history of kidney disease; » Taking medications known to potentially get in the way with bone/soft tissue healing, such as steroids; » Pregnancy » Severe insulin dependent diabetes; and » Extreme obesity as defined by the NIH Clinical Guidelines Body Mass Index (i.e., BMI ≥40) It is important that you inform your doctor about any allergies you have, any medications you take on a regular basis, if you are pregnant, or if you have any other treated or untreated illnesses that may help your doctor decide if the PRESTIGE® LP Cervical Disc is right for you.			
89.	Manufacturer:	Metal Bone Pins	Bone Pins	C	Used for fixation of human body fracture, bone graft,	CONTRAINDICATIONS: The physician's	EC	ŃiŃRŃŃkb	ŃiŃRŃŃkb

SI No	cŃZKviŃKi big	ewŃR`K big	ŃgvŃŃKj ŃŃfŃBŃmi big	KŃm	ŃbŃ`Rbv	Contraindication & Side-effect	FSC/CPP	ŃŃKŃbK`vj mve KŃqŃŃi mŃvi ŃmŃŃŃŃ	mŃvi ŃmŃŃŃŃ
	Medtronic Bangladesh Pvt. Ltd, Santa Western tower , Tejgaon, Dhaka				superior side of the facet, across the facet joint at (usually) a single level, and into the pedicle. In the second fixation method, the UCSS™ SCREW SET screws are inserted bilaterally through the superior side of the facet, across the facet joint, and into the pedicle at multiple levels at the same time that a DYNA-LOK® Plate is attached to the base of the spinous processes at the corresponding levels with UCSS™ SCREW SET Screws. The second fixation method should be used when the spine has increased instability or multiple levels need to be fused. Bone graft must be used for both fixation methods.	mechanical fixation.			
92.	Medtronic SofamorDanek USA INC, 1800 Pyramid ,USA Local Agent: Medtronic Bangladesh Pvt. Ltd, Santa Western tower , Tejgaon, Dhaka	Kyphopak tray	Fracture Management system	B	The Kypho Pak Trays are convenience kits used in bone fracture reduction, The indications for use of the tray components are provided in their corresponding instructions for use, which accompany the trays		CFG-USA,	AbŃgv`b Kiv thŃZ cŃŃi	AbŃgv`b Kiv nj
93.	Manufacturer: Changzhou Kanghui Medical Innovation Co. Ltd., China Local Agent: Medtronic Bangladesh Pvt. Ltd.	Intramedullary Nails	Intramedullary Nails	C	Nails are for various fractures for humeral, ulna, radius, humeral shaft, proximal and distal humeral, comminuted fractures, and nonunion	Contraindications: For specific contraindications of the respective Intramedullary Nailing Implant it is mandatory to consult the corresponding Surgical Technique Guide of the product system being used. Potential risks As with all major surgical procedures, risks, side effects and adverse events can occur. While many possible reactions may occur, some of the most common include: Problems resulting from anesthesia and patient positioning (e.g. nausea, vomiting, dental injuries, neurological impairments, etc.), thrombosis, embolism, infection, excessive bleeding, iatrogenic neural and vascular injury,	EC Certificate	ŃiŃRŃŃkb MŃBŃŃj vBb AbŃgvŃqŃ FSC/CPP cŃŃqŃRbŃq ŃŃKŃŃU ŃŃŃŃj i kŃZ® AbŃgv`b Kiv thŃZ cŃŃi	ŃiŃRŃŃkb MŃBŃŃj vBb AbŃgvŃqŃ FSC/CPP cŃŃqŃRbŃq ŃŃKŃŃU ŃŃŃŃj i kŃZ® AbŃgv`b Kiv nj

SI No	cŃZKviŃKi big	ewŃrŃK big	ŃgŃŃŃKj ŃŃfŃBŃmi big	KŃm	ŃbŃŃ Rbv	Contraindication & Side-effect	FSC/PPP	ŃUKŃbKŃŃj mŃe KŃgŃŃŃi mŃfvi ŃmŃŃŃŃŃŃ	mŃfvi ŃmŃŃŃŃŃŃ
						damage to soft tissues incl. swelling, abnormal scar formation, functional impairment of the musculoskeletal system, Sudeck's disease, allergy/hypersensitivity reactions, and side effects associated with hardware prominence, malunion, non-union.			
94.	Medtronic SofamorDanek USA , INC, 1800 Pyramid ,USA Local Agent: Medtronic Bangladesh Pvt. Ltd, Santa Western tower , Tejgaon, Dhaka	Atlas cable system	Surgical Wire	C	It is intended to provide immobilization and stabilization of spinal segments as an adjunct to fusion for the following acute and chronic instabilities of the craniocervical junction, the cervical spine (C1 to C7) and the thoracic spine from T1-T3: traumatic spinal fractures and/or traumatic dislocations; instability or deformity; failed previous fusions (e.g., pseudarthrosis); tumors involving the cervical spine; and degenerative disease, including intractable radiculopathy and/or myelopathy, neck and/or arm pain of discogenic origin as confirmed by radiographic studies, and degenerative disease of the facets with instability.	Contraindications include, but are not limited to: Active infectious process or significant risk of infection (immunocompromise).Signs of local inflammation.Fever or leukocytosis.Morbidobesity.Pregnancy.	CFG USA	AbŃgŃŃ b Kiv thŃZ cŃŃi	AbŃgŃŃ b Kiv nj
95.	Medtronic Xomed Inc., 6743 Southpoint Drive North Jacksonville, Florida USA Local Agent: Medtronic Bangladesh Pvt. Ltd, Santa Western tower , Tejgaon, Dhaka	Skeeter® Otologic Drill System and Components	Drill System and Components	B	These products can be used with our NIM Nerve Monitoring Systems during ENT surgeries, including otologic procedures with our high-speed drills.	When not operating handpiece, eliminate accidental foot control activation. Control energy to and through the handpiece to prevent unintended tissue, bone, or nerve resection.	CFG-USA	AbŃgŃŃ b Kiv thŃZ cŃŃi	AbŃgŃŃ b Kiv nj
96.	Medtronic Xomed Inc., 6743 Southpoint Drive North Jacksonville, Florida USA Local Agent: Medtronic Bangladesh Pvt. Ltd, Santa Western tower , Tejgaon, Dhaka	Visao® High-Speed Otologic Drill and Components	Drill System and Components	B	These products can be used with our NIM Nerve Monitoring Systems during ENT surgeries, including otologic procedures with our high-speed drills	When not operating handpiece, eliminate accidental foot control activation. Control energy to and through the handpiece to prevent unintended tissue, bone, or nerve resection.	CFG-USA	AbŃgŃŃ b Kiv thŃZ cŃŃi	AbŃgŃŃ b Kiv nj
97.	Medtronic Xomed Inc., 6743 Southpoint Drive North Jacksonville, Florida USA	Indigo High-Speed Otologic Drill and Components	Drill System and Components	B	The new Indigo High-Speed Otologic Drill offers excellent surgical access and visibility in a wide range of otologic procedures.	When not operating handpiece, eliminate accidental foot control activation. Control energy to and through the handpiece to prevent unintended tissue, bone, or nerve resection.	CFG-USA	AbŃgŃŃ b Kiv thŃZ cŃŃi	AbŃgŃŃ b Kiv nj

SI No	cŌZKviŤKi big	ewŤR`K big	ŤgŤŤKj ŤŤŤBŤmi big	Km	ŤbŤ`Rbv	Contraindication & Side-effect	FSC/CEP	ŤUKŤbK`vj mve KugŤŤi mfvŤ Ťm×ŤŤŤ	mfvŤ Ťm×ŤŤŤ
	Local Agent: Medtronic Bangladesh Pvt. Ltd, Santa Western tower , Tejgaon, Dhaka								
98.	Medtronic Neurosurgery, 125 Cremona Drive, Goleta, CA 93117 USA Florida USA Local Agent: Medtronic Bangladesh Pvt. Ltd, Santa Western tower , Tejgaon,	Catheter Passers	Passers	B	Catheter Passers, used to pass the distal catheter to the peritoneum.	Contraindications : None Side effects : None	CFG-USA, CE	AbŤgŤv`b Kiv thŤZ cŤŤi	AbŤgŤv`b Kiv nj
99.	M/S. ev3, incorporation , 4600, Nathan Lane North, Polymouth MN, USA Local Agent: Medtronic Bangladesh Pvt. Ltd, Santa Western tower , Tejgaon, Dhaka	Protege RX self-expanding peripheral stent system	Peripheral self-expanding Carotid stent	D	Stent for Peripheral Vessel Neptun is used in the following Cases:- Unsatisfactory effect of a procedure (PTA)/residual stenosis,- Internal delamination of tunica intima or vessel lesion,- Recurrent Stenosis or loss of patency following previous intravascular procedures.		CFG-USA, CE	AbŤgŤv`b Kiv thŤZ cŤŤi	AbŤgŤv`b Kiv nj
100.	M/S. ev3, incorporation , 4600, Nathan Lane North, Polymouth MN, USA Local Agent: Medtronic Bangladesh Pvt. Ltd, Santa Western tower , Tejgaon, Dhaka	Everflex self-expanding peripheral stent with entrust delivery system	Peripheral self-expanding stent	D	Stent for Peripheral Vessel Neptun is used in the following Cases:- Unsatisfactory effect of a procedure (PTA)/residual stenosis,- Internal delamination of tunica intima or vessel lesion,- Recurrent Stenosis or loss of patency following previous intravascular procedures.	N/A	CFG-USA, CE	AbŤgŤv`b Kiv thŤZ cŤŤi	AbŤgŤv`b Kiv nj
101.	M/S. ev3, incorporation , 4600, Nathan Lane North, Polymouth MN, USA Local Agent:	Protegeeverflex Self expanding peripheral stent system	Peripheral self-expanding stent	D	Stent for Peripheral Vessel Neptun is used in the following Cases:- Unsatisfactory effect of a procedure (PTA)/residual stenosis,- Internal delamination of tunica	N/A	CFG-USA, CE	AbŤgŤv`b Kiv thŤZ cŤŤi	AbŤgŤv`b Kiv nj

SI No	cŃZKviŃKi big	ewŃR`K big	ŃgŃŃKj ŃŃFŃŃmi big	KŃm	ŃbŃ`RbŃ	Contraindication & Side-effect	FSC/PPP	ŃŃKŃbK`vj mŃe KŃgŃŃŃi mŃvi ŃŃŃŃŃŃŃŃ	mŃvi ŃŃŃŃŃŃŃŃŃ
	Medtronic Bangladesh Pvt. Ltd, Santa Western tower , Tejgaon, Dhaka				intima or vessel lesion,- Recurrent Stenosis or loss of patency following previous intravascular procedures.				
102.	Medtronic Neurosurgery, 125 Cremona Drive, Goleta, CA 93117 USA Florida USA Local Agent: Medtronic Bangladesh Pvt. Ltd, Santa Western tower , Tejgaon, Dhaka	PERITONEAL CATHETERS	Catheter	C	Commonly used peritoneal catheters are with preformed inter cuff arc bend, two cuffs, and straight or coiled tips straight intercuff segment, two cuffs, and straight or coiled tips one-cuff, coiled-tip abdominal catheter, two-cuff extension catheter with preformed intercuff arc bend, and titanium double-barbed connector.	Contraindications : None Side effects : None	CFG-USA	AbŃgŃ`b Kiv thŃZ cŃŃi	AbŃgŃ`b Kiv nj
103.	M/S. ev3, incorporation , 4600, Nathan Lane North, Polymouth MN, USA Local Agent: Medtronic Bangladesh Pvt. Ltd, Santa Western tower , Tejgaon, Dhaka	Cutter drive for Plaque Excision system	Accessories for Plaque Excision system	C	Cutter drive for Plaque Excision is system indicated to facilitate the place balloon dilatation catheter.		CFG –USA, CE	AbŃgŃ`b Kiv thŃZ cŃŃi	AbŃgŃ`b Kiv nj
104.	Manufacturer: Southwest Technologies, Inc, 1746 Levee Rd, North Kansas City, MO USA 64116. Local Agent: Zuellig Pharma BD Ltd, Haque Tower(4th Floor) 191/A, Mir Shawkat Shoroni (Tejgaon-Gulshan Link Road) Tejgaon I/A, Dhaka	GOLD DUST Super Absorbent Wound Filler 3gm Pouch	absorbent wounds filler, hydrophilic polymer, white granular solid)	B	Gold Dust is intended for heavily/moderately exudating wounds.	Possible Adverse Effects: Consult a physician if signs of irritation or infection occur: redness, fever, swelling, etc.	USA	AbŃgŃ`b Kiv thŃZ cŃŃi	AbŃgŃ`b Kiv nj
105.	Micro Therapeutics, Inc. d/b/a ev3 Neurovascular, 9775 Toledo Way, Irvine, CA 92618,USA	Cadence	Precision Injector thread syringe	B	The Cadence Precision Injector is intended for the controlled delivery of fluids in the inflation and deflation of temporary occlusion balloons.	Contraindications: None Side Effects: None	CFG-USA	AbŃgŃ`b Kiv thŃZ cŃŃi	AbŃgŃ`b Kiv nj

SI No	cŌZKviŧKi big	ewŨr'R'K big	ŧgŨŨŧKj ŨŨFŨBŧmi big	KŨm	Ũbŧ`RbŨ	Contraindication & Side-effect	FSC/CPP	ŧUKŨbK`vj me KŨgŨŨi mŨvi Ũm×ŨŨŨŨ	mŨvi Ũm×ŨŨŨŨ
	Local Agent: Medtronic Bangladesh Pvt. Ltd.								
106.	Medtronic Puerto Rico Operations Co., Road 31, KM24, HM 4, Ceiba Norte Industrial Park, Juncos, Puerto Rico 00777 USA Local Agent: Medtronic Bangladesh Pvt. Ltd, Santa Western tower , Tejgaon, Dhaka	Medication Reservoir	Insulin Reservoir	B	Reservoir is indicated for the subcutaneous infusion of medication, including insulin, from a Medtronic MiniMed infusion pump and infusion set.	Reservoir is contraindicated for the infusion of blood or blood products.	CFG-USA	AbŧgŨ`b KŨv thŧZ cŨŨi	AbŧgŨ`b KŨv nj
107.	Medtronic Puerto Rico Operations Co., Road 31, KM24, HM 4, Ceiba Norte Industrial Park, Juncos, Puerto Rico 00777 USA Local Agent: Medtronic Bangladesh Pvt. Ltd, Santa Western tower , Tejgaon, Dhaka	Paradigm Reservoir	Insulin Reservoir	B	It is indicated for the subcutaneous infusion of medication, including insulin, from a Medtronic MiniMed infusion pump and infusion set.	Reservoir is contraindicated for the infusion of blood or blood products.	EC Certificate	AbŧgŨ`b KŨv thŧZ cŨŨi	AbŧgŨ`b KŨv nj
108.	Manufacturer : Boston Scientific Corporation, USA Local Agent : Vastech Limited, Nurjehan Tower (6th Floor), 80/22 Mymensingh Road Dhaka	Trapezoid RX Wire guided Retrieval Baskets	Endoscopic Retrieval Basket	B	The Trapezoid RX Wireguided Retrieval Basket is indicated for endoscopic crushing and removal of biliary calculi. The lithotripter compatible basket should not be used for any other purpose other than its intended application.	Contraindications: The Trapezoid RX Wireguided Retrieval Basket is contraindicated whenever Endoscopic Retrograde Cholangiopancreatography (ERCP) or Endoscopic Retrograde Sphincterotomy (ERS) would be contraindicated. Adverse events: Possible complications include, but may not be limited to: Pancreatitis, Bleeding, Stone impaction, Cholangitis, Septicemia, Perforation by catheter tip	USA EC Certificate	AbŧgŨ`b KŨv thŧZ cŨŨi	AbŧgŨ`b KŨv nj

SI No	cŌZKviŧKi big	ewŨr`K big	ŧgvŨŧKj ŨfŨBŧmi big	Km	Ũbŧ`Rbv	Contraindication & Side-effect	FSC/CEP	ŧUKŨbK`vj me KugŨŨi mŨvi Ũm×ŨŧŨ	mŨvi Ũm×ŨŧŨ
109.	Manufacturer : Micro Therapeutics, Inc. dba ev3 eurovascular,9775 Toledo Way, Irvine, CA 92618,USA Local Agent: Medtronic Bangladesh Pvt. Ltd, Santa Western tower , Tejgaon, Dhaka	Solitaire 2 Revascularization device	Revascularization Device	C	The Solitaire™ Revascularization Device is indicated for use to restore blood flow in the neurovasculature by removing thrombus for the treatment of acute ischemic stroke to reduce disability in patients with a persistent, proximal anterior circulation, large vessel occlusion, and smaller core infarcts who have first received intravenous tissue plasminogen activator (IV t-PA). Endovascular therapy with the device should be started within 6 hours of symptom onset. The Solitaire™ Revascularization Device is indicated to restore blood flow by removing thrombus from a large intracranial vessel in patients experiencing ischemic stroke within 8 hours of symptom onset. Patients who are ineligible for IV t-PA or who fail IV t-PA therapy are candidates for treatment.	Contraindications Use of the SOLITAIRE™ AB Neurovascular Remodeling Device is contraindicated under these circumstances. • Patients in whom anticoagulant, antiplatelet therapy or thrombolytic drugs are contraindicated. • Patients with known hypersensitivity to nickel-titanium. Potential complications: Potential complications include, but are not limited to: • Hematoma at the puncture site • Perforation or dissection of the vessel • Vascular spasm • Hemorrhaging • Ruptured or perforated aneurysm • Coil herniation • Confusion • Device migration	CFG- USA, CE	Abŧgv`b Kiv thŧZ cŨŨi	Abŧgv`b Kiv nj
110.	M/s Micro Therapeutics, Inc. dba ev3 Neurovascular, 9775 Toledo Way, Irvine, CA 92618,USA Local Agent: Medtronic Bangladesh Pvt. Ltd, Santa Western tower , Tejgaon, Dhaka	The Solitaire™ revascularization device	Revascularization Device	C	It is indicated for use to restore blood flow in the neurovasculature by removing thrombus for the treatment of acute ischemic stroke to reduce disability in patients with a persistent, proximal anterior circulation, large vessel occlusion, and smaller core infarcts who have first received intravenous tissue plasminogen activator (IV t-PA). Endovascular therapy with the device should be started within 6 hours of symptom onset. The Solitaire™ Revascularization Device is indicated to restore blood flow by removing thrombus from a large intracranial vessel in patients experiencing ischemic stroke within 8 hours of symptom onset. Patients who are ineligible for IV t-PA or who fail IV t-PA therapy are candidates for treatment.	Contraindications Use of the SOLITAIRE™ AB Neurovascular Remodeling Device is contraindicated under these circumstances. • Patients in whom anticoagulant, antiplatelet therapy or thrombolytic drugs are contraindicated. • Patients with known hypersensitivity to nickel-titanium. Potential complications: Potential complications include, but are not limited to: • Hematoma at the puncture site • Perforation or dissection of the vessel • Vascular spasm • Hemorrhaging • Ruptured or perforated aneurysm • Coil herniation • Confusion • Device migration	CFG- USA, CE	Abŧgv`b Kiv thŧZ cŨŨi	Abŧgv`b Kiv nj
111.	Medtronic MiniMed, 18000 Devonshire Street, Northridge, CA 91325, USA	ENLITE Sensor	Sensor for glucose monitoring	C	Enlite Sensor is intended for use with Medtronic Diabetes (Medtronic) glucose sensing systems to continuously monitor glucose levels in persons with diabetes.	Do not expose your ENLITE Sensor to MRI equipment, diathermy, or other devices that generate strong magnetic fields.	CFG-USA	Abŧgv`b Kiv thŧZ cŨŨi	Abŧgv`b Kiv nj

SI No	cŌZKviŧKi big	ewŮr`K big	ŧgŮŮŧKj ŮŮfBŧmi big	KŮm	Ůbŧ`Rbv	Contraindication & Side-effect	FSC/CPP	ŧUKŮbK`vj mve KŮgŮŮi mŮvi Ům×ŮŧŮ	mŮvi Ům×ŮŧŮ
	Cremona Drive, Goleta, CA 93117 USA Florida USA Local Agent: Medtronic Bangladesh Pvt. Ltd, Santa Western tower , Tejgaon, Dhaka		Catheter		peritoneal catheters. ... Prior to implantation, the StrataVarius®Adjustment System is used to adjust the Strata NSC LP valve pressure/flow performance level.	Side effects : None			
116.	Medtronic Neurosurgery, 125 Cremona Drive, Goleta, CA 93117 USA Florida USA Local Agent: Medtronic Bangladesh Pvt. Ltd, Santa Western tower , Tejgaon, Dhaka	STRATA II	Valve, Shunt Kit and Shunt Assembly with Catheter	B	The Strata® II LP Shunt is a combination of the Strata II LP Valve and attached lumbar and peritoneal catheters. ... Prior to implantation, the StrataVarius®Adjustment System is used to adjust the Strata II LP valve pressure/flow performance level.	Despite appropriate maintenance and surveillance of an EVD, complications such as obstruction and infection may arise given the invasive nature of the device	CFG-USA	AbŧgŮv`b Kiv thŧZ cŮŧi	AbŧgŮv`b Kiv nj
117.	Medtronic SofamorDanek USA , INC, 1800 Pyramid USA Local Agent: Medtronic Bangladesh Pvt. Ltd, Santa Western tower , Tejgaon, Dhaka	Capstone spinal system Implants	Intervertebral body fusion Device	B	The CAPSTONE® System is indicated for use with autogenous bone graft for interbody spinal fusion procedure in patients with degenerative disc disease (DDD) at one or two levels from L2-S1. These DDD patients may also have up to Grade I spondylolisthesis or retrolisthesis at the involved level. DDD is defined as discogenic back pain with degeneration of the disc confirmed by patient history and radiographic studies. • These patients should be skeletally mature and have had six months of non-operative treatment. These implants may be implanted via an open or a minimally invasive posterior approach. • Alternatively, these implants may also be implanted via a transforaminal approach. Alternatively, implants larger than 40 mm length should be implanted via direct lateral approach. These devices are intended to be used with supplemental fixation instrumentation, which has been cleared for use in the lumbar spine.	CONTRAINDICATIONS: Contraindications include, but are not limited to: 1. Active infectious process or significant risk of infection (immunocompromise). 2. Signs of local inflammation. 3. Fever or leukocytosis. 4. Morbid obesity. 5. Pregnancy. 6. Mental illness. Grossly distorted anatomy caused by congenital abnormalities. 8. Any other medical or surgical condition which would preclude the potential benefit of spinal implant surgery, such as the presence of congenital abnormalities, elevation of sedimentation rate unexplained by other diseases, elevation of white blood count (WBC), or a marked left shift in the WBC differential count. 9. Rapid joint disease, bone absorption, osteopenia, osteomalacia and/or osteoporosis. 10. Suspected or documented metal allergy or intolerance. 11.	CFG-USA	AbŧgŮv`b Kiv thŧZ cŮŧi	AbŧgŮv`b Kiv nj

SI No	cŃZKviŃKi big	ewŃiR`K big	ŃgŃŃKj ŃŃfŃBŃmi big	KŃm	ŃbŃ`Rbv	Contraindication & Side-effect	FSC/ CPP	ŃUKŃbK`vj mve KugŃŃi mfvŃ Ńm×ŃŃŃ	mfvŃ Ńm×ŃŃŃ
						<p>Any case not needing a bone graft and fusion. 12. Any case where the implant components selected for use would be too large or too small to achieve a successful result. 13. Any patient having inadequate tissue coverage over the operative site or inadequate bone stock or quality. 14. Any patient in which implant utilization would interfere with anatomical structures or expected physiological performance. 15. Any patient unwilling to follow postoperative instructions. 16. Any case not described in the indications.</p> <p>POTENTIAL ADVERSE EVENTS: All of the possible adverse events associated with spinal fusion surgery without instrumentation are possible. With instrumentation, a listing of potential adverse events includes, but is not limited to: 1. Early or late loosening of any or all of the components. 2. Disassembly, bending, and/or breakage of any or all of the components. 3. Foreign body (allergic) reaction to implants, debris, corrosion products (from crevice, fretting, and/or general corrosion), including metallosis, staining, tumor formation, and/or autoimmune disease. 4. Pressure on the skin from component parts in patients with inadequate tissue coverage over the implant possibly causing skin penetration, irritation, fibrosis, neurosis, and/or pain. Bursitis. Tissue or nerve damage caused by improper positioning and placement of implants or instruments. 5. Post-operative change in spinal curvature, loss of correction, height, and/or reduction. 6. Infection. 7. Dural tears, pseudomeningocele, fistula, persistent CSF leakage, meningitis. 8. Loss of neurological</p>			

SI No	cŃZKviŃKi big	ewŃr`K big	ŃgŃŃKj ŃŃfŃŃmi big	KŃm	ŃbŃ`Rbv	Contraindication & Side-effect	FSC/ CPP	ŃUKŃK`vj mve KŃgŃŃi m fvi Ńm`vŃŃŃ	m fvi Ńm`vŃŃŃ
						<p>function (e.g., sensory and/or motor), including paralysis (complete or incomplete), dysesthesias, hyperesthesia, anesthesia, paresthesia, appearance of radiculopathy, and/or the development or continuation of pain, numbness, neuroma, spasms, sensory loss, tingling sensation, and/or visual deficits.</p> <p>9. Cauda equina syndrome, neuropathy, neurological deficits (transient or permanent), paraplegia, paraparesis, reflex deficits, irritation, arachnoiditis, and/or muscle loss.</p> <p>10. Urinary retention or loss of bladder control or other types of urological system compromise.</p> <p>11. Scar formation possibly causing neurological compromise or compression around nerves and/or pain.</p> <p>12. Fracture, microfracture, resorption, damage, or penetration of any spinal bone (including the sacrum, pedicles, and/or vertebral body) and/or bone graft or bone graft harvest site at, above, and/or below the level of surgery.</p> <p>Retropulsed graft.</p> <p>13. Herniated nucleus pulposus, disc disruption or degeneration at, above, or below the level of surgery.</p> <p>14. Non-union (or pseudarthrosis). Delayed union. Mal-union.</p> <p>15. Cessation of any potential growth of the operated portion of the spine.</p> <p>16. Loss of or increase in spinal mobility or function.</p> <p>17. Inability to perform the activities of daily living.</p> <p>18. Bone loss or decrease in bone density, possibly caused by stresses shielding.</p> <p>19. Graft donor site complications including pain, fracture, or wound healing problems.</p> <p>20. Ileus, gastritis, bowel obstruction or loss of bowel control or other types of gastrointestinal system compromise.</p> <p>21. Hemorrhage, hematoma, occlusion, seroma, edema, hypertension, embolism, stroke, excessive bleeding,</p>			

SI No	cŃZKviŃKi big	ewŃr`K big	ŃgŃŃKj ŃŃfBŃmi big	KŃm	ŃbŃ`Rbv	Contraindication & Side-effect	FSC/ CPP	ŃUKŃK`vj mve KugŃŃi mfvŃ Ńm`vŃŃŃ	mfvŃ Ńm`vŃŃŃ
						<p>patient unwilling to follow postoperative instructions. 16. Any case not described in the indications.</p> <p>POTENTIAL ADVERSE EVENTS: All of the possible adverse events associated with spinal fusion surgery without instrumentation are possible. With instrumentation, a listing of potential adverse events includes, but is not limited to: 1. Early or late loosening of any or all of the components. 2. Disassembly, bending, and/or breakage of any or all of the components. 3. Foreign body (allergic) reaction to implants, debris, corrosion products (from crevice, fretting, and/or general corrosion), including metallosis, staining, tumor formation, and/or autoimmune disease. 4. Pressure on the skin from component parts in patients with inadequate tissue coverage over the implant possibly causing skin penetration, irritation, fibrosis, neurosis, and/or pain. Bursitis. Tissue or nerve damage caused by improper positioning and placement of implants or instruments. 5. Post-operative change in spinal curvature, loss of correction, height, and/or reduction. 6. Infection. 7. Dural tears, pseudomeningocele, fistula, persistent CSF leakage, meningitis. 8. Loss of neurological function (e.g., sensory and/or motor), including paralysis (complete or incomplete), dysesthesias, hyperesthesia, anesthesia, paresthesia, appearance of radiculopathy, and/or the development or continuation of pain, numbness, neuroma, spasms, sensory loss, tingling sensation, and/or visual deficits. 9. Cauda equina syndrome, neuropathy, neurological deficits (transient or permanent), paraplegia, paraparesis, reflex deficits,</p>			

SI No	cŌZKviŧKi big	ewŨr`K big	ŧgŨŧKj ŨfŨBŧmi big	KŨm	Ũbŧ`Rbv	Contraindication & Side-effect	FSC/PPP	ŧUKŨbK`vj me KugŨŨi mfvi Ũm×vŨŧ	mfvi Ũm×vŨŧ
119.	Medtronic SofamorDanek USA , INC, 2500 Warsaw, USA Local Agent: Medtronic Bangladesh Pvt. Ltd, Santa Western tower , Tejgaon, Dhaka	CD Horizen Spinal system Implants	Orthosis spinal pedicle fixation for degenerative disc disease	C	The CD HORIZON® Spinal System is intended for posterior, non-cervical fixation for the following indications: degenerative disc disease (defined as back pain of discogenic origin with degeneration of the disc confirmed by history and radiographic studies); spondylolisthesis; trauma (i.e., fracture or dislocation); spinal stenosis; curvatures (i.e., scoliosis, kyphosis and/or lordosis); tumor; pseudarthrosis; and/or failed previous fusion	CONTRAINDICATIONS: Contraindications include, but are not limited to: 1. Active infectious process or significant risk of infection (immunocompromise). 2. Signs of local inflammation. 3. Fever or leukocytosis. 4. Morbid obesity. 5. Pregnancy. 6. Mental illness. Grossly distorted anatomy caused by congenital abnormalities. 8. Any other medical or surgical condition which would preclude the potential benefit of spinal implant surgery, such as the presence of congenital abnormalities, elevation of sedimentation rate unexplained by other diseases, elevation of white blood count (WBC), or a marked left shift in the WBC differential count. 9. Rapid joint disease, bone absorption, osteopenia, osteomalacia and/or osteoporosis. 10. Suspected or documented metal allergy or intolerance. 11. Any case not needing a bone graft and fusion. 12. Any case where the implant components selected for use would be too large or too small to achieve a successful result. 13. Any patient having inadequate tissue coverage over the operative site or inadequate bone stock or quality. 14. Any patient in which implant utilization would interfere with anatomical structures or expected physiological performance. 15. Any patient unwilling to follow postoperative instructions. 16. Any case not described in the indications. POTENTIAL ADVERSE EVENTS: All of the possible adverse events associated with spinal fusion surgery without instrumentation are possible. With instrumentation, a listing of potential adverse events includes, but is not limited to: 1. Early or late loosening of	CFG-USA	AbŧgŨv`b Kiv thŧZ cŨŧi	AbŧgŨv`b Kiv nj

SI No	cŃZKviŃKi big	ewŃR`K big	ŃgŃŃKj ŃŃfŃBŃmi big	KŃm	ŃbŃ`Rbv	Contraindication & Side-effect	FSC/CPP	ŃUKŃbK`vj mve KŃgŃŃŃi m fvi ŃmŃŃŃŃŃ	m fvi ŃmŃŃŃŃŃ
						<p>any or all of the components. 2. Disassembly, bending, and/or breakage of any or all of the components. 3. Foreign body (allergic) reaction to implants, debris, corrosion products (from crevice, fretting, and/or general corrosion), including metallosis, staining, tumor formation, and/or autoimmune disease. 4. Pressure on the skin from component parts in patients with inadequate tissue coverage over the implant possibly causing skin penetration, irritation, fibrosis, neurosis, and/or pain. Bursitis. Tissue or nerve damage caused by improper positioning and placement of implants or instruments. 5. Post-operative change in spinal curvature, loss of correction, height, and/or reduction. 6. Infection. 7. Dural tears, pseudomeningocele, fistula, persistent CSF leakage, meningitis. 8. Loss of neurological function (e.g., sensory and/or motor), including paralysis (complete or incomplete), dysesthesias, hyperesthesia, anesthesia, paresthesia, appearance of radiculopathy, and/or the development or continuation of pain, numbness, neuroma, spasms, sensory loss, tingling sensation, and/or visual deficits. 9. Cauda equina syndrome, neuropathy, neurological deficits (transient or permanent), paraplegia, paraparesis, reflex deficits, irritation, arachnoiditis, and/or muscle loss. 10. Urinary retention or loss of bladder control or other types of urological system compromise. 11. Scar formation possibly causing neurological compromise or compression around nerves and/or pain. 12. Fracture, microfracture, resorption, damage, or penetration of any spinal bone (including the sacrum, pedicles, and/or vertebral body) and/or bone graft or bone graft harvest site</p>			

SI No	cŃZKviŃKi big	ewŃr`K big	ŃgŃŃKj ŃŃfŃBŃmi big	KŃm	ŃbŃ`Rbv	Contraindication & Side-effect	FSC/ CPP	ŃUKŃbK`vj mve KŃgŃŃŃi m fvi Ńm`vŃŃŃ	m fvi Ńm`vŃŃŃ
						at, above, and/or below the level of surgery. Retropulsed graft. 13. Herniated nucleus pulposus, disc disruption or degeneration at, above, or below the level of surgery. 14. Non-union (or pseudarthrosis). Delayed union. Mal-union. 15. Cessation of any potential growth of the operated portion of the spine. 16. Loss of or increase in spinal mobility or function. 17. Inability to perform the activities of daily living. 18. Bone loss or decrease in bone density, possibly caused by stresses shielding. 19. Graft donor site complications including pain, fracture, or wound healing problems. 20. Ileus, gastritis, bowel obstruction or loss of bowel control or other types of gastrointestinal system compromise. 21. Hemorrhage, hematoma, occlusion, seroma, edema, hypertension, embolism, stroke, excessive bleeding, phlebitis, wound necrosis, wound dehiscence, damage to blood vessels, or other types of cardiovascular system compromise. 22. Reproductive system compromise, including sterility, loss of consortium, and sexual dysfunction. 23. Development of respiratory problems, e.g. pulmonary embolism, atelectasis, bronchitis, pneumonia, etc. 24. Change in mental status. 25. Death.			
120.	Medtronic SofamorDanek USA , INC, 2500 Warsaw, USA Local Agent:	Vertex reconstruction system	Spinal interlaminar fixation orthosis	B	When intended as an adjunct to fusion of the occipitocervical spine, cervical spine, and the thoracic spine (Occiput-T3), the VERTEX® Reconstruction System is indicated for skeletally mature patients using allograft and/or autograft for the following: DODD (neck	Contraindications: Contraindications include, but are not limited to: 1. Active infectious process or significant risk of infection (immunocompromise). 2. Signs of local inflammation. 3. Fever or leukocytosis.	CFG USA	AbŃgv`b Kiv thŃZ cŃŃi	AbŃgv`b Kiv nj

SI No	cŃZKviŃKi big	ewŃrŃK big	ŃgŃŃKj ŃŃfŃBŃmi big	KŃm	ŃbŃŃ RbŃ	Contraindication & Side-effect	FSC/ CPP	ŃŃKŃbKŃŃj mŃe KŃgŃŃŃi mŃfŃi ŃmŃŃŃŃŃ	mŃfŃi ŃmŃŃŃŃŃ
	Medtronic Bangladesh Pvt. Ltd, Santa Western tower , Tejgaon, Dhaka				pain of discogenic origin with degeneration of the disc confirmed by history and radiographic studies), spondylolisthesis, spinal stenosis, fracture, dislocation, failed previous fusion, and/or tumors.	<p>4. Morbid obesity. 5. Pregnancy. 6. Mental illness. 7. Grossly distorted anatomy caused by congenital abnormalities. 8. Any other medical or surgical condition which would preclude the potential benefit of spinal implant surgery, such as the presence of congenital abnormalities, elevation of sedimentation rate unexplained by other diseases, elevation of white blood count (WBC), or a marked left shift in the WBC differential count. 9. Rapid joint disease, bone absorption, osteopenia, osteomalacia and/or osteoporosis. Osteoporosis or osteopenia is a relative contraindication since this condition may limit the degree of obtainable correction, stabilization, and/or the amount of mechanical fixation. 10. Suspected or documented metal allergy or intolerance. 11. Any case not needing a bone graft and fusion. 12. Any case where the implant components selected for use would be too large or too small to achieve a successful result. 13. Any case that requires the mixing of metals from two different components or systems. 14. Any patient having inadequate tissue coverage over the operative site or inadequate bone stock or quality. 15. Any patient in which implant utilization would interfere with anatomical structures or expected physiological performance. 16. Any patient unwilling to follow postoperative instructions. 17. Any case not described in the indications.</p> <p>Potential Adverse Events: All of the possible adverse events associated with spinal fusion surgery without instrumentation are possible. With instrumentation, a listing of potential adverse events includes, but is</p>			

SI No	cŃZKviŃKi big	ewŃrŃK big	ŃgŃŃKj ŃŃfŃŃi big	KŃm	ŃbŃŃ Rbv	Contraindication & Side-effect	FSC/ CPP	ŃUKŃKŃj mve KŃgŃŃi mŃvi ŃmŃŃŃŃ	mŃvi ŃmŃŃŃŃ
						<p>not limited to: 1. Early or late loosening of any or all of the components. 2. Disassembly, bending, and/or breakage of any or all of the components. 3. Foreign body (allergic) reaction to implants, debris, corrosion products (from crevice, fretting, and/or general corrosion), including metallosis, staining, tumor formation, and/or autoimmune disease. 4. Pressure on the skin from component parts in patients with inadequate tissue coverage over the implant possibly causing skin penetration, irritation, fibrosis, necrosis, and/or pain. Bursitis. Tissue or nerve damage caused by improper positioning and placement of implants or instruments. 5. Post-operative change in spinal curvature, loss of correction, height, and/or reduction. 6. Infection. 7. Dural tears, pseudomeningocele, fistula, persistent CSF leakage, meningitis. 8. Loss of neurological function (e.g., sensory and/or motor), including paralysis (complete or incomplete), dysesthesias, hyperesthesia, anesthesia, paresthesia, appearance of radiculopathy, and/or the development or continuation of pain, numbness, neuroma, spasms, sensory loss, tingling sensation, and/or visual deficits. 9. Neuropathy, neurological deficits (transient or permanent), paraplegia, paraparesis, reflex deficits, irritation, arachnoiditis, and/or muscle loss. 10. Urinary retention or loss of bladder control or other types of urological system compromise. 11. Scar formation possibly causing neurological compromise or compression around nerves and/or pain. 12. Fracture, microfracture, resorption, damage, or penetration of any spinal bone (including the sacrum, pedicles, and/or vertebral body) and/or bone graft or bone graft harvest site</p>			

SI No	cŌZKviŤKi big	ewŤrŤK big	ŤgŤŤKj ŤŤfŤŤi big	KŤm	ŤbŤ RbŤ	Contraindication & Side-effect	FSC/ CPP	ŤUKŤK'vj me KŤgŤŤi mŤvi ŤŤŤŤŤŤ	mŤvi ŤŤŤŤŤŤ
						at, above, and/or below the level of surgery. Retropulsed graft. 13. Herniated nucleus pulposus, disc disruption or degeneration at, above, or below the level of surgery. 14. Non-union (or pseudarthrosis). Delayed union. Mal-union. 15. Cessation of any potential growth of the operated portion of the spine. 16. Loss of or increase in spinal mobility or function. 17. Inability to perform the activities of daily living.			
121.	Medtronic SofamorDanek USA , INC, 1800 Pyramid,USA Local Agent: Medtronic Bangladesh Pvt. Ltd, Santa Western tower , Tejgaon, Dhaka	T2 Allitude Expandable corceptomy system	Spinal Interverbal body fixation orthosis	B	The T2 ALTITUDE™ Expandable Corpectomy System is a vertebral body replacement system intended for use in the thoracolumbar spine (T1-L5) to replace a collapsed, damaged, or unstable vertebral body due to tumor or trauma (i.e., fracture). The T2 ALTITUDE™ Expandable Centerpiece may be used with or without optional modular endcaps which accommodate individual anatomic requirements. The device is to be used with supplemental fixation. Specifically, the construct is to be used with the VANTAGE® Anterior Fixation System, the TSRH® Spinal System, the CD HORIZON®	Contraindications: ➤ Severe osteoporosis ➤ Reconstruction of more than three adjacent vertebral bodies.	CFG USA	AbŤgŤv`b Kiv thŤZ cŤŤi	AbŤgŤv`b Kiv nj
122.	Medtronic SofamorDanek USA , INC, 2500 Warsaw, USA Local Agent: Medtronic Bangladesh Pvt. Ltd, Santa Western tower , Tejgaon, Dhaka	Atlantis Anterior cervical Plate system	Spinal intervertebral body fixation orthosis	C	The system is indicated for use in the temporary stabilization of the anterior spine during the development of cervical spinal fusions in patients with: 1) degenerative disc disease (as defined by neck pain of discogenic origin with degeneration of the disc confirmed by patient history and radiographic studies), 2) trauma (including fractures), 3) tumors, 4) deformity (defined as kyphosis, lordosis, or scoliosis), 5) pseudarthrosis, and/or 6) failed previous fusions.	Contraindications: Contraindications include, but are not limited to: 1. Patients with infection in or adjacent to the spine or spinal structures 2. Inadequate tissue coverage over operative site 3. Patients with morbid obesity 4. Pregnancy 5. Bone absorption, rapid joint disease, osteomalacia, osteopenia, and/or osteoporosis 6. Any spinal surgery case not needing a fusion 7. Any reuse, or multiple use 8. Fever or leukocytosis 9. Any patient unwilling or resistant to following postoperative instructions 10. Mental illness 11. Cardiovascular complications 12. Allergic or other reaction to the metallic components and/or implants.	CFG-USA	AbŤgŤv`b Kiv thŤZ cŤŤi	AbŤgŤv`b Kiv nj

SI No	cŌZKviŧKi big	ewŨr`K big	ŧgŨŧKj ŨŨfİBŧmi big	KŨm	Ũbŧ`Rbv	Contraindication & Side-effect	FSC/CE	ŧUKİbK`vj me KŨgŨŨi mŨvi Ũm×vŨŧ	mŨvi Ũm×vŨŧ
						<p>Potential Adverse Effects: The following potential adverse affects associated with the procedure have been shown to occur with the use of similar spinal systems. All patients considered candidates for fusion should be informed concerning the pathogenesis of their spinal abnormality, the rationale for fusion with instrumentation, and the potential adverse affects. The following are potential adverse affects, but not limited to: 1. Loss of proper spinal curvature, correction, height, and/or reduction 2. Infection 3. Non-Union or delayed union 4. Foreign body reaction to the implants 5. Hemorrhaging 6. Loss of neurological function, dural tear, pain, and/ or discomfort 7. Bone graft fracture, vertebral body fracture or discontinued growth of fusion at, above and/or below the surgery level 8. Bending, loosening, fracture, disassembly, slippage and/ or migration of the components 9. Revision surgery 10. Dysphagia 11. Bursitis 12. Bone loss and/or bone fracture due to stress shielding 13. Loss of bladder and/or bowel control 14. Injury to recurrent laryngeal nerve resulting in alteration of voice 15. Injury to esophagus and/or trachea 16. Death</p>			
123.	<p>Medtronic SofamorDanek USA , INC, 1800 Pyramid ,USA Local Agent: Medtronic Bangladesh Pvt. Ltd, Santa Western tower , Tejgaon, Dhaka</p>	CORNERSTONE PSR Cervical fusion Sytem	Spinal Intervertebral body fixation orthosis	C	The CORNERSTONE® PSR device is indicated for cervical interbody fusion procedures in skeletally mature patients with cervical disc disease at one level from the C2-C3 disc to the C7-T1 disc. Cervical disc disease is defined as intractable radiculopathy and/or myelopathy with herniated disc and/or osteophyte formation on posterior vertebral endplates producing symptomatic nerve root and/or spinal cord compression confirmed by radiographic studies. This device is to be used in patients who have had six weeks of non-operative treatment. The CORNERSTONE® PSR device is to be used with supplemental fixation. The	<p>Possible Adverse Effects: Breakage, slippage, misuse, or mishandling of instruments, such as on sharp edges, may cause injury to the patient or operative personnel. Improper maintenance, handling, or poor cleaning procedures can render the instrument unsuitable for its intended purpose, or even dangerous to the patient or surgical staff. Proper patient selection and operative care are critical to the success of the device and avoidance of injury during surgery. Read and follow all other product</p>	CFG-USA CE	Abŧgv`b Kiv thŧZ cŨŧi	Abŧgv`b Kiv nj

SI No	cŃZKviŃKi big	ewŃrŃK big	ŃgŃŃKj ŃŃfŃŃmi big	KŃm	ŃbŃŃ Rbv	Contraindication & Side-effect	FSC/ CPP	ŃUKŃbKŃvj mve KugŃŃi mŃvi ŃmŃŃŃŃŃ	mŃvi ŃmŃŃŃŃŃ
					CORNERSTONE® PSR device is also required to be used with autograft.	<p>information supplied by the manufacturer of the implants or the instruments. Special precautions are needed during pediatric use. Care should be taken when using instruments in pediatric patients, since these patients can be more susceptible to the stresses involved in their use. There are particular risks involved in the use of instruments used for bending and cutting rods. The use of these types of instruments can cause injury to the patient by virtue of the extremely high forces which are involved. Do not cut rods in situ. In addition, any breakage of an instrument or the implant in this situation could be extremely hazardous. The physical characteristics required for many instruments does not permit them to be manufactured from implantable materials, and if any broken fragments of instruments remain in the body of a patient, they could cause allergic or infectious consequences. Over-bending, notching, striking and scratching of the implants with any instrument should be avoided to reduce the risk of breakage. Under no circumstances should rods or plates be sharply or reverse bent, since this would reduce the fatigue life of the rod and increase the risk of breakage. When the configuration of the bone cannot be fitted with an available device and contouring of the device is absolutely necessary, contouring should be performed only with proper bending equipment, and should be performed gradually and with great care to avoid notching or scratching the device. Extreme care should be taken to ensure that this instrument remains in good working order. Any surgical techniques applicable for use of this system should be</p>			

SI No	cŌZKviŧKi big	ewŨr`K big	ŧgŨŧKj ŨŨfBŧmi big	KŨm	Ũbŧ`Rbv	Contraindication & Side-effect	FSC/CEP	ŧUKŨbK`vj me KugŨŨi mŨvi Ũm×vŨŧ	mŨvi Ũm×vŨŧ
						cleaned and sterilized. 4. Pain, discomfort, or abnormal sensations resulting from the presence of the device. 5. Nerve damage due to surgical trauma. 6. Dural leak in cases of excessive load application. 7. Impingement of close vessels, nerves and organs by slippage or misplacement of the instrument. 8. Damage due to spontaneous release of clamping devices or spring mechanisms of certain instruments. 9. Cutting of skin or gloves of operating staff. 10. Bony fracture, in cases of deformed spine or weak bone. 11. Tissue damage to the patient, physical injury to operating staff and/or increased operating time that may result from the disassembly of multi-component instruments occurring during surgery.			
124.	Medtronic SofamorDanek USA , INC, 1800 Pyramid ,USA Local Agent: Medtronic Bangladesh Pvt. Ltd, Santa Western tower , Tejgaon, Dhaka	Verte –Stack spinal system (Cornerstone PSR)	Spinal Intervertebral body fixation orthosis	C	The VERTE-STACK® Spinal System is a vertebral body replacement device intended for use in the thoracolumbar spine (T1-L5) to replace a collapsed, damaged, or unstable vertebral body due to tumor or trauma.	N/A	CFG-USA, CE	Abŧgr`b Kiv thŧZ cŧŧi	Abŧgr`b Kiv nj
125.	Manufacturer: Changzhou Kanghui Medical Innovation Co. Ltd., China	Spine Internal Fixation system (G5 Spine system)	Spine Internal Fixation system	C	Spinal Fixation System is a posterior, non-pedicle supplemental fixation device, intended for use at a single level in the non-cervical spine (T1-S1). It is intended for plate fixation/ attachment to spinous processes for the purpose of achieving supplemental	Contraindications: Contraindications may be relative or absolute. The choice of a particular device must be carefully weighed against the patient's overall evaluation. Circumstances listed below may reduce the	FSC-China EC Certificate	Abŧgr`b Kiv thŧZ cŧŧi	Abŧgr`b Kiv nj

SI No	cŃZKviŃKi big	ewŃrŃK big	ŃgŃŃKj ŃŃfŃBŃmi big	KŃm	ŃbŃŃ Rbv	Contraindication & Side-effect	FSC/CPP	ŃUKŃbKŃvj mve KugŃŃŃi mŃvi ŃmŃŃŃŃŃŃ	mŃvi ŃmŃŃŃŃŃŃ
	Local Agent: Medtronic Bangladesh Pvt. Ltd.				fusion in the following conditions: degenerative disc disease (DDD) (defined as back pain of discogenic origin with degeneration of the disc confirmed by history and radio-graphic studies); spondylolisthesis; trauma (i.e., fracture or dislocation); tumor. It is not intended for stand-alone use.	chance of a successful outcome. Contraindications include, but are not limited to: <ul style="list-style-type: none"> • An allergy to titanium, or foreign body sensitivity. Where material sensitivity is suspected, appropriate tests must be made prior to implantation. • Known or suspected infection/immune system incompetence. Acute infectious process or significant risk of infection • Any abnormality present which affects the normal process of bone remodeling including, but not limited to, severe osteoporosis involving the spine, bone absorption, osteopenia, active infection at the site or certain metabolic disorders affecting osteogenesis. • Morbid Obesity. • Any neuromuscular deficit which places an unusually heavy load on the device during the healing period. • Open Wounds. • Pregnancy. • Any other medical or surgical condition which would preclude the potential benefit of spinal surgery, such as the presence of congenital abnormalities, elevation of sedimentation rate unexplained by other diseases, elevation of the white blood count (WBC), or a marked left shift in the WBC differential count. • Any case requiring the mixing of components from other manufacturers' systems. • Any case requiring the mixture of stainless steel with titanium, or stainless steel with cobalt chrome implant components. • Fever or leukocytosis. • Signs of local infection or inflammation. • Senility, mental illness or substance abuse, of a severity that the patient may ignore certain necessary limitations and precautions in the use of the implant, leading to failure or other complications. • Previous history of infection. • Alcoholism or heavy smoking. • Any patient which implant utilization would interfere with anatomical structures or expected physiological performance. • Any patient unwilling to follow postoperative instructions. • Inadequate tissue coverage over the operative site. • The StabiLink® device is also contraindicated for incompetent or missing posterior arch (e.g., laminectomy, pars defect, severe 			

SI No	cŌZKviŧKi big	ewŮr`K big	ŧgŮŮŧKj ŮŮfŮBŧmi big	Km	Ůbŧ`Rbv	Contraindication & Side-effect	FSC/CPP	ŧUKŮbK`vj mve KugŮŮi mfvi Ům×ŮŠŮ	mfvi Ům×ŮŠŮ
	Local Agent : Vastech Limited, Nurjehan Tower (6th Floor), 80/22 Mymensingh Road Dhaka				reconstruction, biceps tenodesis, deltoid repair. Wrist Indications – Scapholunate ligament reconstruction. Elbow Indications – Biceps tendon reattachment, Ulnar or radial collateral ligament reconstruction. Knee Indications – Extra capsular Repair: Medial collateral ligament repair, lateral collateral ligament repair, posterior oblique ligament repair, joint capsule closure, iliotibial band tenodesis reconstruction, and patellar ligament and tendon repair, vastus medialis obliquus (VMO) muscle advancement. □ Hip: Capsular repair, acetabular labral repair	incapable of following postoperative care instructions.; Foreign body sensitivity. Where material sensitivity is suspected, testing is to be completed prior to implantation of the device. Possible Adverse Effects Non-union or delayed union, which may lead to breakage of the implant.; Bending or fracture of the implant.; Loosening or migration of the implant.; Metal sensitivity or allergic reaction to a foreign body.; Pain, discomfort, or abnormal sensation due to the presence of the device.; Nerve damage due to surgical trauma.; Necrosis of bone or tissue.; Inadequate healing.; Intraoperative or postoperative bone fracture and/or postoperative pain.		ŮKŧgŮŮ `ŮLŧj i kŧZ® AbŧgŮ`b Kiv thZ cŮŧi	ŮKŧgŮŮ `ŮLŧj i kŧZ® AbŧgŮ`b Kiv nj
130.	Manufacturer : Boston Scientific Ltd., Ireland Local Agent : Vastech Limited, Nurjehan Tower (6th Floor), 80/22 Mymensingh Road Dhaka	Ultraflex Tracheobronchial Stent System	Metal Tracheo-Bronchial stent	C	It is indicated for use in the treatment of tracheobronchial strictures produced by malignant neoplasm.	Contraindications: The Ultraflex Tracheobronchial Stent System is contraindicated for: • Concurrent fistula of the tracheobronchial tree, unless a covered stent is being used. • Tracheobronchial obstruction with a luminal diameter which cannot be dilated to and maintained at least 4 mm, or preventing passage of either a rigid or flexible bronchoscope • Patients for whom bronchoscopic procedures are contraindicated • Any use other than those specifically outlined under Indications for Use Adverse events: Complications have been reported in the literature for tracheobronchial stent placement with both conventional plastic stents and available expandable metal stents. These include, but are not limited to the following: Procedural Complications; Stent misplacement; Bleeding; Tracheobronchial	USA EC Certificate	AbŧgŮ`b Kiv thZ cŮŧi	AbŧgŮ`b Kiv nj

SI No	cŃZKviŃKi big	ewŃrŃK big	ŃgŃŃŃKj ŃŃfŃBŃmi big	KŃm	ŃbŃŃ Rbv	Contraindication & Side-effect	FSC/ CPP	ŃUKŃbKŃvj mve KŃgŃŃŃi mŃvi ŃmŃŃŃŃŃ	mŃvi ŃmŃŃŃŃŃ
	Terumo BCT, Inc 10811 West Collins Avenue, Lakewood, Colorado, USA Local Agent : Trades worth Ltd. 78, Motijheel C/A (1 st & 2 nd) Floor, Dhaka-1000.	A Solution (Cat # 8PB1AC500E8B)	Dextrose Solution A 500ml		with and without leukocyte removal filter	Side effects : None		thŃZ cŃŃi	
134.	Manufacturer: NTC S.r.L Via Luigi Razza, 320124 Milano, MI, Italy Local Agent: Zas Corporation 80/22 Mymensingh Road, Nurjehan Tower (3 rd Floor) Dhaka	BLEFASTOP Sterile Ophthalmic Preparations	Blephapad Wipes with Hyaluronic Acid & Terpinem (Young)	C	Adjuvant in Blepharitis treatment, wipes for cleaning and treating	Contra-indication: N/A Side-Effects: N/A	FSC-Italy	AbŃgvŃ b Kiv thŃZ cŃŃi	AbŃgvŃ b Kiv nj
135.	Manufacturer: NTC S.r.L Via Luigi Razza, 320124 Milano, MI, Italy Local Agent: Zas Corporation 80/22 Mymensingh Road, Nurjehan Tower (3 rd Floor) Dhaka	BLEFASTOP PLUS WIPES	Blephapad Wipes with Hyaluronic Acid & Terpinem Warming [Adult]	C	Adjuvant in Blepharitis treatment, wipes for cleaning and treating	Contra-indication: N/A Side-Effects: N/A	FSC-Italy	AbŃgvŃ b Kiv thŃZ cŃŃi	AbŃgvŃ b Kiv nj
136.	Manufacturer: NTC S.r.L Via Luigi Razza, 320124 Milano, MI, Italy	CMC LUVIS 0.5% Sterile Ophthalmic Solution	Carboxymethylcellulose 0.5%	B	Lasting and Soothing relief in mild to moderate dry eyes. Provide Protection against burning, irritation and discomfort associated with ocular dryness	Contra-indication: Pregnancy and Breast Feeding Side-Effects: Visual disturbances, Eye irritation and eye pain	FSC-Italy	AbŃgvŃ b Kiv thŃZ cŃŃi	AbŃgvŃ b Kiv nj

SI No	cŃZKviŃKi big	ewŃR`K big	ŃgvŃŃKj ŃŃfŃBŃmi big	KŃm	ŃbŃ`RbŃ	Contraindication & Side-effect	FSC/ CPP	ŃUKŃbK`vj mŃe KŃgŃŃi mŃvi Ńm`vŃŃŃ	mŃvi Ńm`vŃŃŃ
	Local Agent: Zas Corporation 80/22 Mymensingh Road, Nurjehan Tower (3 rd Floor) Dhaka								
137.	Evaux Laboratories 67 Avenue del la Republique 23110 EVAUX-LES- BAINS, France Local Agent: Zas Corporation 80/22 Mymensingh Road , Nurjehan Tower (3 rd Floor) Dhaka	Evomucy Mouth Spray	Evaux thermal spring water, Glycerine, Cocamidopro pyl Betanamide, MEA chloride, Pircotone olamine, Citric acid, Phenoxyethanol, Methyl paraben, Butyl paraben, Isobutyl paraben, Ethyl paraben, Propyl paraben, Sodium saccharin	C	It is an effective and well-tested solution against mouth ulcers and other problems related to chemotherapy and/or radiotherapy.	Contraindication: Allergy to any ingredients of Evomucy Spray Side Effects: No side effects has been seen.	FSC- France	AbŃgv`b Kiv ŃhŃZ cŃŃi	AbŃgv`b Kiv nj
138.	Medtronic SofamorDanek USA , INC, 1800 Pyramid ,USA Local Agent: Medtronic Bangladesh Pvt. Ltd.	Kyphopak tray	Fracture Management system	B	The Kypho Pak Trays are convenience kits used in bone fracture reduction, The indications for use of the tray components are provided in their corresponding instructions for use, which accompany the trays	Contraindications: None Side Effects: None	CFG USA	AbŃgv`b Kiv ŃhŃZ cŃŃi	AbŃgv`b Kiv nj
139.	Manufacutrer: NTC S.r.L Via Luigi Razza, 320124 Milano, MI, Italy	LUVIS LIPO	Hyaluronic Acid + Levocarnitine + Zinc + Castor oil	C	Lasting and soothing relief in mild to moderate dry eyes. Provide protection against burning, irritation.	Contra-indication: N/A Side-Effects: N/A	FSC-Italy	AbŃgv`b Kiv ŃhŃZ cŃŃi	AbŃgv`b Kiv nj

SI No	cŃZKviŃKi big	ewŃrŃK big	ŃgvŃŃKj ŃŃfŃBŃmi big	KŃm	ŃbŃŃ Rbv	Contraindication & Side-effect	FSC/CPP	ŃUKŃbKŃvj mve KŃgŃŃŃi mŃvi ŃmŃŃŃŃŃ	mŃvi ŃmŃŃŃŃŃ
	Local Agent: Zas Corporation 80/22 Mymensingh Road, Nurjehan Tower (3 rd Floor) Dhaka								
140.	Manufacturer: Rocamed France Local Agent: M/S. Swadesh 30, Bijoy Nagar Road (3 rd Floor), Dhaka – 1000.	Family ROJ	Ureteral Stent	C	Ensure drainage of urine from the kidney towards the bladder	Contraindication: Not Known Side Effect: Not Known	FSC-France	AbŃgvŃ b Kiv ŃhŃZ cŃŃi	AbŃgvŃ b Kiv nj
141.	Manufacturer: Rocamed France Local Agent: M/S. Swadesh 30, Bijoy Nagar Road (3 rd Floor), Dhaka – 1000.	Family RON Rocanephro	Nephro dilators	B	Rocanephro dilators are intended to facilitate access into the kidney in percutaneous Procedures. Rocanephro catheters are intended to provide drainage of the kidney by percutaneous positioning. Rocanephro needles are intended for the initial puncture during the percutaneous nephrostomy procedures. The Roca wire guide wire is designed to facilitate the positioning of device during percutaneous nephrostomy procedures.	Contraindication: Not Known Side Effect: Not Known	FSC-France	AbŃgvŃ b Kiv ŃhŃZ cŃŃi	AbŃgvŃ b Kiv nj
142.	Manufacturer: Rocamed France Local Agent: M/S. Swadesh	ROTU ROCATUB Catheter	Catheter	B	The Rocamed Roca tub ureteral catheter is indicated to facilitate drainage and flushing of the upper urinary tract. These devices consist of a flexible tube, tapered, perforated and with position marks. It is radio opaque and hydrophilic coated. The device includes a stylet for	Contraindication: Not Known Side Effect: Not Known	FSC-France	AbŃgvŃ b Kiv ŃhŃZ cŃŃi	AbŃgvŃ b Kiv nj

SI No	cŌZKvi:Ki big	ewM'R`K big	tgM:Kj MfB:mi big	Km	ib: Rbv	Contraindication & Side-effect	FSC/PPP	UKibK`vj me Kuglji mfvi m×všl	mfvi m×všl
	30, Bijoy Nagar Road (3 rd Floor), Dhaka – 1000.				insertion and a connector for syringe. the device is offered in various sizes, from 4 to 8 Fr in 80 cm length, and with various shapes. it can be placed a guide wire and allows injecion or aspiration of fluids.				
143.	Manufacturer: Rocamed France Local Agent: M/S. Swadesh 30, Bijoy Nagar Road (3 rd Floor), Dhaka – 1000.	ROUS- Biflex Access Sheath	Access Sheath	B	It is intended to be a conduit for passage of endoscopes and other urological devices for the purpose of performing ureteroscopy procedures. The dual working lumen dilator with lure lock connections allows the use to insert guide wires and fluids. The bi-flex ureteral access sheath is designed to create as cinduit for urological procedural instruments. the device consists of two components : a flexible, coil reinforced sheath and a semi- rigid dual lumen dilator catheter with tapered distal top. Both components are radioopaque and have hydrophilic coating. This device is sold in two sizes, 10/12 and 12/14 FR, and two lengths, 35 and 45cm.	Contraindication: Not Known Side Effect: Not Known	FSC-France	Abtgv`b Kiv thZ cti	Abtgv`b Kiv nj
144.	Manufacturer: Rocamed France Local Agent: M/S. Swadesh 30, Bijoy Nagar Road (3 rd Floor), Dhaka – 1000.	ROWI Nephrostomy ROCAWIRE Guide	Nephrostomy Guide wire	B	Rocawire guidewires are intended to facilitate the placement of endourological devices during endourological procedures.	Contraindication: Not Known Side Effect: Not Known	FSC-France	Abtgv`b Kiv thZ cti	Abtgv`b Kiv nj
145.	Manufacturer: Rocamed France Local Agent: M/S. Swadesh	ROF: Rocaflo-3way Silicone Prostatic Catheter	Prostatic Catheter	B	The Rocamed RocaFlow Catheter are indicated for use in the drainage and irrigation ofthe bladder.	Contraindication: Not Known Side Effect: Not Known	FSC-France	Abtgv`b Kiv thZ cti	Abtgv`b Kiv nj

SI No	cŃZKviŃKi big	ewŃrŃK big	ŃgŃŃKj ŃŃfŃBŃmi big	KŃm	ŃbŃŃ Rbv	Contraindication & Side-effect	FSC/CPP	ŃUKŃbKŃvj mve KŃgŃŃŃi mŃvi ŃmŃŃŃŃŃ	mŃvi ŃmŃŃŃŃŃ
	30, Bijoy Nagar Road (3 rd Floor), Dhaka – 1000.								
146.	Manufacturer: Rocamed France Local Agent: M/S. Swadesh 30, Bijoy Nagar Road (3 rd Floor), Dhaka – 1000.	Family OE-OJ-On-QE	Irrigation devices	B	Rocamed Irrigation devices are intended to be used for urology, laparoscopy or hysteroscopy procedure for irrigation/ washing in anatomical cavities.	Contraindication: Not Known Side Effect: Not Known	FSC-France	AbŃgŃŃ b Kiv thŃZ cŃŃi	AbŃgŃŃ b Kiv nj
147.	Manufacturer: Rocamed France Local Agent: M/S. Swadesh 30, Bijoy Nagar Road (3 rd Floor), Dhaka – 1000.	Family ROS	Stone extractors	B	Rocastone extractor stone extractors are intended for grasping and/or maneuvering and/or extraction of stones during ureteroscopy procedures.	Contraindication: Not Known Side Effect: Not Known	FSC-France	AbŃgŃŃ b Kiv thŃZ cŃŃi	AbŃgŃŃ b Kiv nj
148.	Manufacturer: Meran Tip Ürünleri Teknoloji San.ve tic.ltd.ŃŃi Istanbul, Turkey Local Agent: Zas Corporation 80/22 Mymensingh Road , Nurjehan Tower Bangladesh	Merdecalin	Perfluorodecalin 5 ml	B	It is used as Per-operative devices, for transitory intra-ocular endotamponade. In particular retinal detachment, RD with giant tear, RD with proliferative vitreal retinopathy including diabetic proliferative retinopathy, retrieval of luxated or artificial lens in the vitreous.	Contraindication: It should not be allowed to infiltrate under the sub -retinal tissues since there are no specific studies on tolerance. Side Effect: None	FSC- Turkey	AbŃgŃŃ b Kiv thŃZ cŃŃi	AbŃgŃŃ b Kiv nj
149.	Manufacturer: Meran Tip Ürünleri Teknoloji San.ve Tic.Ltd.Sti Istanbul, Turkey	Merdecalin	Perfluorodecalin 10ml Vial	B	It is used as Per-operative devices, for transitory intra-ocular endotamponade. In particular retinal detachment, RD with giant tear, RD with proliferative vitreal retinopathy including diabetic proliferative retinopathy, retrieval of luxated or artificial lens in the	Contraindication: It should not be allowed to infiltrate under the sub -retinal tissues since there are no specific studies on tolerance.	FSC- Turkey	AbŃgŃŃ b Kiv thŃZ cŃŃi	AbŃgŃŃ b Kiv nj

